vtvt-20240630

0001641489-24-000061.txt : 20240808 0001641489-24-000061.hdr.sgml : 20240808 20240808162011 ACCESSION NUMBER: 0001641489-24-000061 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: vTv Therapeutics Inc. CENTRAL INDEX KEY: 0001641489 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473916571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37524 FILM NUMBER: 241188712 BUSINESS ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 BUSINESS PHONE: 336-841-0300 MAIL ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 FORMER COMPANY: FORMER CONFORMED NAME: VTV Therapeutics Inc. DATE OF NAME CHANGE: 20150506 10-Q 1 vtvt-20240630.htm 10-Q vtvt-20240630

000164148912-312024Q2false0.3330.50.0250.025

(*) Adjusted retroactively for reverse stock split

(*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 7)

(*) Adjusted retroactively for reverse stock split

xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureutr:Rate00016414892024-01-012024-06-300001641489us-gaap:CommonClassAMember2024-08-080001641489us-gaap:CommonClassBMember2024-08-0800016414892024-06-3000016414892023-12-310001641489us-gaap:RelatedPartyMember2024-06-300001641489us-gaap:RelatedPartyMember2023-12-310001641489us-gaap:NonrelatedPartyMember2024-06-300001641489us-gaap:NonrelatedPartyMember2023-12-310001641489us-gaap:CommonClassAMember2023-12-310001641489us-gaap:CommonClassAMember2024-06-300001641489us-gaap:CommonClassBMember2023-12-310001641489us-gaap:CommonClassBMember2024-06-3000016414892024-04-012024-06-3000016414892023-04-012023-06-3000016414892023-01-012023-06-300001641489us-gaap:NonrelatedPartyMember2024-04-012024-06-300001641489us-gaap:NonrelatedPartyMember2023-04-012023-06-300001641489us-gaap:NonrelatedPartyMember2024-01-012024-06-300001641489us-gaap:NonrelatedPartyMember2023-01-012023-06-300001641489us-gaap:RelatedPartyMember2024-04-012024-06-300001641489us-gaap:RelatedPartyMember2023-04-012023-06-300001641489us-gaap:RelatedPartyMember2024-01-012024-06-300001641489us-gaap:RelatedPartyMember2023-01-012023-06-300001641489us-gaap:CommonClassAMember2024-04-012024-06-300001641489us-gaap:CommonClassAMember2023-04-012023-06-300001641489us-gaap:CommonClassAMember2024-01-012024-06-300001641489us-gaap:CommonClassAMember2023-01-012023-06-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-03-310001641489us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-03-310001641489us-gaap:AdditionalPaidInCapitalMember2024-03-310001641489us-gaap:RetainedEarningsMember2024-03-310001641489us-gaap:ParentMember2024-03-310001641489us-gaap:NoncontrollingInterestMember2024-03-3100016414892024-03-310001641489us-gaap:RetainedEarningsMember2024-04-012024-06-300001641489us-gaap:ParentMember2024-04-012024-06-300001641489us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001641489us-gaap:NoncontrollingInterestMember2024-04-012024-06-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-06-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-06-300001641489us-gaap:AdditionalPaidInCapitalMember2024-06-300001641489us-gaap:RetainedEarningsMember2024-06-300001641489us-gaap:ParentMember2024-06-300001641489us-gaap:NoncontrollingInterestMember2024-06-300001641489vtvt:RedeemableNoncontrollingInterestsMember2023-03-310001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-03-310001641489us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-03-310001641489us-gaap:AdditionalPaidInCapitalMember2023-03-310001641489us-gaap:RetainedEarningsMember2023-03-3100016414892023-03-310001641489vtvt:RedeemableNoncontrollingInterestsMember2023-04-012023-06-300001641489us-gaap:RetainedEarningsMember2023-04-012023-06-300001641489us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001641489vtvt:RedeemableNoncontrollingInterestsMember2023-06-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-06-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-06-300001641489us-gaap:AdditionalPaidInCapitalMember2023-06-300001641489us-gaap:RetainedEarningsMember2023-06-3000016414892023-06-300001641489vtvt:RedeemableNoncontrollingInterestsMember2023-12-310001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-12-310001641489us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-12-310001641489us-gaap:AdditionalPaidInCapitalMember2023-12-310001641489us-gaap:RetainedEarningsMember2023-12-310001641489us-gaap:ParentMember2023-12-310001641489us-gaap:NoncontrollingInterestMember2023-12-310001641489us-gaap:RetainedEarningsMember2024-01-012024-06-300001641489us-gaap:ParentMember2024-01-012024-06-300001641489vtvt:RedeemableNoncontrollingInterestsMember2024-01-012024-06-300001641489us-gaap:NoncontrollingInterestMember2024-01-012024-06-300001641489us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-01-012024-06-300001641489us-gaap:AdditionalPaidInCapitalMemberus-gaap:CommonClassAMember2024-01-012024-06-300001641489vtvt:RedeemableNoncontrollingInterestsMember2024-06-300001641489vtvt:RedeemableNoncontrollingInterestsMember2022-12-310001641489us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-12-310001641489us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-12-310001641489us-gaap:AdditionalPaidInCapitalMember2022-12-310001641489us-gaap:RetainedEarningsMember2022-12-3100016414892022-12-310001641489vtvt:RedeemableNoncontrollingInterestsMember2023-01-012023-06-300001641489us-gaap:RetainedEarningsMember2023-01-012023-06-300001641489us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001641489srt:ParentCompanyMember2024-06-300001641489vtvt:VTvLLCMember2024-01-012024-06-300001641489us-gaap:CommonClassBMembervtvt:VTvLLCMember2024-06-300001641489us-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2024-02-272024-02-270001641489us-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2024-02-270001641489vtvt:PrivatePlacementPreFundedWarrantsMemberus-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2024-02-270001641489vtvt:PrivatePlacementPreFundedWarrantsMemberus-gaap:PrivatePlacementMember2024-02-270001641489us-gaap:PrivatePlacementMember2024-02-272024-02-270001641489us-gaap:PrivatePlacementMember2024-03-050001641489us-gaap:CommonClassAMembervtvt:TDCowenSalesAgreementMember2024-02-2800016414892024-02-280001641489vtvt:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-06-300001641489vtvt:G42InvestmentsMember2022-05-312022-05-310001641489vtvt:G42InvestmentsMember2022-05-310001641489vtvt:G42InvestmentsMembervtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember2022-05-312022-05-310001641489vtvt:G42InvestmentsMembervtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember2022-05-310001641489vtvt:G42InvestmentsMember2023-02-282023-02-280001641489vtvt:G42InvestmentsMember2023-02-280001641489vtvt:CognaMembervtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember2022-05-312022-05-310001641489vtvt:G42InvestmentsMembervtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember2024-06-300001641489vtvt:G42InvestmentsMembervtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember2024-01-012024-06-300001641489vtvt:G42InvestmentsMembervtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember2024-04-012024-06-300001641489vtvt:G42InvestmentsMembervtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember2023-02-282023-02-280001641489vtvt:G42InvestmentsMembervtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember2023-02-280001641489vtvt:NewsoaraBiopharmaCoLtdMemberus-gaap:CollaborativeArrangementMember2024-06-260001641489vtvt:NewsoaraBiopharmaCoLtdMembervtvt:LicenseAndTechnologyTransferServicesMemberus-gaap:CollaborativeArrangementMember2024-01-012024-06-300001641489vtvt:NewsoaraBiopharmaCoLtdMemberus-gaap:CollaborativeArrangementMember2023-01-012023-06-300001641489vtvt:JDRFInternationalMemberus-gaap:CollaborativeArrangementMember2017-08-012017-08-310001641489us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001641489us-gaap:EmployeeStockOptionMember2024-06-300001641489us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001641489us-gaap:EmployeeStockOptionMember2024-02-230001641489us-gaap:EmployeeStockOptionMember2024-02-232024-02-230001641489us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001641489us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001641489us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001641489us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001641489us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001641489us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001641489us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001641489us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001641489vtvt:TypeOneDiabetesMembervtvt:DevelopmentalAndRegulatoryMilestonePaymentMembervtvt:NovoLicenseAgreementMember2007-02-280001641489vtvt:TypeTwoDiabetesMembervtvt:DevelopmentalAndRegulatoryMilestonePaymentMembersrt:MaximumMembervtvt:NovoLicenseAgreementMember2007-02-280001641489vtvt:OtherIndicationMembervtvt:DevelopmentalAndRegulatoryMilestonePaymentMembersrt:MaximumMembervtvt:NovoLicenseAgreementMember2007-02-280001641489vtvt:SalesBasedMilestonesPaymentMembervtvt:NovoLicenseAgreementMember2007-02-2800016414892022-11-300001641489us-gaap:CommonClassAMembervtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember2024-01-012024-06-3000016414892024-02-270001641489us-gaap:CommonClassAMember2021-05-042021-05-040001641489us-gaap:CommonClassAMember2021-05-040001641489us-gaap:CommonStockMember2021-05-0400016414892021-05-040001641489us-gaap:CommonClassAMember2023-11-200001641489us-gaap:CommonClassBMember2023-11-2000016414892023-11-200001641489vtvt:PrivatePlacementPreFundedWarrantsMember2024-02-270001641489vtvt:PrivatePlacementPreFundedWarrantsMember2024-06-300001641489vtvt:PrivatePlacementPreFundedWarrantsMemberus-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2024-06-300001641489vtvt:CinRxInvestmentMember2022-07-222022-07-220001641489vtvt:CinRxInvestmentMember2022-07-220001641489us-gaap:CommonStockMembervtvt:CinRxInvestmentMember2022-07-220001641489us-gaap:CommonClassBMember2023-11-202023-11-200001641489us-gaap:CommonClassAMember2023-11-202023-11-200001641489us-gaap:RelatedPartyMemberus-gaap:CommonClassBMembervtvt:MacAndrewsAndForbesIncorporatedMember2024-06-300001641489us-gaap:RelatedPartyMemberus-gaap:CommonClassAMembervtvt:MacAndrewsAndForbesIncorporatedMember2024-06-300001641489us-gaap:RelatedPartyMembervtvt:MacAndrewsAndForbesIncorporatedMember2024-01-012024-06-300001641489vtvt:MFTTPHoldingsLLCMember2024-01-012024-06-300001641489us-gaap:CommonClassBMember2024-01-012024-06-300001641489us-gaap:CommonClassBMember2023-01-012023-06-300001641489us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001641489us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001641489us-gaap:WarrantMember2024-01-012024-06-300001641489us-gaap:WarrantMember2023-01-012023-06-300001641489us-gaap:FairValueMeasurementsRecurringMemberus-gaap:RelatedPartyMemberus-gaap:WarrantMember2024-06-300001641489us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:RelatedPartyMemberus-gaap:WarrantMember2024-06-300001641489us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:RelatedPartyMemberus-gaap:WarrantMember2024-06-300001641489us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:RelatedPartyMemberus-gaap:WarrantMember2024-06-300001641489us-gaap:FairValueMeasurementsRecurringMemberus-gaap:NonrelatedPartyMember2024-06-300001641489us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:NonrelatedPartyMember2024-06-300001641489us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:NonrelatedPartyMember2024-06-300001641489us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:NonrelatedPartyMember2024-06-300001641489us-gaap:FairValueMeasurementsRecurringMember2024-06-300001641489us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001641489us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001641489us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001641489us-gaap:FairValueMeasurementsRecurringMember2023-12-310001641489us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001641489us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001641489us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001641489us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641489us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641489us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641489us-gaap:FairValueInputsLevel3Memberus-gaap:RelatedPartyMember2023-12-310001641489us-gaap:FairValueInputsLevel3Memberus-gaap:RelatedPartyMember2024-01-012024-06-300001641489us-gaap:FairValueInputsLevel3Memberus-gaap:RelatedPartyMember2024-06-300001641489us-gaap:FairValueInputsLevel3Memberus-gaap:NonrelatedPartyMember2023-12-310001641489us-gaap:FairValueInputsLevel3Memberus-gaap:NonrelatedPartyMember2024-01-012024-06-300001641489us-gaap:FairValueInputsLevel3Memberus-gaap:NonrelatedPartyMember2024-06-300001641489us-gaap:FairValueInputsLevel3Member2023-12-310001641489us-gaap:FairValueInputsLevel3Member2024-01-012024-06-300001641489us-gaap:FairValueInputsLevel3Member2024-06-300001641489us-gaap:FairValueInputsLevel3Member2022-12-310001641489us-gaap:FairValueInputsLevel3Member2023-01-012023-06-300001641489us-gaap:FairValueInputsLevel3Member2023-06-300001641489vtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2024-06-300001641489vtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2024-06-300001641489vtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:WeightedAverageMember2024-06-300001641489vtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2023-12-310001641489vtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2023-12-310001641489vtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:WeightedAverageMember2023-12-310001641489vtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2024-06-300001641489vtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2024-06-300001641489vtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:WeightedAverageMember2024-06-300001641489vtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2023-12-310001641489vtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2023-12-310001641489vtvt:LetterAgreementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:WeightedAverageMember2023-12-310001641489vtvt:CinRxWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2024-06-300001641489vtvt:CinRxWarrantsMember2024-06-300001641489vtvt:CinRxWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-06-300001641489vtvt:CinRxWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2024-06-30

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________

FORM 10-Q

_____________________________

(Mark One)


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-37524

_____________________________

vTv Therapeutics Inc.

(Exact name of registrant as specified in its charter)

_____________________________


Delaware			47-3916571
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

3980 Premier Dr, Suite 310 High Point, NC			27265
(Address of principal executive offices)			(Zip Code)

(336) 841-0300

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

_____________________________

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, par value $0.01 per share	VTVT	NASDAQ Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x


Class of Stock						Shares Outstanding as of August 8, 2024
Class A common stock, par value $0.01 per share						2,432,857
Class B common stock, par value $0.01 per share						577,349

Table of Contents

vTv THERAPEUTICS INC. AND SUBSIDIARIES

INDEX TO FORM 10-Q

FOR THE QUARTER ENDED JUNE 30, 2024


		PAGE NUMBER

PART I – FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Balance Sheets as of June 3 0 , 2024 (Unaudited) and December 31, 2023	4

	Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 3 0 , 2024 and 2023	5

	Unaudited Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit) for the three and six months ended June 3 0 , 2024 and 2023	6

	Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 3 0 , 2024 and 2023	8

	Notes to Unaudited Consolidated Financial Statements	9

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	32

Item 4.	Controls and Procedures	33

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	33

Item 1A.	Risk Factors	34

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	34

Item 3.	Defaults Upon Senior Securities	34

Item 4.	Mine Safety Disclosures	34

Item 5.	Other Information	34

Item 6.	Exhibits	34

	Signatures	35

Table of Contents

PART I – FINANCIAL INFORMATION

The financial statements and other disclosures contained in this report include those of vTv Therapeutics Inc. (“we”, the “Company” or the “Registrant”), which is the registrant, and those of vTv Therapeutics LLC (“vTv LLC”), which is the principal operating subsidiary of the Registrant. Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to the “Company”, “we”, “us” and “our” refer to vTv Therapeutics Inc. and its consolidated subsidiaries.

Table of Contents

vTv Therapeutics Inc.

Condensed Consolidated Balance Sheets

(in thousands, except number of shares and per share data)


	June 30, 2024		December 31, 2023
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	45,526	$	9,446
Accounts receivable	306		102

Prepaid expenses and other current assets	303		1,044
Current deposits	65		65
Total current assets	46,200		10,657
Property and equipment, net	72		117
Operating lease right-of-use assets	186		244

Total assets	$	46,458	$	11,018
Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable and accrued expenses	$	6,791	$	10,242
Current portion of operating lease liabilities	177		169
Current portion of contract liabilities	17		17
Current portion of notes payable	—		191
Total current liabilities	6,985		10,619
Contract liabilities, net of current portion	18,669		18,669
Operating lease liabilities, net of current portion	79		169
Warrant liability, related party	158		110
Warrant liability	130		—
Total liabilities	26,021		29,567
Commitments and contingencies
Redeemable noncontrolling interest	—		6,131
Stockholders’ equity (deficit):
Class A common stock, $0.01 par value; 200,000,000 shares authorized, 2,432,857 and 2,084,973 shares outstanding as of June 30, 2024 and December 31, 2023, respectively	24		21
Class B common stock, $0.01 par value; 100,000,000 shares authorized, and 577,349 outstanding as of June 30, 2024 and December 31, 2023	6		6

Additional paid-in capital	307,746		256,335
Accumulated deficit	(291,301)		(281,042)
Total stockholders’ equity (deficit) attributable to vTv Therapeutics Inc.	16,475		(24,680)
Noncontrolling interest	3,962		—
Total stockholders’ equity (deficit)	20,437		(24,680)
Total liabilities, redeemable noncontrolling interest and stockholders’ equity (deficit)	$	46,458	$	11,018

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

Table of Contents

vTv Therapeutics Inc.

Condensed Consolidated Statements of Operations - Unaudited

(in thousands, except number of shares and per share data)


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Revenue	$	—	$	—	$	1,000	$	—
Operating expenses:
Research and development	3,439		4,691		6,088		8,633
General and administrative	3,716		3,309		7,694		6,794
Total operating expenses	7,155		8,000		13,782		15,427
Operating loss	(7,155)		(8,000)		(12,782)		(15,427)
Other income, net	72		335		72		2,126
Other income (expense) – related party	121		303		(250)		65
Interest income	553		153		632		253
Interest expense	—		(2)		—		(2)
Loss before income taxes and noncontrolling interest	(6,409)		(7,211)		(12,328)		(12,985)
Income tax provision	—		—		100		—
Net loss before noncontrolling interest	(6,409)		(7,211)		(12,428)		(12,985)
Less: net loss attributable to noncontrolling interest	(1,229)		(1,592)		(2,383)		(2,867)
Net loss attributable to vTv Therapeutics Inc.	$	(5,180)	$	(5,619)	$	(10,045)	$	(10,118)
Net loss attributable to vTv Therapeutics Inc. common shareholders	(5,180)		(5,619)		(10,045)		(10,118)
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted (*)	$	(0.81)	$	(2.69)	$	(1.97)	$	(4.85)
Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted (*)	6,403,444		2,084,973		5,098,877		2,084,973
(*) Adjusted retroactively for reverse stock split

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

Table of Contents

vTv Therapeutics Inc.

Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit) - Unaudited

(in thousands, except number of shares)


For the three months ended June 30, 2024
	Class A Common Stock			Class B Common Stock
	Shares	Amount		Shares	Amount		Additional Paid-in Capital		Accumulated Deficit		Total vTv Therapeutics Inc Stockholders’ Equity (Deficit)		Noncontrolling Interest		Total Stockholders' Equity (Deficit)
Balances at March 31, 2024	2,432,857	$	24	577,349	$	6	$	306,887	$	(286,121)	$	20,796	$	5,191	$	25,987
Net loss attributable to vTv Therapeutics Inc.	—	—		—	—		—		(5,180)		(5,180)		—		(5,180)



Share-based compensation	—	—		—	—		859		—		859		—		859

Net loss attributable to noncontrolling interest	—	—		—	—		—		—		—		(1,229)		(1,229)
Balances at June 30, 2024	2,432,857	$	24	577,349	$	6	$	307,746	$	(291,301)	$	16,475	$	3,962	$	20,437


For the three months ended June 30, 2023
			Class A Common Stock			Class B Common Stock
	Redeemable Noncontrolling Interest		Shares(*)	Amount(*)		Shares(*)	Amount(*)		Additional Paid-in Capital(*)		Accumulated Deficit		Total Stockholders' Deficit
Balances at March 31, 2023	$	19,600	2,084,973	$	21	577,349	$	6	$	255,100	$	(274,319)	$	(19,192)
Net loss	(1,592)		—	—		—	—		—		(5,619)		(5,619)
Share-based compensation	—		—	—		—	—		399		—		399
Change in redemption value of noncontrolling interest	871		—	—		—	—		—		(871)		(871)
Balances at June 30, 2023	$	18,879	2,084,973	$	21	577,349	$	6	$	255,499	$	(280,809)	$	(25,283)
(*) Adjusted retroactively for reverse stock split

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

Table of Contents

vTv Therapeutics Inc.

Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit - Unaudited

(in thousands, except number of shares)


For the six months ended June 30, 2024
			Class A Common Stock			Class B Common Stock
	Redeemable Noncontrolling Interest		Shares	Amount		Shares	Amount		Additional Paid-in Capital		Accumulated Deficit		Total vTv Therapeutics Inc Stockholders’ Equity (Deficit)		Noncontrolling Interest		Total Stockholders' Equity (Deficit)
Balances at December 31, 2023	$	6,131	2,084,973	$	21	577,349	$	6	$	256,335	$	(281,042)	$	(24,680)	$	—	$	(24,680)
Net loss attributable to vTv Therapeutics Inc.	—		—	—		—	—		—		(10,045)		(10,045)		—		(10,045)
Net loss attributable to redeemable noncontrolling interest(*)	(1,085)		—	—		—	—		—		—		—		—		—
Change in redemption value of redeemable noncontrolling interest	214		—	—		—	—		—		(214)		(214)		—		(214)
Reclassification of redeemable noncontrolling interest to permanent equity (See Note 7)	(5,260)		—	—		—	—		—		—		—		5,260		5,260
Share-based compensation	—		—	—		—	—		1,079		—		1,079		—		1,079
Issuance of Class A common stock and pre-funded warrants, net offering costs	—		347,884	3		—	—		50,332		—		50,335		—		50,335
Net loss attributable to noncontrolling interest	—		—	—		—	—		—		—		—		(1,298)		(1,298)
Balances at June 30, 2024	$	—	2,432,857	$	24	577,349	$	6	$	307,746	$	(291,301)	$	16,475	$	3,962	$	20,437
(*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 7)


For the six months ended June 30, 2023
			Class A Common Stock			Class B Common Stock
	Redeemable Noncontrolling Interest		Shares(*)	Amount(*)		Shares(*)	Amount(*)		Additional Paid-in Capital(*)		Accumulated Deficit		Total Stockholders' Deficit
Balances at December 31, 2022	$	16,579	2,084,973	$	21	577,349	$	6	$	254,757	$	(265,524)	$	(10,740)
Net loss	(2,867)		—	—		—	—		—		(10,118)		(10,118)
Share-based compensation	—		—	—		—	—		742				742
Change in redemption value of noncontrolling interest	5,167		—	—		—	—		—		(5,167)		(5,167)
Balances at June 30, 2023	$	18,879	2,084,973	$	21	577,349	$	6	$	255,499	$	(280,809)	$	(25,283)
(*) Adjusted retroactively for reverse stock split

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

Table of Contents

vTv Therapeutics Inc.

Condensed Consolidated Statements of Cash Flows - Unaudited

(in thousands)


	Six Months Ended June 30,
	2024		2023
Cash flows from operating activities:
Net loss before noncontrolling interest	$	(12,428)	$	(12,985)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
Depreciation expense	45		45
Loss from promissory note early redemption	—		313
Non-cash interest income	—		(100)
Share-based compensation expense	1,079		742
Change in fair value of investments	—		(2,439)
Change in fair value of warrants, related party	250		(65)
Change in fair value of warrants	(72)		—
Changes in assets and liabilities:
Accounts receivable	(204)		173
Prepaid expenses and other current assets	741		1,213
Other assets	58		—
Accounts payable and accrued expenses	(3,451)		1,770

Other liabilities	(82)		—
Net cash used in operating activities	(14,064)		(11,333)



Cash flows from financing activities:
Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs	50,335		—
Proceeds from promissory note early redemption related to sale of Class A common stock to collaboration partner	—		12,030

Repayment of notes payable	(191)		(224)
Net cash provided by financing activities	50,144		11,806
Net increase in cash and cash equivalents	36,080		473
Total cash and cash equivalents, beginning of period	9,446		12,126
Total cash and cash equivalents, end of period	$	45,526	$	12,599

Non-cash activities:
Change in redemption value of noncontrolling interest	$	(214)	$	5,167
Reclassification of noncontrolling interest to additional paid-in capital	$	5,260	—

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

Table of Contents

vTv Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements – Unaudited

(dollar amounts are in thousands, unless otherwise noted)

Note 1: Description of Business and Basis of Presentation

Description of Business

vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection.

Principles of Consolidation

vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.

The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Condensed Consolidated Financial Statements. The assets and liabilities of vTv LLC represent substantially all of the Company's consolidated assets and liabilities with the exception of the Warrants and $26.1 million of cash and cash equivalents.

Various holders own non-voting interests in vTv LLC, representing a 19.2% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 80.8% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company’s Class B common stock, par value $0.01 (“Class B common stock”)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 8). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (“M&F Group”), a related party and an affiliate of MacAndrews & Forbes Incorporated (together with its affiliates “MacAndrews”) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a “Letter Agreement” and collectively, the “Letter Agreements”). vTv Therapeutics Inc. entered into a common stock purchase agreement with G42 Investments AI Holding RSC Ltd (“G42 Investments”) (the “G42 Purchase Agreement”), the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the “CinRx Purchase Agreement”). In addition vTv Therapeutics Inc. also entered into a Securities Purchase Agreement with Private Placement Investors and the sales agreement with Cowen and Company, LLC (“TD Cowen”) (“TD Cowen Sales Agreement”). vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.

Liquidity

To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through June 30, 2024, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of June 30, 2024, the Company had an accumulated deficit of $291.3 million and has generated net losses in each year of its existence. As of June 30, 2024, the Company’s liquidity sources included cash and cash equivalents of $45.5 million.

Table of Contents

Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements for at least the next twelve months.

On February 27, 2024, we entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Private Placement Investors”), pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (the “Private Placement”) (i) an aggregate of 464,377 shares (the “Private Placement Shares”) of our Class A common stock, at a purchase price of $11.81 per share, and (ii) pre-funded warrants (the “Private Placement Pre-Funded Warrants”) to purchase up to an aggregate of 3,853,997 shares of our Class A common stock (the “Private Placement Warrant Shares”) at a purchase price of $11.80 per Private Placement Pre-Funded Warrant (representing the $11.81 per Private Placement Share purchase price less the exercise price of $0.01 per Private Placement Warrant Share). We received aggregate gross proceeds from the Private Placement of approximately $51.0 million, before deducting offering expenses payable by us. The Private Placement Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire.

On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants.

On February 28, 2024, we entered into the TD Cowen Sales Agreement, pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the “TD Cowen ATM Offering”). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements.

Note 2: Summary of Significant Accounting Policies

Unaudited Interim Financial Information

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of June 30, 2024, Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit) for the three and six months ended June 30, 2024 and 2023 and Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of June 30, 2024, the results of operations for the three and six months ended June 30, 2024 and 2023 and cash flows for the six months ended June 30, 2024 and 2023. The December 31, 2023 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.

The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year.

The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Table of Contents

On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.

Concentration of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.

One customer represented 100% of the revenue earned during the six months ended June 30, 2024. The Company did not have any revenue during the six months ended June 30, 2023 or during the three months ended June 30, 2024 and 2023.

Cash and Cash Equivalents

The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Investments

Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.

Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.

Revenue Recognition

The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.

The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied.

The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.

Table of Contents

Research and Development

Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.

The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.

The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.

Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.

Recently Issued Accounting Pronouncements Not Yet Adopted

Segment Reporting: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): “Improvements to Reportable Segment Disclosures” (ASU 2023-07). The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. For public entities, the provisions within ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and for interim periods of fiscal years beginning after December 15, 2024. The Company is currently assessing the impact the adoption of ASU 2023-07 will have on its Consolidated Financial Statement and disclosures.

Income Taxes: In December 2023, the FASB issued ASU 2023-09: “Improvements to Income Tax Disclosures” (“ASU 2023-09”). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, and we expect considerable changes to our income tax disclosures.

Note 3: Collaboration Agreements

G42 Purchase Agreement and Cogna Collaborative and License Agreement

The Company and G42 Investments AI Holding RSC Ltd, a private limited company (“G42 Investments”), entered into a Common Stock Purchase Agreement (the “G42 Purchase Agreement”), pursuant to which the Company sold to G42 Investments 259,657 shares of the Company’s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the “G42 Promissory Note”). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company’s Condensed Consolidated Statements of Operations.

G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and

Table of Contents

Drug Administration (“FDA”) approval in the U.S. for cadisegliatin, the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.

Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the “Cogna Agreement”) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (“Cogna”), which requires Cogna to work with the Company in performing clinical trials for cadisegliatin as well as jointly creating a global development plan to develop, market, and commercialize cadisegliatin in certain countries in the Middle East, Africa, and Central Asia (the “Partner Territory”). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercialize cadisegliatin in the Partner Territory, but will not have access to the various intellectual property (“IP”) related to the license and cadisegliatin. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of cadisegliatin needed to conduct the trials.

Under the Cogna Agreement, Cogna has the right to develop and commercialize the cadisegliatin in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, cadisegliatin for commercial sale under terms to be agreed upon by the parties at a later date.

Separately, the Company will conduct its clinical trials for cadisegliatin outside of the Partner Territory at its own cost. The Company may combine the results of each party’s clinical trials to seek FDA approval in the United States for cadisegliatin. On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (“G42 Healthcare”), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.

The G42 Purchase Agreement also provides for, following the receipt of the cadisegliatin FDA Approval, at the option of G42 Investments, either (a) the issuance of the Company’s Class A common stock (the “Milestone Shares”) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the “Milestone Cash Payment”). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the cadisegliatin FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the cadisegliatin FDA Approval will be granted or as to the timing thereof.

Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of cadisegliatin for a period of at least ten years after the first commercial sale of cadisegliatin in the Partner Territory.

A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.

The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of cadisegliatin, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company’s behalf to complete research and development activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (“JDC”) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.

By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall

Table of Contents

within the 808 unit of account are concentrated in the clinical trials. As of June 30, 2024, the clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and six months ended June 30, 2024.

The Company identified certain commitments that are in the scope of ASC 606 as Cogna’s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after cadisegliatin is approved by the FDA. The Company will recognize revenue from the material right related to Cogna’s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and six months ended June 30, 2024.

On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company’s Condensed Consolidated Statements of Operations. The G42 Promissory Note receivable was classified and accounted for under ASC 310 “Receivables“ (“ASC 310”) and was initially measured at its fair value of $11.9 million. The Company also recorded the $18.7 million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and six months ended June 30, 2024.

Newsoara License Agreement

The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (“Newsoara”) (the “Newsoara License Agreement”) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company’s phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound HPP737, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the “Newsoara License Territory”). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company’s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.

The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the “First Newsoara Amendment”). On June 26, 2024, the Company entered into the second amendment to the Newsoara License Agreement (the “Second Newsoara Amendment”) which expanded the global license contingent upon Newsoara paying an upfront global rights fee (the “Upfront Fees”) of $20.0 million. Newsoara has up to one year from the date of the Second Newsoara Amendment to pay the Upfront Fees; if it fails to do so, then the Second Newsoara Amendment will be null and void. As amended, the Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to $76.5 million. In addition, Newsoara is obligated to pay the Company royalty payments at mid to upper single digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. There are no new performance obligations to be considered within the Second Newsoara Amendment. The Second Amendment has a potential impact to increase the transaction price by $20.0 million. If the Company receives the Upfront Fees, $20.0 million of revenue will be recognized at a point in time.

The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The revenue for this performance obligation has been fully recognized as of June 30, 2024. In the first quarter of 2024, the transaction price for this performance obligation was increased by $1.0 million due to the satisfaction of a development milestone under the Newsoara License Agreement. This amount was fully recognized as revenue during the six months ended June 30, 2024, as the related performance obligation was fully satisfied. No revenue related to this performance obligation was recognized and there were no changes to the transaction price during the three and six months ended June 30, 2023.

Table of Contents

Note 4: Share-Based Compensation

The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of June 30, 2024, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $4.7 million, which is expected to be recognized over a weighted average period of 2.5 years. The weighted average grant date fair value of options granted during the six months ended June 30, 2024 and 2023 was $14.88 and $30.59 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at June 30, 2024 was de minimis.

On February 23, 2024, in connection with the Private Placement, several directors resigned as members of the Company’s Board of Directors, effective on the closing of the Private Placement. As a result of their resignations, 14,340 stock options to purchase shares of common stock were modified to increase the time period to exercise the options and 7,590 stock options to purchase shares of common stock were modified to accelerate vesting at the termination date. All the unvested options were modified to be fully vested as of the posting of the Private Placement which resulted in a reduction in their fair value. The Company incurred $0.1 million reduction in stock compensation expense for the modifications for the six months ended June 30, 2024.

The following table summarizes the activity related to the stock option awards for the six months ended June 30, 2024:


	Number of Shares	Weighted Average Exercise Price
Awards outstanding at December 31, 2023	249,247	$	77.53
Granted	406,799	12.68
Forfeited	(1,875)	30.87
Awards outstanding at June 30, 2024	654,171	$	37.34
Options exercisable at June 30, 2024	199,812	$	86.34
Weighted average remaining contractual term	6.8 Years
Options vested and expected to vest at June 30, 2024	499,109	$	44.32
Weighted average remaining contractual term	8.4 Years

Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Research and development	$	217	$	105	$	283	$	203
General and administrative	642		294		796		539
Total share-based compensation expense	$	859	$	399	$	1,079	$	742

Note 5: Commitments and Contingencies

Legal Matters

From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.

Novo Nordisk

In February 2007, the Company entered into an Agreement (the “Novo License Agreement”) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo Nordisk”) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as cadisegliatin. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use.

Table of Contents

Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products.

Note 6: Leases

In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election is not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. As a result of the remeasurement of the associated lease liabilities, the Company recognized additional right of use assets and corresponding lease liabilities of $0.1 million. Further, the second amendment to the lease does not include any material residual value guarantee or restrictive covenants.

At each of June 30, 2024 and December 31, 2023, the weighted average incremental borrowing rate for the operating leases held by the Company was 9.5%. At June 30, 2024 and December 31, 2023, the weighted average remaining lease terms for the operating leases held by the Company were 1.4 years and 1.9 years, respectively.

Maturities of lease liabilities for the Company’s operating leases as of June 30, 2024 were as follows (in thousands):


2024 (remaining six months)	$	97
2025	177
2026	—
2027	—
2028	—
Thereafter	—
Total lease payments	274
Less: imputed interest	(18)
Present value of lease liabilities	$	256

Operating lease cost and the related operating cash flows for the six months ended June 30, 2024 was $0.1 million and was immaterial for the six months ended June 30, 2023.

Note 7: Noncontrolling Interest

The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 19.2% noncontrolling interest in vTv LLC outstanding as of June 30, 2024 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.

On February 27, 2024, in connection with the Private Placement financing, the Investor Rights Agreement altered M&F TTP Holdings Two LLC (“M&F”) governance rights such that directors designated by M&F no longer comprised a majority of the Company’s Board of Directors (see Note 9). The redeemable noncontrolling interest redemption feature to exchange vTv Units for cash rather than shares of Class A common stock is a contingent event that is now within control of the Company through the Company’s independent Board of Directors. As a result, $5.3 million representing the fair value of redeemable noncontrolling interest on February 27, 2024, was reclassified from temporary equity in the mezzanine section of the Condensed Consolidated Balance Sheets to noncontrolling interest as a component of permanent equity.

Prior to February 27, 2024, the Company recorded redeemable noncontrolling interest at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the

Table of Contents

balance sheet date. At December 31, 2023, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $6.1 million.

Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2024		2023		2024		2023
Net loss attributable to vTv Therapeutics Inc. common shareholders	$	(5,180)	$	(5,619)	$	(10,045)	$	(10,118)
Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances	—		1,275		9,564		2,620
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest	$	(5,180)	$	(4,344)	$	(481)	$	(7,498)

Note 8: Stockholders’ Equity (Deficit)

Amendment to Certificate of Incorporation

On May 4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.

On November 20, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation as amended, to effect a reverse stock split at a ratio of 1-for-40 (the "Reverse Stock Split"). Pursuant to the Reverse Stock Split, every 40 shares of the Company’s Class A common stock was combined into one issued and outstanding share of Class A Common Stock and every 40 shares of the Company’s Class B common stock was combined into one issued and outstanding share of Class B Common Stock. The Reverse Stock Split did not reduce the number of authorized shares of Class A and Class B common stock, which remained at 200,000,000 and 100,000,000 respectively and did not change the par value of the common stock, which remained at $0.01 per share. The Reverse Stock Split did not have any effect on the number of authorized shares of the Company’s preferred stock, par value of $0.01 per share, which would remain at 50,000,000 shares. Currently no shares of preferred stock are outstanding.

Common Stock and Pre-funded Warrants

In February 2024, the Company entered into a Securities Purchase Agreement with certain Private Placement Investors, pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (i) an aggregate of 464,377 shares of our Class A common stock, at a purchase price of $11.81 per share and (ii) issued pre-funded warrants to purchase an aggregate of 3,853,997 shares of the Company’s Class A common stock at a price of $11.80 per pre-funded warrant. The pre-funded warrants were immediately exercisable, have an exercise price of $0.01 and may be exercised at any time after the date of issuance. A holder of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. A holder of the pre-funded warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. As of June 30, 2024, there were pre-funded warrants to purchase an aggregate of 3,970,587 shares of the Company’s common stock that remained available for exercise.

The pre-funded warrants were classified as a component of permanent equity in the Company's Condensed Consolidated Balance Sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the pre-funded warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because

Table of Contents

the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants.

G42 Investments Transaction

On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 259,657 shares of the Company's Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the “G42 Promissory Note”). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company’s Condensed Consolidated Statements of Operations.

CinPax and CinRx Transaction

On July 22, 2022 (the “Transaction Date”), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (“CinPax”) and CinRx-Pharma, LLC (“CinRx”), pursuant to which the Company agreed to sell to CinPax 103,864 shares of the Company’s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022.

The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 30,000 shares of common stock at an initial exercise of price of approximately $28.80 per share (the “CinRx Warrants”). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 12)

The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (“FDA Approval”) to market and distribute the pharmaceutical product containing the Company’s proprietary candidate, cadisegliatin (the “Product”), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.

Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (“CinRx MSA”) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 9)

The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par. The Company, CinPax and CinRx subsequently amended the CinRx Purchase Agreement on February 27, 2024, in connection with the Private Placement. The CinRx Purchase Agreement provides CinPax the right for two years following the Closing to designate a board observer, which has been subsequently approved by the Company’s board.

ATM Offering

On February 28, 2024, we entered into a sales agreement (the “TD Cowen Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the “TD Cowen ATM Offering”). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered

Table of Contents

on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. As of June 30, 2024 we have not sold any shares pursuant to the TD Cowen Sales Agreement.

Note 9: Related-Party Transactions

MacAndrews & Forbes Incorporated

MacAndrews directly or indirectly controls 577,108 shares of Class B common stock. Further, as of June 30, 2024, MacAndrews directly or indirectly holds 912,982 shares of the Company’s Class A common stock. As a result, MacAndrews’ holdings represent approximately 49.5% of the combined voting power of the Company’s outstanding common stock.

The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:

Letter Agreements

The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A common stock.

The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company’s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital.

Exchange Agreement

Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company’s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of June 30, 2024, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.

Tax Receivable Agreement

The Company and MacAndrews are party to a tax receivable agreement (the “Tax Receivable Agreement”), which provides for the payment by the Company to M&F TTP Holdings Two LLC (“M&F”), as successor in interest to vTv Therapeutics Holdings, LLC (“vTv Therapeutics Holdings”), and M&F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of June 30, 2024.

Investor Rights Agreement

The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement,

Table of Contents

M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. The Investor Rights Agreement was amended on February 27, 2024 to alter M&F governance rights that now entitles M&F the right to designate two members of our Board of Directors, and as part of the Private Placement, the Private Placement Investors have rights to designate three members of our Board of Directors, making it more difficult for a third party to acquire control of our Board. The agreement with the Private Placement Investors also provides that five of our directors must approve certain actions including any acquisition by a third party, which makes it more difficult for our Board of Directors to approve such a transaction.

Note 10: Income Taxes

The Company is subject to U.S. federal income taxes as well as state taxes. The Company’s income tax provision for the six months ended June 30, 2024 was $0.1 million representing foreign withholding taxes accrued in connection with revenue recorded under license agreements with foreign entities. The Company did not record an income tax provision for the three months ended June 30, 2024 and 2023. The Company did not record an income tax provision for the six months ended June 30, 2023.

Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on June 30, 2024, is due to the valuation allowance against the Company’s expected net operating losses.

As discussed in Note 9, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of June 30, 2024.

Note 11: Net Loss per Share

Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2024		2023		2024		2023
Numerator:
Net loss	$	(6,409)	$	(7,211)	$	(12,428)	$	(12,985)
Less: Net loss attributable to noncontrolling interests	(1,229)		(1,592)		(2,383)		(2,867)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted	(5,180)		(5,619)		(10,045)		(10,118)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted (1)(*)	6,403,444		2,084,973		5,098,877		2,084,973
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted (*)	$	(0.81)	$	(2.69)	$	(1.97)	$	(4.85)
(*) Adjusted retroactively for reverse stock split

Table of Contents


			(1)			The shares underlying the pre-funded warrants to purchase shares of the Company’s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and six months ended June 30, 2024.

Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:


	June 30, 2024	June 30, 2023
Class B common stock (1)(*)	577,349	577,349
Common stock options granted under the Plan (*)	654,171	238,636
Common stock warrants (*)	75,595	80,359
Total (*)	1,307,115	896,344
(*) Adjusted retroactively for reverse stock split

___________________________


			(1)			Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.

Note 12: Fair Value of Financial Instruments

The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.

The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The following table summarizes the conclusions reached regarding fair value measurements as of June 30, 2024 and December 31, 2023 (in thousands):


	Balance at June 30, 2024		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)




Liabilities:
Warrant liability, related party (1)(2)	$	158	$	—	$	—	$	158
Warrant liability	$	130	$	—	$	—	$	130
Total	$	288	$	—	$	—	$	288


	Balance at December 31, 2023		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)




Liabilities:
Warrant liability, related party (1)	$	110	$	—	$	—	$	110
Total	$	110	$	—	$	—	$	110

_____________________________

Table of Contents


(1)			Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
(2)			CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.


	Changes in Level 3 instruments for the six months ended June 30,
	Balance at January 1		Net Change in fair value included in earnings		Purchases / Issuance		Sales / Repurchases		Balance at June 30,
2024
Warrant liability, related party (1)	$	110	$	250	$	—	$	—	$	360
Warrant liability	$	—	$	(72)	$	—	$	—	$	(72)
Total	$	110	$	178	$	—	$	—	$	288

2023
Warrant liability, related party	$	684	$	(65)	$	—	$	—	$	619
Total	$	684	$	(65)	$	—	$	—	$	619


(1)			CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.

There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and six months ended June 30, 2024. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income (expense), related party in the Company’s Condensed Consolidated Statements of Operations.

The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of June 30, 2024 and December 31, 2023, were:


	June 30, 2024		December 31, 2023
	Range	Weighted Average	Range	Weighted Average
Expected volatility	98.96% - 145.41%	106.42%	79.96% - 89.61%	81.55%
Risk-free interest rate	4.62% - 5.36%	4.79%	4.01% - 4.87%	4.15%

The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of June 30, 2024, were:


Expected volatility	91.7	%
Expected life of options in years	3.0
Risk-free interest rate	4.5	%
Expected dividend yield	—	%

The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.

Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.

Table of Contents

Note 13: Subsequent Events

On July 26, 2024 the Company announced that the Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (“CATT1”) Phase 3 trial in type 1 diabetes.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

As used in this Quarterly Report on Form 10-Q, the “Company”, the “Registrant”, “we” or “us” refer to vTv Therapeutics Inc. and “vTv LLC” refers to vTv Therapeutics LLC. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes that appear elsewhere in this report. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, assumptions and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this report under “Part II, Other Information—Item 1A, Risk Factors.” Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies and operations, financing plans, potential growth opportunities, potential market opportunities, potential results of our drug development efforts or trials, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s plans, estimates, assumptions and beliefs only as of the date of this report. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Company Overview

We are a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. We have an innovative pipeline of first-in-class small molecule clinical and preclinical drug candidates. Our lead program is cadisegliatin, an orally administered, small molecule, liver-selective glucokinase activator (“GKA”) as an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”).

Recent Developments

Table of Contents

The following table summarizes our drug candidates*, their partnership status and their respective stages of development:

vTv Therapeutics_grayscale pipeline for 10-Q_v3.jpg

* These product candidates are under investigation and their safety and efficacy have not been established. There is no guarantee that these products will receive health authority approval or become commercially available for the uses being investigated.

Our Type 1 Diabetes Program – Cadisegliatin (TTP399)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation in 2021 for cadisegliatin as an adjunctive therapy to insulin for the treatment of type 1 diabetes. The Breakthrough Therapy designation provides a sponsor with added support and the potential to expedite development and review timelines for a promising new investigational medicine. The Breakthrough Therapy designation for cadisegliatin in T1D was supported by the positive results from the Phase 2 SimpliciT-1 Study, a multi-center, randomized, double-blind, adaptive study assessing the safety and efficacy of cadisegliatin as an adjunct to insulin therapy in adults with T1D. In this trial, treatment with cadisegliatin resulted in a statistically significant improvement in HbA1c relative to placebo and a clinically meaningful decrease (40%) in the frequency of severe and symptomatic hypoglycemia. Cadisegliatin demonstrated a favorable safety profile, in which abnormal levels of serum or urine ketones were detected less frequently in patients taking cadisegliatin than those taking placebo.

In May of 2023, the FDA issued new draft guidance on "Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products" which, for the first time, permitted the use of hypoglycemia as an endpoint to support a label claim. Consistent with this guidance and with input from the FDA, we initiated our CATT1 trial to assess the effect of cadisegliatin on reducing the frequency of Level 2 hypoglycemia (blood glucose levels are less than 54 mg/dL or 3 mmol/L, regardless of symptoms) and Level 3 hypoglycemia ("severe" hypoglycemia e.g., requiring assistance of another person) in 150 patients with type 1 diabetes. On July 26, 2024, the FDA issued a clinical hold for the cadisegliatin program, including the CATT1 trial, based on the discovery of a chromatographic signal in a recent human absorption, distribution, metabolism, and excretion (ADME) study of cadisegliatin that could not be resolved by standard mass spectroscopy. The FDA will require a single in vitro study to characterize this signal before the cadisegliatin program, including the CATT1 trial, can resume. At the time of the clinical hold, no patient had been dosed in the CATT1 trial and past clinical studies did not reveal any clinically concerning safety issues. The Company has initiated activities to address the issue identified by FDA and restart clinical trial activities.

The Company continues to work on the design for two international registrational studies for cadisegliatin in type 1 diabetes, which we expect to start in 2026.

In addition, we continue to work with our partner, G42 Investments AI Holding RSC Ltd. (“G42”), to initiate a double-blind, randomized, controlled Phase 2 trial in the Middle East region in 450 insulin-using patients with type 2 diabetes. We expect that trial to begin in 2024.

Table of Contents

Holding Company Structure

vTv Therapeutics Inc. is a holding company and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the principal operating subsidiary. We have determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results under the VIE accounting model in its consolidated financial statements.

Financial Overview

Revenue

To date, we have not generated any revenue from drug sales. Our revenue has been primarily derived from milestone payments, up-front proceeds and research fees under collaboration and license agreements.

In the future, we may generate revenue from a combination of product sales, license fees, milestone payments and royalties from the sales of products developed under licenses of our intellectual property. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the development of our drug candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue and our results of operations and financial position will be materially adversely affected.

Research and Development Expenses

Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for our drug candidates. We recognize research and development expenses as they are incurred. Our direct research and development expenses consist primarily of external costs such as fees paid to investigators, consultants, central laboratories and clinical research organizations in connection with our clinical trials, and costs related to acquiring and manufacturing clinical trial materials. Our indirect research and development costs consist primarily of cash and share-based compensation costs, the cost of employee benefits and related overhead expenses for personnel in research and development functions. Since we typically use our employee and infrastructure resources across multiple research and development programs such costs are not allocated to the individual projects.

Our research and development expenses by project for the three and six months ended June 30, 2024 and 2023 were as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Direct research and development expense:
Cadisegliatin	$	2,034	$	4,033	$	3,597	$	7,089


Other projects*	182		59		405		312
Indirect research and development expense	1,223		599		2,086		1,232
Total research and development expense	$	3,439	$	4,691	$	6,088	$	8,633

*Includes HPP737 and Azeliragon

We plan to continue to incur significant research and development expenses for the foreseeable future as we continue the development of cadisegliatin and further advance the development of our other drug candidates, subject to the availability of additional funding.

The successful development of our clinical and preclinical drug candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our clinical or preclinical drug candidates or the period, if any, in which material net cash inflows

Table of Contents

from these drug candidates may commence. This is due to the numerous risks and uncertainties associated with the development of our drug candidates, including:

•the uncertainty of the duration of the clinical hold placed on the cadisegliatin program and the scope, rate of progress and expense of our clinical trials once resumed as well as any additional, clinical trials and other research and development activities;

•the potential benefits of our candidates over other therapies;

•our ability to market, commercialize and achieve market acceptance for any of our drug candidates that we are developing or may develop in the future;

•future clinical trial results;

•our ability to enroll patients in our clinical trials;

•the timing and receipt of any regulatory approvals;

•our ability to secure sufficient capital and cash resources, including access to available debt and equity financing and revenues from operations, to satisfy all of our short-term and longer-term cash requirements and other cash needs, at the times and in the amounts needed;

•legislation and regulatory actions and changes in laws or regulations; and

•the filing, prosecuting, defending and enforcing of patent claims and other intellectual property rights, and the expense of doing so.

A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a drug candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time with respect to the development of that drug candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, benefits and related costs for employees in executive, finance, corporate development, human resources and administrative support functions. Other significant general and administrative expenses include accounting and legal services, expenses associated with obtaining and maintaining patents, cost of various consultants, occupancy costs and information systems.

Interest Income

Interest income represents noncash interest income related to the imputed interest from the G42 Promissory Note receivable using the effective interest method, which ended in 2023, and cash interest income from dividends and interest from our money market account, all of which are recognized in our Condensed Consolidated Statement of Operations.

Other Income (Expense), net

Other income (expense) primarily consists of unrealized gains or losses attributable to the changes in fair value of the equity investments in Reneo Pharmaceuticals, Inc. ("Reneo"), the recognition of changes in fair value of the warrants to purchase shares of our Class A common stock and the loss from the G42 promissory note early redemption on February 28, 2023.

Table of Contents

Results of Operations

Comparison of the three months ended June 30, 2024 and 2023

The following table sets forth certain information concerning our results of operations for the periods shown:


(dollars in thousands)	Three Months Ended June 30,
Statement of operations data:	2024		2023		Change
Revenue	$	—	$	—	$	—
Operating expenses:
Research and development	3,439		4,691		(1,252)
General and administrative	3,716		3,309		407
Total operating expenses	7,155		8,000		(845)
Operating loss	(7,155)		(8,000)		845
Interest income	553		153		400
Interest expense	—		(2)		2
Other income, net	193		638		(445)
Loss before income taxes and noncontrolling interest	(6,409)		(7,211)		802
Income tax provision	—		—		—
Net loss before noncontrolling interest	(6,409)		(7,211)		802
Less: net loss attributable to noncontrolling interest	(1,229)		(1,592)		363
Net loss attributable to vTv Therapeutics Inc.	$	(5,180)	$	(5,619)	$	439

Revenue

There was no revenue for the three months ended June 30, 2024 and 2023.

Research and Development Expenses

Research and development expenses were $3.4 million and $4.7 million for the three months ended June 30, 2024 and 2023, respectively. The decrease in research and development expenses during this period of $1.3 million or 26.7%, was primarily driven by i) lower spending on cadisegliatin of $2.0 million, due to decreases in toxicity study costs and drug manufacturing related costs partially offset by increases in clinical trial start-up costs, and ii) an increase in indirect costs and other projects of $0.7 million.

General and Administrative Expenses

General and administrative expenses were $3.7 million and $3.3 million for the three months ended June 30, 2024 and 2023, respectively. The increase in general and administrative expenses during this period of $0.4 million, or 12.3%, was primarily driven by i) increases of $0.3 million in share-based expense, ii) increases of $0.2 million in legal expenses, iii) increases of $0.1 million in payroll related costs, partially offset by iv) decreases of $0.2 million in other general and administrative costs.

Interest Income

Interest income for the three months ended June 30, 2024, of $0.6 million, is related to dividend income from our money market accounts. Interest income for the three months ended June 30, 2023, of $0.2 million, is related to imputed interest on the promissory notes.

Other Income, Net

Other income was $0.2 million for the three months ended June 30, 2024, and was driven by gains related to the change in the fair value of the outstanding warrants to purchase shares of our own stock. Other income was $0.6 million for the three months ended June 30, 2023, and was driven by an unrealized gain related to our investment in Reneo, as well as gains related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to related parties.

Table of Contents

Comparison of the six months ended June 30, 2024 and 2023

The following table sets forth certain information concerning our results of operations for the periods shown:


(dollars in thousands)	Six Months Ended June 30,
Statement of operations data:	2024		2023		Change
Revenue	$	1,000	$	—	$	1,000
Operating expenses:
Research and development	6,088		8,633		(2,545)
General and administrative	7,694		6,794		900
Total operating expenses	13,782		15,427		(1,645)
Operating loss	(12,782)		(15,427)		2,645
Interest income	632		253		379
Interest expense	—		(2)		2
Other (expense) income, net	(178)		2,191		(2,369)
Loss before income taxes and noncontrolling interest	(12,328)		(12,985)		657
Income tax provision	100		—		100
Net loss before noncontrolling interest	(12,428)		(12,985)		557
Less: net loss attributable to noncontrolling interest	(2,383)		(2,867)		484
Net loss attributable to vTv Therapeutics Inc.	$	(10,045)	$	(10,118)	$	73

Revenue

Revenue for the six months ended June 30, 2024 includes a $1.0 million increase to the transaction price for the license performance obligation under the Newsoara License Agreement due to the satisfaction of a development milestone. There was no revenue for the three months ended June 30, 2023.

Research and Development Expenses

Research and development expenses were $6.1 million and $8.6 million for the six months ended June 30, 2024 and 2023, respectively. The decrease in research and development expenses during the period of $2.5 million, or 29.5%, was primarily driven by i) lower spending on cadisegliatin of $3.4 million due to decreases in toxicity study costs and drug manufacturing related costs, partially offset by increases in clinical trial start-up costs, and ii) increases in indirect costs and other projects of $0.9 million.

General and Administrative Expenses

General and administrative expenses were $7.7 million and $6.8 million for the six months ended June 30, 2024 and 2023, respectively. The increase of $0.9 million or 13.2%, was primarily driven by i) increases of $0.9 million in payroll costs, ii) increases of $0.5 million in legal expense, iii) increases of $0.2 million in share-based expense, partially offset by iv) decreases of $0.7 million in other general and administrative costs.

Interest income

Interest income for the six months ended June 30, 2024, of $0.6 million, is related to dividend income from our money market accounts. Interest income for the six months ended June 30, 2023 of 0.3 million is related to imputed interest on the G42 Promissory Note and dividend income from our money market account..

Other (Expense) Income, Net

Other expense was $0.2 million for the six months ended June 30, 2024, driven by losses related to the change in the fair value of the outstanding warrants to purchase shares of our own stock. Other income was $2.2 million for the six months ended June 30, 2023, and was driven by an unrealized gain recognized related to the Company’s investment in Reneo as well as gains related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to related parties.

Table of Contents

Liquidity and Capital Resources

Liquidity

As of June 30, 2024, we had an accumulated deficit of $291.3 million. Since our inception, we have experienced a history of negative cash flows from operating activities. We anticipate that we will continue to incur losses and negative cash flow from operations for the foreseeable future as we continue our clinical trials. Further, we expect that we will need additional capital to continue to fund our operations. As of June 30, 2024, we had cash and cash equivalents of $45.5 million.

On February 27, 2024, the Company closed a private placement financing of up to $51.0 million and additionally granting investors the right to purchase up to an additional $30.0 million of common stock 18 months following the closing of the private placement financing. The financing raised will allow the Company to further advance its lead program for cadisegliatin.

In addition to available cash and cash equivalents and available funds discussed above, we are seeking possible additional partnering opportunities for our GKA, GLP-1r and other drug candidates which we believe may provide additional cash for use in our operations and the continuation of the clinical trials for our drug candidates. We are evaluating several financing strategies to fund our planned and ongoing clinical trials, including direct equity investments and future public offerings of our common stock. The timing and availability of such additional financing are not yet known.

ATM Offering

TD Cowen Sales Agreement

On February 28, 2024, we entered into a sales agreement (the "TD Cowen Sales Agreement") with Cowen and Company, LLC (“TD Cowen”) pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock having an aggregate offering price of up to $50.0 million, although we may only offer and sell under the TD Cowen ATM Offering up to one-third of the aggregate market value of our Class A common stock held by non-affiliates during any 12 calendar month period pursuant to General Instruction I.B.6 of Form S-3. We are not obligated to sell any shares under the TD Cowen Sales Agreement. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. As of June 30, 2024 we have not sold any shares pursuant to the TD Cowen Sales Agreement

Cash Flows


	Six Months Ended June 30,
	2024		2023
(dollars in thousands)
Net cash used in operating activities	$	(14,064)	$	(11,333)

Net cash provided by financing activities	50,144		11,806
Net increase in cash and cash equivalents	$	36,080	$	473

Operating Activities

For the six months ended June 30, 2024, our net cash used in operating activities increased by $2.7 million from the six months ended June 30, 2023. The significant contributor to the change in cash used during the year was working capital changes.

Investing Activities

There were no cash flows from investing activities for the six months ended June 30, 2024 and 2023.

Financing Activities

For the six months ended June 30, 2024, net cash provided by financing activities was driven by sales of our Class A common stock and proceeds from pre-funded warrants of $51.0 million from the Private Placement financing. For the six months ended June 30, 2023, net cash provided by financing activities was driven by the receipt of proceeds of $12.0 million from the G42 promissory note early redemption.

Table of Contents

Future Funding Requirements

To date, we have not generated any revenue from drug product sales. We do not know when, or if, we will generate any revenue from drug product sales. We do not expect to generate revenue from drug sales unless and until we obtain regulatory approval of and commercialize any of our drug candidates. At the same time, we expect our expenses to continue or to increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our drug candidates. In addition, subject to obtaining regulatory approval of any of our drug candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations.

Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements for at least the next twelve months. We plan to finance our operations through the use of our cash and cash equivalents, including funding activities needed to lift the clinical hold and resume the CATT1 trial. We continue to evaluate financing strategies to fund future clinical trials of cadisegliatin, including direct equity investments and the potential licensing and monetization of other Company programs. The timing of any such transactions is not certain, and we may not be able to complete such transactions on acceptable terms, or at all. Even if we are able to complete such transactions, they may contain restrictions on our operations or cause substantial dilution to our stockholders. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our drug candidates. Additionally, we may rely on our ability to sell shares of our Class A common stock pursuant to the ATM Offering. However, the ability to use this source of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company’s Class A common stock.

Our future capital requirements will depend on many factors, including:

•the costs, results and timing needed to lift the clinical hold on the cadisegliatin program;

•the progress, costs, results and timing of restarting our trials to evaluate cadisegliatin as a potential adjunctive therapy for the treatment of type 1 diabetes;

•the willingness of the FDA to lift the clinical hold and to rely upon our completed and planned clinical and preclinical studies and other work, as the basis for review and approval of our drug candidates;

•our ability to maintain control over our costs in line with our budget for our lead product candidate, cadisegliatin;

•the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;

•the number and characteristics of drug candidates that we pursue, including our drug candidates in preclinical development;

•the ability of our drug candidates to progress through clinical development successfully;

•our need to expand our research and development activities;

•the costs associated with securing, establishing and maintaining commercialization capabilities;

•the costs of acquiring, licensing or investing in businesses, products, drug candidates and technologies;

•our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;

•our need and ability to hire additional management, scientific, and medical personnel;

•the effect of competing technological and market developments;

•our need to implement additional internal systems and infrastructure, including financial and reporting systems;

•the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future; and

•the amount of any payments we are required to make to M&F TTP Holdings Two LLC in the future under the Tax Receivable Agreement.

Table of Contents

Until such time, if ever, as we can generate substantial revenue from drug sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements.

To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants that will further limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or drug candidates or grant licenses on terms that may not be favorable to us.

Off-Balance Sheet Arrangements

As of June 30, 2024, we did not have outstanding any off-balance sheet arrangements as defined under SEC rules.

Discussion of Critical Accounting Policies and Estimates

For a discussion of our critical accounting policies and estimates, please refer to Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to our critical accounting policies and estimates in 2024.

Forward-Looking Statements

This quarterly report includes certain forward-looking statements within the meaning of the federal securities laws regarding, among other things, our management’s intentions, plans, beliefs, expectations, or predictions of future events, which are considered forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Forward-looking statements include information concerning our possible or assumed future results of operations, including descriptions of our business strategy. These statements often include words such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. These statements are based upon assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances. As you read this quarterly report, you should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties, and assumptions, including those described under the heading “Risk Factors” under Item 1A of Part I in our Annual Report on Form 10-K and under Item 1A of Part II of this Quarterly Report on Form 10-Q. Although we believe that these forward-looking statements are based upon reasonable assumptions, you should be aware that many factors, including those described under the heading “Risk Factors” under Item 1A of Part I in our Annual Report on Form 10-K and under Item 1A of Part II of this Quarterly Report on Form 10-Q, could affect our actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements.

Our forward-looking statements made herein are made only as of the date of this quarterly report. We expressly disclaim any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this quarterly report.

Effect of Recent Accounting Pronouncements

See discussion of recent accounting pronouncements in Note 2, “Summary of Significant Accounting Policies”, to the Condensed Consolidated Financial Statements in this Form 10-Q.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk

We do not currently have any material interest rate exposure.

Table of Contents

Market Risk

Our exposure to market risk is limited to our cash and cash equivalents, all of which have maturities of one year or less. The goals of our investment strategy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain cash and cash equivalents with multiple financial institutions that management believes to be of high credit quality.

Foreign Currency Risk

We do not have any material foreign currency exposure.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our Chief Executive Officer (our Principal Executive Officer) and Chief Financial Officer (our Principal Financial Officer), management has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934) as of June 30, 2024. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2024, our disclosure controls and procedures were effective in causing material information relating to us (including our consolidated subsidiaries) to be recorded, processed, summarized, and reported by management on a timely basis and to ensure the quality and timeliness of our public disclosures pursuant to SEC disclosure obligations.

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error and mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls.

The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or because the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.

Changes to Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Website Availability of Reports and other Corporate Governance Information

The Company maintains a comprehensive corporate governance program, including Corporate Governance Guidelines for its Board of Directors, Board Guidelines for Assessing Director Independence, and charters for its Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee. The Company maintains a corporate investor relations website, www.vtvtherapeutics.com, where stockholders and other interested persons may review, without charge, among other things, corporate governance materials and certain SEC filings, which are generally available on the same business day as the filing date with the SEC on the SEC’s website http://www.sec.gov. The contents of our website are not made a part of this Quarterly Report on Form 10-Q.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are not currently a party to any material legal proceedings.

Table of Contents

ITEM 1A. RISK FACTORS

Our risk factors are set forth under the heading “Risk Factors” under Item 1A of Part I in our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to our risk factors from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Plans

During the second fiscal quarter ended June 30, 2024, none of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”

ITEM 6. EXHIBITS


Exhibit Number						Description

31.1*						Certification of President and Chief Executive Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*						Certification of Chief Financial Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*						Certification of President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*						Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS						Inline XBRL Instance Document

101.SCH						Inline XBRL Taxonomy Extension Schema

101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase

101.DEF						Inline XBRL Taxonomy Extension Definition Document

101.LAB						Inline XBRL Taxonomy Extension Label Linkbase

101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase

104						Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

___________________________

* Filed herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 8, 2024


						VTV THERAPEUTICS INC.
						(Registrant)

			By:			/s/ Paul J. Sekhri
						Paul J. Sekhri
						President, Chief Executive Officer and Executive Chairperson

			By:			/s/ Steven Tuch
						Steven Tuch
						Executive Vice President and Chief Financial Officer

EX-31.1 2 vtvt-20240630xexx311.htm EX-31.1 Document

Exhibit 31.1

SECTION 302 CERTIFICATION

I, Paul J. Sekhri, certify that:

1.I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the “registrant”);

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2024


			By:			/s/ Paul J. Sekhri
						Paul J. Sekhri
						President, Chief Executive Officer and Executive Chairperson

EX-31.2 3 vtvt-20240630xexx312.htm EX-31.2 Document

Exhibit 31.2

SECTION 302 CERTIFICATION

I, Steven Tuch, certify that:

1.I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the “registrant”);

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2024


			By:			/s/ Steven Tuch
						Steven Tuch
						Executive Vice President and Chief Financial Officer

EX-32.1 4 vtvt-20240630xexx321.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of vTv Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul J. Sekhri, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 8, 2024


			By:			/s/ Paul J. Sekhri
						Paul J. Sekhri
						President, Chief Executive Officer and Executive Chairperson

EX-32.2 5 vtvt-20240630xexx322.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of vTv Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Tuch, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 8, 2024


			By:			/s/ Steven Tuch
						Steven Tuch
						Executive Vice President and Chief Financial Officer

EX-101.SCH 6 vtvt-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Operations - Unaudited link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - Description of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Noncontrolling Interest link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Noncontrolling Interest (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Description of Business and Basis of Presentation (Detail) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Collaboration Agreements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Noncontrolling Interest - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Related-Party Transactions - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vtvt-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vtvt-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vtvt-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Reclassification of redeemable noncontrolling interest to permanent equity Reclassification of redeemable noncontrolling interest to permanent equity Reclassifications of Temporary to Permanent Equity Stock conversion ratio Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio Redeemable non controlling interest exchange agreement stock conversion ratio. vTv Therapeutics LLC V Tv L L C [Member] vTv LLC. Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement Statistical Measurement [Domain] Related-Party Transactions Related Party Transactions Disclosure [Text Block] Cover [Abstract] Cover [Abstract] Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Current portion of notes payable Notes Payable, Current Schedule of Maturities of Lease Liabilities for Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Proceeds from collection of notes receivable Proceeds from Collection of Notes Receivable Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Non-qualified stock option awards vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Collaborative arrangement, contingent consideration Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent. Class A Common Stock Common Class A [Member] Pay vs Performance Disclosure [Line Items] Discount rate Notes Receivable, Discount Rate Notes Receivable, Discount Rate Redeemable noncontrolling interest Beginning balance Ending balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounts receivable Increase (Decrease) in Accounts Receivable Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Receivables, fair value disclosure Receivables, Fair Value Disclosure Fair Value of Financial Instruments Fair Value Disclosures [Text Block] MacAndrews & Forbes Incorporated Mac Andrews And Forbes Incorporated [Member] MacAndrews and Forbes Incorporated. Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Type 2 Diabetes Type Two Diabetes [Member] Type 2 diabetes. Leases Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Beginning balance, shares (in shares) Ending balance, shares (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Lessee, operating lease, termination period Lessee, Operating Lease, Termination Period Lessee, Operating Lease, Termination Period Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization consolidation and presentation of financial statements. Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Warrants, term Expected life of options in years Warrants and Rights Outstanding, Term Current portion of contract liabilities Contract with Customer, Liability, Current Sale of stock, price per share (in usd per share) Sale of Stock, Price Per Share Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Redeemable noncontrolling interest, equity, fair value Redeemable Noncontrolling Interest, Equity, Fair Value Equity Components Equity Components [Axis] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Research and Development Research and Development Expense, Policy [Policy Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Options vested and expected to vest (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Measurement Frequency Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Proceeds from promissory note early redemption related to sale of Class A common stock to collaboration partner Proceeds From Sale Of Common Stock Proceeds From Sale Of Common Stock Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Reclassification of noncontrolling interest to additional paid-in capital Noncontrolling Interest, Reclassification to Additional Paid-in-Capital Noncontrolling Interest, Reclassification to Additional Paid-in-Capital Compensation Amount Outstanding Recovery Compensation Amount Non-cash activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Novo License Agreement Novo License Agreement [Member] Novo license agreement. Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Weighted Average Weighted Average [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Number of securities called by warrants or rights (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Redeemable Noncontrolling Interest Redeemable Noncontrolling Interests [Member] Redeemable noncontrolling interests. Expected dividend yield Measurement Input, Expected Dividend Rate [Member] Summary of Net Income Attributable to Vtv Therapeutics Inc Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block] Total cash and cash equivalents, beginning of period Total cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Current assets: Assets, Current [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service Product and Service [Domain] Stock Option Common stock options granted under the Plan Share-Based Payment Arrangement, Option [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Depreciation expense Depreciation 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Common stock warrants Warrant liability, related party Warrant [Member] Security Exchange Name Security Exchange Name Award Type Award Type [Axis] Revenue recognized from change in estimated transaction prices Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Related Party Transaction [Domain] Related Party Transaction [Domain] Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Noncontrolling interest Equity, Attributable to Noncontrolling Interest Options exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Sale of stock, consideration received on transaction, gross Sale of Stock, Consideration Received on Transaction, Gross Sale of Stock, Consideration Received on Transaction, Gross Common stock par value (in usd per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Share held by related party (in shares) Investment Owned, Balance, Shares Current portion of operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Entity Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration risk percentage Concentration Risk, Percentage Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and Contingencies. CinRx Warrants CinRx Warrants [Member] CinRx Warrants MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Percent of public float Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float Aggregate offering price Sale Of Stock, Aggregate Offering Price Aggregate offering price. Total stockholders’ equity (deficit) attributable to vTv Therapeutics Inc. Equity, Attributable to Parent Net loss attributable to redeemable noncontrolling interest Temporary Equity, Net Income Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Related Party Related Party [Member] Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Amount of cash savings percentage Percentage Of Amount Of Cash Savings Percentage of amount of cash savings. Collaborate arrangement, contingent consideration transferred, cash Collaborate Arrangement, Contingent Consideration Transferred, Cash Collaborate Arrangement, Contingent Consideration Transferred, Cash Type 1 Diabetes Type One Diabetes [Member] Type 1 diabetes. Concentration Risk Type Concentration Risk Type [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Stock Conversion Description Stock Conversion Description [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] G42 Investments G42 Investments [Member] G42 Investments Sale of Stock [Domain] Sale of Stock [Domain] Other liabilities Increase (Decrease) in Other Operating Liabilities Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Income Taxes [Table] Income Taxes [Table] Income taxes. All Executive Categories All Executive Categories [Member] Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Nonrelated Party Nonrelated Party [Member] Options exercisable, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Total vTv Therapeutics Inc Stockholders’ Equity (Deficit) Parent [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Maximum Maximum [Member] Parent Company Parent Company [Member] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Antidilutive Securities Antidilutive Securities [Axis] Accounting Policies [Abstract] Accounting Policies [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Statistical Measurement Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income taxes and noncontrolling interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Expense reduction Share-Based Payment Arrangement, Expense Reduction, Amount Share-Based Payment Arrangement, Expense Reduction, Amount Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type Award Type [Domain] Name Outstanding Recovery, Individual Name Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Collaborative Arrangements Collaborative Arrangement [Member] Class Of Stock [Line Items] Class of Stock [Line Items] Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants Recently Issued Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share) Earnings Per Share, Diluted Class of Stock Class of Stock [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Number of days used to determine exchange value based on weighted average price of Class A common stock Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock Period used to determine exchange value based on weighted average price of Class A common stock. Newsoara Biopharma Co Ltd Newsoara Biopharma Co Ltd [Member] Newsoara Biopharma Co Ltd. Options vested and expected to vest, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term EX-101.PRE 10 vtvt-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 vtvt-20240630_g1.jpg GRAHPIC begin 644 vtvt-20240630_g1.jpg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�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�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
9&;FW.YY(P'4Q2EF5PDL\13CI\3*R[5VN ' &-^/7'7TQTQ0!\LO^QAXJ_X M26V'[N[K^/ MO[$7_!H_^TA^S;^VC$?B)KGC3X*76B^ ?&NC>(]0AL=6U5[J:WL[Z&XE6)7 MTY$,A2-@H9U4DC+ 1MK-M4 MG"C+'Z#UK\(/^"QG_!L?\?/^"BO_ 4C^)7QB\%^+?@]I7AKQ8^FK:6VM:OJ M,5]$+73+2S"*_>%E#J58!E88(/>HFL]ZJⅅ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ⅅ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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Cover - shares
6 Months Ended

Jun. 30, 2024

Aug. 08, 2024

Document Information [Line Items]

Document Type 10-Q

Document Quarterly Report true

Document Period End Date Jun. 30, 2024

Document Transition Report false

Entity File Number 001-37524

Entity Registrant Name vTv Therapeutics Inc.

Entity Incorporation, State or Country Code DE

Entity Tax Identification Number 47-3916571

Entity Address, Address Line One 3980 Premier Dr

Entity Address, Address Line Two Suite 310

Entity Address, City or Town High Point

Entity Address, State or Province NC

Entity Address, Postal Zip Code 27265

City Area Code 336

Local Phone Number 841-0300

Title of 12(b) Security Class A common stock, par value $0.01 per share

Trading Symbol VTVT

Security Exchange Name NASDAQ

Entity Current Reporting Status Yes

Entity Interactive Data Current Yes

Entity Filer Category Non-accelerated Filer

Entity Small Business true

Entity Emerging Growth Company false

Entity Shell Company false

Entity Central Index Key 0001641489

Current Fiscal Year End Date --12-31

Document Fiscal Year Focus 2024

Document Fiscal Period Focus Q2

Amendment Flag false

Class A Common Stock

Document Information [Line Items]

Entity Common Stock, Shares Outstanding (in shares) 2,432,857

Class B Common Stock

Document Information [Line Items]

Entity Common Stock, Shares Outstanding (in shares) 577,349

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an quarterly report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-Q
-Number 240
-Section 308
-Subsection a
+ Details

Name: dei_DocumentQuarterlyReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine2

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Jun. 30, 2024

Dec. 31, 2023

Current assets:

Cash and cash equivalents $ 45,526 $ 9,446

Accounts receivable 306 102

Prepaid expenses and other current assets 303 1,044

Current deposits 65 65

Total current assets 46,200 10,657

Property and equipment, net 72 117

Operating lease right-of-use assets 186 244

Total assets 46,458 11,018

Current liabilities:

Accounts payable and accrued expenses 6,791 10,242

Current portion of operating lease liabilities 177 169

Current portion of contract liabilities 17 17

Current portion of notes payable 0 191

Total current liabilities 6,985 10,619

Contract liabilities, net of current portion 18,669 18,669

Operating lease liabilities, net of current portion 79 169

Total liabilities 26,021 29,567

Commitments and contingencies

Redeemable noncontrolling interest 0 6,131

Stockholders’ equity (deficit):

Additional paid-in capital 307,746 256,335

Accumulated deficit (291,301) (281,042)

Total stockholders’ equity (deficit) attributable to vTv Therapeutics Inc. 16,475 (24,680)

Noncontrolling interest 3,962 0

Total stockholders’ equity (deficit) 20,437 (24,680)

Total liabilities, redeemable noncontrolling interest and stockholders’ equity (deficit) 46,458 11,018

Related Party

Current liabilities:

Warrant liability, related party 158 110

Nonrelated Party

Current liabilities:

Warrant liability, related party 130 0

Class A Common Stock

Stockholders’ equity (deficit):

Common stock value 24 21

Class B Common Stock

Stockholders’ equity (deficit):

Common stock value $ 6 $ 6

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-2
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset recognized for present right to economic benefit.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset recognized for present right to economic benefit, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_DepositsAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(21))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(14))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 29: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(21))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 360
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478451/942-360-50-1
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Subparagraph (12)(c)
-Section S99
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Subparagraph (16)(c)
-Paragraph 3A
-Section S99
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (15)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (14)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A
+ Details

Name: us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of accumulated undistributed earnings (deficit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-24

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 23
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-23

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-5

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 34: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-3

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-15

Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-16

Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476166/350-60-65-1
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Warranty Liability
+ References
No definition available.
+ Details

Name: vtvt_WarrantyLiability

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares

Jun. 30, 2024

Dec. 31, 2023

Nov. 20, 2023

May 04, 2021

Common stock par value (in usd per share) $ 0.01

Class A Common Stock

Common stock par value (in usd per share) $ 0.01 $ 0.01

Common stock, shares authorized (in shares) 200,000,000 200,000,000 200,000,000 200,000,000

Common stock, shares outstanding (in shares) 2,432,857 2,084,973

Class B Common Stock

Common stock par value (in usd per share) $ 0.01 $ 0.01

Common stock, shares authorized (in shares) 100,000,000 100,000,000 100,000,000

Common stock, shares outstanding (in shares) 577,349 577,349

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Condensed Consolidated Statements of Operations - Unaudited - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Revenue $ 0 $ 0 $ 1,000,000 $ 0

Operating expenses:

Research and development 3,439,000 4,691,000 6,088,000 8,633,000

General and administrative 3,716,000 3,309,000 7,694,000 6,794,000

Total operating expenses 7,155,000 8,000,000 13,782,000 15,427,000

Operating loss (7,155,000) (8,000,000) (12,782,000) (15,427,000)

Interest income 553,000 153,000 632,000 253,000

Interest expense 0 (2,000) 0 (2,000)

Loss before income taxes and noncontrolling interest (6,409,000) (7,211,000) (12,328,000) (12,985,000)

Income tax provision 0 0 100,000 0

Net loss before noncontrolling interest (6,409,000) (7,211,000) (12,428,000) (12,985,000)

Less: net loss attributable to noncontrolling interest (1,229,000) (1,592,000) (2,383,000) (2,867,000)

Net loss attributable to vTv Therapeutics Inc. (5,180,000) (5,619,000) (10,045,000) (10,118,000)

Net loss attributable to vTv Therapeutics Inc. common shareholders (5,180,000) (5,619,000) (10,045,000) (10,118,000)

Nonrelated Party

Operating expenses:

Other income, net 72,000 335,000 72,000 2,126,000

Related Party

Operating expenses:

Other income, net $ 121,000 $ 303,000 $ (250,000) $ 65,000

Class A Common Stock

Operating expenses:

Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share) ^[1] $ (0.81) $ (2.69) $ (1.97) $ (4.85)

Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share) ^[1] $ (0.81) $ (2.69) $ (1.97) $ (4.85)

Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) ^[1] 6,403,444 2,084,973 5,098,877 2,084,973

Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) ^[1] 6,403,444 2,084,973 5,098,877 2,084,973

[1]
(*) Adjusted retroactively for reverse stock split

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest expense classified as operating.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details

Name: us-gaap_InterestExpenseOperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(7)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 6.B)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4K
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-2

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-16
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited - USD ($)
$ in Thousands

Total

Redeemable Noncontrolling Interest

Class A Common Stock

Class B Common Stock

Common Stock

Class A Common Stock

Common Stock

Class B Common Stock

Additional Paid-in Capital

Additional Paid-in Capital

Class A Common Stock

Accumulated Deficit

Total vTv Therapeutics Inc Stockholders’ Equity (Deficit)

Noncontrolling Interest

Beginning balance at Dec. 31, 2022 $ 16,579

Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]

Change in redemption value of noncontrolling interest $ 5,167 5,167

Net loss attributable to vTv Therapeutics Inc. (2,867)

Ending balance at Jun. 30, 2023 18,879

Beginning balance, shares (in shares) at Dec. 31, 2022 2,084,973 577,349

Beginning balance at Dec. 31, 2022 (10,740) $ 21 $ 6 $ 254,757 $ (265,524)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss attributable to vTv Therapeutics Inc. (10,118) (10,118)

Change in redemption value of noncontrolling interest (5,167) (5,167)

Share-based compensation 742 742

Ending balance, shares (in shares) at Jun. 30, 2023 ^[1] 2,084,973 577,349

Ending balance at Jun. 30, 2023 (25,283) $ 21 ^[1] $ 6 ^[1] 255,499 ^[1] (280,809)

Beginning balance at Mar. 31, 2023 19,600

Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]

Change in redemption value of noncontrolling interest 871

Net loss attributable to vTv Therapeutics Inc. (1,592)

Ending balance at Jun. 30, 2023 18,879

Beginning balance, shares (in shares) at Mar. 31, 2023 ^[1] 2,084,973 577,349

Beginning balance at Mar. 31, 2023 (19,192) $ 21 ^[1] $ 6 ^[1] 255,100 ^[1] (274,319)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss attributable to vTv Therapeutics Inc. (5,619) (5,619)

Change in redemption value of noncontrolling interest (871) (871)

Share-based compensation 399 399 ^[1]

Ending balance, shares (in shares) at Jun. 30, 2023 ^[1] 2,084,973 577,349

Ending balance at Jun. 30, 2023 (25,283) $ 21 ^[1] $ 6 ^[1] 255,499 ^[1] (280,809)

Beginning balance at Dec. 31, 2023 6,131 6,131

Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]

Net loss attributable to redeemable noncontrolling interest ^[2] (1,085)

Change in redemption value of noncontrolling interest (214) 214

Reclassification of redeemable noncontrolling interest to permanent equity 5,260 (5,260) $ 5,260

Ending balance at Jun. 30, 2024 0 0

Beginning balance, shares (in shares) at Dec. 31, 2023 2,084,973 577,349 2,084,973 577,349

Beginning balance at Dec. 31, 2023 (24,680) $ 21 $ 6 256,335 (281,042) $ (24,680) 0

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss attributable to vTv Therapeutics Inc. (10,045) (10,045) (10,045)

Change in redemption value of noncontrolling interest (214) (214) (214)

Reclassification of redeemable noncontrolling interest to permanent equity 5,260 (5,260) 5,260

Share-based compensation 1,079 1,079 1,079

Issuance of Class A common stock and prefunded warrants, net offering costs (in shares) 347,884

Issuance of Class A common stock and pre-funded warrants, net offering costs 50,335 $ 3 $ 50,332 50,335

Net loss attributable to noncontrolling interest (1,298) (1,298)

Ending balance, shares (in shares) at Jun. 30, 2024 2,432,857 577,349 2,432,857 577,349

Ending balance at Jun. 30, 2024 20,437 $ 24 $ 6 307,746 (291,301) 16,475 3,962

Ending balance at Jun. 30, 2024 0 $ 0

Beginning balance, shares (in shares) at Mar. 31, 2024 2,432,857 577,349

Beginning balance at Mar. 31, 2024 25,987 $ 24 $ 6 306,887 (286,121) 20,796 5,191

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss attributable to vTv Therapeutics Inc. (5,180) (5,180) (5,180)

Share-based compensation 859 859 859

Net loss attributable to noncontrolling interest (1,229) (1,229)

Ending balance, shares (in shares) at Jun. 30, 2024 2,432,857 577,349 2,432,857 577,349

Ending balance at Jun. 30, 2024 $ 20,437 $ 24 $ 6 $ 307,746 $ (291,301) $ 16,475 $ 3,962

[1]
(*) Adjusted retroactively for reverse stock split

[2]
(*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 7)

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481089/718-20-55-13

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481089/718-20-55-12
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInTemporaryEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Subparagraph (16)(c)
-Paragraph 3A
-Section S99
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (15)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (14)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details

Name: us-gaap_MinorityInterestChangeInRedemptionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Portion of net income (loss) attributable to nonredeemable noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (3)
-SubTopic 10
-Topic 480
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A
+ Details

Name: us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-3
+ Details

Name: us-gaap_ReclassificationsOfTemporaryToPermanentEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Subparagraph (12)(c)
-Section S99
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Subparagraph (16)(c)
-Paragraph 3A
-Section S99
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (15)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (14)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A
+ Details

Name: us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-24

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 23
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-23

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-5

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 34: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-3

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-15

Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-16

Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476166/350-60-65-1
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The portion of net income or loss attributable to temporary equity interest.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityNetIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Change In Redemption Value Of Noncontrolling Interest
+ References
No definition available.
+ Details

Name: vtvt_ChangeInRedemptionValueOfNoncontrollingInterest

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Cash flows from operating activities:

Net loss before noncontrolling interest $ (12,428) $ (12,985)

Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:

Depreciation expense 45 45

Loss from promissory note early redemption 0 313

Non-cash interest income 0 (100)

Share-based compensation expense 1,079 742

Change in fair value of investments 0 (2,439)

Changes in assets and liabilities:

Accounts receivable (204) 173

Prepaid expenses and other current assets 741 1,213

Other assets 58 0

Accounts payable and accrued expenses (3,451) 1,770

Other liabilities (82) 0

Net cash used in operating activities (14,064) (11,333)

Cash flows from financing activities:

Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs 50,335 0

Proceeds from promissory note early redemption related to sale of Class A common stock to collaboration partner 0 12,030

Repayment of notes payable (191) (224)

Net cash provided by financing activities 50,144 11,806

Net increase in cash and cash equivalents 36,080 473

Total cash and cash equivalents, beginning of period 9,446 12,126

Total cash and cash equivalents, end of period 45,526 12,599

Non-cash activities:

Change in redemption value of noncontrolling interest (214) 5,167

Reclassification of noncontrolling interest to additional paid-in capital 5,260 0

Related Party

Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:

Change in fair value of warrants 250 (65)

Nonrelated Party

Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:

Change in fair value of warrants $ (72) $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-SubTopic 230
-Topic 830
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477401/830-230-45-1
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 25
-Paragraph 13
-SubTopic 10
-Topic 480
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481766/480-10-25-13
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481303/470-50-40-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481303/470-50-40-4
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating liabilities classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column E)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 45
-Paragraph 39
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477346/946-830-45-39

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(1)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6
+ Details

Name: us-gaap_InterestIncomeOperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Subparagraph (16)(c)
-Paragraph 3A
-Section S99
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (15)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (14)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details

Name: us-gaap_MinorityInterestChangeInRedemptionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4K
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-2

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 15
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-15
+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of unrealized gain (loss) on investment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_UnrealizedGainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Noncontrolling Interest, Reclassification to Additional Paid-in-Capital
+ References
No definition available.
+ Details

Name: vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Proceeds From Sale Of Common Stock
+ References
No definition available.
+ Details

Name: vtvt_ProceedsFromSaleOfCommonStock

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Description of Business and Basis of Presentation
6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Description of Business and Basis of Presentation Description of Business and Basis of Presentation
Description of Business
vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection.
Principles of Consolidation
vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.
The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Condensed Consolidated Financial Statements. The assets and liabilities of vTv LLC represent substantially all of the Company's consolidated assets and liabilities with the exception of the Warrants and $26.1 million of cash and cash equivalents.
Various holders own non-voting interests in vTv LLC, representing a 19.2% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 80.8% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company’s Class B common stock, par value $0.01 (“Class B common stock”)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 8). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (“M&F Group”), a related party and an affiliate of MacAndrews & Forbes Incorporated (together with its affiliates “MacAndrews”) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a “Letter Agreement” and collectively, the “Letter Agreements”). vTv Therapeutics Inc. entered into a common stock purchase agreement with G42 Investments AI Holding RSC Ltd (“G42 Investments”) (the “G42 Purchase Agreement”), the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the “CinRx Purchase Agreement”). In addition vTv Therapeutics Inc. also entered into a Securities Purchase Agreement with Private Placement Investors and the sales agreement with Cowen and Company, LLC (“TD Cowen”) (“TD Cowen Sales Agreement”). vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.
Liquidity
To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through June 30, 2024, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of June 30, 2024, the Company had an accumulated deficit of $291.3 million and has generated net losses in each year of its existence. As of June 30, 2024, the Company’s liquidity sources included cash and cash equivalents of $45.5 million.
Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements for at least the next twelve months.
On February 27, 2024, we entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Private Placement Investors”), pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (the “Private Placement”) (i) an aggregate of 464,377 shares (the “Private Placement Shares”) of our Class A common stock, at a purchase price of $11.81 per share, and (ii) pre-funded warrants (the “Private Placement Pre-Funded Warrants”) to purchase up to an aggregate of 3,853,997 shares of our Class A common stock (the “Private Placement Warrant Shares”) at a purchase price of $11.80 per Private Placement Pre-Funded Warrant (representing the $11.81 per Private Placement Share purchase price less the exercise price of $0.01 per Private Placement Warrant Share). We received aggregate gross proceeds from the Private Placement of approximately $51.0 million, before deducting offering expenses payable by us. The Private Placement Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire.
On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants.
On February 28, 2024, we entered into the TD Cowen Sales Agreement, pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the “TD Cowen ATM Offering”). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 235
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/235/tableOfContent

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 275
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/275/tableOfContent

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/205/tableOfContent
+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Summary of Significant Accounting Policies
6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Unaudited Interim Financial Information
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of June 30, 2024, Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit) for the three and six months ended June 30, 2024 and 2023 and Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of June 30, 2024, the results of operations for the three and six months ended June 30, 2024 and 2023 and cash flows for the six months ended June 30, 2024 and 2023. The December 31, 2023 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.
The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year.
The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
Concentration of Credit Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.
One customer represented 100% of the revenue earned during the six months ended June 30, 2024. The Company did not have any revenue during the six months ended June 30, 2023 or during the three months ended June 30, 2024 and 2023.
Cash and Cash Equivalents
The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.
Investments
Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.
Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.
Revenue Recognition
The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.
The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied.
The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.
Research and Development
Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.
The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.
The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.
Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.
Recently Issued Accounting Pronouncements Not Yet Adopted
Segment Reporting: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): “Improvements to Reportable Segment Disclosures” (ASU 2023-07). The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. For public entities, the provisions within ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and for interim periods of fiscal years beginning after December 15, 2024. The Company is currently assessing the impact the adoption of ASU 2023-07 will have on its Consolidated Financial Statement and disclosures.
Income Taxes: In December 2023, the FASB issued ASU 2023-09: “Improvements to Income Tax Disclosures” (“ASU 2023-09”). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, and we expect considerable changes to our income tax disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483426/235-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 235
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/235/tableOfContent
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Collaboration Agreements
6 Months Ended

Jun. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaboration Agreements Collaboration Agreements
G42 Purchase Agreement and Cogna Collaborative and License Agreement
The Company and G42 Investments AI Holding RSC Ltd, a private limited company (“G42 Investments”), entered into a Common Stock Purchase Agreement (the “G42 Purchase Agreement”), pursuant to which the Company sold to G42 Investments 259,657 shares of the Company’s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the “G42 Promissory Note”). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company’s Condensed Consolidated Statements of Operations.
G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and
Drug Administration (“FDA”) approval in the U.S. for cadisegliatin, the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.
Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the “Cogna Agreement”) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (“Cogna”), which requires Cogna to work with the Company in performing clinical trials for cadisegliatin as well as jointly creating a global development plan to develop, market, and commercialize cadisegliatin in certain countries in the Middle East, Africa, and Central Asia (the “Partner Territory”). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercialize cadisegliatin in the Partner Territory, but will not have access to the various intellectual property (“IP”) related to the license and cadisegliatin. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of cadisegliatin needed to conduct the trials.
Under the Cogna Agreement, Cogna has the right to develop and commercialize the cadisegliatin in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, cadisegliatin for commercial sale under terms to be agreed upon by the parties at a later date.
Separately, the Company will conduct its clinical trials for cadisegliatin outside of the Partner Territory at its own cost. The Company may combine the results of each party’s clinical trials to seek FDA approval in the United States for cadisegliatin. On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (“G42 Healthcare”), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.
The G42 Purchase Agreement also provides for, following the receipt of the cadisegliatin FDA Approval, at the option of G42 Investments, either (a) the issuance of the Company’s Class A common stock (the “Milestone Shares”) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the “Milestone Cash Payment”). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the cadisegliatin FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the cadisegliatin FDA Approval will be granted or as to the timing thereof.
Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of cadisegliatin for a period of at least ten years after the first commercial sale of cadisegliatin in the Partner Territory.
A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.
The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of cadisegliatin, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company’s behalf to complete research and development activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (“JDC”) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.
By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall
within the 808 unit of account are concentrated in the clinical trials. As of June 30, 2024, the clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and six months ended June 30, 2024.
The Company identified certain commitments that are in the scope of ASC 606 as Cogna’s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after cadisegliatin is approved by the FDA. The Company will recognize revenue from the material right related to Cogna’s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and six months ended June 30, 2024.
On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company’s Condensed Consolidated Statements of Operations. The G42 Promissory Note receivable was classified and accounted for under ASC 310 “Receivables“ (“ASC 310”) and was initially measured at its fair value of $11.9 million. The Company also recorded the $18.7 million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and six months ended June 30, 2024.
Newsoara License Agreement
The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (“Newsoara”) (the “Newsoara License Agreement”) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company’s phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound HPP737, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the “Newsoara License Territory”). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company’s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.
The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the “First Newsoara Amendment”). On June 26, 2024, the Company entered into the second amendment to the Newsoara License Agreement (the “Second Newsoara Amendment”) which expanded the global license contingent upon Newsoara paying an upfront global rights fee (the “Upfront Fees”) of $20.0 million. Newsoara has up to one year from the date of the Second Newsoara Amendment to pay the Upfront Fees; if it fails to do so, then the Second Newsoara Amendment will be null and void. As amended, the Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to $76.5 million. In addition, Newsoara is obligated to pay the Company royalty payments at mid to upper single digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. There are no new performance obligations to be considered within the Second Newsoara Amendment. The Second Amendment has a potential impact to increase the transaction price by $20.0 million. If the Company receives the Upfront Fees, $20.0 million of revenue will be recognized at a point in time.
The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The revenue for this performance obligation has been fully recognized as of June 30, 2024. In the first quarter of 2024, the transaction price for this performance obligation was increased by $1.0 million due to the satisfaction of a development milestone under the Newsoara License Agreement. This amount was fully recognized as revenue during the six months ended June 30, 2024, as the related performance obligation was fully satisfied. No revenue related to this performance obligation was recognized and there were no changes to the transaction price during the three and six months ended June 30, 2023.

X

- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org/808/tableOfContent
+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Share-Based Compensation
6 Months Ended

Jun. 30, 2024

Share-Based Payment Arrangement [Abstract]

Share-Based Compensation Share-Based Compensation
The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of June 30, 2024, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $4.7 million, which is expected to be recognized over a weighted average period of 2.5 years. The weighted average grant date fair value of options granted during the six months ended June 30, 2024 and 2023 was $14.88 and $30.59 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at June 30, 2024 was de minimis.
On February 23, 2024, in connection with the Private Placement, several directors resigned as members of the Company’s Board of Directors, effective on the closing of the Private Placement. As a result of their resignations, 14,340 stock options to purchase shares of common stock were modified to increase the time period to exercise the options and 7,590 stock options to purchase shares of common stock were modified to accelerate vesting at the termination date. All the unvested options were modified to be fully vested as of the posting of the Private Placement which resulted in a reduction in their fair value. The Company incurred $0.1 million reduction in stock compensation expense for the modifications for the six months ended June 30, 2024.
The following table summarizes the activity related to the stock option awards for the six months ended June 30, 2024:
Number of Shares Weighted
Average Exercise Price
Awards outstanding at December 31, 2023 249,247 $ 77.53
Granted 406,799 12.68
Forfeited (1,875) 30.87
Awards outstanding at June 30, 2024 654,171 $ 37.34
Options exercisable at June 30, 2024 199,812 $ 86.34
Weighted average remaining contractual term 6.8 Years
Options vested and expected to vest at June 30, 2024 499,109 $ 44.32
Weighted average remaining contractual term 8.4 Years
Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):
Three Months Ended June 30, Six Months Ended June 30,
2024 2023 2024 2023
Research and development $ 217 $ 105 $ 283 $ 203
General and administrative 642 294 796 539
Total share-based compensation expense $ 859 $ 399 $ 1,079 $ 742

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/718/tableOfContent

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Commitments and Contingencies
6 Months Ended

Jun. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Commitments and Contingencies
Legal Matters
From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.
Novo Nordisk
In February 2007, the Company entered into an Agreement (the “Novo License Agreement”) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo Nordisk”) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as cadisegliatin. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use.
Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 405
-SubTopic 30
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/405-30/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 440
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/450/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 954
-SubTopic 440
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478522/954-440-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 440
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 440
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/440/tableOfContent
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Leases
6 Months Ended

Jun. 30, 2024

Leases [Abstract]

Leases Leases
In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election is not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. As a result of the remeasurement of the associated lease liabilities, the Company recognized additional right of use assets and corresponding lease liabilities of $0.1 million. Further, the second amendment to the lease does not include any material residual value guarantee or restrictive covenants.
At each of June 30, 2024 and December 31, 2023, the weighted average incremental borrowing rate for the operating leases held by the Company was 9.5%. At June 30, 2024 and December 31, 2023, the weighted average remaining lease terms for the operating leases held by the Company were 1.4 years and 1.9 years, respectively.
Maturities of lease liabilities for the Company’s operating leases as of June 30, 2024 were as follows (in thousands):
2024 (remaining six months) $ 97
2025 177
2026 —
2027 —
2028 —
Thereafter —
Total lease payments 274
Less: imputed interest (18)
Present value of lease liabilities $ 256
Operating lease cost and the related operating cash flows for the six months ended June 30, 2024 was $0.1 million and was immaterial for the six months ended June 30, 2023.

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/842-20/tableOfContent
+ Details

Name: us-gaap_LesseeOperatingLeasesTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Noncontrolling Interest
6 Months Ended

Jun. 30, 2024

Noncontrolling Interest [Abstract]

Noncontrolling Interest Noncontrolling Interest
The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 19.2% noncontrolling interest in vTv LLC outstanding as of June 30, 2024 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.
On February 27, 2024, in connection with the Private Placement financing, the Investor Rights Agreement altered M&F TTP Holdings Two LLC (“M&F”) governance rights such that directors designated by M&F no longer comprised a majority of the Company’s Board of Directors (see Note 9). The redeemable noncontrolling interest redemption feature to exchange vTv Units for cash rather than shares of Class A common stock is a contingent event that is now within control of the Company through the Company’s independent Board of Directors. As a result, $5.3 million representing the fair value of redeemable noncontrolling interest on February 27, 2024, was reclassified from temporary equity in the mezzanine section of the Condensed Consolidated Balance Sheets to noncontrolling interest as a component of permanent equity.
Prior to February 27, 2024, the Company recorded redeemable noncontrolling interest at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the
balance sheet date. At December 31, 2023, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $6.1 million.
Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:
For the Three Months Ended June 30, For the Six Months Ended June 30,
2024 2023 2024 2023
Net loss attributable to vTv Therapeutics Inc. common shareholders $ (5,180) $ (5,619) $ (10,045) $ (10,118)
Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances — 1,275 9,564 2,620
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest $ (5,180) $ (4,344) $ (481) $ (7,498)

X

- Definition
The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 810
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/810/tableOfContent
+ Details

Name: us-gaap_MinorityInterestDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Stockholders' Equity (Deficit)
6 Months Ended

Jun. 30, 2024

Equity [Abstract]

Stockholders' Equity (Deficit) Stockholders’ Equity (Deficit)
Amendment to Certificate of Incorporation
On May 4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.
On November 20, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation as amended, to effect a reverse stock split at a ratio of 1-for-40 (the "Reverse Stock Split"). Pursuant to the Reverse Stock Split, every 40 shares of the Company’s Class A common stock was combined into one issued and outstanding share of Class A Common Stock and every 40 shares of the Company’s Class B common stock was combined into one issued and outstanding share of Class B Common Stock. The Reverse Stock Split did not reduce the number of authorized shares of Class A and Class B common stock, which remained at 200,000,000 and 100,000,000 respectively and did not change the par value of the common stock, which remained at $0.01 per share. The Reverse Stock Split did not have any effect on the number of authorized shares of the Company’s preferred stock, par value of $0.01 per share, which would remain at 50,000,000 shares. Currently no shares of preferred stock are outstanding.
Common Stock and Pre-funded Warrants
In February 2024, the Company entered into a Securities Purchase Agreement with certain Private Placement Investors, pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (i) an aggregate of 464,377 shares of our Class A common stock, at a purchase price of $11.81 per share and (ii) issued pre-funded warrants to purchase an aggregate of 3,853,997 shares of the Company’s Class A common stock at a price of $11.80 per pre-funded warrant. The pre-funded warrants were immediately exercisable, have an exercise price of $0.01 and may be exercised at any time after the date of issuance. A holder of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. A holder of the pre-funded warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. As of June 30, 2024, there were pre-funded warrants to purchase an aggregate of 3,970,587 shares of the Company’s common stock that remained available for exercise.
The pre-funded warrants were classified as a component of permanent equity in the Company's Condensed Consolidated Balance Sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the pre-funded warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because
the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants.
On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants.
G42 Investments Transaction
On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 259,657 shares of the Company's Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the “G42 Promissory Note”). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company’s Condensed Consolidated Statements of Operations.
CinPax and CinRx Transaction
On July 22, 2022 (the “Transaction Date”), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (“CinPax”) and CinRx-Pharma, LLC (“CinRx”), pursuant to which the Company agreed to sell to CinPax 103,864 shares of the Company’s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022.
The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 30,000 shares of common stock at an initial exercise of price of approximately $28.80 per share (the “CinRx Warrants”). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 12)
The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (“FDA Approval”) to market and distribute the pharmaceutical product containing the Company’s proprietary candidate, cadisegliatin (the “Product”), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.
Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (“CinRx MSA”) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 9)
The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par. The Company, CinPax and CinRx subsequently amended the CinRx Purchase Agreement on February 27, 2024, in connection with the Private Placement. The CinRx Purchase Agreement provides CinPax the right for two years following the Closing to designate a board observer, which has been subsequently approved by the Company’s board.
ATM Offering
On February 28, 2024, we entered into a sales agreement (the “TD Cowen Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the “TD Cowen ATM Offering”). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered
on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Related-Party Transactions
6 Months Ended

Jun. 30, 2024

Related Party Transactions [Abstract]

Related-Party Transactions Related-Party Transactions
MacAndrews & Forbes Incorporated
MacAndrews directly or indirectly controls 577,108 shares of Class B common stock. Further, as of June 30, 2024, MacAndrews directly or indirectly holds 912,982 shares of the Company’s Class A common stock. As a result, MacAndrews’ holdings represent approximately 49.5% of the combined voting power of the Company’s outstanding common stock.
The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:
Letter Agreements
The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A common stock.
The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company’s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital.
Exchange Agreement
Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company’s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of June 30, 2024, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.
Tax Receivable Agreement
The Company and MacAndrews are party to a tax receivable agreement (the “Tax Receivable Agreement”), which provides for the payment by the Company to M&F TTP Holdings Two LLC (“M&F”), as successor in interest to vTv Therapeutics Holdings, LLC (“vTv Therapeutics Holdings”), and M&F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of June 30, 2024.
Investor Rights Agreement
The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement,
M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. The Investor Rights Agreement was amended on February 27, 2024 to alter M&F governance rights that now entitles M&F the right to designate two members of our Board of Directors, and as part of the Private Placement, the Private Placement Investors have rights to designate three members of our Board of Directors, making it more difficult for a third party to acquire control of our Board. The agreement with the Private Placement Investors also provides that five of our directors must approve certain actions including any acquisition by a third party, which makes it more difficult for our Board of Directors to approve such a transaction.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Income Taxes
6 Months Ended

Jun. 30, 2024

Income Tax Disclosure [Abstract]

Income Taxes Income Taxes
The Company is subject to U.S. federal income taxes as well as state taxes. The Company’s income tax provision for the six months ended June 30, 2024 was $0.1 million representing foreign withholding taxes accrued in connection with revenue recorded under license agreements with foreign entities. The Company did not record an income tax provision for the three months ended June 30, 2024 and 2023. The Company did not record an income tax provision for the six months ended June 30, 2023.
Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on June 30, 2024, is due to the valuation allowance against the Company’s expected net operating losses.
As discussed in Note 9, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of June 30, 2024.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income tax.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Net Loss per Share
6 Months Ended

Jun. 30, 2024

Earnings Per Share [Abstract]

Net Loss per Share Net Loss per Share
Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):
For the Three Months Ended June 30, For the Six Months Ended June 30,
2024 2023 2024 2023
Numerator:
Net loss $ (6,409) $ (7,211) $ (12,428) $ (12,985)
Less: Net loss attributable to noncontrolling interests (1,229) (1,592) (2,383) (2,867)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted (5,180) (5,619) (10,045) (10,118)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted (1)(*)
6,403,444 2,084,973 5,098,877 2,084,973
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted (*)
$ (0.81) $ (2.69) $ (1.97) $ (4.85)
(*) Adjusted retroactively for reverse stock split
(1)
The shares underlying the pre-funded warrants to purchase shares of the Company’s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and six months ended June 30, 2024.
Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:
June 30, 2024 June 30, 2023
Class B common stock (1)(*)
577,349 577,349
Common stock options granted under the Plan (*)
654,171 238,636
Common stock warrants (*)
75,595 80,359
Total (*)
1,307,115 896,344
(*) Adjusted retroactively for reverse stock split
___________________________
(1) Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/260/tableOfContent

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-3
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Fair Value of Financial Instruments
6 Months Ended

Jun. 30, 2024

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments Fair Value of Financial Instruments
The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.
The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The following table summarizes the conclusions reached regarding fair value measurements as of June 30, 2024 and December 31, 2023 (in thousands):
Balance at June 30, 2024 Quoted Prices in Active
Markets for Identical Assets
(Level 1) Significant Other Observable
Inputs
(Level 2) Significant Unobservable Inputs
(Level 3)
Liabilities:
Warrant liability, related party (1)(2)
$ 158 $ — $ — $ 158
Warrant liability $ 130 $ — $ — $ 130
Total $ 288 $ — $ — $ 288
Balance at December 31, 2023 Quoted Prices in Active
Markets for Identical Assets
(Level 1) Significant Other Observable
Inputs
(Level 2) Significant Unobservable Inputs
(Level 3)
Liabilities:
Warrant liability, related party (1)
$ 110 $ — $ — $ 110
Total $ 110 $ — $ — $ 110
_____________________________
(1) Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
(2)
CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.
Changes in Level 3 instruments for the six months ended June 30,
Balance at January 1 Net Change in
fair value included in
earnings Purchases /
Issuance Sales /
Repurchases Balance at June 30,
2024
Warrant liability, related party (1)
$ 110 $ 250 $ — $ — $ 360
Warrant liability $ — $ (72) $ — $ — $ (72)
Total $ 110 $ 178 $ — $ — $ 288
2023
Warrant liability, related party $ 684 $ (65) $ — $ — $ 619
Total $ 684 $ (65) $ — $ — $ 619
(1)
CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.
There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and six months ended June 30, 2024. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income (expense), related party in the Company’s Condensed Consolidated Statements of Operations.
The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of June 30, 2024 and December 31, 2023, were:
June 30, 2024 December 31, 2023
Range Weighted Average Range Weighted Average
Expected volatility
98.96% - 145.41%
106.42%
79.96% - 89.61%
81.55%
Risk-free interest rate
4.62% - 5.36%
4.79%
4.01% - 4.87%
4.15%
The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of June 30, 2024, were:
Expected volatility 91.7 %
Expected life of options in years 3.0
Risk-free interest rate 4.5 %
Expected dividend yield — %
The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.
Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Subsequent Events
6 Months Ended

Jun. 30, 2024

Subsequent Events [Abstract]

Subsequent Events Subsequent Events
On July 26, 2024 the Company announced that the Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (“CATT1”) Phase 3 trial in type 1 diabetes.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/855/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Pay vs Performance Disclosure

Net loss attributable to vTv Therapeutics Inc. $ (5,180) $ (5,619) $ (10,045) $ (10,118)

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-K
-Number 229
-Section 402
-Subsection v
-Paragraph 1
+ Details

Name: ecd_PvpTable

Namespace Prefix: ecd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Insider Trading Arrangements
3 Months Ended

Jun. 30, 2024

Trading Arrangements, by Individual

Rule 10b5-1 Arrangement Adopted false

Non-Rule 10b5-1 Arrangement Adopted false

Rule 10b5-1 Arrangement Terminated false

Non-Rule 10b5-1 Arrangement Terminated false

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-K
-Number 229
-Section 408
-Subsection a
-Paragraph 1
+ Details

Name: ecd_NonRule10b51ArrAdoptedFlag

Namespace Prefix: ecd_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-K
-Number 229
-Section 408
-Subsection a
-Paragraph 1
+ Details

Name: ecd_NonRule10b51ArrTrmntdFlag

Namespace Prefix: ecd_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-K
-Number 229
-Section 408
-Subsection a
-Paragraph 1
+ Details

Name: ecd_Rule10b51ArrAdoptedFlag

Namespace Prefix: ecd_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-K
-Number 229
-Section 408
-Subsection a
-Paragraph 1
+ Details

Name: ecd_Rule10b51ArrTrmntdFlag

Namespace Prefix: ecd_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-K
-Number 229
-Section 408
-Subsection a
-Paragraph 2
-Subparagraph A
+ Details

Name: ecd_TradingArrByIndTable

Namespace Prefix: ecd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Summary of Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Unaudited Interim Financial Information
Unaudited Interim Financial Information
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of June 30, 2024, Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit) for the three and six months ended June 30, 2024 and 2023 and Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of June 30, 2024, the results of operations for the three and six months ended June 30, 2024 and 2023 and cash flows for the six months ended June 30, 2024 and 2023. The December 31, 2023 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.
The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year.
The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.

Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.

Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.
One customer represented 100% of the revenue earned during the six months ended June 30, 2024. The Company did not have any revenue during the six months ended June 30, 2023 or during the three months ended June 30, 2024 and 2023.

Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Investments
Investments
Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.
Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.

Revenue Recognition
Revenue Recognition
The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.
The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied.
The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.

Research and Development
Research and Development
Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.
The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.
The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.
Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.

Recently Issued Accounting Pronouncements Not Yet Adopted
Recently Issued Accounting Pronouncements Not Yet Adopted
Segment Reporting: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): “Improvements to Reportable Segment Disclosures” (ASU 2023-07). The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. For public entities, the provisions within ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and for interim periods of fiscal years beginning after December 15, 2024. The Company is currently assessing the impact the adoption of ASU 2023-07 will have on its Consolidated Financial Statement and disclosures.
Income Taxes: In December 2023, the FASB issued ASU 2023-09: “Improvements to Income Tax Disclosures” (“ASU 2023-09”). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, and we expect considerable changes to our income tax disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-1
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478898/942-825-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investment in financial asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(f)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(f)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(f)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 12
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 19
-Subparagraph (2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19
+ Details

Name: us-gaap_InvestmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483044/730-10-05-1
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue from contract with customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-17

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-19

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-18

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-18

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-20

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (e)
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483426/235-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent
+ Details

Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-12

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-8
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Unaudited interim financial information policy.
+ References
No definition available.
+ Details

Name: vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock

Namespace Prefix: vtvt_

Data Type: dtr-types1:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Share-Based Compensation (Tables)
6 Months Ended

Jun. 30, 2024

Share-Based Payment Arrangement [Abstract]

Summary of Stock Award Activity for the Period
The following table summarizes the activity related to the stock option awards for the six months ended June 30, 2024:
Number of Shares Weighted
Average Exercise Price
Awards outstanding at December 31, 2023 249,247 $ 77.53
Granted 406,799 12.68
Forfeited (1,875) 30.87
Awards outstanding at June 30, 2024 654,171 $ 37.34
Options exercisable at June 30, 2024 199,812 $ 86.34
Weighted average remaining contractual term 6.8 Years
Options vested and expected to vest at June 30, 2024 499,109 $ 44.32
Weighted average remaining contractual term 8.4 Years

Summary of Compensation Expense Related to Grants of Stock Options
Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):
Three Months Ended June 30, Six Months Ended June 30,
2024 2023 2024 2023
Research and development $ 217 $ 105 $ 283 $ 203
General and administrative 642 294 796 539
Total share-based compensation expense $ 859 $ 399 $ 1,079 $ 742

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Leases (Tables)
6 Months Ended

Jun. 30, 2024

Leases [Abstract]

Schedule of Maturities of Lease Liabilities for Operating Leases
Maturities of lease liabilities for the Company’s operating leases as of June 30, 2024 were as follows (in thousands):
2024 (remaining six months) $ 97
2025 177
2026 —
2027 —
2028 —
Thereafter —
Total lease payments 274
Less: imputed interest (18)
Present value of lease liabilities $ 256

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Noncontrolling Interest (Tables)
6 Months Ended

Jun. 30, 2024

Noncontrolling Interest [Abstract]

Summary of Net Income Attributable to Vtv Therapeutics Inc The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:
For the Three Months Ended June 30, For the Six Months Ended June 30,
2024 2023 2024 2023
Net loss attributable to vTv Therapeutics Inc. common shareholders $ (5,180) $ (5,619) $ (10,045) $ (10,118)
Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances — 1,275 9,564 2,620
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest $ (5,180) $ (4,344) $ (481) $ (7,498)

X

- Definition
The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4M
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4M

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (d)
-SubTopic 10
-Topic 810
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A
+ Details

Name: us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Net Loss per Share (Tables)
6 Months Ended

Jun. 30, 2024

Earnings Per Share [Abstract]

Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):
For the Three Months Ended June 30, For the Six Months Ended June 30,
2024 2023 2024 2023
Numerator:
Net loss $ (6,409) $ (7,211) $ (12,428) $ (12,985)
Less: Net loss attributable to noncontrolling interests (1,229) (1,592) (2,383) (2,867)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted (5,180) (5,619) (10,045) (10,118)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted (1)(*)
6,403,444 2,084,973 5,098,877 2,084,973
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted (*)
$ (0.81) $ (2.69) $ (1.97) $ (4.85)
(*) Adjusted retroactively for reverse stock split
(1)
The shares underlying the pre-funded warrants to purchase shares of the Company’s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and six months ended June 30, 2024.

Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share
Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:
June 30, 2024 June 30, 2023
Class B common stock (1)(*)
577,349 577,349
Common stock options granted under the Plan (*)
654,171 238,636
Common stock warrants (*)
75,595 80,359
Total (*)
1,307,115 896,344
(*) Adjusted retroactively for reverse stock split
___________________________
(1) Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Fair Value of Financial Instruments (Tables)
6 Months Ended

Jun. 30, 2024

Fair Value Disclosures [Abstract]

Summarizes the Conclusions Reached Regarding Fair Value Measurements The following table summarizes the conclusions reached regarding fair value measurements as of June 30, 2024 and December 31, 2023 (in thousands):
Balance at June 30, 2024 Quoted Prices in Active
Markets for Identical Assets
(Level 1) Significant Other Observable
Inputs
(Level 2) Significant Unobservable Inputs
(Level 3)
Liabilities:
Warrant liability, related party (1)(2)
$ 158 $ — $ — $ 158
Warrant liability $ 130 $ — $ — $ 130
Total $ 288 $ — $ — $ 288
Balance at December 31, 2023 Quoted Prices in Active
Markets for Identical Assets
(Level 1) Significant Other Observable
Inputs
(Level 2) Significant Unobservable Inputs
(Level 3)
Liabilities:
Warrant liability, related party (1)
$ 110 $ — $ — $ 110
Total $ 110 $ — $ — $ 110
_____________________________
(1) Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
(2)
CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.
Changes in Level 3 instruments for the six months ended June 30,
Balance at January 1 Net Change in
fair value included in
earnings Purchases /
Issuance Sales /
Repurchases Balance at June 30,
2024
Warrant liability, related party (1)
$ 110 $ 250 $ — $ — $ 360
Warrant liability $ — $ (72) $ — $ — $ (72)
Total $ 110 $ 178 $ — $ — $ 288
2023
Warrant liability, related party $ 684 $ (65) $ — $ — $ 619
Total $ 684 $ (65) $ — $ — $ 619
(1)
CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.

Fair Value Measurement Inputs and Valuation Techniques Significant inputs utilized in the valuation of the Letter Agreement Warrants as of June 30, 2024 and December 31, 2023, were:
June 30, 2024 December 31, 2023
Range Weighted Average Range Weighted Average
Expected volatility
98.96% - 145.41%
106.42%
79.96% - 89.61%
81.55%
Risk-free interest rate
4.62% - 5.36%
4.79%
4.01% - 4.87%
4.15%
The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of June 30, 2024, were:
Expected volatility 91.7 %
Expected life of options in years 3.0
Risk-free interest rate 4.5 %
Expected dividend yield — %

X

- Definition
Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 103
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-103

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Description of Business and Basis of Presentation (Detail) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended

Feb. 27, 2024

Jun. 30, 2024

Mar. 05, 2024

Feb. 28, 2024

Feb. 28, 2024

Feb. 28, 2024

Dec. 31, 2023

Nov. 20, 2023

Organization Consolidation And Presentation Of Financial Statements [Line Items]

Cash and cash equivalents $ 45,526 $ 9,446

Common stock par value (in usd per share) $ 0.01

Retained earnings (accumulated deficit) (291,301) $ (281,042)

Entity public float, threshold $ 75,000

Percent of public float 33.30% 3.00%

Parent Company

Organization Consolidation And Presentation Of Financial Statements [Line Items]

Cash and cash equivalents $ 26,100

Private Placement

Organization Consolidation And Presentation Of Financial Statements [Line Items]

Proceeds from issuance of private placement $ 51,000

Private placement, shares (in shares) 116,493

Private placement pre-funded warrants, shares (in shares) 116,590

Private Placement | Private Placement Pre-Funded Warrants

Organization Consolidation And Presentation Of Financial Statements [Line Items]

Exercise price of warrants or rights (in usd per share) $ 0.01

Class A Common Stock

Organization Consolidation And Presentation Of Financial Statements [Line Items]

Common stock par value (in usd per share) $ 0.01 $ 0.01

Class A Common Stock | Private Placement

Organization Consolidation And Presentation Of Financial Statements [Line Items]

Shares sold (in shares) 464,377

Sale of stock, price per share (in usd per share) $ 11.81

Class A Common Stock | Private Placement | Private Placement Pre-Funded Warrants

Organization Consolidation And Presentation Of Financial Statements [Line Items]

Sale of stock, price per share (in usd per share) $ 11.80

Number of securities called by warrants or rights (in shares) 3,853,997 3,970,587

Class A Common Stock | TD Cowen Sales Agreement

Organization Consolidation And Presentation Of Financial Statements [Line Items]

Aggregate offering price $ 50,000

Class B Common Stock

Organization Consolidation And Presentation Of Financial Statements [Line Items]

Common stock par value (in usd per share) $ 0.01 $ 0.01

vTv Therapeutics LLC

Organization Consolidation And Presentation Of Financial Statements [Line Items]

Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC 19.20%

Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC 80.80%

vTv Therapeutics LLC | Class B Common Stock

Organization Consolidation And Presentation Of Financial Statements [Line Items]

Common stock par value (in usd per share) $ 0.01

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of accumulated undistributed earnings (deficit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares
+ References
No definition available.
+ Details

Name: vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares

Namespace Prefix: vtvt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Common Stock, Par or Stated Value of Private Placement, Shares
+ References
No definition available.
+ Details

Name: vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares

Namespace Prefix: vtvt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Entity Public Float, Threshold
+ References
No definition available.
+ Details

Name: vtvt_EntityPublicFloatThreshold

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Organization consolidation and presentation of financial statements.
+ References
No definition available.
+ Details

Name: vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems

Namespace Prefix: vtvt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of non voting economic interest.
+ References
No definition available.
+ Details

Name: vtvt_PercentageOfNonVotingEconomicInterest

Namespace Prefix: vtvt_

Data Type: dtr-types1:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of non voting economic interest by parent.
+ References
No definition available.
+ Details

Name: vtvt_PercentageOfNonVotingEconomicInterestByParent

Namespace Prefix: vtvt_

Data Type: dtr-types1:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate offering price.
+ References
No definition available.
+ Details

Name: vtvt_SaleOfStockAggregateOfferingPrice

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float
+ References
No definition available.
+ Details

Name: vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat

Namespace Prefix: vtvt_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=vtvt_PrivatePlacementPreFundedWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=vtvt_TDCowenSalesAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=vtvt_VTvLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Summary of Significant Accounting Policies - Additional Information (Detail)
6 Months Ended

Jun. 30, 2024

Revenue | Customer | One Customer

Summary Of Significant Accounting Policies [Line Items]

Concentration risk percentage 100.00%

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-20

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Summary of significant accounting policies.
+ References
No definition available.
+ Details

Name: vtvt_SummaryOfSignificantAccountingPoliciesLineItems

Namespace Prefix: vtvt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=vtvt_OneCustomerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Collaboration Agreements - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended

Feb. 28, 2023

May 31, 2022

Aug. 31, 2017

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Jun. 26, 2024

Dec. 31, 2023

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Gain (loss) on extinguishment of debt $ 0 $ (313)

Contract liabilities, net of current portion $ 18,669 18,669 $ 18,669

Revenue 0 $ 0 1,000 0

G42 Investments

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Shares sold (in shares) 259,657

Sale of stock, price per share (in usd per share) $ 96.40

Sale of stock, consideration received on transaction, gross $ 25,000

Sale of stock, consideration received on transaction 12,500

Accounts and financing receivable, after allowance for credit loss 12,500

Proceeds from collection of notes receivable $ 12,000

Discount rate 3.75%

Gain (loss) on extinguishment of debt $ (300)

G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Sale of stock, consideration received on transaction, gross 25,000

Accounts and financing receivable, after allowance for credit loss 12,500

Proceeds from collection of notes receivable $ 12,000

Discount rate 3.75%

Gain (loss) on extinguishment of debt $ (300)

Collaborative arrangement, contingent consideration 30,000

Collaborate arrangement, contingent consideration transferred, cash $ 30,000

Contract liabilities, net of current portion 18,700 18,700

Discount on note receivable 600

Collaboration revenue recognized 0 0

Revenue 0 0

Receivables, fair value disclosure $ 11,900 11,900

G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | Cogna

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Royalties receivable, period 10 years

Collaborative Arrangements | Newsoara Biopharma Co Ltd

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Contract with customer, liability, revenue recognized $ 0

Collaborative Arrangements | JDRF

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Maximum funding percentage of research and development milestones 50.00%

Collaborative Arrangements | Newsoara Biopharma Co Ltd

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

License fee received $ 20,000

License fee received, term 1 year

License fee price increase $ 20,000

Potential development and regulatory milestone payments $ 76,500

Collaborative Arrangements | Newsoara Biopharma Co Ltd | License And Technology Transfer Services

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Revenue recognized from change in estimated transaction prices $ 1,000

X

- Definition
Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-2
+ Details

Name: us-gaap_AccountsNotesAndLoansReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1
+ Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8
+ Details

Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481303/470-50-40-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481303/470-50-40-4
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-12
+ Details

Name: us-gaap_ProceedsFromCollectionOfNotesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-10

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
+ Details

Name: us-gaap_ReceivablesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479428/808-10-45-3
+ Details

Name: us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Collaborate Arrangement, Contingent Consideration Transferred, Cash
+ References
No definition available.
+ Details

Name: vtvt_CollaborateArrangementContingentConsiderationTransferredCash

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value
+ References
No definition available.
+ Details

Name: vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Collaborative Arrangement, Note Receivable, Discount Paid
+ References
No definition available.
+ Details

Name: vtvt_CollaborativeArrangementNoteReceivableDiscountPaid

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Collaborative Arrangement, Royalties Receivable, Period
+ References
No definition available.
+ Details

Name: vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod

Namespace Prefix: vtvt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
License Fee Price Increase
+ References
No definition available.
+ Details

Name: vtvt_LicenseFeePriceIncrease

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
License Fee Received
+ References
No definition available.
+ Details

Name: vtvt_LicenseFeeReceived

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
License Fee Received, Term
+ References
No definition available.
+ Details

Name: vtvt_LicenseFeeReceivedTerm

Namespace Prefix: vtvt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Maximum funding percentage of research and development milestones.
+ References
No definition available.
+ Details

Name: vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones

Namespace Prefix: vtvt_

Data Type: dtr-types1:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Notes Receivable, Discount Rate
+ References
No definition available.
+ Details

Name: vtvt_NotesReceivableDiscountRate

Namespace Prefix: vtvt_

Data Type: dtr-types1:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Potential development and regulatory milestone payments receivable.
+ References
No definition available.
+ Details

Name: vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sale of Stock, Consideration Received on Transaction, Gross
+ References
No definition available.
+ Details

Name: vtvt_SaleOfStockConsiderationReceivedOnTransactionGross

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=vtvt_CognaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=vtvt_NewsoaraBiopharmaCoLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=vtvt_JDRFInternationalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=vtvt_NewsoaraBiopharmaCoLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=vtvt_LicenseAndTechnologyTransferServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Share-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
6 Months Ended

Feb. 23, 2024

Jun. 30, 2024

Jun. 30, 2023

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted (in shares) 406,799

Stock Option

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Non-qualified stock option awards vesting period 3 years

Non-qualified stock option awards expiration term 10 years

Unrecognized compensation cost related to non-vested share-based compensation arrangements $ 4.7

Weighted average period to recognize unrecognized share-based compensation cost 2 years 6 months

Weighted average grant date fair value of options granted (in usd per share) $ 14.88 $ 30.59

Modified common stock (in shares) 14,340

Accelerated vesting (in shares) 7,590

Expense reduction $ 0.1

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-Based Compensation Arrangement by Share-Based Payment Award, Modified Common Stock
+ References
No definition available.
+ Details

Name: vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock

Namespace Prefix: vtvt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Share-Based Payment Arrangement, Expense Reduction, Amount
+ References
No definition available.
+ Details

Name: vtvt_ShareBasedPaymentArrangementExpenseReductionAmount

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)
6 Months Ended

Jun. 30, 2024

$ / shares

shares

Number of Shares

Awards outstanding, Beginning balance (in shares) | shares 249,247

Granted (in shares) | shares 406,799

Forfeited (in shares) | shares (1,875)

Awards outstanding, Ending balance (in shares) | shares 654,171

Options exercisable (in shares) | shares 199,812

Options exercisable, weighted average remaining contractual term 6 years 9 months 18 days

Options vested and expected to vest (in shares) | shares 499,109

Options vested and expected to vest, weighted average remaining contractual term 8 years 4 months 24 days

Weighted Average Exercise Price

Awards outstanding, Beginning balance (in usd per share) | $ / shares $ 77.53

Granted (in usd per share) | $ / shares 12.68

Forfeited (in usd per share) | $ / shares 30.87

Awards outstanding, Ending balance (in usd per share) | $ / shares 37.34

Options exercisable (in usd per share) | $ / shares 86.34

Options vested and expected to vest (in usd per share) | $ / shares $ 44.32

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Total share-based compensation expense $ 859 $ 399 $ 1,079 $ 742

Research and development

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Total share-based compensation expense 217 105 283 203

General and administrative

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Total share-based compensation expense $ 642 $ 294 $ 796 $ 539

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Commitments and Contingencies - Additional Information (Detail) - Novo License Agreement
$ in Millions

Feb. 28, 2007

USD ($)

Developmental and Regulatory Milestone Payment | Type 1 Diabetes

Commitments And Contingencies [Line Items]

Potential milestone payment $ 9.0

Developmental and Regulatory Milestone Payment | Type 2 Diabetes | Maximum

Commitments And Contingencies [Line Items]

Potential milestone payment 50.5

Developmental and Regulatory Milestone Payment | Other Indication | Maximum

Commitments And Contingencies [Line Items]

Potential milestone payment 115.0

Sales-based Milestones Payment

Commitments And Contingencies [Line Items]

Potential milestone payment $ 75.0

X

- Definition
Commitments and Contingencies.
+ References
No definition available.
+ Details

Name: vtvt_CommitmentsAndContingenciesLineItems

Namespace Prefix: vtvt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Potential milestone payment.
+ References
No definition available.
+ Details

Name: vtvt_PotentialMilestonePayment

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=vtvt_NovoLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeOneDiabetesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeTwoDiabetesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_OtherIndicationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Leases - Additional Information (Details) - USD ($)
6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Dec. 31, 2023

Nov. 30, 2022

Leases [Abstract]

Lessee, operating lease, renewal term 5 years

Lessee, operating lease, termination period 3 years

Present value of lease liabilities $ 256,000 $ 100,000

Operating lease right-of-use assets $ 186,000 $ 244,000 $ 100,000

Weighted average incremental borrowing rate 9.50% 9.50%

Remaining operating lease term 1 year 4 months 24 days 1 year 10 months 24 days

Operating lease cost $ 100,000 $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-3
+ Details

Name: us-gaap_LesseeOperatingLeaseRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 53
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479589/842-20-55-53

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details

Name: us-gaap_OperatingLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 53
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479589/842-20-55-53

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 53
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479589/842-20-55-53

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Lessee, Operating Lease, Termination Period
+ References
No definition available.
+ Details

Name: vtvt_LesseeOperatingLeaseTerminationPeriod

Namespace Prefix: vtvt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) - USD ($)
$ in Thousands

Jun. 30, 2024

Nov. 30, 2022

Leases [Abstract]

2024 (remaining six months) $ 97

2025 177

2026 0

2027 0

2028 0

Thereafter 0

Total lease payments 274

Less: imputed interest (18)

Present value of lease liabilities $ 256 $ 100

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee, Operating Lease, Liability, to be Paid, After Year Four
+ References
No definition available.
+ Details

Name: vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Operating leases imputed interest.
+ References
No definition available.
+ Details

Name: vtvt_OperatingLeasesImputedInterest

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Noncontrolling Interest - Additional Information (Detail) - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2024

Feb. 27, 2024

Dec. 31, 2023

Noncontrolling Interest [Line Items]

Redeemable noncontrolling interest, equity, fair value $ 5,300

Redeemable noncontrolling interest $ 0 $ 6,131

Class A Common Stock

Noncontrolling Interest [Line Items]

Number of days used to determine exchange value based on weighted average price of Class A common stock 20 days

Class A Common Stock | Exchange of Redeemable Non controlling Interest To Class A Common Stock

Noncontrolling Interest [Line Items]

Stock conversion ratio 1

vTv Therapeutics LLC

Noncontrolling Interest [Line Items]

Noncontrolling interest ownership percentage 19.20%

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Subparagraph (12)(c)
-Section S99
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Subparagraph (16)(c)
-Paragraph 3A
-Section S99
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (15)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (14)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A
+ Details

Name: us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Subparagraph (12)(c)
-Section S99
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Subparagraph (16)(c)
-Paragraph 3A
-Section S99
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (15)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (14)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A
+ Details

Name: us-gaap_RedeemableNoncontrollingInterestEquityFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage of non voting economic interest.
+ References
No definition available.
+ Details

Name: vtvt_PercentageOfNonVotingEconomicInterest

Namespace Prefix: vtvt_

Data Type: dtr-types1:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period used to determine exchange value based on weighted average price of Class A common stock.
+ References
No definition available.
+ Details

Name: vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock

Namespace Prefix: vtvt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Redeemable non controlling interest exchange agreement stock conversion ratio.
+ References
No definition available.
+ Details

Name: vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio

Namespace Prefix: vtvt_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConversionOfStockByUniqueDescriptionAxis=vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=vtvt_VTvLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Noncontrolling Interest [Abstract]

Net loss attributable to vTv Therapeutics Inc. common shareholders $ (5,180) $ (5,619) $ (10,045) $ (10,118)

Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances 0 1,275 9,564 2,620

Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest $ (5,180) $ (4,344) $ (481) $ (7,498)

X

- Definition
This element represents the total net income attributable to the parent for the period and the effect of net changes during the period impacting the parent's ownership interest in a subsidiary as it relates to the total (consolidated) equity attributable to the parent. The changes to the parent's ownership interest in a subsidiary represented by this element did not result in a deconsolidation of the subsidiary from the consolidated financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4M
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4M

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (d)
-SubTopic 10
-Topic 810
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A
+ Details

Name: us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 6.B)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent.
+ References
No definition available.
+ Details

Name: vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Stockholders' Equity (Deficit) - Additional Information (Detail)
$ / shares in Units, $ in Thousands
6 Months Ended

Feb. 27, 2024

$ / shares

shares

Nov. 20, 2023

$ / shares

shares

Feb. 28, 2023

USD ($)

Jul. 22, 2022

USD ($)

$ / shares

shares

May 31, 2022

USD ($)

$ / shares

shares

May 04, 2021

shares

Jun. 30, 2024

USD ($)

$ / shares

shares

Jun. 30, 2023

USD ($)

Mar. 05, 2024

shares

Feb. 28, 2024

Feb. 28, 2024

USD ($)

Feb. 28, 2024

Rate

Dec. 31, 2023

$ / shares

shares

Class Of Stock [Line Items]

Capital stock, shares authorized (in shares) 350,000,000 250,000,000

Common stock par value (in usd per share) | $ / shares $ 0.01

Preferred stock, par or stated value per share (in usd per share) | $ / shares $ 0.01

Shares authorized (in shares) 50,000,000

Gain (loss) on extinguishment of debt | $ $ 0 $ (313)

Entity public float, threshold | $ $ 75,000

Percent of public float 33.30% 3.00%

Private Placement Pre-Funded Warrants

Class Of Stock [Line Items]

Percent of securities called by warrants 9.99% 19.99%

Private Placement

Class Of Stock [Line Items]

Private placement, shares (in shares) 116,493

Private placement pre-funded warrants, shares (in shares) 116,590

Private Placement | Private Placement Pre-Funded Warrants

Class Of Stock [Line Items]

Exercise price of warrants or rights (in usd per share) | $ / shares $ 0.01

G42 Investments

Class Of Stock [Line Items]

Shares sold (in shares) 259,657

Sale of stock, price per share (in usd per share) | $ / shares $ 96.40

Sale of stock, consideration received on transaction, gross | $ $ 25,000

Sale of stock, consideration received on transaction | $ 12,500

Accounts and financing receivable, after allowance for credit loss | $ $ 12,500

Sale of stock, consideration, receivables, payment term 1 year

Proceeds from collection of notes receivable | $ $ 12,000

Discount rate 3.75%

Gain (loss) on extinguishment of debt | $ $ (300)

CinRx Investment

Class Of Stock [Line Items]

Shares sold (in shares) 103,864

Sale of stock, price per share (in usd per share) | $ / shares $ 96.40

Sale of stock, consideration received on transaction, gross | $ $ 10,000

Sale of stock, consideration received on transaction | $ 6,000

Accounts and financing receivable, after allowance for credit loss | $ $ 4,000

Warrants, term 5 years

Class A Common Stock

Class Of Stock [Line Items]

Increase in shares authorized (in shares) 100,000,000

Common stock, shares authorized (in shares) 200,000,000 200,000,000 200,000,000 200,000,000

Common stock par value (in usd per share) | $ / shares $ 0.01 $ 0.01

Stock split conversion ratio 0.025

Class A Common Stock | Private Placement

Class Of Stock [Line Items]

Shares sold (in shares) 464,377

Sale of stock, price per share (in usd per share) | $ / shares $ 11.81

Class A Common Stock | Private Placement | Private Placement Pre-Funded Warrants

Class Of Stock [Line Items]

Sale of stock, price per share (in usd per share) | $ / shares $ 11.80

Number of securities called by warrants or rights (in shares) 3,853,997 3,970,587

Class A Common Stock | TD Cowen Sales Agreement

Class Of Stock [Line Items]

Aggregate offering price | $ $ 50,000

Common Stock

Class Of Stock [Line Items]

Common stock, shares authorized (in shares) 300,000,000

Common Stock | CinRx Investment

Class Of Stock [Line Items]

Number of securities called by warrants or rights (in shares) 30,000

Exercise price of warrants or rights (in usd per share) | $ / shares $ 28.80

Warrants, fair value | $ $ 400

Class B Common Stock

Class Of Stock [Line Items]

Common stock, shares authorized (in shares) 100,000,000 100,000,000 100,000,000

Common stock par value (in usd per share) | $ / shares $ 0.01 $ 0.01

Stock split conversion ratio 0.025

X

- Definition
Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-2
+ Details

Name: us-gaap_AccountsNotesAndLoansReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483014/272-10-45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482987/272-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481303/470-50-40-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481303/470-50-40-4
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-12
+ Details

Name: us-gaap_ProceedsFromCollectionOfNotesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4
+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights
+ References
No definition available.
+ Details

Name: vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: vtvt_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Common stock and preferred stock shares authorized.
+ References
No definition available.
+ Details

Name: vtvt_CommonStockAndPreferredStockSharesAuthorized

Namespace Prefix: vtvt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares
+ References
No definition available.
+ Details

Name: vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares

Namespace Prefix: vtvt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Common Stock, Par or Stated Value of Private Placement, Shares
+ References
No definition available.
+ Details

Name: vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares

Namespace Prefix: vtvt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Entity Public Float, Threshold
+ References
No definition available.
+ Details

Name: vtvt_EntityPublicFloatThreshold

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Increase in common stock shares authorized.
+ References
No definition available.
+ Details

Name: vtvt_IncreaseInCommonStockSharesAuthorized

Namespace Prefix: vtvt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Notes Receivable, Discount Rate
+ References
No definition available.
+ Details

Name: vtvt_NotesReceivableDiscountRate

Namespace Prefix: vtvt_

Data Type: dtr-types1:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate offering price.
+ References
No definition available.
+ Details

Name: vtvt_SaleOfStockAggregateOfferingPrice

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sale Of Stock, Consideration, Receivable, Term
+ References
No definition available.
+ Details

Name: vtvt_SaleOfStockConsiderationReceivableTerm

Namespace Prefix: vtvt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Sale of Stock, Consideration Received on Transaction, Gross
+ References
No definition available.
+ Details

Name: vtvt_SaleOfStockConsiderationReceivedOnTransactionGross

Namespace Prefix: vtvt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float
+ References
No definition available.
+ Details

Name: vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat

Namespace Prefix: vtvt_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=vtvt_PrivatePlacementPreFundedWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=vtvt_CinRxInvestmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=vtvt_TDCowenSalesAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Related-Party Transactions - Additional Information (Detail) - Related Party - MacAndrews & Forbes Incorporated
6 Months Ended

Jun. 30, 2024

shares

Related Party Transaction [Line Items]

Ownership percentage of majority owner 49.50%

Amount of cash savings percentage 85.00%

Class B Common Stock

Related Party Transaction [Line Items]

Share held by related party (in shares) 577,108

Class A Common Stock

Related Party Transaction [Line Items]

Share held by related party (in shares) 912,982

X

- Definition
Number of shares of investment owned.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477439/946-210-55-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6
+ Details

Name: us-gaap_InvestmentOwnedBalanceShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Ownership percentage of majority owner.
+ References
No definition available.
+ Details

Name: vtvt_OwnershipPercentageOfMajorityOwner

Namespace Prefix: vtvt_

Data Type: dtr-types1:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of amount of cash savings.
+ References
No definition available.
+ Details

Name: vtvt_PercentageOfAmountOfCashSavings

Namespace Prefix: vtvt_

Data Type: dtr-types1:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=vtvt_MacAndrewsAndForbesIncorporatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Income Taxes - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Income Taxes [Line Items]

Income tax provision $ 0 $ 0 $ 100,000 $ 0

M&F TTP Holdings LLC

Income Taxes [Line Items]

Amount of cash savings percentage 85.00%

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Income taxes.
+ References
No definition available.
+ Details

Name: vtvt_IncomeTaxesLineItems

Namespace Prefix: vtvt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of amount of cash savings.
+ References
No definition available.
+ Details

Name: vtvt_PercentageOfAmountOfCashSavings

Namespace Prefix: vtvt_

Data Type: dtr-types1:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Numerator:

Net loss $ (6,409) $ (7,211) $ (12,428) $ (12,985)

Less: net loss attributable to noncontrolling interest (1,229) (1,592) (2,383) (2,867)

Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted (5,180) (5,619) (10,045) (10,118)

Net loss attributable to common shareholders of vTv Therapeutics Inc., basic $ (5,180) $ (5,619) $ (10,045) $ (10,118)

Class A Common Stock

Denominator:

Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) ^[1] 6,403,444 2,084,973 5,098,877 2,084,973

Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) ^[1] 6,403,444 2,084,973 5,098,877 2,084,973

Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share) ^[1] $ (0.81) $ (2.69) $ (1.97) $ (4.85)

Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share) ^[1] $ (0.81) $ (2.69) $ (1.97) $ (4.85)

[1]
(*) Adjusted retroactively for reverse stock split

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetIncomeLossAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 6.B)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 6.B)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-16

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 40
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-40

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 40
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-40

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 40
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 40
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-40
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4K
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-2

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-16
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) - shares
6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) 1,307,115 896,344

Class B Common Stock

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) 577,349 577,349

Common stock options granted under the Plan

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) 654,171 238,636

Common stock warrants

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) 75,595 80,359

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Dec. 31, 2023

Significant Unobservable Inputs (Level 3)

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Beginning Balance $ 110 $ 684

Net Change in fair value included in earnings 178 (65)

Purchases / Issuance 0 0

Sales / Repurchases 0 0

Ending Balance 288 $ 619

Significant Unobservable Inputs (Level 3) | Related Party

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Beginning Balance 110

Net Change in fair value included in earnings 250

Purchases / Issuance 0

Sales / Repurchases 0

Ending Balance 360

Significant Unobservable Inputs (Level 3) | Nonrelated Party

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Beginning Balance 0

Net Change in fair value included in earnings (72)

Purchases / Issuance 0

Sales / Repurchases 0

Ending Balance (72)

Fair Value, Measurements, Recurring

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 288 $ 110

Fair Value, Measurements, Recurring | Nonrelated Party

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 130

Fair Value, Measurements, Recurring | Warrant liability, related party | Related Party

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 158

Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 0 0

Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Nonrelated Party

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 0

Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liability, related party

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 0

Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liability, related party | Related Party

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 0

Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 0 0

Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Nonrelated Party

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 0

Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Warrant liability, related party

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 0

Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Warrant liability, related party | Related Party

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 0

Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 288 110

Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Nonrelated Party

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: 130

Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Warrant liability, related party

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: $ 110

Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Warrant liability, related party | Related Party

Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]

Liabilities: $ 158

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of financial and nonfinancial obligations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_LiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value of assets and liabilities measured on recurring basis.
+ References
No definition available.
+ Details

Name: vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems

Namespace Prefix: vtvt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)

Jun. 30, 2024

Dec. 31, 2023

CinRx Warrants

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]

Expected life of options in years 3 years

Expected volatility | CinRx Warrants

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]

Inputs utilized in the valuation of warrants 0.917

Risk-free interest rate | CinRx Warrants

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]

Inputs utilized in the valuation of warrants 0.045

Expected dividend yield | CinRx Warrants

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]

Inputs utilized in the valuation of warrants 0

Minimum | Expected volatility | Letter Agreement Warrants

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]

Inputs utilized in the valuation of warrants 0.9896 0.7996

Minimum | Risk-free interest rate | Letter Agreement Warrants

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]

Inputs utilized in the valuation of warrants 0.0462 0.0401

Maximum | Expected volatility | Letter Agreement Warrants

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]

Inputs utilized in the valuation of warrants 1.4541 0.8961

Maximum | Risk-free interest rate | Letter Agreement Warrants

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]

Inputs utilized in the valuation of warrants 0.0536 0.0487

Weighted Average | Expected volatility | Letter Agreement Warrants

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]

Inputs utilized in the valuation of warrants 1.0642 0.8155

Weighted Average | Risk-free interest rate | Letter Agreement Warrants

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]

Inputs utilized in the valuation of warrants 0.0479 0.0415

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 103
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-103

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=vtvt_CinRxWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=vtvt_LetterAgreementWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_WeightedAverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
/6@TQ=D+[JA-(<*,V%TCPHS8?2 B@M[-B2(FC4&$7C!?C& M^$/^F3F%71SNZDEF%=3%Z2U#),V!TEPHS8/2?"@M@-+";@TI@@:-431>A8V% MAJ@]-)_K$9+3VA.[T.;Y:DVS,JF5*!6:+ER?D:FW989T-,R@- =*&4V[ABBML=(IQ^"I'B=?I"+$^J)(:(I MADSL86LR8P8-ZD!I+I3F06D^E!9 :2&4%D%I,8K&*[.QQQ!;.57RCE^5!: *6%4%H$I<4H&J_TQGY#U/X;W"@NU']#1,?)>$3: M#V6HL09*HW3J &4^DEV-*9$8@:Z*W M50KU[D!I+I3F06D^E!9 :2&4%D%I,8K&J[0Q&1&E[^&HX2:HEVA'.V0NAP9U MH#072O.@-!]*"Z"T$$J+H+081>-7&FCL0KK:+M399WYH_.GZ0* ]LSCJ7'TU M#J7-H#0'2G-UT5HCG\61))3.XD"+%T!I(90606DQBL;KMW$;Z6JWT7%CQ;K$ M$4(FI-U'G:J#]]83U%L$I;D[FG(BYT!5[)G(D9#;$SE'@7U))>J61=IC]!^/ MH@?0RQO*&IP^,@W2GLB!AHU1-%ZSV[7"J+D=OE4)M25": M"Z5Y4)H/I0506MBM(470H#&*QLNOL2[I:N\);')&E_A+A/F4J;HTO44(M3-! M:2Z4YD%I/I060&EAIW8406/&*!JOP<:DI*M-2GT,]KIH)C+:?K.I.EYOE4&- M25":"Z5Y4)K?I:H^'F@:^]XHH2XE*"V"TF(4C9=FXU+2^ZSB<[0M_T"4?0.Z M4 \3E#:#TAPHS=7%M8_V#.B*">4#NE#C$9060FD1E!:C:+QX&^.1KC8>'3%/ MJHNF(*DM7QVYMYB@+B,HS=W1U*.YZGK8-YHKDH71W&/ OJ02I;;\H^@!]/*& MT@8GL^5#P\8H&J_,QF>D_\U5@>3B%-U -C&$5\PNJ6;J O:6'-0R!*5Y4)H/ MI0506@BE15!:C*+Q@FLL0[IZ8:)O[+;7H?8B*&T&I3E0F@NE>5":#Z4%4%H( MI4506HRB\5LL-"XDX\A%BXIF-Z'NP[K7!Z+]KLNW8H!:D0SIVC=CJ_5(AP9U MH#072O.@-!]*"Z"T$$J+H+081>.%WMB5C']H<21#9B@AK34:IY)40J*9NLB] M)0BU)4%I'I3F0VD!E!9":1&4%J-HO 0;4Y*A7AGI$YW7N[8M[Y;S[81-+;S# MC]GZ8;RFQ2K)ZLT+Z;8O+M6EN$"/I=OM-7 EJ4[%9#/UF?16)M15!*5Y4)H/ MI0506@BE15!:;(C;WG&MDE?&&W\<+NXX7=R N[DQ=V*Z]O80LR&EN0H;8%';5G@G305AVH]ZL@U#]D MB%X3Z42A(TDHFRATNP*]CD ?>KX!E!9":1&4%J-HO'P:1X]QQ+)#AZ4BVSW+ MM,?"XPIJ[X'2'"C-W=&46Q](TK3W/I!<6-VR#:,U@A1 "Q]*JW-,ANU%-B/) M&1O)R#MTFRLHS8'27"C-@])\*"V TL).[2CJ ME"I&E8S75F-4,=1KVWSC(75QX1K9D+J82CJD#C660&DNE.9!:3Z4%D!I(906 M06GQH<;+*/HT-PU3;,+RRW&Q'^-B#ZJ9^=&E7M8Q6[-%5UH,H6I(M M-!;Y;I,MF,*>DJ)(LJK\4+^D$VS\N*&UN7J@\Y=SZ%TF90F@.E MN:9H73',T7C4)H+I7E0F@^E!5!:"*5%4%I\ ML)'S FQ<'*;:Q='_U^M2!Y4Z2N]^)]3"84H<%Z:AC]L;VSN2A%(+1U>@UQ'H M0\\W@-)"*"V"TF(4C==.8^$PU1:.(YR&IL1F,#2-]B[#ZL"]!0"U;T!IKBFQ M;P@O78?M&Y+K:@Q'(]-NCV5 [1N2J*?ZA!C#]EI$DH3$-D="9TRV'(RM[[G' M-P8.L\\*)=W:J;CL17L(?)?$WI]DIBY7[X8']5- :1Z4YD-I 9060FD1E!:C M:+S.&C^%J?93'+6ZNUQ^T&V,H+09E.9 ::XI6=9#WC,3$\I[9E#+!)060FD1 ME!:C:+P2&_N%><3B(8=5)\Y^Z]9D+'3.H&8+*,V!TMP=3=TY$],(G3/QNAI# M>]R^L &T\*$DZJD^MDG;'1S)JGTXFMCMSIF8S"(3LJ=SUK@93/6R&UAWK0E= M90-*FT%I#I3F0FD>E.9#:0&4%D)I$906HVBM)5G4PB+" M;SW4Y>BK4BC-@=)<*,V#TGPH+8#2PFX-*>J6+$:5C==5XZ:PU&Z*/F8D2YS6 M'UMM+Y(Z7F_]0%T.4)H+I7E0FM^EJ@)HR!!*B[J<0(P*R6NG<2Y8:N<"8KK5 MDJPF071=4!74G0"E.5":"Z5Y4)H/I0506@BE15!:?+"1\P)L_ Y6G\4ICIYN M54?I^YH'ICY!E!:"*5%4%J,HO':::P*5A^K M0C>=F.( EF2Z51VXMP"0- =*+1]I^E6[ MRPMVY)$6)=T92,MUNJR>LZ1IWOS,*;SQMA[2;1_N*6'].):QW*25=E?D*ZUZ MH.Q[Z]=1DM\]:>RP0V^+35)\U?31LWZT=Y\IU<*\HMKHO4RP@_*!TFJ:5,GE M^8H6]_2&IFG)WL$V655?Q3='62GNZDW*SZ[)R4 X[I*SGV7'/7+VB^RX3\X^ MRHY?6=99Q.I%]A>;_<6N_S)HBGIYOD[N:9 4]\NLU%)ZQXH]_#!BSXMB>?_P M^J7*UQ0!@ =!X !@ !X;"]W;W)KU9DRC;WE6J*O!6NO-Q6BDDC7+ MJ7HC-JR 7U9"YE3#K7P8J8UD-+6+\FQ$@F \RBDO!O-+^^Q6SB_%5F>\8+<2 MJ6V>4_EXPS*QOQK@P=.#._ZPUN;!:'ZYH0_LGNG/FUL)=Z-:2\IS5B@N"B39 MZFIPC2\686066(D_.-NK@VMD3%D*\<7<_))>#0*#B&4LT48%A:\=6[ L,YH MQ]=*Z:#^3[/P\/I)^SMK/!BSI(HM1/8G3_7Z:C =H)2MZ#;3=V+_GE4&Q49? M(C)E/]&^D@T&*-DJ+?)J,2#(>5%^TV^5(PX6@![W E(M(.T%4<^"L%H06D-+ M9-:LMU33^:44>R2--&@S%]8W=C58PPL3QGLMX5<.Z_1$8H4@L)2!%=*9#RE M&F[N-7Q!M+1"8H465*W1.XBX0D/TN:#;E!LAN+Y_BWYX]2-ZA7B!/JW%5M$B M59%&/T011ZK=#/@"8]7C\"BVJSR)-9-\2K\-=M\0:% MP6M$ A(Y\"R>OSSTP EK+X=67]CG9>/ E77@2HH<015*JGGQ4*8QUYRI"Y?; M2K616ZTI\0NUH0F[&D -*R9W;##__CL\#GYRV7PF94<>B&H/1#[M\X_0D3*A M%%HRZ#T,%:)((.129)EQ R\T@S_5+A^4BL=6L>E*N_D0DXA,+T>[0^N<8K-I M7(L=X8YKW+$W9Y!99$03DP%;4V=0*<\.?WS. M$])V9$;Q[4;Q][POV6@-.'4MF[V;6-:CLO@4DM\$,0H;L79*W($;E*#FWC! M_6;":.MR Q]<*2$?(9Z:(49E]@A!3UF^,=!=D"<=/$$+<5+':O*W\EJP4G? M.D2&) IG/8@/>!O[*<4B5@8R58I!>P+J11FG2Y[U-Y1*Z9DZRKFT';N -"X@ MWJ!=)XG8FL8,K87Q'5UFSJRJM!Q'((C:<>I*X4E/E>*&][&75.>WDFTH3Y^2 MO@R2T&LF8;B3$O*JBIX3>.A(==S&W17"I*^]X(:NL9^O?[<8/=BBSM_&;49V MR/0T%=S0,?;25!/S#7TT ;<.I4DBMZSQLA-PW,V",(H[[NR*XF M#0WBZ8L&ZQ4O*,QGIR%]E1*"N7TV@ZIL$BL5DP:_R5"]51^EX#C M( S;8YI#K"=/2&M;@,K.;61C!O3Z!WV$;G=&ED.6(LJ%2%TRZ MK">G&=\A@DD0]EG?,#[QTNG\#JCDT8PBQA!C<=T$G4"QH^1F[7;GDB(DZH': M,#/Q,W/=4"!&.VX2;?GHK$TG\BX3QP&.VCW%(8;Q-!CW8&\HF_@IVV"'85HR M&%U-+[1VF+*Q%^SK%B:-K&\@)%TV#L?!M),B7;&H;]@@#6<3/V=_$IIF_7A? MPU;U@1>%B0!D$+1X+E*G$5W>GD71N&U#5PH&#]+G_X;AB9_A3UK!S CEQ=_E M\"B.2<< !]63>-8SF9.&Z\G8RTGUWNP$!1'OR/!2"CJ7MF.CFQ&"^$>(9@-U MT(#K;=0+WO80QZA <*?XNU(Q'D]Z0M>,$\2_K;YCB2$(ON))R03]V UKT#3E M1@SRU4SY0]LM-ASRUVE9=YL-2=EI#;[M^K%9S7Q _//!746$M\!KCTYHWO4O M3L4S:3M^U=I,"6'P/WYE%WI'F!>_LCV3MF-7-B-'Z!\Y^EZ+/(V-3@=T1PH2 MM[/<(30<][S&"YNQ(SPQ=HA"GDIUOXH7Q^=,VHX-/CA6\)\K_,>I?M[3B7_C M>")LAJ?0/SS]HU1WG#E,VAMVAU"[H8\.SN]R)A_LL:9"]DU'>>95/ZV/3J_M M@6'K^0V^6)0'H(V:\CSV Y4P^RF4L16H#-Y,H/1D><19WFBQL:>$2Z&UR.WE MFM&422, OZ\$[#BJ&_,']4'S_&]02P,$% @ @H((61&R4B:9# NB( M !@ !X;"]W;W)K/95&YUWL+[^OOCXYNMDKF MO*@LCB:CT=E1*76U]^85O[NS;UZ9QA>Z4G=6N*8LI7VZ5H59OMX;[[4O/NKY MPM.+HS>O:CE7]\K_5M]9/!VE77)=JLII4PFK9J_WKL;?7Y_0?)[P6:NEZWT6 MI,G4F"_T<)N_WAN10*I0F:<=)/X]J!M5%+01Q/@C[KF7CJ2%_<_M[N]8=^@R ME4[=F.)WG?O%Z[V+/9&KF6P*_]$L?U)1GU/:+S.%X[]B&>:>CO9$UCAORK@8 M$I2Z"O_E8\2AM^!BVX))7#!AN<-!+.5;Z>6;5]8LA:79V(T^L*J\&L+IBHQR M[RU&-=;Y-V^5RZRN&2$S$]>-PP3GA*QR<2V==O3VSBJG*B]IUJLCCV-I\5$6 MC[@.1TRV''$F/IC*+YSXHMS->3G1O^W%1#<3P:B,EH]J MF:G7>S4A9Q_4WIOOOAF?C5[ND/8D27NR:_=_QV+_\A%BVXJ'3P_BTT)96:O& MZ\R)VRH;B@._4.*[;RXFD]'+&U/6LGH:\./XI>@-?51S34:H?!J-(TO5OC"V M?=>X^.Z%6$HG=)496QLKOJD$MI%0U(S.R)Y7*RREYD\BU4\@; M3GA#$:Q+_:O!\4DLZA#@3-$;/6% 6M M4'\TV@.1"J(JYPFU9^>\?W\C#J(I:!#/K3T&#'[$E5Z.SU_V3T6%L0$TUTR= MSC6JPT L%SI;_!,KJ&J.T61LP)Z9!V6?6,]:5G.!D[-17,#%/G+$BE5.Y6G6@! M3\P561CQD$,NZ45$)ZCV(*V6TT(=)G A(8'=8OGY]H?DUZC!*&,I6=4-')P< MBQ1,6V^T/@$"P*GNBJFJ%.0GE F*5IRIRB2\F((S.!^Y1BDK.0_N7$Z5?>8" MM#"0/5PK[=.PMG=B_#22\@$B/*VI@EY*&S@SZ>+91K MBR@19$BLHWE<]K77(5CB3LF[JJQH:K_@9>HQ4ZFR MT(O?I:6B$);L3\Z&8^159*HP(Y-NP2/\@5+7@RR")I\1;*9QG F5A?C+2E2F M.GPP#&WKW*[GW8-.,9HBQ?AR./FVL_V&@!@(-9LI9IO0GP:MSGCU1M](AD]; MP> 7H^'%MSUXGSM==),!P?U_\GFL@CM;*C5M"IPUOK$*4Q:F*?(MK@D_RQ:T M2.:Y)I@IDW6@(+N6 +:IR&_Z"?XW>I-24S^V$+_Q1!(B@1UF\#+DQ$Q3W!FR M[D)6R.JN04#&8[R9*PJ7X 0.^3XXVZ8Z[4R5QQ@"GG6BY4 )<%^:#6YFEL520)U_ #(Y:DT;B^3+AM%P30U&PP>F(A(MC?Q#(NN0.()!5Q!/ MX52A8N&4C(K5-DQ1%"E\L=64&(R!/UMRAA;%V[M?D^4A 9&G 9]MF;)Q.8VI M.*W%O \2DM'LRXY\2 *+QJ'45#'Q.)P::SF]-TA3EB7\##CAR^*] 1FBM?>H MTI8*90_M'G?D>6FH8X:$PD_&ZC\I9ZIL49G"S)]BYB,@ F?DAI%.039"Q"%S M%(5Z OFMOG3>.>B3U?>*9.UQ4"XPQ$15%0!!?)N(UMDV%UB92[L7RGNJ86(?OI-E_?)=&.GXF(2A"DZ^B!,?&!+A M.@/#T9$C]X[@3=I#;OO$>BU2V:#M)JZ%IMNI[S1O518X!? X'XB?&R1+?+P8 MK(S@L>\U]Z@$:2QZ47_ZI3A0$K-E9Q;&;]T30H$ O6WS])HM5QK+@V-:'8=WB:<]<>]I<5I7%.DF1'S;CZZ$T:>W M84:'_-J N.==-^@*[38IN*16HC*>[2 M]AP[A%_(!]0L=,ZPJ]5MC^JB[*#L@=%NYF[(Y8Q5PF$ M:F-OR]*@FAET!7\&&E@8!T+Y7L-R.56A3^@](.%*J\L%G6P\1X<2\B6]A8GS M!I71 HH*!(4P;&AKJ#-OV&)0Y<'$RIZX:DF.]JVWLL[:508P> MUJ=X$99J/A3OK"DCB"W3;AWAYZ92Z:KMN7(S*M#! SHI8Z.ID1;:;3@E3G%B M2^/K&*AU&ZA,16)^(D# N<$;*"C"Y0/G&\65@-*VG*8JG9+T0#3US (4:WTI"\H$-\>-?,&,1&N MCZY8BYV8A3J;94W9A *<$_&.W-/G&]OI%C6D]/A:2OJD&X%P_T7N2#2M&6/ M3/_;LS,W8OT GY MR'@?\6&I"AQ<\E7T4/Q:B7=J:ANZ!)FSO*T2D S MI$!)K7CEO/9-C$AX!0[6X;ZRK5K]$W94MZ[.][N2R$&CQ%Q?M',QY3@%7"/+ MW%4W(:=\'J^[!>OJI'[!#C^' /-(+$_.3@;'Y^=MH[5;PWN>U&\SR?*;.K,! M&5UV5H+(&9^W/QX/+\9T2Q..#%7K0$,T9)G#F,.6[:7";GGNL.)=6-%>0R3A MJ'RWIX.'D_^LJ7X\N#@]'EQ>GO>ZS&WZ_(T@\?1U@'9A,&(,OD8G<;!RZT&" M]%#<8J7U8ZG$QPL<93.](@[WY)OW6E$,!.IW(DB9TE05.S#G%GFPZV-G5,(V M>S*.DS4F/FJB$"A*^Z?CX:A-7<1!^$X.VC?AEB9UK.JQIEKAJ()P)9X^(06% M(OQ5GB$(E:@];T#601GPNL3GF0^]K48"MQI4"SF PI,;46;G+4>$(,ANG+1" M,W2ZJ;BL9:[USK&[ =@5[<_3Q]^MZ')+NLI9=_OQ^&QP.I2A9K2*YF]ZR 3 M+JIL_$Z/=W7M+7.XCHBW0"LVZHL;/%C&>SVZ%E;<+I<4O]P)@.X=^H6V>0MI MO,":%48RM:\!?QC__RT@W%*[W-WTC?=3[/4&I[)Q_-4&W]DWEPT\+TMOT MPXRK\'N$;GKX50?RU9P +-0,2T?#\],]8<,O)<*#-S7_.F%JO#]V7%O/4J#%VG_?4+T[JK9P?;A@P-5#2&Z M+BV&!IWMY?_Z4[)#L>#Q\9X%IVG!*>LM&[&6+W74SY]Z=Z4\/0UI](&/RJNA MG.W)*1?1XU>+=?'YA3A#N96ZL.O>KFRE^ZC.JLH-?;3]6KUUK:VL"4^/(O:C M54=5DOU"9)_ND?U(_>#ZV 3UJJ]-O;W^"'J.RIYF95^G#6^0]& __@.4]V"-OQRG5?\Z6(7H$RW]W'5CD/=PMCQ+H2=CHRCP[0(8$ MXR_-P?.__.GDT?%WMVC[<-3VX6W2?Z>K_BC9ZGVOA]I&4ZLW?33>=NJU[75? M6=WB&X$)RK>?&X.P6(;[2'6]KS. MUWC:(!UBPW\G/3;>0LBFA29KTQNOV_::?C>;*&LC]GW?LX(7M$^@0YUUT+32 MZMY?_O3X]/3XN^_/SM[RQY/O[A_>5/7<(6+[ !'X%'#R6I.\%[IEG2X8+C5+ M1DR:,287^U9>3"?&FI\VT)N,%!3LQ1K'QALHT=->V=%KVHPF195]$5WUL7%L;'\A" M)]]^IU[].MAXK>Z]-(@+&^]_N=;\X;-L=*Y#HUZC9DPV^NP]O%%#CE+V;BB^ M^#UQ2%KX@6*/-O-F/;3)C]#X9N!=F&KP-MKT_*M/%;L#Q^XZ&[BNY8"\>'6> MXY'/:U-N3>UUPO:^%K53O4NXJFJ'6KXI&VS3L5"5F/E7,2C M4,H;.):.NKQ6E!&\,Z5!:Z+9::=LS9TV#(T;6@B#C4 /R'Z(L@]#+_5W-."M M?B %XSP=1=LSHI=&!:QI"?IN^+9^ZJ' MJ4(@C(].]E1)E4W+E@)G5UPQPEA B@0_^K^ &#C#Q5E_^I+LE^< M>",P/@_24_;4J@$@PBE7.#2 $+P1X>I==W?\+H>(5$2TSI.QMJ%J71@\%22O M?E<"%K_@%)K/[J":W\KUM..8"4A;V14!$)L].>Q-RW9)SWR!][;!-W.$'"3T M,YDFAZ-% -J^1FTF=DXQE)\D4^@>FT58B)->SIY"=;(R9R)]0X9S?2X@8A#Z MSIN&NHA+@D+\31%+Z(DS$";!.!8K]L3'Q&VF\K20I"7Y!EJ:Q:1+("C *$BOH?RZ]2 M0(<25"B6.OW1*#.J2M&B QK!C8!%;#0,M5H1R@FD$#AC!]V17KP%GC>I0+16 M+VT[%=8IM\3"?!*V_9XU8[TF ^?/M]:C71IYE@/FW(=<"+@<%W6L16 MA7E<374[#HS1$N,5%\S:XN0^ PPR=K+4H?J)BC9*R]J1'"XKBRWKFDO=#FQ5 M"J%QY2*AC^A"0F>IO?;$\.M<"!2)85L887OZ2OLZ[;7] 'Z@M0PDF\&#U$!Z M:+276.!(;F%Z=4;1#M" 04$J=XF:GGVQX]DAF-70PG67(GGCJ<"0;F1PJ+GA MK,H^VA:]JZS59HEZ"A=2Q:3\#=N80OW]S(Y4U1L464?QW;*;O354,AAU>VP( MUPXAX/)=T?](8%*A<43/)RC]$"_=S9\+$#&]FB !]F&C[!!U4!* M,1+@_!1+L_2N2LE\DDI$>Q*=:$J&%I9#CU"-ISIEF&,($G4P!:'/%O&%+^+ MHL5=RU2TDY=94((P9!$" [JPKI4Q-0$>00,9 XB71,!&#M(I'UA'P8W"/%R) M67"F(Q1PL+%@:%"09=!7=]0+Q$/J8;DB#82:NSLS/E>16" M$+0=7?='ZB63]H+&R7I7 (_FNCP_P8%)8R$$&_!%B@S$G1P?_SD;) &30LTD M(EP@TNU5?%9@;;U=7[/8SY7W@(A.\;"0B<_B<.?9\OSA56'Y4D,.+&I46;W& MKAMXO;5XFBH5,BX19;$J0M[;-<*JA=7CD/VSI1441N7+F;K7_\1K)O'E9RN, MANZI:G,TL49.K \9DY M2'(-MUM$I&JP1E1UQI82#8ET582RV(9*6,@8?\-(=TB2 "E7D>@.@,8)!JPH M=B4P9834ZM?!<]R7FXBW!786&CL!H"U;C(VI[8?E?$2 M)MB*-';H77&6BV?8=FL2R_%UAX*S$DKQS3-W81HI-J2F?K$1 H46>9)&X*BU M%GM9+]VQ75'V+]2F'3A_Y8DJ#;ZDN/+XD>B56])4EJ5+%%;3@(P"@/OA*7JF M[A/&15H3 V!+=K;5OCB).E3O$CJ^0RC!T.,,-!MF"(D69QCUQ8-K0!:7-,B# M=C8T$OMG%^?JT?&CQ2C]-9WBG)P*#8/ZA7Q\GNI!&*=):=DTX?P%#0M\', M$6#-=>(EJ7L9C1 H>(0<[UM"X)"+RT1E6='6PCB"@2A4"IIQ2YZ.T56:J$I6"CS6H0ZX$IJV=;^A2T* M2C3.ZFJ"3;?)S:L$?#(.31_\0!VCJX49T%+N64<*:E*QLPSNI1,H3Q)CQ=Q6EG)! M[ FR1O$VC(6#4C'S#GIFJQW<=B!5]ERFN"VK# _ZB,+E2?TXQ+/*]@//2J 9-PQ14#*0..'_ASST3ZOT9ZJMTJV-C. MW-%4-Y6BJ&];5^51!P?BG@P90FY-YBY8TG58G@'D\)&:V-)Q@I&K,]F3AB:T MS=Y$NI&T/Q>L'B9I\/@0DL)YU[W;62C-WKG:,'FB>:C7!.5? MTRUT/C[/TR9"Q(79>"-M$-=]XWO+Q$U'Y'H_UW;4+(=:UHVL$- *5]++%:FJ M?J"".IL;^_+ALOY))Y'I.+>$M!*%-1&4FMIQJJ YLZCDZ^"XEL2K<:?*.@FB6'8 M4 >&_2 F#T[IV04;OJ$;/EYZ ^_X_L*RT],#?.MH""&TK=.\B!B*SA-6X9QC MX\SX@6>(5BCXG2[T]EN1FT=9Z'8#ZM(TNEW-XN"F:PE>D]N8J<'5 R'^=MT3 M+A>(X/B!K#76FV)FN-H.R8RK"V56R CJA6@?9H1],5.^HEP-8^;:,LN5SI-I:(]TS?WPCIDF7A.!F7NX/EI2Y)LR&RK.-03M\/3(N M&OM*9H_#SZTHO2Y=DJ\VTP![1BC'T>*,14[3/Z%Q8M!@YM40E.V#$4+3F[6+ M=KKFYHHGHSRBDR7WF7@)6^TZ$6;2=>@),4<2R5>0A^JM_!EVD ^B'N1*"@ R MOD,;ECLFN7YA<)0<]-RM$"G,A75\R%&YR"($PT6V8-$:K(0Y\J+NQ30>YW;/3 M71,"<_;-W$0ZC!:V7S2ZRF%<'-+P=4Q)'XCNS CQ'5 K%WZLJ^V6A$5URBW- M3WQ-UTG,**;I0GI^E89+U#_B3P*-Y,J]5DPF(*TJN1IX$$ &>7[;=[U^%PE M(_SHHOJWB>JL=GSQ>6'XXB6]-D(+GA"D_HA:R)-)>?F$C/+Z[.(%\DKD7[SG M7[X^_G:Q0\2]G]T&077Z^/C^$Y4F)^I-1\1ERBYYG&,I2WA9O$N01BSJ7K'7 M?26125_A[# '8F< [ZW&&OL5?"7"RA<3EM?I!I>ANGQC8;4U/LQKQ[ K_$E< MP//]=Z*&"2'.?WKY WMFWLXR=1[O5_/ D'9,NT#2RG)^TL1VP7,L:6S$T0'= M]28'@>5KU6Y\;86R+(VTDCATXETB)?D-G]E1=5*'C9Z6?15F>N1+;$,UBSJ: MF847:70/*P3.I'32QFX#P[ M=N.+#;>^SC";[3%=X?'[S_H37,*I-FI\5ZK]=7\N35)WY] XO1QE;;\D2C]P M:QR%O%&[UC>,[V.+3.^"]=5UBLV*G9]NLHEGR1B-U8A08^O0TK)#]'B7%-.F MNJX]+98!G/.=X*_KANQK%WRDVZD>2RT1/5GSC4 M)"^3]^VW$"<[C5W7=C@/T]!5WH%+G>84CG\'::4N6-[3^H8&.=\?"M4T\L0.5;+ 3)=WNS[- M6WCX,IF=KH7WQ,&N=\6/BE?\T02L^1\R\ LD?92W_<=OQW\K<2;_1&!Z7/ZA MQ0\$ BJ-2LL/3[\]IL#&:WF/Z+;\#\86+H87<CRG$ZD_1VIEUQ M>O=A:Q\@$I(P(0DV0%K1_/H]]P(@08JRG:UYVWWHCDR1P/T\]]P+ZO76V&]N MHU0COI=%Y=X<;9JF_OGDQ&4;54HW-[6J\,W*V%(V^-.N3UQME M7IZ44E=';U_SM1O[]K5IFT)7ZL8*UY:EM+MWJC#;-T=G1_'"%[W>-'3AY.WK M6J[5K6K^J&\L_CKI5LEUJ2JG326L6KTYNCK[^=T%W<\W_(=66Y=\%J3)TIAO M],>G_,W1*0FD"I4UM(+$/W?J6A4%+00Q_@QK'G5;TH/IY[CZ!]8=NBRE4]>F M^$^=-YLW1R^/1*Y6LBV:+V;[405]GM-ZF2D<_U]LP[VG1R)K76/*\# D*'7E M_Y7?@QT>\\ B/+!@N?U&+.5[V>:?J.:]W?F"]W^U:5OJ?K.E, M7)O*F4+G7G%9Y>+&*@?5_06S$A]T):M,RT+_O4O9Y>GK^Y1[Z)3[^*^U7_(D_^[E<3?+A;B MIK79!FG07V?C79MU)47RY)WBZ[_I#!FO1JOPU;-7 M3V<"?RF+!W35&$$2EB64NFU,]FU*E^,&XB5K[M_2+UVWUK42#V'E[49G&]$D MNB&Z+Y_-3 MP$I1<$YX);;2B5KJ7!SKI^+)V6+^/-X!(XI,N@T)0D)GA7'D)W+CL9ZZF^ZB MRL%28E]3:N>,W8G*-"S!V#HPV%+Y[;')9[D3YV>, .?[KNE7^SM6BWZ9B]\K M\4$M;8LB(Q8O_=.S@6^FXD[B'P 7WW=/H);#47W/5!VT^P 8-EL2D(REOM?: M=E6-_ $H:6N"$&T KBOXW<U\?"))D9$*E3.M0L]C:]]E%04TF\)0M:80.@V!4[;,!DR&QBL!'Y&3%]RQFK]1[\?R7 M7U6VJ4QAUCMQ:XK69^IOOUW/N-:N5IJ"<[*T':>;]"PB@C42GQSF=R%&@6ZF MMTM4$$Z$(ZBDDL\S4#<8N #"@*>ZB1Q!4FPI)O#O/PRL EMG:-X8G:58%V:) MIW-UA^ZL9G/4!?3 ]N':#,V&_::"4RG8E25.#,0>[43A%<.,*H75RL4$_JSS MO%#B%^FPT-4*R"?]@M?8TD*"*Z?EP!,WTC85(O>KL@ATU*2^O/_152WXNDP8 MU,!WLW!ABX(CS)+EDIW[AVD!N\!&B*\6HB!08>&&8AZR(8 03LO=P DPCZKD M$AII3FC4PQ5MHZG0+ N]]F6&-53?R6!.\9 QIJ?%]FPV M$\NV\19 909"$BD'-W$NPM"=!.2W[H %8L1^NNDRP:I"!H2EY[MT(@D',LW% MK:]-",]B-\Q2ELBSUR@ ]@2"HIE-@1UNG8AY\NO&.7BI4AT*OFKWXG8<>;* (!*9T0BN8!T@*W"+; M3^=]09L-1/4KE@!GKG9J@"MC._20'%SF1B$2@"\I@9V$$!"Z^>TRP-5256J% M5 Q,1CLR0K.QIEW[16JS579 #T;I[!F']\T!4 2/\21M&,NDKFOKNF!OD9=F M1/UZ6Y2R:HDFMQ8<=NAWANO.)LP;(S8PLOEF*/#2%KPX.K*& \@?W!!2CE@F M7\@YA:^X#9S(N!C8%%(/5P[3-HXR*835@\$Y'W3VI#E46Y*W."^X)V"P9B)+ M&O3\?2P-,5NEO@F0PGTR6.F.VT_)S?U?1U@7'4V@,4XE$$^!W9>"PX@?N6(BV1>P. D&E&Z(WHPH?Y P M:8+[YWI&\0 1F:/:"AD\TG=N=X'= :ZI=02-(K"!> '@<('I,WV_I-R&_+EG MG=0B[>GAX^%0)UTXTR<^+$[CBK1I27J(?;RDL+@*83&+PPA3QQ9GI"_(H^;F MZE@^Y3N)I1,#_J'92TI./FLT> W:5''+++NKC@!>/P])IBZ0$5 (>D?A;<23 M\].^52>D.%X^'4P)1ER#&N?!(W$&,RW0-7UUXY?J*=/7":W'2I LJ1Q[MZ5+ MS[A;!^HA:\&#P%LN60\(QKB)!V/EH)%:1YX:789PMPZGZ-:^0W M6)>)QSU,;0^MPW!'6+-#2B75ET9N*!2Y7A/><,WS*1JX ,U)P@AB3')X)!C[ M?!H&-*)0(.6".LD=4 =V7C4!J5;:NF:O/NVM>4@EP PR7)6Z+?N18A!Q,L,0 M^..6B8+_[.7\13_:(N5XBL$#1&\C9N)Q0!4F39?Q$8H [3I)\#$A.K[ >J+7 MC6C">)1MQ7Z@LRUR=$KM>T#OH-QU ]00-*#:)!'VH;7\$U>WU^+EZ4L*)/IX M>7K)ATILF2B83$=J+F"4\XO?;S CC1 M:O?-A4G95MK<]59BF5O?Q41DF>@& "<.H$M(EK*(>5!C*@ZDN%-5#L\,ZX+( M6SO==XB:T&;&K3H'R/1T^M2CK0G'@AAI/H@YH,IE64[I[0U'?QIVK MG\50TRIKF8$1#R-A&&LL:A(#HZYM9*\8MV'LX_JY)QG"*QK;LUDDN^38H3%" MFQ4G!>GD)1B&)Q #=;V0C5(=J?GU_74_!R17=G$YRH09UY]=0AAHD-QU%25P M#93;TW?X#W$:(+'+.PIK2?1J:,J(OGXN/=+$0OBJ]>A \#OMNW&RWU$&ZE(- MHQ@PQV8+(8;A#!6HNWNV&.@8]*,1U-:''L(J 6E5-?U:1K)PRTU!7B>K; M<&>H:S1^GICQ)\_ZHPY&W57''N!-6_DQL#=5XIDYT!W0EWN^^("-9V*-OLY. MC ],6P!"U)KX*$O(%B)WW*-D& ?QLY7JDYZ*!SZV88HQZ"5S50#H["[JCJJE M&C_:5_9.=T/4 ]M.0B\#]8HJ"_6X 38GXIOA,:..GT9DW%Y,0BS3>3SV:PN. M%H_+9Y.XN)$>4+BF8^$<,Z_5V4 M_@T!?] V$'B8@DGH3I4T-N&A$D8I$7NV#H(9 *EP;W1-V,\K,(_H<#4HY0;( MZ<5**].TJQ\C$[X[/O-WB*;%"$"H8 M'=%"F,2(W@VSY( &AFG'@&,?0L\.+^,ATP'5[]'9GWISZ2#;$HSR_"=5 _X% MWH<9TH-6Z0J>XQ.,K.G1@-GOB."Z.![JK =&\6-:CTR:U.-AG";3KNZT/A;S MD?G]L*D?3\3[W8$'.EF"S .V:K*LM0GW#T0E@7U-"([5QIARK%=!@%QE?HPW MECT^<4"0IX.!Q/ZA'B%6>DS,[O;V[0$V9MF_!(K^K[U (/[_#8(??H/@ZP&= MDY:4I,NHT_7^)H$/M83G9Z=QEB.^="NX>"F2XW!K3Y"##4)R(KD"[1A#P^K?^NMLY(*Q]X*8VF M!32=]H5O_\"8CR:ZM=YI@RX0PN/Y^8Q>5\/_H[_B79W#TJ'=87&ZVWV ^&3L M;O>'F1Q0]-9'T;KXLAUZ7B\NAU^4_,'#J'$NU!OC\%^.1@;U@&%\!RYS 7]O M])*&._UA]LW[7RXZ<5$DUU:6X[<8.".ABOAX<_/B_(5@!+@&]94S\='@IG_' M_V;BL\QD.Q-?I=Y*G]X^>ZG=I6,HJ\OD*.J8F*I_)2#V!X?L.G&&?)7[0:)O M+GH4.^R3(7#V/J"8?M:Y83;TP2Q,[W;/5A2DC_)()+R=*&BI%(]$NH,%.IAX MMJ'70X=]_=B1Y)SHE)@O5M:J;6#.UOF1XJ9%XKGQ<<]A(WK8N">7")!B+<3Z MR+U3GGUL9+7NU5NU=")&\!+&RZ'(A6/:@HV$JSZU__+! (7U!-&5'#\(18XP'>M, R4)+\^ \ MT-6@3O@]/!L.L:'"2"/-'N.N#2@XE^#W/Y 0A 4*B5VU-&I,': "< M$/5P>D2?#RK)9$]Z4IQN_HI>#J,N6FI_G)<;X0Q[HGI@Q3@]K8@B4"S<&9U[ MBNB#:C3E -BC8NC0QD=&([L$3QJ;0>]AU;I%]O!))F$G37$]>7"8ONO)8(^XXZY72W>L@/D>CI3KZY<$A"?T&:_*MH,KTAF\RZA=$ M!U%&^Q&2IC-MKH85'2X-YOXAM/ATG0Y]P5ANZ;6P_C0AVAF;<[DPR?LQW6// MEKMGXVL!LPB(=_1]^$B":1=>&"0M"9HBL/7?0;QRZQ)V&M$FS]80UVV*O9E^T<>Z&Y'2/%I M. D/V>7V\GTV?# =_\4X2WGZ7D<_Y**D '4(Q$H+D\G8@>Q+//$:$M_8GYQW ML^PXL>MZF]K_WH-L%?+LP!AOJ4!,O-'0Z2MV9L-S^*4/@Z6BR$6# Q3/FC!R M .\VVQ')3FR0#I+YE95#,T07:12]I4G!_8Q^KP&BWVQH9'P7WX4;Z1EFRO$E MS\=M1H9GPNVM/VRMQC-&1KT^/?Y$G]GX_.FK[O2QVGTB^';&ARG/6YZ<)7%% M/6>LVZ/N40YF\3V$/X;?7>\[Y\6G)^7SJITLGR0_2@)EK M_MF=\[#H?YO67>U^V7?E?]#6W^Y_%OA9VK4&0!9JA4=/YR^>'WF,CW\TIN:? MMRU-TYB2/VZ4A,_I!GR_,@#"\ =MT/W>\>W_ %!+ P04 " ""@@A9C64V M:!$C2[1Y MT'3W6*QV =:&MM$)-(EJ3C>7[\SI.0XB1VT MP+Y(/.;XYB1YNM;FUBX1'=S7E;)GO:5SJY-^WQ9+K(6-]0H5[I:F,TE5GI]UDMZW<)G MN5@Z7NB?GZ[$ F_0_;&Z-C3K;Z64LD9EI59@<'[6NTA.+G.F]P1_2ES;G3&P M)3.M;WGR:WG6&S @K+!P+$'0[PZOL*I8$,'XULKL;54RX^ZXD_[!VTZVS(3% M*UU]E:5;GO4F/2AQ+IK*?=;K7["U9\CR"EU9_X5UH,VS'A2-=;INF0E!+57X MB_O6#SL,D\$!AK1E2#WNH,BC?"^<.#\U>@V&J4D:#[RIGIO 2<5!N7&&=B7Q MN?.;I3!X?$EVE7"E:XJU%>RNT[XCZ4S3+UI)ET%2>D#2"#YJY986?E(EEH_Y M^X1J"RWMH%VF+PK\K5$Q9(,(TD&:OR OVYJ:>7G9=YAZ+3:460XNC!%J@7[\ M]\7,.D-I\L\^XX/L?+]L+IT3NQ(%GO6H-BR:.^R=OWZ5C ;O7D">;Y'G+TG_ MH2"]*&D_SD/BX .K0-#J3^CB;XC/0+;U 86*&1NO3R"<03*7B_(C4@YBZP MH:E!S^FO@)DMS(VN/5\I'/+6@M+%Q7!A>4()BML$C3S=@[=(GW:B@D:1(7JA MY+^=KXYGWM/%KJ<)"8T1J,N"="2]<99<4TJUV.M@TBY6*Z/O)34F),N/\GA, M_:&JB"B"]5(62PJ7EULX9# P0]B!TKIJ[=L6S07-*6"=PTA!&@^#&WP(GE-Z M7P3/S(4T<">JQCLI0+6!@!C*QK =[!\K[Z$.;0*Y33SVH0\3#3)84[8=)7D\ MF?BUHVP0#Z>,K14>D2F63:.67FT"0+%8&%PP'*D<:;2R>,#$RJ4ZIM\QZ:=, M[!RYXVCAGL!A%"5RVY6U)#=\4O !9Z:ATPO2K(N[5)S+JCUFUM(MO;9K(^\8 MS'5%Y1;JP"*[KGI(;K9"+A0[U4*-]0R-[="VJ?3ZU21-QN\L7&H"S)OO.^X( M<#X//@#2S$Q%I2V;TLIXA@%\[@K62[77DE'L @Z?BR0VR:,L'SQ*/%_3J\84 MU C[4)7!]<1)><.!*)N0.%*UL7@HIOA1!R9G-H;HX6@0)UVM M/Q80/'&PLS"L8$L10KU=?;DN XZYKN@*YRN9FBVV]SAJ)M:+\/9^D/J9[$>:OZ:E^./8F\[_^^ M/!X7,YU+E,M54X8BX'N(H-KV^$MJD95>^7KA>7O0^[$HN1/S'[>CS(9!'0.V9OLE@R.-) MQM\!)=IAX*,\A72:PW@Z@F$VA2_^HN#;VDMW \J5(8;!=W3ZN+L*;XH$\O,P^"K.@XQ0JG!/K(!X/>V#" M:R=,G%[Y%\9,.WJO^.&2'HAHF(#VYUJ[;L(*MD_.\_\ 4$L#!!0 ( (*" M"%FT.YP_6@0 *D) 9 >&PO=V]R:W-H965T7U"33*@F1%=URF!0:=O^ MRZ)%<3=H@IRTGY2%ZW&KH MQ?F-JRH=$>48A+2%N'$V:KLBJS2%Z2C"! N.5 =WW<)-O@!W)NX 4 ;QG2VH MV-#P0D_'DY #><>_O<<([_C_^BGSA,'VDEC;B3,9(/XKUWE8CH5!%=^A^(6!)4JEK:9Z&#T';MS)H* M+,1:>NV:($S"J+U31 6@8*6GY#(,L.(O39T$!Y&6D M8I^_5,HWU(:A:.L#.Y:0E6ML'(J?][VU+J)SO012W5KRGW#>8E*C]\?D^*6"33P%-N&*Q\D2<+O$5B[U]M,$/I121='EU]S4E5Y"W'_(-IE'O45K(@#TH9G1?WWOV)Z8F1%,M] M=HO1P^>6NLL>?U."8_Z\1]SE4::4@#0]*8.31O0FCC>GL=QX+!STMR:_ 5L<8K5 ^0!=LLT=MH M]($HY9IV3Y#_)G1%@C8@KY O_7>JGZ)1 ,5;F)Q"OZP14+PNR XJ*37,(!6D M=P9F=-0KF5X?:-32H#[;W5*4#4SRL;2:ZQPL48JH+!P!H- LB*)8A%1 K!)+ M5-/C>U+VI_VWR&+]OE]$6\_8NZD7VG+TVT)U?'P_#1K MH[C=1%>GQSAW$4][6I;XEB+/ KA?.A>W&S;0?YW-_P%02P,$% @ @H(( M6<,2ARC\! PPL !D !X;"]W;W)K&ULG5;; M;ALW$/V5@9(&,>#JLI*OL0783H*F2%HCZ>6AZ .U.Y*(<$F%Y$I6O[YGN-J5 M%#M"VA=I2<[ES)D+>;5R_G.8,T=Z*(T-UYUYC(O+7B_DF'A615)J32]K-\_[95*V\[X*NW=^_&5JZ+1EN\]A:HLE5_?LG&KZ\Z@ MTVQ\U+-YE(W>^&JA9OR)X^^+>X]5K[52Z))MT,Z2Y^EUYV9P>3L2^23PA^95 MV/DFB63BW&=9O"NN.WT!Q(;S*!84_I9\Q\:((<#XLK'9:5V*XNYW8_UMBAVQ M3%3@.V?^U$6<7W?..U3P5%4F?G2KGW@3SXG8RYT)Z9=6M>P PGD5HBLWRD!0 M:EO_JX<-#SL*Y_UO*&0;A2SAKATEE*]55.,K[U;D11K6Y".%FK0!3EM)RJ?H M<:JA%\?O&2&%JUZ$+=GIY1N]VUHO^X;>*7UP-LX#O;$%%_OZ/6!H@60-D-OL MH,&?*]NE8?^8LGXV.F!OV 8V3/:&!P.COVXF(7KD_N^G8JQ-C)XV(?UP&18J MY^L."CZP7W)G_.+9X+3_Z@# 40MP=,CZ >:_1X_>6;JI9B@0$#:X.*8X9[IS MY4+9-1D1*WY'(")7%/:@I["0.$%H:343>EG'W$9*#(5ME( MNEQXT6,+)*4JF";KI&4X!.?%&V^<:9N;JD"@"52R%QW&@$6C2RR*IFCG']>L MX)=]22K0"LTM_WLJN&8+&NX]P)U-=?YG.9J"5#,,G%R-[/Z M'X0+DPLP)E)"H6<#C$'+634QZX:TKN1XA^8LV\\R2$R:VB)*10%X+;""W$((3K$W=![3 M2WU4$UA4J 8Y"%(&4A@N8OR"M )"M10_(&'%5CV1>+RA2$!''2NA0%'I"HTR MJ\N(E^*X+J:;3W=T/LK$[O&.I=R J:V&I%(.$WU )_=(:'/X52W>8!LR 1-7 M:!<]:."L\JFFFDT8<[E..7J4C'T.=Y-<%%H@*?-D8H6>W'EX7X#F%M1>GJ'Q MO-\=8$X;(\%UZ6WEI;[$*?'A%%'AN*Z*3>F3 ,2]PUX+)D:E5/A8*E,QS9 [ M=!0J&03B+'J=[C=@7*9>"Z K$BLD#+ P7;F=KBF6UYS7A349,:9H.KMA>H6<7G1/?DBP_C^)R&!$2)$8.W44#W86#-714 *1Q=UD(OMQ$'_8!VDUOWB)[3Q9D( MG-#@+'V<4G*>O9+%V>[BO%U@NF+,I"G8;CE);!W80JWKR9R=C>@])O*E#.S4 MYSK-&EPV+P?G1W0OMR'*MR[%)XEY3MG)*?VZ3P.*$R;49K(T8W3+5:["G*:) MBX;8;[3 V[3UWIO9V'5U ^SK7C]O/V@_$Q&F^$I5/O=LY-./6>:172+]$R;N(A'7_J4NYJ] M".!^D5%WH\'@YU^ MP:5JG1SY;Y?FY$A7+I=*7!IFJZ+@YNY,Y'IQW(I:RP^?Y2QS]*%_2_PAQ0+NS)FY,E$ZQMZ>9\>MP8$ M2.0B<:2!XS$7YR+/21%@?*MUMAJ3M'!UO-1^X7V'+Q-NQ;G._Y2IRXY;>RV6 MBBFO#KT^H8_YRG[ZW1BG4%U_+W)Z:!SM%DG=-8A'3VG_F=S\*T7L.A/L7!WB895S/!3F=&"#2B0VVZ#*UHRQ6Q^?6 ,Z( M;Y6$9F_:5L8(5*(A95PQS/&?<6G;&$ET4H IT77+#P'BL M+3O,9IRT8E$0.UT7(VK!CW@-^==X$DD@F'XQ5B?<9JQ-Q)&2*&&;25(-TULU(]XI (A0_-#15D96W'U1)(Z7<9=4!=2^^K%7ASM'@)2Z8FP MS4.("J[XC")>B-6H(!]0L5(+@87 V,"EYL($/N9(!D^_8HZ,6A^M -B6.>+: MK=]2.948PIUZM5%L"^'\Z_[MB%V)B*C(0[X9J[Q(T6%/UQN6;CJ!> M&CDGRY7/#SA*D$.NU[@/1#"L&%^;[4KO<%S:KJ4?7S%B_+P@EU?7[)W M.J>&L^QZH7T7MJE2XL%A+>3?HL,.FVDX3H8$,T&QK1*"A#I+T7$)3%)[9I:.890=,;:W+![4H!(XM3HPOF$%YM2)+(%PFMNZH0W[]SA3YC MMJ[BQGERBJH (ZMSF?J*.>.YKZ\K.LA82M(V=#Q$'685!0=J2Q %]R\!0X\: M!?F$D@U^K&8 _FB#T\ISHE)S:H8&"%S9CCJ,2D>B@"3VEI4XEWD%E$E2%57N MW1/<*&JU?JZM14DAB#J1?JKI[JWIP$82=[S(2CD'0V&OI*E)'@HD@< M>R.20.[#R =@V&T4_<#?.M\A/FO;UT^AH)F7.[UH69\]=NY[SRXKY=$FM5!@ MV4R6&P\*BTP"\WH.':X>UJ?B1\<,M#.E15>*(D\]#^AUX>((J"SWM0KZ)KI> MM2+M\GB14ET%[M]>*UA=J_4[ [%EH)QZOYMBA5[X-53.]8V(8J4$(49] ZES M1DXJY],$H^0%%AM>BLK)Q(+NDUY 2MBG"-L3C7/ +J@G8/PZPZZP=EJ_/VTM M9:[D[18)?QZC2EH9?0)HJNQG0EZR*-%KADV(@+]D[7$WVAMTPF@GVO>C:- = MC,;+813M=4@%;I]6+!/[6+^GYUKQK\M$M&G?3Z3KA)3P7#PX!MXS*DT\8'HZ MMZX$;=8>C41CM1?ZY MVQWM[W4V74;Z*Y?&0IB9OQI3#Z$[POVQ^=K/%S=/W(SHQ[,Q11+ M![U=7'9-N Z'%Z=+?P6=:(?3E!]F@L-1$L#\5&-CKU_(0/.?Q,D_4$L#!!0 M ( (*""%G.%1*#7@T HH 9 >&PO=V]R:W-H965T=?8!(2$)#$BP M6O;^^OW. 4B1$F4WW>Y#8I$$#L[U.Q?R]<;8SVZME!5:X-T=K[\MO3T]= MLE:Y=$-3J@)/EL;FTN/2KDY=:95,>5.>G4Y&H_/37.KBZ.UKOG=GW[XVE<]T MH>ZL<%6>2_MXHS*S>7,T/JIO?-*KM:<;IV]?EW*EYLK_4MY97)TV5%*=J\)I M4PBKEF^.KL??WLQH/2_XIU8;U_HM2)*%,9_IXD/ZYFA$#*E,)9XH2/RY5[OGVM34;86DUJ-$/%I5W@SE=D%'FWN*IQC[_=NY-\GEMLE19]XWX[O=*^T=Q M_$XM=:+]R]>G'F?0RM,DTKL)]"8'Z)V+CZ;P:R>^*U*5=O>?@K>&P4G-X,WD M28(_5,503$<#,1E-9D_0FS8"3YG>] "]*.*_KA?.6_C$O_MD#"1F_20H3KYU MI4S4FR,$@E/V7AV]_?IOX_/1JR<8G#4,SIZB_B*C?!0SMM)X(/Q:B5N3 ME[)X%$N=J51(!&";G/8NT.=GJ?BDG ?I].ESCHDP\3L9O;I=2^N5W7+)]\>O M7C+Y(@%$.<6<%%6^P$)0<]BC'/VZS:0#!R(Q>0["CO2!Q=)W>-=.R,JOC=7_ M 6M$U[E*B:4UN1B/1H-1^/F4F-N[.R0__X>Y5^Q.DX!) MT_^?MTL7J*AT0$34XCLMK>UY(W8<< ;-I)ML BI; *CC&% M"C$4]( J 8H(MF;Z[:"X#:3FC?6^B)6;OXZ5FPXK0_%SOZY$JE-1& _[I%6R M"STMI]V/_\-A$SS:*JJOB%/?B2':UT8$"AW%=4[VR ]KEI*U+%:!I5):<2^S M2M7Z>^[ %Z/A:"Q*B,&,/R__6MXK0<$0/=84?T07?:;.;RL0+3R45)@6"SO'"?:"K5\,]UWRSJJ39<5Q_:NT%L'D$,3BO5K8 M"C4N%RU=@,"QRM8^*,5<)9757H,!A"/,!)U>KZQ2#!T,VPDP@D2YL_J><.(N M0S+GQQ^*>P")L0Z*:<5R5 -L0(1:>8LX1D&79='!U=?%G<"LPV>%MQ+SM1S!N0(_L2%_F_X("X.IB M-#B[?"X ]@O@+?;?2YV1NPI4$RV=/NGQ"0442AK:[[B@RU'-$720,RHTTGRA M0K,1Z[K(U#>(1U1^:/FI-#*%,YE.N4ZZD1FYMICSH *$L>N1\7D)B&O\8ZD+ M+(,?@C#:NXH@RP6IY%/1F)H0#_G"I)0XA5ED>A6J,)*]#>#0.@KT6N\4$.3Q M41&F*>3#Y (GZ8J%CBPIJ:SLR8#N:,&X@[=OLD>0^Y-F, M,@NEBKHF3FN-;WA-(YZPF<4-LP]+.PL#@;/)_",^7I*-G-VL_EU_V$_=R.;38' M (5Z;C?KCQJU+.)JIOWW>IF*+Z?32)3(;I^QGTG MD_8<8#IFM4VZ:B,K[6[>JK*&1%K14PD=.Z70>X&]Z#(\JQ>0CA+IUB+.*!*$7ES+K7'+#$WQM$> 5M(DE_FFI)4C M*(SE@GD&G];D \Y-')4FZ0E,30'5N9 (!F%3,0KQQR)JM.0XO MV3)"-JXG.1R(VUKZLJ_A[O.JV#4_Q0'75R8-B:I9UV6#A)=)HC)"GKIY>N3M M*:IIQM]0UV#Q?CO=3 &U $](T9,#RF;K.44=3NVI#%V9+4!-)F;:H^9/D$R MJE>DF XOSKY"F^82VC<@AR <%0[ ZI;1>>I:#?MH%.6JS(=1#$&="74/:M1I MXU:D2FJO(8)9%=S5[6=^PS4DLI#)098R1S?U;POR_@)@3O.28%U0^ZF,R8!Z M.5W5+H2ZJ8SQ"!W0^^Q^[G[\(Y\:C?9%DOB@7\C,F=@@T-R4E_46\549IJ([T]T]ZY",VE.9VW1PW.E%?>\8:G)9 MMZ_!E)TA.C-3)_Z.96:-,2I7UZ MG59HNE&WT'RJMO/^#,_ ,Y6GW)=0GT960+4C05VM:)"@NR]V[@+=+00"83C* M=]_,).@AR3K0EZ1>W4;[#Q@,L8!:)LM&18,8_5:&/HH'&H$JE5,%SW/D]QT%TY:N\RQ&#AN'1(U;W*3#G@^"7KR@S),4YVBHKR;655 MY\SHN+\@RNJ%$R)PZH-FL O]WI-&%5 M)X..-PYZ[@4/50^ECA,Y:I(7_./\ZOFX#:%D< -L)@BI)(PNF_>.H?!&^%H16YH$E9[ M+/)S3E8JA&!S?OD%WL19A(9W@)]!JVS3+8+Z4[^;#= M51TT2Z?3N:BG)R&<"K4337L3AV<*J78-18QN]<]#NHV)X+T@"$_?Q0_+9>*JX">UA6:V*A= M4$"8*=>:'G4ZE'U4 ^3+Q@4?%P34_#&^&YW0.??(EYB=3]EU@ >?; MD ^A*VZVW/;5'=C5+EBU[PN@T];W64#;%7^%1J-WQ&3X5*NYVWSH=AV^[]HN M#U_)?906O;]#1[_$UA$:^J,0 O6%-R5_[;4PWIN$$' M-)__O?TO4$L#!!0 ( (*""%DPDO,L[P@ /(8 9 >&PO=V]R:W-H M965T<:_YX8N>S0/],+J^+.5,?57A6WGO M\#1JM62Z4,9K:X13TZO>S?'[VU.29X'_:K7TG>^"/$FL?:2'W[.KWI@,4KE* M VF0^%BH.Y7GI AF_%7K[+5'TL;N]T;[!_8=OB32JSN;_ZFS,+_JG?=$IJ:R MRL,7N_RH:G_>D+[4YI[_BF64/8%P6OE@BWHS+"BTB9_RJ8Y#9\/Y^,"&2;UA MPG;'@]C*7V60UY?.+H4C:6BC+^PJ[X9QVE!2O@:'58U]X?J+RF50V>M[Z<)* M/#AIO.1X^'I__O\SNJ/=VOENKF MO2]EJJYZ* ROW$+UKE_]MT:?/:?_!#/VL+O%9IC"6+ M\D( ](GRXG>36E=:QX'K"&7:H;#RE;!.:-,^I4" R;%F[.SP?'X7/BY1$R$ MG8J[7'HO;B%2%*A'0#M]'(H/E0MSY09"LA!2KMJ4#_[%@7.;9UZ\.YX,WIU/ M.J=!J;BS12G-ZM4OYY/CLPM?6W"S9<&-%Q+\XE''W0/K77R -C,/$*%BM9%4.T&LPG; MH:0P_@PX2SV5L"@;@A*$S#)-O#$ #JCF3=UD.?7DNZ2BZAPVA7<8(?@(/(-Y M$"_&4*H6'2C(',/_[VO-OEH*1V4PMP^"5.)3<87VZK$G[44KQ]? M<*C+RJ7P4;5.H;1^AD<>]D2O/1!17"@ 5]$H T9%@Z08U58+%&F"2@VK 99C MDRJ9HRF@VNRWPJ*LC(K8E1^(I$)15,EW0+'9)A0;%PLE15T*DGB8@Y6OEFB 3Z,K?@FXAO..T C])&ZC95 MD422WX+-GH9W)""!4HKF,P%06?3UT4]@CM(JB2A?0\=K(DQD6S/[]S4TIM+/ M1;^+@)A_C-^/F/<9!C]T'I**YH%$<(LKMS*TFY2C0<-#.ZVO9%CTH9&6"VGD MC&)9J":6^[("?9T,Q_$85PG")5IBO"A0*Y#9=ZQ%^J+P1NM]B0H#F\2G3"\ M98/A@= !W)+#8/-4\D"$N0!DDX'@?8W?AI*E:?/'RCG*.';./0ZK+S#S4H/# M,6PT\P/*J!/49-5P))UU:Z5CBOZ5YQWK/,\KSPY*U&N,#:V1!/]58U35MF*, M, OV[9FB D?()U1.JO2"L;JNF^Z(L-7L".&1O:CJ18 *MU;13BT;3'WHG(:H M!V(YU^A2;'6F?-M,2KEB977<.KWR,\^Q'\3#P[WXV QQ#TO+!-"OSZV%UL< MD+Y*4^4]SYG4H\!WG@&W \E&[6!#YT&QSBD4L7WVL1X"U;HK$OU0P_13&**X MNBV#C? Z,XHF!HB=KX=06=@J4AMCT\M%-%)/"0K?:QQ\ \;#9D--0R3PG[I>Y_AL6P@$^Q).25+NT M*FC.15 W6[DF.D&:LUA>O/NHZ1PTCY,+?7D4*Z)!YX&K!%3;F>+ ,$O':7P_ M3[>\/HCT\./,2SEJBA_Y["='')Q$&36EA#5=G&:UHJQ"G)@CDM8^)XI;X39X MMR) 2P?KD)+63X]:P&Q8(4-P&GV1]]"H$XNE2P.'%#//&-O$9CV^K&D%5G>J M_N5N(/J9]B!M:DR8NFB%F!EB(S-69C0PB3E(8?PN9*5YN?=HV MX'#(=@F4AMH%<@/]_%[*'V Z(';-;$0.]287-ZVY+=Z!8H7_)*EL\.-!\QI. MB>/<82]:XFQHARUL4),I=. ,1#!7^3324ZEGLU4B@76'ZQ:]'.&.77O*NZFV MZEY,:'OI1D+7 AK>GS=E!F XPS-I/ NW0E6J6,+U%.,!CH8:V_OY@7.[U\^# MX1FL;2%X@1HT4QJUX9#'8C46'9IY$N#[;AV-NW5UQJFE99#=KLW.PV7P-6G8 MLR?>E8)2SVAY*<=DNZQ'7KC_026NHO%HK76AN*8S:V2OXE!S8+ M@(,]U0O5*,Y:P!088..+)JPVM=&\K$-_SBLNB-B 8:3GNQ5Q\H83S=P$MY4_ MX/7^4+'[]?D@+[KVA/4+P^&^-YNCSGOH0KD9OVVG6R.FD?A*NOVU?:%_$]]C MK\7C?P,^2X?[@!>YFF+K>'CVIA?SWCP$6_);[<0&7 +XZURA)S@2P/K4VM \ MT 'MOSFN_P%02P,$% @ @H((6?_0[&ULI59M;]LV$/XKA+H&*Y#8CIVF65X,).V*=4"& MH"_;AV$?:.IL<:5(C:3L>+]^SY&29A>I.V!?;)'B/?? M:V/#35'%V%R.QT%55,LP<@U9O%DZ7\N(I5^-0^-)ELFH-N/I9'(^KJ6VQ?PZ M[3WX^;5KH]&6'KP(;5U+O[TCXS8WQ6G1;[S7JRKRQGA^W<@5?:#XJ7GP6(T' ME%+79(-V5GA:WA2WIY=W9WP^'?A5TR;L/ N.9.'<9UZ\*V^*"1,B0RHR@L3? MFEZ3,0P$&G]UF,7@D@UWGWOTMREVQ+*0@5X[\YLN8W537!2BI*5L37SO-C]1 M%\]+QE/.A/0K-OGL;%8(U8;HZLX8#&IM\[]\[/*P8W Q^8K!M#.8)M[946+Y M1D8YO_9N(SR?!AH_I%"3-:MC%^3NK7$WBHWRD<#V.0.3]L>JL M[[+U]"O6Y^+>V5@%\:,MJ=RW'X/)0&?:T[F;'@3\N;4C,9LG8 ;S:$ M-TMXLV^&)][HH(P+K2?Q^^TB1 ]!_/%4R!GQ[&E$;I++T$A%-P6Z()!?4S$_ M>G9Z/KDZP/=LX'MV"/V;Y?COUN)C1>*UJQMIMT('=-WB3W2"B$Y\>8B265 MY*41.MO$9".#V*!!^#]$&;OMT2[6T;.+Z>FKJ[!C*!KOUCJU*::$B#@<]*.H MLS2(I2%06!H**S9P\-UD= I%&Y/;.R731FU7#()FLNB$6%7.E+S7\5/*MT#3 M5BAG;=?9? X(:[(MX5\YSQY;^/7":(4)0D*N/!&&20SY>.^#74;]18RBU*6P M+G9@0MK#T<8*X(?BE;;DA]G_\G(PIX"^EQ9CE&,4%?)+:VE:U+!,QHT+FN=? MHF)I)=."UKHDJX#=>N^0L93JBK,HC?Y;IO2ZI=!(&T8=><]P8"=#H!B.F;!I M!ZLO)5)IS"^_901T7B 8L/M<&3:038,"R84A+BT(I/I#>K:4OF2?D3RF7@I" M1O!@*=>HW8G1G\EL3[!M3SB)Z3UC/L$3)8>H^=2B#XW*7(M2+W$\Y6!!<4-D M$PAA-WTO$HKG5D 0.S&F0'B=FHF;I4VA[AZ?GCX7R-^>%(XY@!(Z11^R>2Y2 M^CX9?" E$Y$K?$Q#?#*E]-B &'$-H\"G&;XX93F](W$+<,RY%JO4);\X4/GA M>(\Y"#32QRU3D)DP*=+K7(:^3W*;2+PS24399%-I565MENC'7IJ-W":;Q7;/ M$QS<'\FZN7HKOL=)13XBLEY0F, V9]W6;,\ M>*5DJ$20:\3-"ERB%%M6XMY<.^X&&)?).+4WZ-C;$LX5])DW!O$,U56Q14&V MO5H"!Y"#/W(65EN M \[>#D1?[B3/71P. L6IZG).\%?A.PM3MC1I:LM/Y*+^_SDT%(A$!"Y@B!X^,6+D!* M D(:WUK,0;\E*>Z.._2?O>UHRXI;N-#RB\A=<3*8#U@.:UY+]TEO?X'6G@GA M95I:_\^VC6P2#EA66Z?+5AD9E$(U3W[7^F%'87Y((6X58L^[VLL,22,:#;RI7AO)"45!N78&5P7JN=-+C/L';2VKP+#K@ALX'CO$I=5QUF*< M-QCQ 8PI^ZB5*RQ[IW+('^N/D4]/*NY(G M+SF ]XX;)=3&LJO.2/;[V,6-6.KR0PI]GMS2V[*<#P"FHG,LO>JVQ$JJX MO4E@%#\%B4VP%1= MKG OO6ZVLS2ZD!QQSVC?$JL2$SS[RK!;6,>5WSNO#3T($(D*G8_86R$]Q6?8 M;Y Z:L%ZC>5.3+F4K-(.E!,X)-L0 QM 2^4@*/:Y1M?OC2L4846"N!V1LKP$ MQBWU@N\=RAL9H3)9^[Z%%N^R$-;6WI>M0[:ZENAZ5$2)CN((W6,@TRH34G#7 MPA N.A0]ZXBBRK'Y*(TMP;_7EA@J+Y5QF=6R5VR(>H76Y#Z\#\0/10:-1IO6 M6F+WMNR(E[I6SC8[Z=HBJ@T8W&50N5TW-&+#)=/3^QHVF0AHLAC69!'$5^%,5!&L^[X6(^&;(/ M8.V.XM,\5^A\9&+0;DHK@0F X4+#CZ(@CA$?GY-%C,\X2.:)?\ZGL^%AQ,ZK MY)]"RQR,+X>]!17LB=G1)(CFX9">T\@3"(,PG32#*$+KWCZDPY)]>5J+^RMW M7\SW[AX-CUX-&3DW"=(40Q"$\S18S!(V"<+%/)C/9CMSEWL3[']2>.4#&([F M35#CT;2)XL_PN/3E0R@#%L3GZL/JIM ^@0"VUZVTH*1]81 ML:XH:TP^(^_[+F3@];KV";GEQG#*?PQH59NLX!9V>AM)7V!'XNK^Y8MY',W> MV,?55& TL-I!-1TB/UBSN^WT]>%V^M V]W@L\/82DO/%1TL62ZQL2@R^+[$1 MN]K;,2'#GNP$[JBT^Q'U7FU/EVE;9-M.ED\*?/GYA-GY-K'HST,U=[T M@^[J0]$G.=*HN,'Z$Q7&#'/$;QX\&29-I1/\C[ !13D#KHSL _QH;/C";\' MQ[NM?IUYD1+PW,BQ$)I<\K50&8WW#L"#_AW/BA^ 'CF]00P$W@I7,(ZK!NE5 MNKD]4(_YK(0;TLF%YU+!U09\#Z8@: 7/GW>C?1>X\<[U&L^S_7?*67,]?Q!O/G(^[M H?#X0+$ MELCA<%Z>>8;FZ=+8.SG8>S:GI^:RFM5T+45KLIS:5>7I,WRK!-WU@,W M:C;W/- ]/RWEC&[)?RZO+=ZZ&RVIRJEPRA3"4G;6N8A/+H.7]^E9I\<&D:;$LP:)KP5=D=:L"&;\VNCL;+;DA>WGM?9WP7?X,I6. MKHS^HE(_/^M,.B*E3%;:WYCE7ZGQ9\3Z$J-=^!3+6G8P[HBD*%CY5GIY?FK-4EB6AC9^"*Z&U3!.%9R46V\Q MJ[#.G[^3RHJ?I:Y(F$R\4X4L$B6U>%\X;RM$W[O3KL=&+-Y-&J67M=+^'J5C M\=$4?N[$#T5*Z*]'O]8?/Z!MLO!X$?8-O M>_U6N40;5UERXA\74W@-H/QSE\^URN%NE5P$ZZ4"9UU4!V.[((ZY]]_%X][ M;YXQ>+@Q>/B<]C^:IC^M5/PT)Y%(:U>JF F9FZKP+)R0]:AX?O20N#)Y*8O5 M]]]-^O'1&R>RC2ZUU?4*+XFN4M:42#<7LDCK!_JU4@NI:Z$"3"23A'=R*/N$ M,#75A GCZ<' 1JJ4*QX)"@WLL3QE*TJ%5G*JM/(*V95E:R"7\'#!3E?AVZI M_!PT*)@KE5Z!*U@O(L.F;@V 85XDQGDN[\H)A:V4914(6 :?5J]$J3%A;".1 MS&4Q(PZ. _=P.#-K7#7]!1S.26JEK4E%'>JPI=UL.0U;0GX=<@I^!@ @- P M30MB=(KE7"5SEDTT]E?9BD7S$!N2F+%4 A*LM22K3,J @/)-,GW=G9!^QH53 MLT)EB"7*Y)GA\T-NW C,_&0^$A_V)]WH:;SU]7NI?S_V%?=ZUB')=3*D 3AG'@.VEELG=Z]MD M;C3"85:Q H%FC*M M3"E04RM_S*=AC-F[]B\H:/*..4LM5773)#ASM>7S#X&^!NWVNJ%SI^X1BW#^ M(CY_;>N[7?.RJ' (%['X&_IMK9D57U<6;<-AEZZXE3I\[Z6*?PNI_=$^) [& MO9VUO)4X/ ITL&MQF'J(]OCHN>H.5?Q-RU^(\63(ZL>C?3N/X^/-QK]+F*/Q MG$*@(^9)=73H>UG9!D[V = X8,)D*QWX @-H@N)*?DE4=&(Q'5;#L_]!^)I M9==DX.=<92RX'X,,G$C\!8?'IM,;Y$9)C'@R*\0W1[(FA,,X[+5 !M26'XK MA1R:EEK)@01SE*:@^A!;'Q41,X.R/B2P5.'HY6,UJMC)05<&?A7,(WAR1JLT MK+GU^&H.)9GX!!X*1+$^ SSQX@-YL*JXF%D*R[:974KW1RDW)'C'^"/F>T*K M.#ZQ"8DL%6"MOC8<][_,W^W.K.IF7+'QC)@F\QOI;^?L=Q_'7H72/'DD^O2T M<1/P_R7<+<"B"\1*8F#/\*Y$'4^BX_&!>"WBX2@:Q@S&/#:/)$;_%6+\; MYH]8ZT]@^_]P? S'QQWA*0;7:-N)CS@Z$@?;*:VR8%0=^W#86)%$YQA$O6? M,6KK2-6"?U.FC?OK+EB#8[E&K6Q02SNLXJ*Q>S9C\#P(>>!K/H.W?U0_[!(N MVG4)TVW=F^5D9^%VD/%0%;Z^0MN,;BX@+^I[MZUX?7OY4=H9MS1-&9;VHJ-1 M!PZ$&\'ZQ9LRW,)-C?@K=07T(:$5D&W?9CVP8VOB8=C!]NA]-_O M[+2E2%"Q+_'Y[I['S]FYZZ^T>; %HH/G4BH[B KGJHLXMEF!);,M7:&BR%*; MDCG:FCRVE4'& ZB4<9HDO;AD0D7#?O#-S+"O:R>%PID!6Y>&\(Q[V*Y;C/;H?U# MKV2A]8/??..#*/&"4&+F/ .CY0DG**4G(AF/&\YH=Z0'[MM;]NM0.]6R8!8G M6OX2W!6#Z#P"CDM62W>G5U]Q4\^9Y\NTM.$+JR8W_1)!5ENGRPV8%)1"-2M[ MWMS#'N \>0>0;@!IT-T<%%1.F6/#OM$K,#Z;V+P12@UH$B>4?Y1[9R@J".>& M]_7"XF.-RL'5$WUM/W9$ZX-QMJ$8-Q3I.Q0]N-7*%1:N%$?^&A^3G)VF=*MI MG!XDO*E5"SK))TB3M'N K[.KL1/X.A^M$7Z/%M89^B/^O%5NP]9]F\UWR86M M6(:#B-K HGG":'A\U.XEEP>T=G=:NX?8/_8>_TD!WQ7PU5HLG#V+"0T46YIK=VWMUD&C4-^9+>C+5;9G*A M+$A<$C1I?3Z+P#2CHMDX787V7&A'S1[,@J8K&I] \:76;KOQ!^SF]? ?4$L# M!!0 ( (*""%G/&234E0( -X' 9 >&PO=V]R:W-H965TT M_WZV$S*H4H0ZOA#?^7F>\YW-7;AE_%%D !(]%3D5$RN3LAS;MD@R*+ 8L!*H MVEDS7F"I3+ZQ1&&>2Y%E+'^--J6EU(3=Q?[]2_F=Q5 M+BLL8,;RWR25V<2ZLE *:USE\HYMOT.;SU#K)2P7YA=M&^QP:*&D$I(5+5F= MH""T^>*GM@Y[!/$X!6"WQ+\4R,$+2$X-<*P)9C4[29W4[@82QR% MG&T1UVBEIA>F^H:MZD6H?B=+R=4N43P9+? SJ@5: #=OCB: 8B*2G(F* [I$ M#\L8?;CXB"X0H>@^8Y7 -!6A+55LK6 G;9QI$\=[)8Z/;AF5F4!SFD+:PX^/ M\T='^+;*N4O_Y97T'?9C5S0+Z=[VUB4.(&)I9J7 %Z#%;U_YXZ_51#0EV 0%A*3E:5Q*L]#C=POAZBX!^4Z3C \A,U[8:Y[U<&:4MA[#:L MOC&30J"$550VK[;S=L/HVO3@%_ZI.YZY/?Y8#:]FUOR3;R;?+>8;0@7*8:U" M.8//JI_R9IHTAF2E:9&ULG95=;YLP%$#_BL6D/;6!0#ZV#)"2;M-2J5.4=MNS@R]@U=C,-DG[[V<; MPK(IH5)>P#;W'I]KQ"4^"/FL2@"-7BK&5>*56M<+WU=9"156(U$#-T]R(2NL MS506OJHE8.*2*N:'03#S*TRYE\9N;2/36#2:40X;B51355B^KH")0^*-O>/" MEA:EM@M^&M>X@$?0/^J--#._IQ!: 5=4<"0A3[SE>+&:VW@7\)/"09V,D:UD M)\2SG:Q)X@56"!ADVA*PN>WA#ABS(*/QNV-Z_98V\71\I']UM9M:=EC!G6"_ M*-%EXGWP$($<-TQOQ>$;=/5,+2\33+DK.K2QT47O'+]TY MG"08SOF$L$L(G7>[D;/\C#5.8RD.2-IH0[,#5ZK+-G*4VY?RJ*5Y2DV>3M?F M> E(]"0QH;Q 2RDQ+\ -WR$HN &A4$X&>!%?;F1XT47>.?*O$&[5[3FA.XI:3 [5W4+ MG9R'VN]FH6J<0>*9#T.!W(.7OG\WG@6?!I0GO?)DB)YN&P9H'.RFM^-3;;0D MHM;_'W*K.PS,,5,P(#;MQ::#G.^"WUXA-PQ]2V[6R\VN.K4GD.8KPA??](<*9.&ZH$*9:+AN6T6_VC?:9=M?_H:W7?H!RX)R MA1CD)C48S,0 &0 'AL+W=O>IZSSRX6]+,K8S^Y2BDO/C=UZY[O M5=YW3PX/75&I1KH#TZD63Y;&-M+CJUT=NLXJ6?*DICX\GL\?'392MWNGS_BW M=_;TF>E]K5OUS@K7-XVTZQ>J-E?/]X[VT@_O]:KR],/AZ;-.KM2%\A^Z=Q;? M#@'/$$'O$OK:Y<]EG05A;&?*(O;\KG>W/22-6J M\"1"XK]+=:[JFB1!C]^CT+UA39J8?T[27_/FL9F%=.KW/U=Q4W])#D%:9V_*^X"F,?8G#1.V^:.!D:-+H-_\O/T1#9A)/Y#1.. MXX1CUCLLQ%J^E%Z>/K/F2E@:#6GT@;?*LZ&<;LDK%][BJ<8\?WH1O"',4ESH M5:N7NI"M%V=%8?K6ZW8EWIE:%UHY<2]]VG]VZ+$T"3@LXC(OPC+'-RSS2+PU MK:^<>-66JMR0O<_'=JPT'>@VEY%$Q/7"<+]7P/T>*4O51[I]]^<_1H_G2'M@\& M;1_LDG[ZH95]J;TJQ9O6*ZL;\5JWLBVTK/%+B%5@?DKMOT2P^+52"*C"-)UL MUV2TY3#,>>D5XM8[4J\V&NQ[H?6E;P@M9Q!-RS!IH64MS[]IN3X^/YTQ_/SM[QQZ.G M^P?753TWP&#K( *?')Q=2I+W0M:LTP63H63)0)D:4#:[:>;%N&/,^:6#WF0D M)V OUMA75D&)MA1.?Q9-B 1%D;"Y @_!A_NW+T4KG5>R7<$$L,M[52K0]:)6 MXF?3%EC!FKJFW;(?E?,L^\*;XE-EZE)91Q8Z>OQ4O/J]UWXM[KU4B'WM]^^N M-7_X(AN=2U>)U\@(HXV^> VK1)]0RMYUV0]_!H>DA>T)>[285:N^CGZ$QM>! M=Z&*WFJOX_A7GPMV![;=--IQUDJ O'AUGO#(^]4QMD9E]1A;!TR^MH3SZO6, M%EZ+THC6>(PJZKZ$3^HZZ91-9#66QG@,A5)6P;&TU<5:4$3PRA0&M?)JTD[) MFI,V=)7I:PB#C9#\R7Y V<>^#9 3L>S$6=OV6/.]ZHQ%C+2"4K=.&9TE5T^F63 7'-;)%Q4-#9E394(7"/I7E1V3\ M,/4>]HI5F!8QI24OUQ@-T%GZ+1N[+UJ8RCG*X]Z$]<52:@ORG#+2J&IGG [0 MF:([#@CE4-_P4_,7$!M_*"CZEW>)_N#$:\#X,DJ/T5.*"H0(IUQATR!"%(6 MJS7-[?A=]!ZA"+1N!V.I75$;UUM*2%;\J0#,GF 7DO=NH)K=B/6XXA )"-NP M*@#@JQMBV*J:[1+'W,%[F^2;:H0$$GI,IDEPU "@;DOD9BJ]"4-I))E"MEC, MPT(<]&'O$:JCE3D2Z1Z'I/[&-_! MR[P3]O\-:'4=V\M&FZ*G4 M6JH%[>0<4&.!Y4>".4<"Q0[?:_=IBL'N+BTC7MWBF-^' M;;-).V12A#@S$_Q!V-ZBFR*7S)8M@FA+HF/IEJB.Y= 0JGLH=RNNNP(S-G - ML>'&80#8\#V+#O!9Q$(FHHX%14I%5 .HT(5U+90JB8")JL@Y8. H CXSD$[Q MR3H&'LO,P]4)"TXE&@4 ?!XXW0G(TBL6@((&LUH'4@FU*.#S$?CUO$W31T&P MDQ1G9V?"\BP$!8XRC;2?Z'P=M0_9(5KO"F16K?/]$SVIV <#^,%W(?%"W-%\ M_K=DD$B4 G4$'0XRAMQ=V6P5';K@6, MUX" [Q-8-DP$ZZ$L2#1V(QAW6>MDL-;)SBV^&16:C6R2%8,EGD>@&R8;)!KR9K4J) MCK.7%+_WAL,_!#ZV R)#CL-!0OO0A^'307CN$B'JR#-8LNWYM >TT!2$OG,1%?W3!]A1!$;HZ'PX?8TE;YF07UXEAY06(P-5 ( ]TM& M](S="1@784W5&5NRT;6TV4[$+D+Z82"D'W9RRON8:]X#C'#53>W[G4*F;QTF M)&\XK7?Q.)72G@5B".A)_,3:IK7->I6&]H-9W2(6,60S!7 V*3 ;"MHJ G7=;%OEMEAEK < M8!>K$!D>;9T0!Y,!5G&_Z4@$4N 6#M=RL.8JUH_QU#L8P1&PPZ'JIBE$7*EX MBF8^&)P1-?\C^$HBZ9J5_H/+$C.Z3KN1^B2=%0?K\8UK$)7ZGAOL9C)V(RCE MY=_4L6A$5FS_$%B(%6J$(:@TI/F-]3-;9*7KT&#4K?@$W2>P$@BDY:2O/Q M@!4X.6X^/F(/!>:@Q O0R#4+(9*[_I3K^J1+Q>YHX-/0+N@7!/MBM!,H-IR[ MUK&0SW(@W KM%\1S!]3_1E5<5*/L1BD?"U08OH#;<-Z4FX$P*.9N@6WLJ,96 M6[Z' QS.I^>1@I)4;#0GGMP)%"?Q9(&?2^Y_X^>5,25S+QB-B#N&TPC\W,&> M'#E$P B^0"F;QI")^4+G8E>P.7QVY*L#L8/NC^;CQ?O\%L)W.*X4H<1].<)Y M\G+];J+$6XK+K=:IS0?G812*I51Q<-%-,Q&?D>=*.GU1()(38VDDF"IND#C= M3IG%E;C?H@ILAE.K\WW)$37\XH'+.MW&!0<-S^"C?@D/\F$KD\B!G^F0/:)N MRRC1]1T5F5@/8E+?CL;.A+E4MJ)++IXZ2U>!QJX3'V F8R0.X(LWA?DH3,K8 M'B"BDZG!%U+7<#;@X@UCB)U$ 0NA*KW9BEP?AXEF^M9KH2I9+XG^=[J64!S= MQH0/5_?6QEO4(7Q"2G#$D[8G:PVE?-:R"DP7PY'3B*)[E)E02P00E7NT#B>6 M-FMI7E&,]=;U5(9Z,\1A/("@T%>66EU#?&X89DX'B M;6A?+WJ':'%;/MAR(F[J.@0B&WML&2M>Y2]+M7NR?;N6EH9.TE8S& M9D_(!L&@;J,$8-+I%Q]5X,56K8S7XTTOJ18[-Y25<@H=Z8VMMHYYEW3M6V+# M(1?Q+=R!>!>^YF77:"&$O0J=2#*^0367"J]PEUM1[W&X 8EHIE6R[G:\]HI' M-&Y:9Q?K6];-BFP*$IT5&H;-$2^3ID(AHA9+H+184ZKARP$?#^(!W/%.=>BH MQQN:R?Y\3#4R]-6O(3Y0VQ;HD?N"D68#30[1E#7)MZEO.(RFTBT%WM1&4S . M%PV*D),NH49;TS-V!IDU>L5UH''N!D3TQA^*+4],$T-K6JN60 J?I&1YR538 M)0BAA*++F%!?+7O?\Z9NYS;IPN62'J\Z ,RM7[9-)-U@87VGTWF"<;9)Q;5E Y8?+Z@]W*]6&^R;653<+XJ(RQI;D$=_3;0:W3L=#2AR_C.=G*D/QE4@C MNO)&*T83[#J&'F4O!![=4DP4H9O\QKD>>N1OQEG3XG,1#?FS\>+?RHNSTM#= MW63A\G]:2UPHOJ>(;WK0A">4 GY&[N9F47A?A)SX^NSB!7@@R+_XP$^^GS^> M38BX]ZOI$ 3')_/])R(>&,6;ALX"(QN$X8S]).%E=OT?3Y;B7K;6O@B11#_! M5W ?L-ZCOBR&FN [8"L(R]\E6*SCA2>GEOPE@^5&1R?-'<(DPQ_5+I:OK+E+ M-%S/G?_R\BTC:;N*YPIYN(Y,/1Q:,:X"24O-?$)-M!D?WSG#1V Z'"JZ!%K- MMY#-\*8)L4(\R4=Q.( TL8A*+^5L;55&==CH<=IW;DN/=.>K*,?2L6?+PK/8 M3845'$=^W&[FIU A\2TQI1@F,&@".J0W%*C.6NFVY;!=0M'Q192CA^D-I? . MUOB*5[B7=>&N_"M$;5U-((]QK<;!0IMT+ETR4#LLWFI+"HYH]WQ;W-?@=IX9 MWD78^0;"5DN#RRONB/XJ/\,E'&J#QK>%V@\WQ](H=3J&AJ;-(&OSO4YZH!T; MNXW05FW%^8CO7^@H2:]OM<4Z8K-@Y\>+7ZH+0_> U?!08V/3?&\&9_C MHK(L+4T.?0=C.4R5BUV%J$.9"\Y?W@DM?TWAM;6 SPR./Z'(INN&\&K50W(L:ZB81 :$ M49.!FK7>;Y\?-J :WQU(6,W[9G37G5[( %E=TSWA-' MOWQX*^V*;B5JM<34^<'CAWNAHY2^>-/Q"_P+X[UI^",=3Y6E 7A.[WRF+[3 M\"<=I_\#4$L#!!0 ( (*""%E["\)8W@, # ) 9 >&PO=V]R:W-H M965TN:B2RW"I5I1MX7NQ6C-?.=&S/YG(Z%AM= M\AKG$M2FJIA\?E<4@H-"8'FWABS+]TRSZ5B*'4@C M36AF85VUVD2.UR8H"RWI+2<]/5T43.)W#^17#H^BHE@K9J_K[IDM2U3W8U>3 M&2/L9@?(AQ8RN (9PT=1ZT+!ASK'_%S?)7H=Q^#(\2&X"?C+INY#Z/4@\(+H M!E[8^1Q:O/ K?)ZS5THQ#3,I6;U&N_YKME1:4K[\?\Q0ZL1^A8BA" :]H(H@7>0)/U!"#]2-(U^Y,6]9#@$/^C'*5 =KY";\SN_ MER:#>^+03Y,K5LY(0CR(>G[BDX4PZ8<1_&8])8?V*#.N[%5]H>0/A[W4#T@I MC8U2YQ?;HJ2>1Y=H&J]9[-&>'I+(QLT M]9;+\,PZ'JS_)XG7'8/3=%; Z5=GY<;D+C?#2-'M9(4-18Y; M&FV-[1QFO\::+KBT:Y93R^:FF9C9TUEEZE!E"NX(3A=BHTA5XGL#LTY#\_2H9JX3CZ, @F$$R3"&03B$ M9Z%)4-D^NK1]-+MTNY3V Y.!X= \_9Z7F/^$P"XEEGLRQ2J4:SNK%2%O:MT. MM.ZT^QR8M5/P3;S]EOC(Y)I3W$I"J4=I,H)RI'<>R6.1;"G9L2->^LC"T$L6G7L2LMBBPD%2I.DZ0?%T+J:#H. MOKF=CDU%2FJ<6W!540C[/$-E-I.H'>T.-K-HD23P@5+LDC"/X]XA4J MY8&8QM\M9M24](G[ZQWZYZ"=M2R$PRNC?LF,\DDTC"##E:@4W9K-%]SJZ7F\ MI5$N?&%3Q_9[$2PK1Z;8)C.#0NKZ+YZVY["7,$S>2$BW"6G@71<*+#\*$M.Q M-1NP/IK1_")(#=E,3FI_*7=D>5=R'DVOD24Y.+L7"X6N-8Z)0?U6O-P"S&J M] V /MP83;F#3SK#['5^S&0:1NF.T2P]"OBMTN?02=Y#FJ3=(WB=1F$GX'6. M*_Q]N7!D^1'\.:2QAN@>AO"-,7*E6.(DXI?OT#YB-#U]U^XG%T<(=AN"W6/H MTSMNM*Q2"&8%-X(J*TDR8;8"=;B68B%5[>0NA.\E6D%2K^M]=TC/T8J'];PN MK4)I]5]IRA&N3%$*_7SZ;IBV!Q<!#^A!>Q 6?0C%TPMO#/:-86/< MYUQ1K CMB\N04%MAI7CFR4(.TD&7C]&Y$JU+985 0S8["T&8%5L+NZQDJ M/IEH4PGBI9F&=F90Y-ZH*L,DBGIA):0*1@._=V5& UU3*15>&;!U50GSS*\.K<(62RPJ5E5J!PF F,;C C-8N72&Z_(2_8N/ MG6,9"XMGNOPNB+NE:S[_B(IZNP\MT:?T7YHUN]S" K+:DJX4Q M,ZBD:O[B>9&'-8-^](9!LC!(/._&D6?Y29 8#8R>@W':C.8$'ZJW9G)2N:+< MD.%3R78TNM0JTXJ,+OED"N>*T* EV+L5XQ)M:Q 2>W&Z8;9 /&T0DS<0>W#! M@(6%SRK'_+5]R.Q6%),EQ=-D*^"W6NU#)VI#$B7I%KS.*N2.Q^O\8\@_3L:6 M#%^3GYN";C#3S9BN=8[L3&0X#+@W+)HG#$:[.W$O.M[".%TQ3K>ACVZ:C@$] M@4ONTW/F7R&<$!DYKLD5"DC#/3W!;8%&S+ FF5FGMRF2[;X8 2:<&CUWR9$6 MQ+)AG7O%[F7C7OSA_NGV;_?[(%0.G%1E)VBL4U.OLR\7V3\";C(@=GY;&,17 M=PCX!J"_ 4N=&_G\AH:[(^[369-U>$L%9(=24*VMTY8OXG_EX;UE?)RYM=]*TD?JQ_Q^TT\-^:U.+A&LS MK4(S]9/;,IE:43/>5KNKQ^&DF8F_U9N7Y4*8J5062IRP:;1_T W --.Z69"> M^0DYUL3SUHL%/W!HG *?3[2FY<(Y6#V9HU]02P,$% @ @H((6?-1ZFU$ M!0 8 T !D !X;"]W;W)K&ULI5=M;]LV$/XK MA#<4=J':>K5E-S'@I!W6H2V".ET_#,- 2V>+*T5J)!4G_WY'2E;M3':'+4 L MBKP[/G?WW)&ZVDOU51< ACR67.CK06%,M9A,=%9 2?585B!P92M520V^JMU$ M5PIH[I1*/@E]?SHI*1.#Y96;NU/+*UD;S@3<*:+KLJ3JZ0:XW%\/@L%AXA/; M%<9.3)97%=W!&LSGZD[AVZ2SDK,2A&92$ 7;Z\$J6-PD5MX)_,I@KX_&Q'JR MD?*K?7F77P]\"P@X9,9:H/AX@%O@W!I"&'^U-@?=EE;Q>'RP_I/S'7W94 VW MDG]AN2FN!^F Y+"E-3>?Y/YG:/UQ #/)M?LE^U;6'Y"LUD:6K3(B*)EHGO2Q MC<._40A;A=#A;C9R*-]00Y=72NZ)LM)HS0ZZDUJ4"1=4$5D.$]W7#0HZN)P0VLV"1KC=TTQL(SQJ;D@Q2FT.2MR"$_U9\@ ML Y=>$!W$UXT^$LMQB3R/1+Z87S!7M1Y&SE[T1E[;ZD23.PTN>N\_6VUT48A M.7[O\[;LP6ST!7-X'J %:%!/*'8.J_O@ V[L#&EZPO/T$F1<8X MHXZ_1C78*B1BI"14[>@)#("O?^64-.F'!2MY1G->\4;ZAF6:/ >&U0 MKB?O*'?+*4ZMR*TL2]1<&YE][0O+9> KK-8^Z.($>GX$O3Z"GIU"WW30\Q:Z M0.C\ %T_AYXUT+6%3I@F5).MY-A[-!G24M;"Z&8G66NTJCT"CQE4YLA:*S9: M$"Q\A^F^4 GY"9(37#4/,BLV>,9"4M>^Q,=C;HT+EPJG#\_DN'4B_WYR(YF M7A@$;A2$7ARFA^$\34;D/6A]I$B-46Q3&UNWQ$@B,/B(1*'?R'9TUP#2$QT? M!EX8HGU\)O,0GZ$7I9%[IM/9Z+S%0U1M? K)D"^NF:(>?4#C.^C?J#?GO;L' MH^'+$;'!C;PXQA1X?AI[\UE$$L^?IUXZFQW-?>PEV/^$\-(ET!^G35+#\;3) MS]P@'MO,6KE5_B<&>N=!=8@U:1& M\BG^9!-O:8F-Z=6V=H3<4Z6HY3\FM*I55E#=:;4EBH5?4?'TXHAG4,)3] T:=0OI.33JVG?;K_KD\NGG6NX[>H M)?S-*3/: DMF,R^*Y]WS]EA&5A:*)CO+083I>.J0WG$J'/&G2>P%LX"$4>I- MH^FI?L=>*SE+L($E)/6]*)F3>VDH=_.!%_DS;"BX-)\BAOB_%-0?Y_]6]I M3XYNO7B8[MS=WK8L/+R;"W WVWT^K)I;\S?QYMOC U4[AMSDL$55?SS#&$6G%QTG M[P4^"!TA%)A8A\#HL=K)EP@Q>*O&%IW9^WN@W(,4I*X2]5YD6?YAEDV/--J"=I)$YH;>%.]-I'C MTAW*V&I:Y:1GAU>,:_C,1(&@IG#%)9,)9P*NI;&Z(.]; \=W;"+0G)PU+>WH M])K)&OVB1(_WH'?A@Y)V;N"M3#%]K-\DIA7=>$/W(CX(^$LA VB%+R$.X_8! MO%9E?LOCM7YL_AMN$J%,H=' [Z,)F4\1\\_4?RN4 MI;UO-$^(&FF-?.+#F,\DG_*$20L?B;&&CQ-W.MZ8^N(GJ;8+US(OB.=[SB9< M<,O1G,(7IK43%.O)U4NR5#"W:\ZT7<%Q='(M'([?R M!,?-M\)]&K1RIRSEYG.(^_MPW4K--4_]^-]PC[,GVFMIM+7TL-2?AWY^GZMM MX*5H45,))1X4IRZ.*6PO!$ON7XV3N:(*!RKWK2(GYSB!3*4H GC[D%,/(;6% M(C/*D^+&-X,4E/0X3R]L'A2@5"R1GQ29$2- 6K8$)Q]/C\ M A@9/V>H\Y7V>8#UN=.:QAH4=W6!JG\ EW-&,S[HWN,"!;1HN&TS](7AT0Q_ M(%_XMH&N;6SSNY[S3!;T$0$1_$I?+B6R [XI=#(G]QAHPI@)_]Q;*OY6I,:= M?9'8ZH8[>-?RE6#G3*3M4I.P=[UN[FMZE8KLE\WJ0!W&$RE_QK@3M[X^%]ZK61E^"% M2_]OY ->IFB5;YN"\!XMU2(8S326K+;^^-F&^!*6J/'T.]&G]?[69\87_W5* MC$94;>AC>]_TKE(WZ >#[A&\@JC="=K1$41A-VC'1] ;K!?Z@Z!+\_THZ'2. MX+:J5UR2E>BJFBM<[: ;.^E.T"*M=M ;N/\PU-#' M<;,D1_U?T'<4]'\2CM_GY-,8W$3;SOB(@AX<;9<$GWI2I>]]N5\ATP9:07@@ M.#IUC)0O>$K5?VW^I@X=[:H+S=KM)T,]\W<\=R:%M.5%J)JMKI&C\O:T%2_O MH!^8GE%+ H%34@V#'J6^+N]UY8M5N;]+392EFYD?SNDJC-H)T/I4T=?5^L5M M4%VNAW\!4$L#!!0 ( (*""%F@@.P6/@H .)Y 9 >&PO=V]R:W-H M965T M+87(R8]5%&=7O66>KS_T^UFP%"L_NTC6(I:?S)-TY>=R-EWTLW4J_%D9M(KZ MEF&,^BL_C'O7E^6RN_3Z,MGD41B+NY1DF]7*3W_>B"AYNNJ9O><%7\+%,B\6 M]*\OU_Y"W(O\V_HNE7/]+646KD2EVC1X)-EB>K M.EBV8!7&U5__1_U%[ 28@R,!5AU@[0<,CP38=8!]:H9!'3 X-6!8!PQ/#1C5 M :-3 \9UP/C4@$D=,#DU8%H'3$LY5+]?^>,[?NY?7Z;)$TF+M26MF"@55$;+ MWSR,"['?YZG\-)1Q^;4CLB -UZ7PDCFYV61RA2PC?CPC-WX69L72NU1D(L[] MX>\^^4]^87T2;;TY5HDC,FW.,RS,[E03G]=)IM,LK++ M?BY;6^3L!W7+;JN664=:-B*?DSA?9L2-9V*FQO?E5FXWU7K>U!M+"Z3BX8)8 MXS-B&=:@K3WZ\-\V\06QC:/ACC[\LY]>$&-X--P]I?&3H^'T=>'>Z\*9/MP1 M@?SJS#+<;@GG^O#?DT>9W6@+5X1@;S5OESS[".^/=.''X?\J.=\F<99$X:R: M^RAEKZC]CSFA8>S'0>A'Y%XN%+*GSS/RGT\22KBNLB6/HK>];__98Z,7]N$B80Y2)B+A%$DS$/"&!+&03!%^H.M] GC?)D(MNJL(D3 '"7.1,(J$>4@80\)X!1OO"-^X,,RM\!6M MCK9:'6FU^J4H;F,Q(\)/XS!>9.2='P2;U2:2A_Y9<1H5!F'>JE0MN*M2*]AP M9]O.K:EI[VQ>)4)D4A<)HTB8AX2QT4&'>6Y-3&-@[?69H*2*#L=;'8ZU.G3C M/,Q_DO7F(0H#,H\2/S\C^5(F6B;1K$U^6EY7^2%A#A+F(F%T?*"$\= P#%4' M'C(E0\(X"*8H=+)5Z$2KT#N1!K)R+,8'=E7:)DTMJ*LTD3 '"7,KV$0Y'MFV MK:J)(E-Z%6RJ'@+W,C)D1@Z"*9*;;B4WU4M.%HE2<;*>7/OQSS:E:>.[*@T) ME,2B-HVBJ3*U&II:^ MS$BE+G-![B*9H^AZ6^6I9726)Y+F0&DNE$:A- ]*8U :1]%4%3RM \&""ZU3>BLW"A)AB41J$T#TIC4!I'T53A-I:9J??,[O;E M>?9\A4UAFU63K2Z$GMNY2X8Z9C5MU]4PS=%@NC=@Y4*S4BC-@](8E,91-%6S MC75FZKVS \W*3E:#L[_R#_D<)DLH,]II>V_:FVWZACJRT%I#I3F M0FD42O.@- :E<11-57MCXYF3MS]/A#J 4)H#I;E0&H72/"B-06D<15-W@L98 M-/7.HOM#I$&8B>*TL#H_?*Y72)*2M+AC(COQ@K4ZT]'+DFH-0\U%*,V%TBB4 MYD%I#$KC*)IZ=T-C,5I:]^;Z-O*SC'PD]>66]\7EEFT"U6.Z=L90F@.EN5 : MA=(\*(U!:1Q%4X785B05U%Z$T!TISH30*I7E0&H/2.(JF[@2-"6GI M3- <[I0&H72/"B-G?3ME,2B-HVBJN!N3T!J\?;V!-*=NH30'2G.A- JE>5 : M@](XBJ;N!(WA:.D-Q_O*E9':G[UDS5B'-MY@-+#'X[TQ#GW&SBJ%WF\'I5$H MS8/2&)3&4315I8W%:.DMQGL_*D?GRK+XK!ZMV];"IU;'HX.*RS0O)OM#=/JF M=)8O]$X]*(U":1Z4QJ TCJ*I\FV<14OO+)Y:1K_&<-0WH7.E 34E,2B-HVCJ3M 8CM;;&XX6U'"$TAPHS872*)3F06D,2N,HFKH3-(:CI3<< M,87,H=58%#+[=0S4:H327"B-0FD>E,:@-(ZBJ<_/:JQ&6V\U_KY9/4AE%OH5 MP28-\U">.@9^%,G:Y.'G,>]<%&5U*UBQCZ;$_MP3NS3.;&/YZQH MRLUPQN'3DJ!)&93&4315I8W1:&L]G+H-)I]7!=?U&:A'$2GS\F>3&J(8(D3E9A0,(X M%S)S^?S=@[Z?)=&L?'BY/ @4K^$I5CAV/( ^,K6FJ<_ -:?6?B4"-1&A- JE M>5 :@](XBJ:^B:0Q$0=Z$_&5&N=Q\(*T]?F[2KNFJ=*>&!-CY]]^Q0UM@0NE M42C-@](8E,91-%7GC0DYT)N0;94Y^8><.ABHIW=6,=2 A-)<*(U":1Z4QJ T MCJ*I^FX,R,';&Y #J $)I3E0F@NE42C-@](8E,91-'4G: S(P0LW2+YF,%#/ M[JQN^Y3!0&A.%TJC4)H'I3$HC:-HE6K[.^^!78ET4;Y$."-!LHGSZCVIVZ7; M%Q5_+%_/N[?<-3]XU>N&&TSU]N//?KH(XXQ$8BZ1QL5XV*LN\7N>R9-U^;;9 MAR3/DU4YN13^3*3%"O+S>9+DSS-%@NUKG:__#U!+ P04 " ""@@A9U,9G M5U8" "/!0 &0 'AL+W=OV"*&*U52O@ ?'@)I/$6L<.MM,N$A^/+VTH4K?[Q$OB ML3UGSIGQ3'(0\EY5B!H>:L;5+*BT;J9AJ+(*:Z)ZHD%N3@HA:Z*-*P%HQF%!6\AGF>4YM+PF#%_8.PF7UQ@YI0]C()M6%D</1!_#K>"Z4O">YYC_ZQ\:)9V<^"1G$5\%_-3R'@RB5Q!'\? *WJ!+ MS\#A#1_!V^ >>8OP&Y:N%BC-\HYC9U[2?!72=ME4-23#66#:2*'<8Y ^?]8? M1^^N$!YVA(<.??!$/>^>KN?WS\875AIK]>.2C.%_D#'J9(RNYGTI>(9<2__ M)%7WT*"T6V927"+KX=XZ.#N(]FD_"??G#,*S)C&%*]TH4.#RXONEV^VFS=PW MV=_K?E3=$EE2KH!A85RCWL1$E[[]O:%%XUIN)[1Y)6Y9F8F)TEXPYX40^F38 M -T,3O\ 4$L#!!0 ( (*""%F%97!"+@P "65 9 >&PO=V]R:W-H M965TV>GG4EC [;S9Y/,I &$F/9. M)FUW7^SL"\66;:88? 5.FIW[X5=@8JQ 9-,^=S9]T=J8\SO"/0](>A"^>$SE M]VPA1$Y^+.,DN^PM\GQUWN]GDX58\NPX78E$?3)+Y9+GZJV<][.5%'Q:!BWC MOCT8C/M+'B6]JXMRVZV\NDC7>1PEXE:2;+U<,.FE[U!T2(1BTE>(+CZYT'O M#N:>9^(FC?\53?/%9>^T1Z9BQM=Q?I<^!J(ZH%'!FZ1Q5OY-'JM]!STR66=Y MNJR"50N64;+YE_^HOHB= &OX2H!=!=@O YQ7 IPJP'D9,'HE8%@%# \-&%4! MHT./85P%C _-<%(%G!R:X;0*.#TTX*P*.#LTP!H\_\\-R@K:_)>7]>+RG%]= MR/21R&)_Q2M>E$57QJLRB9)"'U]RJ3Z-5%Q^I>HJYO>IY&6U7L^E$*KZ\XQ\ M(-?3:51LY3%AR4:)Q3[O7)'S*'ZO]OCVQ27O?GM/?B-]DBVX%!F)$O(MB?+L M2&U4K[\NTG7&DVEVT<]5:XN<_4G5,G?3,ON5EEGD&^+[ZEK=?M?W\57^TC4!?W!\3^_2(V /;:6G/C3G\,W\BCE5&VVW? MICGZ>CT_KL*MD[8OTQP>KA,5/BBS#UO"_RLP/"[?&KV4-S MN"LFS]_\R^Q:&3E;Q3HES]FOV =!KJ7DR;S2['4R);^GR>2U/_*.M MMI$P%PGSD# ?":-(6("$,20L!,$T,0VW8AJ:Z%=4]2#)NSC-LO=$7=O$CSQ* MYNLH6Y1R26>JJW6?MXG#B.TJ#B3,1<(\),Q'PN@&-BYAQ2#@X6IPT7_8K?CF M'A\A.F&)**MXLI:R M*.A5*HMS?UM!&^E="QH);#&LP>'D> MW)N((8\K!,&TJCK95M6)^7(^M-58]4%D>=DA;JLN(Z!K=2%A+A+F(6$^$D:1 ML )8TA8"()I,CC=RN#T;0P13Y%B0L)<),Q#PGPDC")A 1+&D+ 0!-/$=+85 MTYGQFO)E,[&9I?&4O%.CQ5PUKALVZ.S\>A$OW:[R)P>$N8C M810)"Y PAH2%()A6Z-:@]@(&YE+GL2B&BUF>3KX?D96,)H*LA-S4?%G]ZVQ: M;VD5@3E'5Q54M),=&9R-CX>#G3_6"T5 &^!!:3Z41J&T $IC4%J(HNG"V#') MK"["F*B^4305E6DFQ42H7M2TF$#,Z][3$9G+-&L=@YBS=9:(U1@GVJ/&,-"% M)O6@-!]*HU!: *4Q*"U$T719V+4L;+@L6O5@3--9#W9S5J00Q$L]()-Z4)H/ MI5$H+8#2&)06HFBZ'FIGUC)Z55?7DTFZ+D;97(VR9U'"DTF4S"LE\/M8'!$^ MRU7OB<=Q^J@^%6262C*18AKE)'[M:@$U8BO:7G5 /58HS8?2*)060&D,2@M1 M-%T=M=5JF;W66YE.A)AF9";3)2EFH*I[Y-05)$ES-<:NA=*J@Z:A9]F-?LZ- MN15=YY&@- ]*\Z$T"J4%4!J#TD(43==!;=1:9J?6C;+R,D%41ZF]T#?QI[N. MS?' .1F]K'2HS0JE>5":#Z51*"V TAB4%J)H>J77'J]E-GE_^NX:JVE]?G": M9WJHN0NE>5":#Z51*"V TAB4%J)H>OW7;K2UQX[6W&ARNY:3!<]$?9MU:>G=K^*9J(1-O[3W* P6UN4^?A M3BAM(\*,V'TBB4%D!I#$H+431= M8[75;;T1K]N"FMU0F@NE>5":#Z51*"V TAB4%J)HNJYJU]O:8WN#+0^H-VZU MF>,ME@?4'(?2?"B-0FD!E,:@M!!%TY=PU1:Y;;;(_YHI7G/2KNJH:/NF>*%) M/2C-A](HE!9 :0Q*"U$T71VU3VZ;??)?G>*UFU9VVQ2ON15=.T]0F@>E^5 : MA=("*(U!:2&*INN@-L9MLS&^=XJWBM\[Q6O.T[G2H98WE.9#:11*"Z T!J6% M*)I>Z;7E;9LM[Y^>XJVX>Z9XS=D[US_4U(;2?"B-0FD!E,:@M!!%T^N_-K5M MLZFM3S_Q>G*I'#(78BATH(V>6]6 -#AO*MKN , 9-(?'T*0>E.9#:11*"Z T M!J6%*)HNA]K;MO>M0GZ6PX%BV$P?S814 V2U%\\6K?* KDZVFRM:6^4!-<2A M-!]*HU!: *4Q*"U$T71YU(:X;3;$?W61OAG?60=0_QQ*\^R6IAK"]HV6G$OGJ$G-T^V*"H_G2?1?UN?/??1C.Q<^5 W M&4KS*IKI01?0A'1_P@":D$%I(8JF%W/M^]IFW]?P8!9S9.>:1=)<*,VSF_YR MHV:A_NW^A $T(8/20A1-?R!B;>"Q.@5/56\D3K.U M;"UG,[1K.4-I+I3F533-5K/.&IUI:%+JM+C0S:0!-"F#TD(432_KVDUUS&XJ M_O;12.<,ZBI#:2Z4YD%I/I1&H;0 2F-06HBBZ;JJS6?G0//Y,0FG-VUA#4G*]H9[N=B^,72YT\:$H? M2J-06@"E,2@M1-'T7V.KG?RAVE.9#:11*"Z T!J6% M*)HNG/I>@:'U-OIJ0^B= E":"Z5Y4)H/I5$H+8#2&)06HFBZKNH[!8;FE=S/ M=]',A-@^]:95%E"C'TISH30/2O.A- JE!5 :JVC:SS0T5YV%J*1ZO=<._M!L MDK?5^Q')A5RV5CW4OX?27"C-@])\*(U":0&4QO:4FU7>DM%ZWO]+?A9ZYW>A MS>[]K@XVOX,4)1,I>-9Z*[$9UED'4(<>2O.@-!]*HU!: *6QBK;W[/]76._# MVGH?FI=OWZ:Y&A!$/-8FGHJ)*"GFZYCGJ7RJYZ'(BC^]^AA: MO)')*ZB!#Z6Y4)H'I?E0&H72 BB-06DABJ;KJC;PA^:%Z7>-V[FJ!W,N"OFH M$0U1';EHR7/UPU:/W*=Y MGB[+EPO!IT(6.ZC/9ZD:'L[5_P!02P,$% @ @H((64D= M+FUE! UQ, !D !X;"]W;W)K&ULQ9C;;N,V M$(9?A5 710)LK),/26H;<.S=-D73!AND>U'T@I9HFXA$:DG*3OKT'5**+#DR MLT8%],:6*,[/F8_#XWC'Q9/<$*+0N-T@7N=)SA-7D@ZC&[%_#F5BHQ30F3E#,DR&KBS/SKA=_7!J;&GY3L M9.T9Z5"6G#_IE]MXXGC:(Y*02&D)#'];,B=)HI7 CV^EJ%.UJ0WKSZ_JGTWP M$,P22S+GR5<:J\W$N7103%8X3]07OON%E $-M%[$$VE^T:ZLZSDHRJ7B:6D, M'J24%?_XN011,X! VPV"TB X-!@=,0A+@_![6^B7!@:U6X1B."RPPM.QX#LD M=&U0TP\&IK&&\"G3_?Z@!'RE8*>F#QLLR,4-D(O1G*>03A*;#KE LSBF^A$G MZ)85&:8_G"V(PC0YAQJ/#PMT]N$+ZC20)&"(8T-TQYG:2/2)Q21NVKL09!5I\!KI36 5_$R6/12$'U'@ M!?TV?^SFO^:LAT+OJ/GB^\U#2S1AU6^AT0NM_;9\VV\S(3!;$QB:"BU?4+W> M/7XQQ;,=%C'ZZS>01+>*I/+OEGANBO;[[>WKZ>A:9C@B$P?F&TG$ECC3'W_P MA]Y/;6R[%%MT)-;@WJ^X]VWJTY^!K@*69Y#<1F2 17S/Z#V",ZM- Q*6"S76"]8JC.&) M7&>FQEV;$AHV>#]UM$5Z8_7E5."%F._5EZ;>Z&!=ZJC%!EO?V^]O/2O=KV;G M#Y3PE@@XR91#6N.LL*.\W@5'T>KN:$-J]^!4IN_$$Q1)C(8H-?OCMFSNRJ$F M\MJ1PC\-^5IOFE ,:8Q6F JTQ4E.$%^5TX4L*I2[JES&NH^*;FC=7-F;/YEW MH3:JY;#?[UU>'F1Q2[70ZPWVF[ FK& /*[#"NN-Q,8%"JD&/EO/H.]O+4G/0 M\#GL>TV?Y_:F3UVQNU)K@MH?>'SKOGXZBR*20#[I/'E=GM_#%+[!-!I&D*[4FI?WQQ+>?3SX]Z_F*P-P6Y]&QW;A=X^0!U'^["G@]_W#\='H\<6LW M'BD1:W-S)&$,Y4P55P)5:74[-3-W,@?E%,_,O&PO=V]R:W-H965TV+>,MY$R. M> D%_K/F(F<*AV)CRU( 2XQ1GMFNX_AVSM+"FD_-LR0QF163\,"SKVFBMC,KM$@":[;+U!=^^ 7JA";:7\PS:7[)H7[7 ML4B\DXKGM3$2Y&E17=E+/1$G!F/W@H%;&[B&NPID*#\QQ>93P0]$Z+?1F[XQ MJ1IKA$L+796E$OAOBG9JOMPR ;<+S"LA#SS'8DMFINN6+*M"$;XF2\7C9W)_ M8"(A]WH>4_5*<$D0M07R!"+E"?GP"11+LX]36R&7]F['-<.B8G O,/CD,R_4 M5I+'(H'DK;V-^31)N<>D%FZOP]]VQ8B,G1OB.JY'OBOVX/>;7>R9#',+-Q.$L0>K/D/WU'?^;&'SVOX MO#[O(X?1%$WA=]0^+T4N+?7 MD [A\,\X;FD83+HQ@@8C&%RP1W,=7*W@C,^?>#2@W8!A QCV OY1ZK8@";R MB%/)5MGU1.$9$8VBD+K=1%%#% TENB$'TX:QFFP/ F4%E4-KDY['&)N,0!78 ML8PH$'D7:7]$G[P"$Y)$)*\:%@U)PE[[&@IUVD;L7)7.'J3A+Q+,K$3QPH'B MYO'5$UZ'>K-7HH@Z%_8*/5$+^JV0WUR#=Q#"N@C>L0C8XM\K@MOFY_;V]:]' M]/L:_;%:7*AR(HVA$]?]'_H\;86(]NK(@$Z_DPDI4;3,LM'KIQ7&SKRJN,') M&@J"T61\80FURD3[I>FT[0]%JCQ3>MI)W)$?7F!JE8CV2]%;$1A*-3FG&CNC M$(\TE:9:+\T7:D)0W']#MQ@-/8NX+8*1OLE[))"#.4+SOE"_S)?*V#T.@5[ MK\$.Y0W/]HGGC<;_%3?[Y!L]![$Q)Q&)#7%7J.ISO7G:G';NJV_\]O7JJ/29 M"=S?DF2P1E-G%. "%-7IHQHH7IHO_A57>'XPMUL\L8'0+^#_:\[5<: #-&? M^;]02P,$% @ @H((69NPPZZU P %!$ !D !X;"]W;W)K&ULS5A=CYM&%/TK(QI5B=0LG\;VUD9:&YJF:I35.FD?JC[, MPK5!"PR9&=N;_OK>&5B"6=;:M$3*RS(,YYRY7WOA>G%D_$ZD )+<%WDIED8J M975IFB).H:#B@E50XI,MXP65>,MWIJ@XT$23BMQT+,LW"YJ51K#0>]<\6+"] MS+,2KCD1^Z*@_/,*1;2F"1OR1P5%TUD2Y:Z4 MT(Y/C:C1GJF(W?6#^B_:>73FE@I8L_S/+)'ITI@9)($MW>?RAAU_A<:AB=*+ M62[T7W)LL)9!XKV0K&C(:$&1E?65WC>!Z!!09YC@- 2G3_">(+@-P7WN"5Y# M$Y[PJ0A:-?-VG<=N)!*&BPX.Q*NT*BF%CKZFHWQRDI5*!O)\6F&/!EL4LKA M]0I#G9 U*[#^!-49?$TV=>T0MCU]$MVK-9 ;R*E$FF3D#:>E% JYD2R^(^\K MA13D90B29ODK5/NX"@#WKY]/= M(7?^W^G1?S[])!AN6TZNUG.?T(N**F>? <@&^"&+\:KJBPS4UU6>L[A>OM]B M+<5L5V;_(.H:>,846&!%_?4['D#>2BC$WT.U4EOC#5NCFNREJ&@,2P.[J$"3 MP A^_,'VK9^'$C6F6#BF6#22V$E*O3:EWCGUX .3-"="]XE;G<>XFT>HN\%0 M>3UO/)6<]O M,):4QRG!3H4OGP.^52M\1\HA7\\J?6TACBD6CBD6C21VD@Z_38?_7?46?\R4 MCBD6CBD6C21VDM)IF]+I-^HMM>ZD\^_NV-->;WF,L:U)K[<,Z,S<7FL9P%CN M<&N9M8[/SCK^!DK@Z+KJ+#3![[I,2$[5-_.0LV>UOK82QQ0+QQ2+1A([2 7RGQVN!+NU+67^AM[OM"'^E!]?>_LJ^7-L# M^Z$:^?54^46^_KW@'>6[#.>Y'+9XE'4QQ6;(ZQ&\OI<C/F+9,XL>IE"C0! MK@#X?,N8?+A1![0_A 3_ E!+ P04 " ""@@A9Z&-$FP(# !:"P &0 M 'AL+W=ONJZ,E"*H;,H4$G\RE$M3@4BU0:*6-%$4P,A LR?_I8U&(O8 @.!(0% %!QCM/ ME+$<4T/#OI(;HNQN1+,7F=0L&LFQQ'9E:A0^91AGPI$4@ADLL]&$)C$9R<2P M9 %)Q$"3,S*,8V;+1SFY3G(3V&*>CL%0QM_ACD]R+3:@- _#C%OUL#\O&1^7MF)B33(FF$71%GV-"_[(:HY6#L#LY^:==CKN^L# M^5ME_E8-3@A*)^"=6_K(Q$HT1H'6VK.&[Q]QAK]W6/J5)*844Y_9*2#>64$_>>$@CTK EU9M=]KY08T= M]^LXV?S=T>97GC__W?+FLR.B\W?'W;U)R4Z=MU0M6*()ASD&>8T.&D;E@UR^ M,#+-AJ>9-#B*99=+''Y!V0WX?"Z19+&P\U@Y3H>_ 5!+ P04 " ""@@A9 MG&/75[$# :$ &0 'AL+W=OE"53SQ,HY&X4 M1,'+Q"-?KHR=",?#-5O"$YA/ZP>%H[!AR7D)0G,IB(+%*+B+;K.(6D"UXB\. M.[UW3>Q69E)^L8,/^2B@-B,H8&XL!<.?+=Q#45@FS./?FC1H8EK@_O4+^R_5 MYG$S,Z;A7A:?>6Y6HV 0D!P6;%.81[G[%>H-I99O+@M=_24[MS:- S+?:"/+ M&HP9E%RX7_:U%F(/$"&B&M =760[?W M2K@I,VP\5')'E%V-;/:B4K]"HUY*'?XY)/3U/R[L?WP]!@8 L/YW60B0L2GPC2)Q^E,"M-,I%# M?H@/,>$FZ_@EZTGL)?QM(ZY(CUZ0F,9)2S[W;X?W6N!3/WP*M 2X(%G&%+X]8DL(ZZT.79%E'9 <^I(T/Z?_SP>K/A:MK>(_+O,T- M/WGOM!M>X+EN=$F6=41VX$:_<:/O%>S!4@I#MJS8 )$+9P8I.)OQ K\XT*;E MQ''V*TY[UMF.X[1/*1V&VWW)O:'/E;Q+LNSU!B)*]S=P(.9U(^:U5\P_#Q]I MHNPQZ%(N+C!5Z?/ MU?D0D5OTB.YO"F<*]>; M0F8=A3S0]*;1],:KZ2/8OL/*=E183W[7_'Q154E)0DIW-HP3DK/GULKJ)3I7 MZ3=E%='OIY5UE-:!&Q']=G"G9]6"N=2F]6A.O_>*.9%;UATMF?HS.K=$=L7F M] OW>J 2U+)J/C6JLA'&-1;-;-/@WE5MW='\)+J]=VWJ-QK7-7]D:LF%1KT7 M2$FOKO&[JEPCZ@9&KJM.:R8-]FW5Y0J;=U!V =Y?2&E>!C9 \^^ \7]02P,$ M% @ @H((68H!8W,2 P ,@L !D !X;"]W;W)K&ULK99=;]HP%(;_BI554RNMS0>0 (-(+=6T3>V&2KM=3+LPY$"L.G%F M.T#__6PG32FD88IV W'B]_7SGGSXC#:,/XH80*)M0E,QMF(ILZ%MBT4,"187 M+(-475DRGF"IAGQEBXP#CHPHH;;G.+Z=8)):X))@_ M70%EF['E6L\G[L@JEOJ$'8XRO((9R(=LRM7(KEPBDD J"$L1A^78NG2'$]<( MS(P?!#9BYQCI*'/&'O7@2S2V'$T$%!926V#UMX8)4*J=%,>?TM2JUM3"W>-G M]T\FO HSQP(FC/XDD8S'5M]"$2QQ3N4=VWR&,E!/^RT8%>87;U'"715PWAMP7_/T G6<#\ASO&Z-?-(L_\;6E=Q[+;=5F:I:>56M/./7::[5 MK\NYD%P]?[_K$A46W7H+_5(.1887,+;46R> K\$*W[]S?>=C7;[_9/8J;:=* MVVER#W7-T2D'_2W0MUF0+4I8*F-Q5I>[,/.-F?YVK,-!,++7NVD:UVN9IENE MZ1Y+TZO#+E2]'6PWV.=N=&[)W:NX>\>X_3KNW@&WLT?=Z-N2VJ^H_6/401VU M?Y2ZT;H^W74P5'J1M^6U/V*NM](?1^#VK^7$G@=>_\H>Z-[2_9! MQ3YH9F<24T3-!I/A)]4>R-IM8G"0P@NZ>SD:5VJ9PW5>ME&G,X#7\_>3'4YRG9=GL@"V=QH:W4W>8KXBJ5 82Z5R+@)5/5XT:,5 LLST M.',F5<=D#F/5U +7$]3U)6/R>:#;IJI-#O\"4$L#!!0 ( (*""%ERSDQ/ M! 0 ,,3 9 >&PO=V]R:W-H965TGW<_GDXD)ULN'N4:4<%3FC Y==9*9>>N*Z,UID3V>(9,/UERD1*E MFV+ERDP@B0NC-'$#SQNY*:',F4V*>[=B-N&Y2BC#6P$R3U,BGB\QX=NIXSN[ M&W=TM5;FACN;9&2%]ZB^9;="M]Q:):8I,DDY X'+J7/AGX?^P!@4/?ZBN)4' MUV!"67#^:!I7\=3QC$>88*2,!-%_&YQCDA@E[7#9>E#\(H/ M(_BJ75A+^,1BC)OVKHZG#BK8!749= K^F;,>]+T3"+Q@T.+/O-O\,RYZ$(Q? M-0^[S4.,].A^8=[OB*9?3U&_T.L?.47_7.N.<*4PE?^V02]5!^VJIIZS(9]SYNXFT-NED9L@TS0"(W0 M+KVC,KWE:^G=[5C@%1ZUP>\T/!:^);$&_+,:_MG1A0#^@T\[Y!KF09'4B0^M MF?_ X5=+2J<_Q[X$-L5"2V*->?"]_9K5>Y.B4LE: FI5+;2EUD1ZL WP.Y.[ MS&9-5=>'\>ZV@REM2:9((]F:"3S.9AHS^$K&B3$*"2VWJ]<:ZNHGRQ*AL M*)X59R@+KA1/B\LUDAB%Z:"?+SE7NX89H#ZWF_T 4$L#!!0 ( (*""%G* M%5HW< , -@* 9 >&PO=V]R:W-H965TMZ!)@C5XL*R^U!22VBV5 BZ!IN@]%/]#2V2(BD2Y)V>V_WU&2-=MA MC6P-$,0B^=QS=P_)XXTV4CWJ M' ]ZH4>NP5QJRN?%]G!59,G\D5"EI92%4Q M0T.U]/5*(#5+++X!?.:XT3O? M8#.92_EH![?YV ML0%AB9BP#HY\U3K L+1&%\:WC]'J7UG#W>\O^KLF=)#5VLBJ,Z8(*B[: M7_:]TV''@'CAIU!D[K?YMX(-V6&I2,E M-Z LFMCL1Z-^8TUZ<6'/R;U1M,K)SJ0?I,BD,$J6M+*$6V%0H3;P!N[;DP-R M 1_HO-X2KD*X-D;Q>6W8O$0P$CZ;-7PJ4+$5UH9GVN+@9(J&\?*46![NIW#R MZA1> 1<$E+5F(M.,?A+G -Y3F(6&F<@Q=]A/C]LG1^Q] MTJP7+MH*=Q,=)?RK%FQL3]QL3'V%-[[O^]/3>G@%=\8JJMRZ8PD*6.2KG56U] M)HU/^Q"MTS?#\"(8^>O='7&ADO!R'S5UH,(@B(?[L)D3%H87/6Q/GF$OS_"H M/)0T/:X:;7%R*T(%.'OLI/@=\%O-S0\XH9>(9]R< CW4H!E)2E72$CP(;DAL M^J-'5--C91>VJEHJX%K73&3H%+:-=KB3Y:&H3Q%A='X@UO0IZ'*8Q >*/@5% M212X]4QZ/9.C>DX*)I8("R4K$+]\](">"J#R(?3"CLA4[-<9WM49EY3)L\ZH M Q4/X@.IIB[417B@IP-T'E\>'E!_YZFN4"V;'DE3]K4P;;WM9_LV[+KI/@[F M;\*K2>B8GU+;UG99_]*W/=][II9<:"AQ0:Z"LW/:>]7V4>W R%73*,REH;:C M^2RH]41E ;2^D-)L!]9!W\RF_P!02P,$% @ @H((6=E>9T5N$@ BR&ULM=UK<]I8@L;QKZ+R3.UT MJI(8<;/))JY*K/MM4YWI[1=3\T*&@ZUJ0!Y)V,G4?/B50%@<$ ;19:+B[[O=[XOE M,LY^?!&+]/G3A7ZQ>^#7Y/ZAJ!ZXO/GX&-^+;Z+X[?%K5GYW^:+,DJ58Y4FZ MTC(Q_W3Q6?\0C2?5 IMG_&\BGO.]K[7JI=REZ1_5-^[LTT6O6B.Q$-.B(N+R MKR=Q*Q:+2BK7XU\U>O$R9K7@_M<[W=J\^/+%W,6YN$T7OR>SXN'3Q?6%-A/S M>+TH?DV?'5&_H%'E3=-%OOFO]EP_MW>A3==YD2[KAX>NTJ7=<+7+_V14_J!2:'"^BG-EQOM^5Z!XOHPU.+O&SLPZU];6#[>W?NH?5]]M_\LFJ>J]_*[+RITFY7''SK4BG?SRDBYG(\K]IYK_62?%#^\40 M\V2:%&^T=]KGV2RIWI7Q0G-7VVRIWJ/E4XHX6;S1_JI=:OE#G(E<2U;:;ZND MR-^6#Y9?__TA7>?Q:I9_O"S*-:W&NYS6:^5LUZI_8JW&6IBNBH=<,UYI>^$K3$W7NM?_56Z_?ZP_UUWO[5LH:W:C!*GTJPMP$'KP*- MUZSA=0W^]LW0?OGKFQ;&5#/>>E$R_0W3WS&O6C]+#8?Q#VV@_X1KGW=[PXVK MGT:<$'+[DVV(PP.#'"[2+.<^U_YMHFX+1_ M!.7/-;<0R_R?+:O[98L-V[%J?^M#_AA/Q:>+D*'=]\BI% MWNY2*EX7#VF6_%O,M%_*'9WMHVU1^D6I=\T5$C-(S"0QB\3L+3;:8-5Q[]/- M8-3;_OEX^;0?&L?/[+<_TR57T",QG\0"$@M)+((P*1%&+XDP4B="NER6QS^; M0- >XTQ[BA=KL[^]O?<]7?[% M-<@131*S2,PF,8?$7!+S2,PGL8#$0A*+($Q*CO%+5.0[TW M4:5'6L9%41Y#S>H<>CBBYK@%Q=;3#W+Z_;)"CFB1FD9A-8@Z)N23F MD9A/8@&)A20609@4$MEC: M[W&6Q:NB]=RCVNT<"*1FH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&ER?G2;_*E M3_:R:HU*%5(S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M8C2Y%1IRIZZL@2V?^"2 MB^DZ2XI$Y-HT7BS*O9:[']JS:L=ET+(OV)M,)O*.V:UZ%3J'!]KK1#4+U6Q4 MN""MCM1S4 U$]4L5+-1S4$U M%]4\5/-1+4"U$-4B2I-3I:F$ZN\P3=!^**J% MJ!91FIPF34=45Y=$CR_[_D?[^4O!:&L4U0Q4,U'-0C4;U1Q4'JE>N M:ZR@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:7)L=+T8OOJ7JP][&ONZDGD174D MU)X0: ,6U0Q4,U'-0C4;U1Q4U -5"5(LH34Z5I@';5S=@ZZE \NH#O6;$Z,[*8AVYPH^5,3CZD'[!PII&:@FHEJ5JWMGU2:C-\/>WM_],-T M(5? 0347U3Q4\U$M0+40U2)*D].E*;6[Z\U>ZSM#PJ.C$5B7K$SO&"EFE1S40UJ];&TA[+T0P6-CJH M@VHNJGFHYJ-:@&HAJD64)D=*TY+MJUNR/Q,I)[,$+*[A7BKQ?.B//2)%XOTN?RIT.9IIDTS,4L*;:':2T%+M*AFH)J):E:M MC<\E"]J.1347U3Q4\U$M0+40U2)*DY.EZ=#VU1U:U5[*V[V R:N9WW]L"K5E MSBQ;HP1MT**:@6HFJEEGMI"N_1!QUGI]!RW+HIJ+:AZJ^:@6H%J(:A&ER>'2 ME&7[ZCEJ#]UUJ3;VQPM'>!CFFAFHUJ#JJYJ.:AFH]J :J%J!91 MFIP=_28[E VWF]MD]>OWO8Y\:T2@9594,U#-1#4+U6Q4!LOC6I2*OECHG"JD9J&;6FE3KZ VNQT/YT,A"1[51S4$U%]4\5/-1 M+4"U$-4B2I.SHBFQ#CJ56(&*O'K SI&"=EA1S:RU#J5V"UT!&]4<5'-1S4,U M']4"5 M1+:(T.5V:/NN [[.>J45 MU1Q4ZT#=DOS_:\BK!^X<+&BM%=7,6MO?21FV M! LZX2NJ.:CFHIJ':CZJ!:@6HEI$:7*P-!W6@;K#^OO+K/2G>N]JH'- H U5 M5#//_%.--DWUMA-)%KH>-JHYJ.:BFH=J/JH%J!:B6D1I4F@,F]+J4%U:W5X+ M_JS=ILME>:CFHUJ :B&J190F MQTG3%T\I%GR;W&V;**V.V<,6HI%-1/5+%2S:TTNPM1_Y-,V M#CJPBVH>JOFH%J!:B&H1IA^KI6^NCF_KJ3?<(01NPPY:)3MO?"@8Z ML(EJ%JK9K_]'<5[_5!==1P_5?%0+4"U$M>A5&TQ^9S>MTZ&RJ2:]L[7'.-.> MXL7ZIQIDZH$ZO\E)S4 U$]4L5+-1S:DU]5V%7'1,#]5\5 M0+42UZ-RVD@.B MJ9H.SU1--\F0/RZ2HJIM/(DLWW0VJNI&:PR@1=):TP?RJ^J/#O]'CU9$4;;LBTG:[WM;P0&NBJ&:@FHEJ M%JK9J.:@FHMJ'JKYJ!:@6HAJ$:7)$=.T28=7Z%42M#"*:@:JF:AFH9J-:@ZJ MN:CFH9J/:@&JA:@649J<*DVQ='AF@M37?P"WEO;/R S'P\'5P;V6;M4C=LX* MM .*:A:JV:CFH)J+:AZJ^:@6H%J(:A&ER5G1=$6'Z@(D_P'<>L#]TS>Z_O[Z M\ [>ZO7JG"AH:135+%2S4U -5" M5(LH38ZBIH0Z0DNH([2$BFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%E&:G"K] M)E74)53^D*D>\/"0Z>"(2;U:G0,%;9RBFH5J-JHYJ.:BFH=J/JH%J!:B6D1I M1LDUWZOS*WXWRD6=1/E#NGI0_O\_$R7:*>H3.!SJD M9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1IU -5"5(LH34Z5IE8[4M=J/]^7NR;WU66?=#X7637EV?84 MRHG)S-1?=@S102-*D_.B MZC"#3J&*:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@649J<*DU]=J2NS_[) M^434>N>402NUJ&:BFH5J=JU)UU].3#F"#NRBFH=J/JH%J!:B6D1I4H2,F[[L M^$Q?5KZ.\YK;^ZK%KK&!:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@649J<+$W] M=8S67\=H_175#%0S4%M- M/5[GW$%;LJAFCH_G/AVTW%(/'=1&-0?57%3S4,U'M0#50E2+*$T.E*;^.E;7 M7\WO(ILFN:@O Y?!5Q7_\0;AZ_ M;/B;CX_QO0CC[#Y9Y=I"S,NA>N^ORCV@S47;W3=%^EAFPX5VEQ9%NMQ\^2#B MF&ULM99;;]HP%,>_BI5) M52NMY,*]A4A -ZW3JJ&RR\.T!Y,C/^5R:F5^II(0!5T1P)&$U]B;AQ31T#L[B"X&=.A@C&\I2B#L[N4['7F") M@$*BK00V?UN8 :56R7#\+$6]:D_K>#C>J[]UP9M@EEC!3-"O)-79V!MX*(45 MWE!]*W;OH RH:_42097[1;O2-O!0LE%:L-+9$##"BW]\7R;BP"$*GW&(2H?( M<1<;.!HYP6Y6%EN8I,7XZO@6*-:3G KD%+SYY%?:"RP;J3D7=:5*//^XX2)61'.4@$^#: MG$8D5N8M^R$D,8$(:U!'7>@.G*X]_MLX:'6&W9&_K<'I5CC=1IP)$QNN+4"" M5884WA*^5@=L=22%Y/ WDL$S(+T*I-<(,J-8*31%,\&8*>%"B^2N;N]&E1?6 MKE\Q]H_TQO6/0#VHJ >-F5W8 XQ%#[F(X);P\D&=UV(5P]Z#0 MW7X_# ;UI1Y60,-_*/7DKZ5N5'EATL+@\5,='*G8I?!_!C_H,>&QZETJ'Q9\ M&$;#0?2DX/Y!"V0@UZ[1*Y38;TG1#:O5ZC(Q*5KHHWEQ$[G!)+:Y_^^X.V,NPPWCSR(&D&A+4BI&5BQE-K!M$<9 L&BQ#*BZ MLF"<8*FF?&F+C ..C(BDMNLX/9O@A%K^T*S-N3]D*YDF%.8S:&0Y^H8@A5!J E8_:YA FFJ0NHT?!=,J76KA_GA'OS*Q MJUB>L( )2[\FD8Q'UKF%(EC@52KOV.8:BGBZFA>R5)AOM,EMNWT+A2LA&2G$ MZ@Y(0O-?O"WRL"=0G&J!6PCN@4@LZQ'KJ%P(1NY[&;Q 58 M8G_(V09Q;:UH>F"R;]0J7PG5^^1>EM%78;N[D*_=&N!GU>TA3SG W(=MU-Q/Y/CY5Y5./_G??K/W@^2 MX97[P#,\[YA]\.U&744S"41\KRITCNI4H_3)-A 9#F%DJ:-+ %^#Y9^\:_>< MBZHL-PD+FH1-&X(=U*-3UJ-31]_50^(MRCA;)_IF4Y>LT= ;TFZ]$D+&@2-FT(=E"/?EF/?NWC,29L M125B"Q1B$2.!U^8!R8"'0*5JXJKJ4HM\:UV:A 4Y[-/^\=$Z[[XX8QKRF.?; MWFN+"/"EZ4<%"G5:\S=CN5JVO&/3Z;U8OVP/)NV*]4"UR'E'^QN?]]>WF"\3 M*E *"^7*:?75@\WSGC6?2):9INR)2=7BF6&LVGS@VD!=7S F=Q/MH/SCX/\" M4$L#!!0 ( (*""%D,6;I%YP0 )@5 9 >&PO=V]R:W-H965T[:%I5DV/WWE65CP%P[-&4V#\&2S[FZ.E>^5])PR_A7L:)4HF])G(I19R7E M>F 8(EC1A(@N6]-4O5DPGA"IFGQIB#6G)-2D)#8LT_2,A$1I9SS4?8]\/&29 MC*.4/G(DLB0A_/L]C=EVU,&=7<=3M%S)O,,8#]=D29^I?%D_/%=$&R6#ZQ[6^T MG)!V,&"QT/_1ML2:'11D0K*D)"L/DB@M?LFW4H@# K8;"%9)L.H$MX%@EP2[ M3G :"$Y)<,X=P2T)[KDC>"7!T]H78FFE'X@DXR%G6\1SM+*6/^AP:;82.$KS ME?4LN7H;*9X7Y 5^^NT3MD()&31#[@2QI)<:,ZU?/G%G\O]%G;Q[]2 R[6J*VMF 7E&]H9__P3]LQ?(5DO:6QZ26.S"QD["H!3!QHDFXU M2;=UDA^H$ .4EE-%1$H>S3-)YC%%DJ%4)43UC7,6*^)2Y1M)E= 2DJ08QSWV MSZI+ J'#!?$J0;RSHGXB15"D:)V%5RP.*1=Y!M]\ MWJ@ZX@&A(-2I4 *$@J$-0KE5T+YK4)!51Z:<*N5 M_YK4+VEL>DECLPL9.PI%OPI%O[6J'NS?P+K:OV0(+FEL>DECLPL9.PH!-O>; M;[/U>_BB#SXTO"4;E0V6%*59,E?;XJ8< 6Z3R\2!KJ(RTXAK8*;WK[CR)_X+ MW#B;)QE3U7?;<9Q:]@& END[_5ZM6$T!H&OV?;_7JZ6@,RP>RWYPYL$_0O:R MM+TJ?+LS3<+CB;"O1E8 M^'9GFH0O6+W#TF=V?54D#_YP/0@ R>IZ]>(+P7"W?Q( .9TFW:X>'^0PJW' MA O(?[CDSPA NSM- ;#?$@" ! 4 @$$! & M <@/4L<]^U,';C]V* W0U2_7 MZ"[\.Q.YLIRJ0T9QWQ9_1PO&58_*4H(BH>]$Q#J.)%1\C(-+('5@7NKK.J&V MH%DJBV-0U5M="=[KB[!:_P0/'C#0/\VO$('^.^P,IM@!W[CJC;[9,O8N%7>6 M'PE?1JE ,5TH]\QN3^G$BVO HB'96E];S9F4+-&/*TK4%CH'J/<+QN2ND0]0 M7<:._P502P,$% @ @H((66ZWI:2; P ^ \ !D !X;"]W;W)K&ULS5==;]LV%/TKA 8,*[!%7Y9D9[: V$G1#.U@U-CZ M4.R!D6B+"$6J)!6G_WXDI3"2HV@-(&!^L47JWL-S#^\5>9='QN]%@9 $CR6A M8N444E:7KBNR I507+ *4?5FSW@)I1KR@RLJCF!NG$KB!IX7NR7$U$F79F[+ MTR6K)<$4;3D0=5E"_GV-"#NN'-]YFOB,#X74$VZZK. ![9#\J]IR-7(M2HY+ M1 5F%'"T7SE7_N7&#[6#L?@;HZ/H/ ,=RAUC]WIPFZ\<3S-"!&520T#U]X V MB!"-I'A\:T$=NZ9V[#X_H;\WP:M@[J! &T:^X%P6*V?N@!SM84WD9W;\@-J M(HV7,2+,+SBVMIX#LEI(5K;.BD&):?,/'ULA.@X*9]@A:!V"4X?9*PYAZV"4 M8N4GTS]5IGQD0H *<; K M($?@-[!3R9+7! &V!ULF$948$O(=7&-2:]7!#F4UQQ(C 2B3X)9FI,Y1#C % M&TBRFD"S1\K=N*@W ^O\5$E:.X$F.=3 *^$=-+T#H_0H"+Y@-\-G\N'LX0B>TNQ,:O/ 5 MO"NE?#X@^LUC*_B>LQ)L6%G5TDI^ SG%]"# UDK]]:,"!K<2E>*?(94;%K-A M%OI+4I7T:2K,F_R]-V0A VOR/#2W\Z'U ^]Q/>CI?O05>>EW7P1 MA[.9->O%'=FXH]&X-P0JLFN="J4*92=9=C_$#@NKP^(LZF4QI6 3@?4$\[WGFY%W MIA73$NO60AS-_,0_*9D!NR">M^3X76 MCSIXCCHXBQII:4PEVD1H?=&>;ZC^Z'WN_ZR2\$7V)U&T.+UP#9C-O3 Z/5?< M3@]5(GXPK:4 &:NI;/H'.VO;URO3M)W,KW5;:WJS9YBF)_X$^0&KXX>@O8+T M+A+%B3=M9C.0K#*=VAV3JN\SCX5JS1'7!NK]GBFQVX%>P#;[Z;]02P,$% M @ @H((65"K)C$*"0 ZEH !D !X;"]W;W)K&ULU5QM;]LV$/XKA%<,+9#6UFN<+#&0F"N6H6FR9&T_%/O V+0M5)8\2DK: M83]^E*R8HJ6<^1QWND,T\>0O$E6G >DZ]+/XA.>XLX7AWW M^]%DP9A.N>"#_,PO%DL7RHYCWHY7@;)HU6OI]P&_%B1*EDLFOIUS/WPX[1F]QR]NO/DB3K_HCTY6;,YO>?QA=2WDI_X& M9>HM>1!Y84 $GYWVSHQCZ@[3!MD5'SW^$!7>D]24NS#\DGZXF)[V!NF(N,\G M<0K!Y,L]'W/?3Y'D./[.07N;/M.&Q?>/Z&\SXZ4Q=RSBX]#_Y$WCQ6EOV"-3 M/F.)']^$#[_QW" GQ9N$?I3])0_YM8,>F211'"[SQG($2R]8O[*O.1&%!A*G MNH&9-S"W&]A/-+#R!E;3!G;>P,Z869N2\4!9S$8G(GP@(KU:HJ5O,C*SUM)\ M+TC]?AL+^5]/MHM';YDGR$?F)YR$,_+6"U@P\9A/+H(H%HET M/SPB\8*3<1A,_"1U?41N.)-S<2I?YTQ,O6!."I"7G$6)X&N8EY3'S/-?2;P/ MMY2\?/&*O"!>0/YFX^I-\].?KT9M/C-XEEV$0+R+R:S#E M4[U]7S*QH<-\I./RN5'57+/& MVCC7RO#L)_!NO7G@S;P)"V+R(0CO(B[NV9W/I7=72>J1=_R>^\1Z5<4\")V& MH^-HQ2;\M"?C30K,>Z.??S+=[ ML2>713[3IT3&LAL^281(E\(YB[SHH(+[]!JYB&1KEH:_ S)F_B3QLP_D\TWH M^T2&M0>YHOZJ\HV-Z1M,,(H$IOG&V?C& :?[.9][0;#FW9=QC%=1MX9P,XAT M4[P?&<;@I']?9*1\C3NT]6LH.)1G&NIN#'5!0]_+?&"\8,& M>FE/2)]<1%'RE,,/2W9LN[OV"@J.Y)EV#C=V#N$@SOS,QAN^>K2XRLQAK9FU M5U!P(,\T\VACYA%HIMS!:U;N46G\YG![TAZ55ZYQM&4E.(YG6FD,5+XUP-F3 MR;_2Y7)'D*OYFHGX6V5V!/;5=B- 1:-8:#K/A;S6^ $VZGR06 ["1*-8:+J# M3.4@<_?=.L=PP.T:[J@U+4AH.BTJ93?@G'WGO3W'U^*D4Z(,-2''0M,I4RFY M 6:5C3.!' ;:(^&>6O/2139LJ'38@//AAIE#C@+2@I3MYK1TD3L;*GDVX.RY M/M,PRKFOY98X04I^VK-2Q>)OZD2?Q-. M_!NF)68Y]2_1@IKX8Z'IM*C$WX03__JTQ"QG]A5+"#6SQT+3.5&9O0EG]L6] MLO@LZ4#MD)5$H=X?1T6C6&@ZHTH3F$[#[(-\$!:%R:@*@XL--T)2G%839]Y=!02+-3'&:AH% M-YUZI&@M6-74AP:IX MDN%L;^YP'ZT9Z4+06(7B(UC0- L)?R1AMMR%-Y&3TPO(658)2"Z9^)).WUDH MR,54MO,FS'^ >6O/1A92RE)2R8"GUG2)&G?*H M= 6F0!NCHE$L-+T(6LD]>[#?"&*CJCQ4-(J%IG.O5)X-/U>JBR!P\];4H8HT M&WK6I?.AE)<-*Z__201I<$&NGJJ;,BMO5,"C M:#TC4<4A%IKN :4C;7?/T0!5':*B42PTG7NE#FWXZ5UM-*C_10W<0VL^H YU M(Y4,LV$9UL$2;WA? AY8ZYF'J@6QT'2G*"UH'^UYU:,J.E0TBH6F_W12*3H' M?H!7M^J=Z6>3J"H+"TWG0ZDL!U99W02(Y]R&@ ?:=M*BHE$L--U)2OHY MYGX#AH,JV%#1*!::SKT2; [\>*\V8*#J+50TZI0K*9_(*!PEHIR=:Q4["!A- M[CK V_M"52EAX6F.ZUP8L">RR$=5(V'BD:QT'3NE<9S=BN'=,KED*6, U5W M8:'I?"C=Y6!43>YTI@L\@M:S$57E8:'I["M!Z.RYG-)!U7VH:!0+3>=>Z3YG MMW)*I\G1#W ?K1FIJ.!\JC#:52++Q:B2Q/XQ)CRHMC,/%8UBH>D.42K/W7/% MI(LJWE#1*!::SKT2;^YN%9-N1<5DJ8@:[J,U(UU(*E=)*A>C8K)->'C._09X MD*VG+*IPPT+3':0TGKOG^DD75:JAHE$L-)U[)=7HGX>:MJ4-56BY\ZIS. M2.$4.(QB2\QPT>1N SSHUGY 57A8:+K#E,)S]UQWZ:+J.U0TBH6F7%NBI=]GP'VT9@15=?4+AP ON9AGARE'9!(F0;P^ '?S[>; YK/LF.*M M[\^-X_'ZV&4%LSX%^I*)N1=$Q.K[*CANS".PV7V M=L'9E(OT OG_61C&CQ_2#C;'6X_^ U!+ P04 " ""@@A9L>Y]0_($ "- M(P &0 'AL+W=OBCXPUM@FHHN7I.RDV(]?2E8DRY6X<4P#?HEU MF3GB'/)X3F@-UPE_$@L B9ZC,!8C:R'E\LRVQ70!$16=9 FQNC-+>$2E.N5S M6RPYT"!/BD*;.$[7CBB+K?$POW;'Q\,DE2&+X8XCD481Y2\7$";KD86MUPOW M;+Z0V05[/%S2.7P"^??RCJLSNT0)6 2Q8$F,.,Q&UCD^F[AY0A[QF<%:;!VC MK)3')'G*3JZ#D>5D(X(0IC*#H.IC!1,(PPQ)C>-+ 6J5S\P2MX]?T:_RXE4Q MCU3 ) D?6" 7(ZMOH0!F- WE?;+^"$5!?H8W34*1_T7K(M:QT#05,HF*9#6" MB,6;3_I<$+&5@+V6!%(DD+Z&5E>UB65=#SDR1KQ+%JA90V5$/-'FA/BV%=;(9% M6H;U>QIWD.O\@HA#O(;TB3[]$J8J'>?I;CW=5@25+)&2)9+C>2UX$Q;?/Z,' MRCE5A#25H\W/M'@FEG0*(TN)30!?@37^\0?<=7YM*LX06*U4MRS5S='=[R^( M^YFMX;1A]9R"13LUJL@ #]&:-[F*:1_V1Q+R\<$$%$\WKXI\; M]5!T+2$2_S:1Z9HDTQ!8C4RO)-/3KIO?GI?JZTI1%;)9+K!DF7$A$(O1"U#> MN)3TD&YKXD2;^,Y*_;)2_VV5KI)0S;=:*B_H*_J^;K2H^TZU(; : =V2@.[) MZZ9KDDQ#8#4R>R69/>UJ*AI+FBVD_Q1C2BYR 6A5DJ*DM-:LJ@TZWLQ5YF16 M8Z=9T-@ M-1(&)0F#DQ?-P"29AL!J9&*G\G+.4653P._HQO'\'=WHA_'>,K#] M;?WL:N<8?A17AA3K[>,MBUF41DHKS8[M!J3J1NA\KCI3_C^>5DR&'&?!S#'\ M*ZX,+/9/7TQ&[; IM#JAE2'&6HMXN)@V\-BKN[C^H+LKJ<; WF KL%Y"94.Q MWH=6:FFW:_LIQI#E+ H_AH'%E8/%_=-7C%$O; JM3FCEAK'6'QZNF$&3$!RO M2W85TQ+HX&;%D,J"$KT%O:7/YOJ+_EE[[ZH=P[62RK42?/)J(4;=KRFT.J%; M>[+Z3=E#U5+ UT2 .Y[OX1VU- 4Z'=6'VM12^4VB]YN56@SU%_WS]I[@8WA5 M4GE5XIV^8HQ:7%-H=4(KBTOTF[0'*\9O;!N^N^O(6@*]?J]%,96I)'I3^9#_ M+J?&?KX"3N=@J-$8W3DUA5:GJ#*MI'?ZLC'J+)M^4Z-Q MNMZN+6L*5(T&^WZ+;"IG2?3.LD$VICJ.T?U34VCUGSXK]^HZ)R\=UZCI-856 M)[0RO:Y^J_90Z13P_VLDO<&.=-H"\:YT[*UW);(756XIG[-8H!!F*M'I]%3K MXIMW/S8G,EGFKT\\)E(F47ZX !H SP+4_5F2R->3[(V,\@V<\3=02P,$% M @ @H((6>X,W:A1 P CA4 T !X;"]S='EL97,N>&ULW5A13]LP$/XK M41@32!-IFC5M1EMIJX0T:9N0X&%OR&V=#N=.,@)$_YX*);Y5:Y+;R:70H_\06/R[.U[.O+#^+/O67<3 MF=*1?W?V\<]2ZLL/GKV??#HYZ=R=7^[;SRK@W ^<3GLO<'K1P?T:#',=[[K> M+#\UOAKN*4;N.\A;)DH;O"B=9[+!'"?.9%JI(,1^QUV%-A4M83]$R+ML2P_J M+AH/,RFVS13YUF#\DYQZ]X2/_ GA;*H8L#*2,[ZVYBX89I)+Y6G3Q29@");R MP<*AG4&#UWYR)J2J8ML(]O>T7KX';&8@D''>".SZUC >%D1KJL25F52+*^,3 MR*O'M^O"*)PKL@Z[/7]+J&XFR%2JE*HF3.AO3.,AIQG(46R^@+N610"@UC(W M@Y21N12DTK!AU /C=D8YOX&G_W>VXWN5M7:NVG31#(V@>FC=V GX;WNSOMMN M>V_RZQ7L7NIO2Y..J.;0X/1:T8RMJODJ:P1@WD/<.RD*OO[*V5SDU";_XH#C M(=GPO(54[,%$@U:9&0-5OG=/E6:SMN6O(L4M7>E-.ZTR7'/W"#7_VSK/J:"* M\+9HT_N'7.4W*X[Z[R6Y^E;9%^S46+_2#UUD[QA$QL<@\BAZM,EXYJ)>K9@ M:4K%DX.A<:_)U/RQN>/?K$]I1I9(<_W ;:GSW4(EBG>B5BF>*T!<=<-&$GBWFTL#C"P M78!Q)$@R!7G3W:!PCU8GAX]X?["F)HB1Q(X"Y M%401AL#3B".8 M" (5%4O0?WWD?!YCT5;/\#.WX$4$L#!!0 ( (*""%F7 MBKL
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end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 204 230 1 true 56 0 false 5 false false R1.htm 0000001 - Document - Cover Sheet http://vtvtherapeutics.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - Condensed Consolidated Balance Sheets Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Condensed Consolidated Statements of Operations - Unaudited Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations - Unaudited Statements 4 false false R5.htm 9952154 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited Statements 5 false false R6.htm 9952155 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows - Unaudited Statements 6 false false R7.htm 9952156 - Disclosure - Description of Business and Basis of Presentation Sheet http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation Description of Business and Basis of Presentation Notes 7 false false R8.htm 9952157 - Disclosure - Summary of Significant Accounting Policies Sheet http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 9952158 - Disclosure - Collaboration Agreements Sheet http://vtvtherapeutics.com/role/CollaborationAgreements Collaboration Agreements Notes 9 false false R10.htm 9952159 - Disclosure - Share-Based Compensation Sheet http://vtvtherapeutics.com/role/ShareBasedCompensation Share-Based Compensation Notes 10 false false R11.htm 9952160 - Disclosure - Commitments and Contingencies Sheet http://vtvtherapeutics.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 11 false false R12.htm 9952161 - Disclosure - Leases Sheet http://vtvtherapeutics.com/role/Leases Leases Notes 12 false false R13.htm 9952162 - Disclosure - Noncontrolling Interest Sheet http://vtvtherapeutics.com/role/NoncontrollingInterest Noncontrolling Interest Notes 13 false false R14.htm 9952163 - Disclosure - Stockholders' Equity (Deficit) Sheet http://vtvtherapeutics.com/role/StockholdersEquityDeficit Stockholders' Equity (Deficit) Notes 14 false false R15.htm 9952164 - Disclosure - Related-Party Transactions Sheet http://vtvtherapeutics.com/role/RelatedPartyTransactions Related-Party Transactions Notes 15 false false R16.htm 9952165 - Disclosure - Income Taxes Sheet http://vtvtherapeutics.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 9952166 - Disclosure - Net Loss per Share Sheet http://vtvtherapeutics.com/role/NetLossperShare Net Loss per Share Notes 17 false false R18.htm 9952167 - Disclosure - Fair Value of Financial Instruments Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 18 false false R19.htm 9952168 - Disclosure - Subsequent Events Sheet http://vtvtherapeutics.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 20 false false R21.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 21 false false R22.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies 22 false false R23.htm 9954472 - Disclosure - Share-Based Compensation (Tables) Sheet http://vtvtherapeutics.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://vtvtherapeutics.com/role/ShareBasedCompensation 23 false false R24.htm 9954473 - Disclosure - Leases (Tables) Sheet http://vtvtherapeutics.com/role/LeasesTables Leases (Tables) Tables http://vtvtherapeutics.com/role/Leases 24 false false R25.htm 9954474 - Disclosure - Noncontrolling Interest (Tables) Sheet http://vtvtherapeutics.com/role/NoncontrollingInterestTables Noncontrolling Interest (Tables) Tables http://vtvtherapeutics.com/role/NoncontrollingInterest 25 false false R26.htm 9954475 - Disclosure - Net Loss per Share (Tables) Sheet http://vtvtherapeutics.com/role/NetLossperShareTables Net Loss per Share (Tables) Tables http://vtvtherapeutics.com/role/NetLossperShare 26 false false R27.htm 9954476 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://vtvtherapeutics.com/role/FairValueofFinancialInstruments 27 false false R28.htm 9954477 - Disclosure - Description of Business and Basis of Presentation (Detail) Sheet http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail Description of Business and Basis of Presentation (Detail) Details http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation 28 false false R29.htm 9954478 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 29 false false R30.htm 9954479 - Disclosure - Collaboration Agreements - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail Collaboration Agreements - Additional Information (Detail) Details 30 false false R31.htm 9954480 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 31 false false R32.htm 9954481 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail) Sheet http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail) Details 32 false false R33.htm 9954482 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) Sheet http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) Details 33 false false R34.htm 9954483 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 34 false false R35.htm 9954484 - Disclosure - Leases - Additional Information (Details) Sheet http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 35 false false R36.htm 9954485 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) Sheet http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) Details 36 false false R37.htm 9954486 - Disclosure - Noncontrolling Interest - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail Noncontrolling Interest - Additional Information (Detail) Details 37 false false R38.htm 9954487 - Disclosure - Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) Sheet http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) Details 38 false false R39.htm 9954488 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail Stockholders' Equity (Deficit) - Additional Information (Detail) Details http://vtvtherapeutics.com/role/StockholdersEquityDeficit 39 false false R40.htm 9954489 - Disclosure - Related-Party Transactions - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail Related-Party Transactions - Additional Information (Detail) Details 40 false false R41.htm 9954490 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 41 false false R42.htm 9954491 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) Sheet http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) Details 42 false false R43.htm 9954492 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) Sheet http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) Details 43 false false R44.htm 9954493 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) Details 44 false false R45.htm 9954494 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail) Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail) Details 45 false false All Reports Book All Reports vtvt-20240630.htm vtvt-20240630.xsd vtvt-20240630_cal.xml vtvt-20240630_def.xml vtvt-20240630_lab.xml vtvt-20240630_pre.xml vtvt-20240630_g1.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vtvt-20240630.htm": { "nsprefix": "vtvt", "nsuri": "http://vtvtherapeutics.com/20240630", "dts": { "inline": { "local": [ "vtvt-20240630.htm" ] }, "schema": { "local": [ "vtvt-20240630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "vtvt-20240630_cal.xml" ] }, "definitionLink": { "local": [ "vtvt-20240630_def.xml" ] }, "labelLink": { "local": [ "vtvt-20240630_lab.xml" ] }, "presentationLink": { "local": [ "vtvt-20240630_pre.xml" ] } }, "keyStandard": 192, "keyCustom": 38, "axisStandard": 25, "axisCustom": 0, "memberStandard": 28, "memberCustom": 23, "hidden": { "total": 9, "http://vtvtherapeutics.com/20240630": 2, "http://fasb.org/us-gaap/2024": 2, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 204, "entityCount": 1, "segmentCount": 56, "elementCount": 499, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 544, "http://xbrl.sec.gov/dei/2024": 31, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://vtvtherapeutics.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "unique": true } }, "R3": { "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-139", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations - Unaudited", "shortName": "Condensed Consolidated Statements of Operations - Unaudited", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "unique": true } }, "R5": { "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "longName": "9952154 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited", "shortName": "Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-76", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-76", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R6": { "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited", "shortName": "Condensed Consolidated Statements of Cash Flows - Unaudited", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "unique": true } }, "R7": { "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation", "longName": "9952156 - Disclosure - Description of Business and Basis of Presentation", "shortName": "Description of Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies", "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://vtvtherapeutics.com/role/CollaborationAgreements", "longName": "9952158 - Disclosure - Collaboration Agreements", "shortName": "Collaboration Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://vtvtherapeutics.com/role/ShareBasedCompensation", "longName": "9952159 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://vtvtherapeutics.com/role/CommitmentsandContingencies", "longName": "9952160 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://vtvtherapeutics.com/role/Leases", "longName": "9952161 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://vtvtherapeutics.com/role/NoncontrollingInterest", "longName": "9952162 - Disclosure - Noncontrolling Interest", "shortName": "Noncontrolling Interest", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://vtvtherapeutics.com/role/StockholdersEquityDeficit", "longName": "9952163 - Disclosure - Stockholders' Equity (Deficit)", "shortName": "Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactions", "longName": "9952164 - Disclosure - Related-Party Transactions", "shortName": "Related-Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://vtvtherapeutics.com/role/IncomeTaxes", "longName": "9952165 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://vtvtherapeutics.com/role/NetLossperShare", "longName": "9952166 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstruments", "longName": "9952167 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://vtvtherapeutics.com/role/SubsequentEvents", "longName": "9952168 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-14", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationTables", "longName": "9954472 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://vtvtherapeutics.com/role/LeasesTables", "longName": "9954473 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://vtvtherapeutics.com/role/NoncontrollingInterestTables", "longName": "9954474 - Disclosure - Noncontrolling Interest (Tables)", "shortName": "Noncontrolling Interest (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://vtvtherapeutics.com/role/NetLossperShareTables", "longName": "9954475 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables", "longName": "9954476 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "longName": "9954477 - Disclosure - Description of Business and Basis of Presentation (Detail)", "shortName": "Description of Business and Basis of Presentation (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-85", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "unique": true } }, "R29": { "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "9954478 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-96", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-96", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "longName": "9954479 - Disclosure - Collaboration Agreements - Additional Information (Detail)", "shortName": "Collaboration Agreements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-99", "name": "vtvt:SaleOfStockConsiderationReceivedOnTransactionGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "unique": true } }, "R31": { "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail", "longName": "9954480 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "shortName": "Share-Based Compensation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-113", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "unique": true } }, "R32": { "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail", "longName": "9954481 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)", "shortName": "Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail", "longName": "9954482 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)", "shortName": "Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R34": { "role": "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "longName": "9954483 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-126", "name": "vtvt:PotentialMilestonePayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-126", "name": "vtvt:PotentialMilestonePayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails", "longName": "9954484 - Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R36": { "role": "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail", "longName": "9954485 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)", "shortName": "Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R37": { "role": "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail", "longName": "9954486 - Disclosure - Noncontrolling Interest - Additional Information (Detail)", "shortName": "Noncontrolling Interest - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-132", "name": "us-gaap:RedeemableNoncontrollingInterestEquityFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-132", "name": "us-gaap:RedeemableNoncontrollingInterestEquityFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R38": { "role": "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail", "longName": "9954487 - Disclosure - Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)", "shortName": "Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "unique": true } }, "R39": { "role": "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail", "longName": "9954488 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)", "shortName": "Stockholders' Equity (Deficit) - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-136", "name": "vtvt:CommonStockAndPreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-136", "name": "vtvt:CommonStockAndPreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R40": { "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "longName": "9954489 - Disclosure - Related-Party Transactions - Additional Information (Detail)", "shortName": "Related-Party Transactions - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-150", "name": "vtvt:OwnershipPercentageOfMajorityOwner", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-150", "name": "vtvt:OwnershipPercentageOfMajorityOwner", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R41": { "role": "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail", "longName": "9954490 - Disclosure - Income Taxes - Additional Information (Detail)", "shortName": "Income Taxes - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-151", "name": "vtvt:PercentageOfAmountOfCashSavings", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "unique": true } }, "R42": { "role": "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "longName": "9954491 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)", "shortName": "Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "unique": true } }, "R43": { "role": "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail", "longName": "9954492 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)", "shortName": "Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R44": { "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail", "longName": "9954493 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)", "shortName": "Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-183", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-183", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } }, "R45": { "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "longName": "9954494 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)", "shortName": "Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-202", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-202", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240630.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts and financing receivable, after allowance for credit loss", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable." } } }, "auth_ref": [ "r807" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r53", "r54" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r807" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r725" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r62" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r528", "r796", "r797", "r798", "r799", "r828", "r882" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r738" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r738" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r738" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r738" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r39", "r40", "r305" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r771" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r697", "r707", "r717", "r749" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r700", "r710", "r720", "r752" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r772" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r738" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r745" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r701", "r711", "r721", "r745", "r753", "r757", "r765" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r763" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r334", "r339" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r178" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r18" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r366" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r95", "r105", "r125", "r142", "r182", "r186", "r193", "r194", "r229", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r368", "r372", "r407", "r477", "r564", "r638", "r639", "r668", "r688", "r819", "r820", "r842" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r122", "r129", "r142", "r229", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r368", "r372", "r407", "r668", "r819", "r820", "r842" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r760" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r756" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r759" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r758" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r757" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r757" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "Description of Business and Basis of Presentation", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r52", "r76", "r77" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r13", "r124", "r631" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r14" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Total cash and cash equivalents, beginning of period", "periodEndLabel": "Total cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r13", "r73", "r139" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r73" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "vtvt_ChangeInRedemptionValueOfNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "ChangeInRedemptionValueOfNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in redemption value of noncontrolling interest", "label": "Change In Redemption Value Of Noncontrolling Interest", "documentation": "Change In Redemption Value Of Noncontrolling Interest" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r736" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r733" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r731" ] }, "vtvt_CinRxInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "CinRxInvestmentMember", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "CinRx Investment", "label": "CinRx Investment [Member]", "documentation": "CinRx Investment" } } }, "auth_ref": [] }, "vtvt_CinRxWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "CinRxWarrantsMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "CinRx Warrants", "label": "CinRx Warrants [Member]", "documentation": "CinRx Warrants" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/Cover", "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r118", "r126", "r127", "r128", "r142", "r167", "r168", "r175", "r177", "r184", "r185", "r229", "r250", "r252", "r253", "r254", "r257", "r258", "r263", "r264", "r267", "r270", "r277", "r407", "r517", "r518", "r519", "r520", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r552", "r573", "r596", "r616", "r617", "r618", "r619", "r620", "r775", "r792", "r800" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class Of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r126", "r127", "r128", "r184", "r263", "r264", "r265", "r267", "r270", "r275", "r277", "r517", "r518", "r519", "r520", "r644", "r775", "r792" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of warrants or rights (in usd per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r278" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of securities called by warrants or rights (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r278" ] }, "vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of securities called by warrants", "label": "Class of Warrant or Right, Percent of Securities Called by Warrants or Rights", "documentation": "Class of Warrant or Right, Percent of Securities Called by Warrants or Rights" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r737" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r737" ] }, "vtvt_CognaMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "CognaMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cogna", "label": "Cogna [Member]", "documentation": "Cogna" } } }, "auth_ref": [] }, "vtvt_CollaborateArrangementContingentConsiderationTransferredCash": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "CollaborateArrangementContingentConsiderationTransferredCash", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborate arrangement, contingent consideration transferred, cash", "label": "Collaborate Arrangement, Contingent Consideration Transferred, Cash", "documentation": "Collaborate Arrangement, Contingent Consideration Transferred, Cash" } } }, "auth_ref": [] }, "vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, contingent consideration", "label": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value", "documentation": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Agreements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r108", "r110", "r117" ] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements", "label": "Collaborative Arrangement [Member]", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": [ "r366" ] }, "vtvt_CollaborativeArrangementNoteReceivableDiscountPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "CollaborativeArrangementNoteReceivableDiscountPaid", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Discount on note receivable", "label": "Collaborative Arrangement, Note Receivable, Discount Paid", "documentation": "Collaborative Arrangement, Note Receivable, Discount Paid" } } }, "auth_ref": [] }, "vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod": { "xbrltype": "durationItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "CollaborativeArrangementRoyaltiesReceivablePeriod", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties receivable, period", "label": "Collaborative Arrangement, Royalties Receivable, Period", "documentation": "Collaborative Arrangement, Royalties Receivable, Period" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r366" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r58", "r96", "r479", "r551" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r80", "r244", "r245", "r624", "r813", "r815" ] }, "vtvt_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments And Contingencies [Line Items]", "label": "Commitments And Contingencies [Line Items]", "documentation": "Commitments and Contingencies." } } }, "auth_ref": [] }, "vtvt_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "CommitmentsAndContingenciesTable", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments And Contingencies [Table]", "label": "Commitments And Contingencies [Table]", "documentation": "Commitments And Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/Cover", "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Common Stock", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r882" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/Cover", "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Common Stock", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r882" ] }, "vtvt_CommonStockAndPreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "CommonStockAndPreferredStockSharesAuthorized", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Capital stock, shares authorized (in shares)", "label": "Common Stock And Preferred Stock Shares Authorized", "documentation": "Common stock and preferred stock shares authorized." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r677", "r678", "r679", "r681", "r682", "r683", "r684", "r796", "r797", "r799", "r828", "r881", "r882" ] }, "vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Private placement pre-funded warrants, shares (in shares)", "label": "Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares", "documentation": "Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares" } } }, "auth_ref": [] }, "vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares": { "xbrltype": "sharesItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "CommonStockParOrStatedValueOfPrivatePlacementShares", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Private placement, shares (in shares)", "label": "Common Stock, Par or Stated Value of Private Placement, Shares", "documentation": "Common Stock, Par or Stated Value of Private Placement, Shares" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r61" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r61", "r552" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance, shares (in shares)", "periodEndLabel": "Ending balance, shares (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r7", "r61", "r552", "r570", "r882", "r883" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock value", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r61", "r480", "r668" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r742" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r741" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r743" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r740" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r19", "r20", "r47", "r48", "r197", "r623" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r19", "r20", "r47", "r48", "r197", "r512", "r623" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r19", "r20", "r47", "r48", "r197", "r623", "r777" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r51", "r112" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r19", "r20", "r47", "r48", "r197" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r19", "r20", "r47", "r48", "r197", "r623" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r148", "r368", "r369", "r372", "r373", "r434", "r625", "r818", "r821", "r822" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r148", "r368", "r369", "r372", "r373", "r434", "r625", "r818", "r821", "r822" ] }, "vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": { "parentTag": "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances", "label": "Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent", "documentation": "Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent." } } }, "auth_ref": [] }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net", "documentation": "This element represents the total net income attributable to the parent for the period and the effect of net changes during the period impacting the parent's ownership interest in a subsidiary as it relates to the total (consolidated) equity attributable to the parent. The changes to the parent's ownership interest in a subsidiary represented by this element did not result in a deconsolidation of the subsidiary from the consolidated financial statements." } } }, "auth_ref": [ "r6", "r35", "r46" ] }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/NoncontrollingInterestTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Net Income Attributable to Vtv Therapeutics Inc", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]", "documentation": "The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary." } } }, "auth_ref": [ "r6", "r46" ] }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized from change in estimated transaction prices", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained." } } }, "auth_ref": [ "r645" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of contract liabilities", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r280", "r281", "r292" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities, net of current portion", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r280", "r281", "r292" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with customer, liability, revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r293" ] }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockByUniqueDescriptionAxis", "presentation": [ "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Conversion Description", "label": "Stock Conversion Description [Axis]", "documentation": "Information by description of stock conversions." } } }, "auth_ref": [ "r15", "r16", "r17" ] }, "us-gaap_ConversionOfStockNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockNameDomain", "presentation": [ "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of Stock, Name", "label": "Conversion of Stock, Name [Domain]", "documentation": "The unique name of a noncash or part noncash stock conversion." } } }, "auth_ref": [ "r15", "r16", "r17" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r146", "r147", "r259", "r265", "r432", "r453", "r476", "r632", "r634" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r78", "r197" ] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current deposits", "label": "Deposits Assets, Current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": [ "r785" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r24" ] }, "vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "DevelopmentalAndRegulatoryMilestonePaymentMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Developmental and Regulatory Milestone Payment", "label": "Developmental And Regulatory Milestone Payment [Member]", "documentation": "Developmental and regulatory milestone payment." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r303", "r307", "r335", "r336", "r338", "r652" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r692" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r724" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r735" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r135", "r154", "r155", "r156", "r157", "r158", "r159", "r164", "r167", "r175", "r176", "r177", "r181", "r362", "r365", "r383", "r384", "r472", "r492", "r635" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r135", "r154", "r155", "r156", "r157", "r158", "r159", "r167", "r175", "r176", "r177", "r181", "r362", "r365", "r383", "r384", "r472", "r492", "r635" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r163", "r178", "r179", "r180" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period to recognize unrecognized share-based compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r337" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost related to non-vested share-based compensation arrangements", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r825" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail", "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option", "verboseLabel": "Common stock options granted under the Plan", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r690" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Entity", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r690" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r690" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r774" ] }, "vtvt_EntityPublicFloatThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "EntityPublicFloatThreshold", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Entity public float, threshold", "label": "Entity Public Float, Threshold", "documentation": "Entity Public Float, Threshold" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r690" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r690" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r690" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r690" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r729" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r770" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r770" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r770" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r119", "r132", "r133", "r134", "r149", "r150", "r151", "r153", "r158", "r160", "r162", "r183", "r230", "r231", "r240", "r279", "r352", "r353", "r359", "r360", "r361", "r363", "r364", "r365", "r374", "r375", "r376", "r377", "r378", "r379", "r382", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r417", "r425", "r490", "r506", "r507", "r508", "r528", "r596" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r739" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r697", "r707", "r717", "r749" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r694", "r704", "r714", "r746" ] }, "vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember", "presentation": [ "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange of Redeemable Non controlling Interest To Class A Common Stock", "label": "Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member]", "documentation": "Exchange of redeemable non controlling interest to class A common stock." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r745" ] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of warrants", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r4" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r388", "r389", "r390", "r660" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r388", "r389", "r390", "r660" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r388", "r389", "r660" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r260", "r295", "r296", "r297", "r298", "r299", "r300", "r385", "r387", "r388", "r389", "r390", "r398", "r399", "r401", "r440", "r441", "r442", "r642", "r643", "r648", "r649", "r650", "r657", "r660" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r386", "r387", "r388", "r390", "r657", "r833", "r836" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r394", "r396", "r397", "r398", "r401", "r402", "r403", "r404", "r405", "r471", "r657", "r661" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r260", "r295", "r300", "r387", "r399", "r440", "r648", "r649", "r650", "r657" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r260", "r295", "r300", "r387", "r388", "r399", "r441", "r642", "r643", "r648", "r649", "r650", "r657" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r260", "r295", "r296", "r297", "r298", "r299", "r300", "r387", "r388", "r389", "r390", "r399", "r442", "r642", "r643", "r648", "r649", "r650", "r657", "r660" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r386", "r387", "r388", "r390", "r657", "r833", "r836" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases / Issuance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r393", "r400" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sales / Repurchases", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales", "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r393", "r400" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r391", "r400" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r260", "r295", "r296", "r297", "r298", "r299", "r300", "r385", "r387", "r388", "r389", "r390", "r398", "r399", "r401", "r440", "r441", "r442", "r642", "r643", "r648", "r649", "r650", "r657", "r660" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r657", "r830", "r831", "r832", "r833", "r834", "r836" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net Change in fair value included in earnings", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r392", "r400" ] }, "vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]", "label": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]", "documentation": "Fair value of assets and liabilities measured on recurring basis." } } }, "auth_ref": [] }, "vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]", "label": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]", "documentation": "Fair value of assets and liabilities measured on recurring basis table." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r261", "r275", "r380", "r406", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r491", "r641", "r657", "r658", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r669", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r808", "r809", "r810", "r811", "r829", "r832", "r833", "r834", "r835", "r836" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r701", "r711", "r721", "r753" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r701", "r711", "r721", "r753" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r701", "r711", "r721", "r753" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r701", "r711", "r721", "r753" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r701", "r711", "r721", "r753" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r734" ] }, "vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement", "label": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member]", "documentation": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement" } } }, "auth_ref": [] }, "vtvt_G42InvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "G42InvestmentsMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "G42 Investments", "label": "G42 Investments [Member]", "documentation": "G42 Investments" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss from promissory note early redemption", "verboseLabel": "Gain (loss) on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r4", "r25", "r26" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r70", "r576" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r70" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes and noncontrolling interest", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r67", "r100", "r104", "r474", "r486", "r637", "r638", "r802", "r803", "r804", "r805", "r806" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r241", "r242", "r243", "r392", "r395", "r400", "r503", "r505", "r581", "r628", "r659", "r852" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r242", "r243", "r392", "r395", "r400", "r503", "r505", "r581", "r628", "r659", "r852" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r143", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r354", "r356", "r357", "r358", "r522", "r654" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax provision", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r106", "r115", "r161", "r162", "r182", "r191", "r194", "r345", "r346", "r355", "r494", "r654" ] }, "vtvt_IncomeTaxesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "IncomeTaxesLineItems", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Line Items]", "label": "Income Taxes [Line Items]", "documentation": "Income taxes." } } }, "auth_ref": [] }, "vtvt_IncomeTaxesTable": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "IncomeTaxesTable", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Table]", "label": "Income Taxes [Table]", "documentation": "Income taxes." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "vtvt_IncreaseInCommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "IncreaseInCommonStockSharesAuthorized", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in shares authorized (in shares)", "label": "Increase In Common Stock Shares Authorized", "documentation": "Increase in common stock shares authorized." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r701", "r711", "r721", "r745", "r753", "r757", "r765" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r763" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r693", "r769" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r693", "r769" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r693", "r769" ] }, "us-gaap_InterestExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseOperating", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense, Operating", "documentation": "Amount of interest expense classified as operating." } } }, "auth_ref": [ "r190", "r473", "r789" ] }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOperating", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash interest income", "label": "Interest Income, Operating", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": [ "r189", "r574", "r614", "r615", "r638", "r685", "r686", "r788", "r884" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r182", "r189", "r194", "r638", "r790" ] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalanceShares", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share held by related party (in shares)", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": [ "r540", "r541", "r605", "r611", "r613", "r679" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r493", "r513", "r514", "r515", "r516", "r606", "r607" ] }, "vtvt_JDRFInternationalMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "JDRFInternationalMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "JDRF", "label": "J D R F International [Member]", "documentation": "JDRF international." } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Lease Liabilities for Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r840" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r423" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r423" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r423" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r423" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r423" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remaining six months)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r840" ] }, "vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r839" ] }, "vtvt_LesseeOperatingLeaseTerminationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "LesseeOperatingLeaseTerminationPeriod", "presentation": [ "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, termination period", "label": "Lessee, Operating Lease, Termination Period", "documentation": "Lessee, Operating Lease, Termination Period" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r416" ] }, "vtvt_LetterAgreementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "LetterAgreementWarrantsMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Letter Agreement Warrants", "label": "Letter Agreement Warrants [Member]", "documentation": "Letter agreement warrants." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r10", "r53", "r54", "r55", "r56", "r57", "r58", "r59", "r142", "r229", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r369", "r372", "r373", "r407", "r550", "r636", "r688", "r819", "r842", "r843" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, redeemable noncontrolling interest and stockholders\u2019 equity (deficit)", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r66", "r98", "r483", "r668", "r793", "r812", "r838" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (Deficit)", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r55", "r123", "r142", "r229", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r369", "r372", "r373", "r407", "r668", "r819", "r842", "r843" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r387", "r830" ] }, "vtvt_LicenseAndTechnologyTransferServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "LicenseAndTechnologyTransferServicesMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License And Technology Transfer Services", "label": "License And Technology Transfer Services [Member]", "documentation": "License and technology transfer services." } } }, "auth_ref": [] }, "vtvt_LicenseFeePriceIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "LicenseFeePriceIncrease", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License fee price increase", "label": "License Fee Price Increase", "documentation": "License Fee Price Increase" } } }, "auth_ref": [] }, "vtvt_LicenseFeeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "LicenseFeeReceived", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License fee received", "label": "License Fee Received", "documentation": "License Fee Received" } } }, "auth_ref": [] }, "vtvt_LicenseFeeReceivedTerm": { "xbrltype": "durationItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "LicenseFeeReceivedTerm", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License fee received, term", "label": "License Fee Received, Term", "documentation": "License Fee Received, Term" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "vtvt_MFTTPHoldingsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "MFTTPHoldingsLLCMember", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "M&F TTP Holdings LLC", "label": "M F T T P Holdings L L C [Member]", "documentation": "M&F TTP Holdings LLC." } } }, "auth_ref": [] }, "vtvt_MacAndrewsAndForbesIncorporatedMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "MacAndrewsAndForbesIncorporatedMember", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "MacAndrews & Forbes Incorporated", "label": "Mac Andrews And Forbes Incorporated [Member]", "documentation": "MacAndrews and Forbes Incorporated." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r197", "r647", "r671", "r674", "r824", "r851", "r853", "r854", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880" ] }, "vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "MaximumFundingPercentageOfResearchAndDevelopmentMilestones", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum funding percentage of research and development milestones", "label": "Maximum Funding Percentage Of Research And Development Milestones", "documentation": "Maximum funding percentage of research and development milestones." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r302", "r340", "r390", "r469", "r502", "r504", "r511", "r542", "r543", "r604", "r608", "r609", "r610", "r612", "r626", "r627", "r640", "r644", "r651", "r660", "r661", "r665", "r666", "r672", "r823", "r844", "r845", "r846", "r847", "r848", "r849" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r737" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r737" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r832", "r833", "r834" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r660", "r832", "r833", "r834" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r832", "r833", "r834" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r388", "r389", "r390", "r660" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r388", "r389", "r390", "r660" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r302", "r340", "r390", "r469", "r502", "r504", "r511", "r542", "r543", "r604", "r608", "r609", "r610", "r612", "r626", "r627", "r640", "r644", "r651", "r660", "r661", "r665", "r672", "r823", "r844", "r845", "r846", "r847", "r848", "r849" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r65", "r97", "r142", "r229", "r250", "r252", "r253", "r254", "r257", "r258", "r407", "r482", "r554" ] }, "us-gaap_MinorityInterestChangeInRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestChangeInRedemptionValue", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in redemption value of noncontrolling interest", "label": "Noncontrolling Interest, Change in Redemption Value", "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest." } } }, "auth_ref": [ "r28", "r35", "r83", "r84" ] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/NoncontrollingInterest" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest Disclosure [Text Block]", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r91" ] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestLineItems", "presentation": [ "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestTable", "presentation": [ "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minority Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest." } } }, "auth_ref": [ "r42", "r43", "r65", "r68" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r756" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r764" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r197", "r647", "r671", "r674", "r824", "r851", "r853", "r854", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r738" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r138" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r73", "r74", "r75" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to vTv Therapeutics Inc.", "terseLabel": "Net loss attributable to vTv Therapeutics Inc.", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r69", "r75", "r101", "r121", "r130", "r131", "r134", "r142", "r152", "r154", "r155", "r156", "r157", "r158", "r161", "r162", "r173", "r229", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r362", "r365", "r384", "r407", "r489", "r572", "r594", "r595", "r686", "r819" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Less: net loss attributable to noncontrolling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r45", "r92", "r130", "r131", "r158", "r161", "r162", "r488", "r787" ] }, "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss attributable to noncontrolling interest", "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest", "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest." } } }, "auth_ref": [ "r68" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": { "parentTag": "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet", "weight": 1.0, "order": 1.0 }, "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to vTv Therapeutics Inc. common shareholders", "totalLabel": "Net loss attributable to common shareholders of vTv Therapeutics Inc., basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r136", "r154", "r155", "r156", "r157", "r164", "r165", "r174", "r177", "r365" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r136", "r166", "r169", "r170", "r171", "r172", "r174", "r177" ] }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to vTv Therapeutics Inc.", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity." } } }, "auth_ref": [ "r11", "r92", "r93" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "vtvt_NewsoaraBiopharmaCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "NewsoaraBiopharmaCoLtdMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Newsoara Biopharma Co Ltd", "label": "Newsoara Biopharma Co Ltd [Member]", "documentation": "Newsoara Biopharma Co Ltd." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r737" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r701", "r711", "r721", "r745", "r753" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r728" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r727" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r745" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r764" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r764" ] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Abstract]", "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r41", "r279", "r796", "r797", "r798", "r799", "r882" ] }, "vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "NoncontrollingInterestReclassificationToAdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of noncontrolling interest to additional paid-in capital", "label": "Noncontrolling Interest, Reclassification to Additional Paid-in-Capital", "documentation": "Noncontrolling Interest, Reclassification to Additional Paid-in-Capital" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrelatedPartyMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrelated Party", "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r794", "r795" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of notes payable", "label": "Notes Payable, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r53", "r54" ] }, "vtvt_NotesReceivableDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "NotesReceivableDiscountRate", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Notes Receivable, Discount Rate", "documentation": "Notes Receivable, Discount Rate" } } }, "auth_ref": [] }, "vtvt_NovoLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "NovoLicenseAgreementMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Novo License Agreement", "label": "Novo License Agreement [Member]", "documentation": "Novo license agreement." } } }, "auth_ref": [] }, "vtvt_OneCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "OneCustomerMember", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "One Customer", "label": "One Customer [Member]", "documentation": "One Customer" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r104", "r637", "r802", "r803", "r804", "r805", "r806" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r420", "r667" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails", "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r419" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r419" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r419" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r418" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average incremental borrowing rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r422", "r667" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining operating lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r421", "r667" ] }, "vtvt_OperatingLeasesImputedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "OperatingLeasesImputedInterest", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Operating Leases Imputed Interest", "documentation": "Operating leases imputed interest." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "documentation": "Organization consolidation and presentation of financial statements." } } }, "auth_ref": [] }, "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "documentation": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsAxis", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments", "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsDomain", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments", "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "vtvt_OtherIndicationMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "OtherIndicationMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Indication", "label": "Other Indication [Member]", "documentation": "Other indication." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r71" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r737" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r699", "r709", "r719", "r751" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r702", "r712", "r722", "r754" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r702", "r712", "r722", "r754" ] }, "vtvt_OwnershipPercentageOfMajorityOwner": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "OwnershipPercentageOfMajorityOwner", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage of majority owner", "label": "Ownership Percentage Of Majority Owner", "documentation": "Ownership percentage of majority owner." } } }, "auth_ref": [] }, "srt_ParentCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ParentCompanyMember", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Parent Company", "label": "Parent Company [Member]" } } }, "auth_ref": [ "r148" ] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Total vTv Therapeutics Inc Stockholders\u2019 Equity (Deficit)", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r726" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r736" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r736" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r728" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r745" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r738" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r727" ] }, "vtvt_PercentageOfAmountOfCashSavings": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "PercentageOfAmountOfCashSavings", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of cash savings percentage", "label": "Percentage Of Amount Of Cash Savings", "documentation": "Percentage of amount of cash savings." } } }, "auth_ref": [] }, "vtvt_PercentageOfNonVotingEconomicInterest": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "PercentageOfNonVotingEconomicInterest", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC", "verboseLabel": "Noncontrolling interest ownership percentage", "label": "Percentage Of Non Voting Economic Interest", "documentation": "Percentage of non voting economic interest." } } }, "auth_ref": [] }, "vtvt_PercentageOfNonVotingEconomicInterestByParent": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "PercentageOfNonVotingEconomicInterestByParent", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC", "label": "Percentage Of Non Voting Economic Interest By Parent", "documentation": "Percentage of non voting economic interest by parent." } } }, "auth_ref": [] }, "vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock": { "xbrltype": "durationItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock", "presentation": [ "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of days used to determine exchange value based on weighted average price of Class A common stock", "label": "Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock", "documentation": "Period used to determine exchange value based on weighted average price of Class A common stock." } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r729" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r773" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r728" ] }, "vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Potential development and regulatory milestone payments", "label": "Potential Development And Regulatory Milestone Payments Receivable", "documentation": "Potential development and regulatory milestone payments receivable." } } }, "auth_ref": [] }, "vtvt_PotentialMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "PotentialMilestonePayment", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Potential milestone payment", "label": "Potential Milestone Payment", "documentation": "Potential milestone payment." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par or stated value per share (in usd per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r60", "r263" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r60", "r552" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r786" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "vtvt_PrivatePlacementPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "PrivatePlacementPreFundedWarrantsMember", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement Pre-Funded Warrants", "label": "Private Placement Pre-Funded Warrants [Member]", "documentation": "Private Placement Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromCollectionOfNotesReceivable", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from collection of notes receivable", "label": "Proceeds from Collection of Notes Receivable", "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs", "label": "Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price." } } }, "auth_ref": [ "r791" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of private placement", "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r2" ] }, "vtvt_ProceedsFromSaleOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "ProceedsFromSaleOfCommonStock", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from promissory note early redemption related to sale of Class A common stock to collaboration partner", "label": "Proceeds From Sale Of Common Stock", "documentation": "Proceeds From Sale Of Common Stock" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r195", "r470", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r630", "r646", "r670", "r672", "r673", "r675", "r676", "r816", "r817", "r824", "r851", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r195", "r470", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r630", "r646", "r670", "r672", "r673", "r675", "r676", "r816", "r817", "r824", "r851", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 }, "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before noncontrolling interest", "terseLabel": "Net loss before noncontrolling interest", "verboseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r121", "r130", "r131", "r137", "r142", "r152", "r158", "r161", "r162", "r229", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r362", "r365", "r367", "r370", "r371", "r384", "r407", "r474", "r487", "r527", "r572", "r594", "r595", "r655", "r656", "r687", "r787", "r819" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r424", "r475", "r485", "r668" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r726" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r726" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r294", "r302", "r330", "r331", "r332", "r340", "r390", "r443", "r452", "r469", "r502", "r504", "r511", "r542", "r543", "r604", "r608", "r609", "r610", "r612", "r626", "r627", "r640", "r644", "r651", "r660", "r661", "r665", "r666", "r672", "r679", "r814", "r823", "r833", "r845", "r846", "r847", "r848", "r849" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r294", "r302", "r330", "r331", "r332", "r340", "r390", "r443", "r452", "r469", "r502", "r504", "r511", "r542", "r543", "r604", "r608", "r609", "r610", "r612", "r626", "r627", "r640", "r644", "r651", "r660", "r661", "r665", "r666", "r672", "r679", "r814", "r823", "r833", "r845", "r846", "r847", "r848", "r849" ] }, "us-gaap_ReceivablesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesFairValueDisclosure", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables, fair value disclosure", "label": "Receivables, Fair Value Disclosure", "documentation": "Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables." } } }, "auth_ref": [ "r99", "r830", "r831", "r835", "r837" ] }, "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationsOfTemporaryToPermanentEquity", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of redeemable noncontrolling interest to permanent equity", "verboseLabel": "Reclassification of redeemable noncontrolling interest to permanent equity", "label": "Reclassifications of Temporary to Permanent Equity", "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2." } } }, "auth_ref": [ "r82", "r94" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r694", "r704", "r714", "r746" ] }, "vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "RedeemableNonControllingInterestExchangeAgreementStockConversionRatio", "presentation": [ "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Stock conversion ratio", "label": "Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio", "documentation": "Redeemable non controlling interest exchange agreement stock conversion ratio." } } }, "auth_ref": [] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable noncontrolling interest", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r27", "r28", "r83", "r84" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestEquityFairValue", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable noncontrolling interest, equity, fair value", "label": "Redeemable Noncontrolling Interest, Equity, Fair Value", "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r27", "r28", "r83", "r84" ] }, "vtvt_RedeemableNoncontrollingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "RedeemableNoncontrollingInterestsMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Noncontrolling Interest", "label": "Redeemable Noncontrolling Interests [Member]", "documentation": "Redeemable noncontrolling interests." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r198", "r301", "r429", "r430", "r478", "r484", "r545", "r546", "r547", "r548", "r549", "r569", "r571", "r603" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r144", "r145", "r429", "r430", "r431", "r432", "r478", "r484", "r545", "r546", "r547", "r548", "r549", "r569", "r571", "r603" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r429", "r430", "r841" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r198", "r577", "r578", "r581" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r198", "r301", "r429", "r430", "r478", "r484", "r545", "r546", "r547", "r548", "r549", "r569", "r571", "r603", "r841" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related-Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r426", "r427", "r428", "r430", "r433", "r523", "r524", "r525", "r579", "r580", "r581", "r600", "r602" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of notes payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r72" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r146", "r147", "r259", "r265", "r432", "r453", "r476", "r633", "r634" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r343", "r826" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r343", "r826" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r342", "r628", "r638", "r850" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r341" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r695", "r705", "r715", "r747" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r696", "r706", "r716", "r748" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r703", "r713", "r723", "r755" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "verboseLabel": "Retained earnings (accumulated deficit)", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r63", "r88", "r481", "r509", "r510", "r521", "r553", "r668" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r119", "r149", "r150", "r151", "r153", "r158", "r160", "r162", "r230", "r231", "r240", "r352", "r353", "r359", "r360", "r361", "r363", "r364", "r365", "r374", "r376", "r377", "r379", "r382", "r414", "r417", "r506", "r508", "r528", "r882" ] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration revenue recognized", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": [ "r107", "r827" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r102", "r103", "r182", "r187", "r188", "r192", "r194", "r195", "r196", "r197", "r290", "r291", "r470" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r116", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r629" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r764" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r764" ] }, "vtvt_SaleOfStockAggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "SaleOfStockAggregateOfferingPrice", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate offering price", "label": "Sale Of Stock, Aggregate Offering Price", "documentation": "Aggregate offering price." } } }, "auth_ref": [] }, "vtvt_SaleOfStockConsiderationReceivableTerm": { "xbrltype": "durationItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "SaleOfStockConsiderationReceivableTerm", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, consideration, receivables, payment term", "label": "Sale Of Stock, Consideration, Receivable, Term", "documentation": "Sale Of Stock, Consideration, Receivable, Term" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, consideration received on transaction", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "vtvt_SaleOfStockConsiderationReceivedOnTransactionGross": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "SaleOfStockConsiderationReceivedOnTransactionGross", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, consideration received on transaction, gross", "label": "Sale of Stock, Consideration Received on Transaction, Gross", "documentation": "Sale of Stock, Consideration Received on Transaction, Gross" } } }, "auth_ref": [] }, "vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of public float", "label": "Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float", "documentation": "Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares sold (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, price per share (in usd per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "vtvt_SalesBasedMilestonesPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "SalesBasedMilestonesPaymentMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sales-based Milestones Payment", "label": "Sales Based Milestones Payment [Member]", "documentation": "Sales-based milestones payment." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r197", "r776" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r366" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r801" ] }, "vtvt_ScheduleOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "ScheduleOfEarningsPerShareLineItems", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Earnings Per Share [Line Items]", "label": "Schedule Of Earnings Per Share [Line Items]", "documentation": "Schedule Of Earnings Per Share [Line Items]" } } }, "auth_ref": [] }, "vtvt_ScheduleOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "ScheduleOfEarningsPerShareTable", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Earnings Per Share [Table]", "label": "Schedule Of Earnings Per Share [Table]", "documentation": "Schedule Of Earnings Per Share [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r38" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Compensation Expense Related to Grants of Stock Options", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r38" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summarizes the Conclusions Reached Regarding Fair Value Measurements", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r830", "r831" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r49", "r50", "r577", "r578", "r581" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r304", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Award Activity for the Period", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r8", "r9", "r90" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Stock By Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r29", "r30", "r31", "r32", "r33", "r34", "r81", "r86", "r87", "r88", "r126", "r127", "r128", "r184", "r263", "r264", "r265", "r267", "r270", "r275", "r277", "r517", "r518", "r519", "r520", "r644", "r775", "r792" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r689" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r691" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Non-qualified stock option awards vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r652" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r304", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333" ] }, "vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Modified common stock (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Modified Common Stock", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Modified Common Stock" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r313" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r313" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r317" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r315" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value of options granted (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r325" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Awards outstanding, Beginning balance (in shares)", "periodEndLabel": "Awards outstanding, Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r311", "r312" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Awards outstanding, Beginning balance (in usd per share)", "periodEndLabel": "Awards outstanding, Ending balance (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r311", "r312" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r328" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r328" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r317" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r315" ] }, "vtvt_ShareBasedPaymentArrangementExpenseReductionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "ShareBasedPaymentArrangementExpenseReductionAmount", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expense reduction", "label": "Share-Based Payment Arrangement, Expense Reduction, Amount", "documentation": "Share-Based Payment Arrangement, Expense Reduction, Amount" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated vesting (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number", "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Non-qualified stock option awards expiration term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r653" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r37" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r328" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r76", "r140" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/Cover", "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r118", "r126", "r127", "r128", "r142", "r167", "r168", "r175", "r177", "r184", "r185", "r229", "r250", "r252", "r253", "r254", "r257", "r258", "r263", "r264", "r267", "r270", "r277", "r407", "r517", "r518", "r519", "r520", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r552", "r573", "r596", "r616", "r617", "r618", "r619", "r620", "r775", "r792", "r800" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r61", "r64", "r65", "r119", "r132", "r133", "r134", "r149", "r150", "r151", "r153", "r158", "r160", "r162", "r183", "r230", "r231", "r240", "r279", "r352", "r353", "r359", "r360", "r361", "r363", "r364", "r365", "r374", "r375", "r376", "r377", "r378", "r379", "r382", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r417", "r425", "r490", "r506", "r507", "r508", "r528", "r596" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r149", "r150", "r151", "r183", "r417", "r470", "r513", "r539", "r544", "r545", "r546", "r547", "r548", "r549", "r552", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r571", "r575", "r576", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r596", "r680" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r149", "r150", "r151", "r183", "r198", "r417", "r470", "r513", "r539", "r544", "r545", "r546", "r547", "r548", "r549", "r552", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r571", "r575", "r576", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r596", "r680" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r698", "r708", "r718", "r750" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A common stock and prefunded warrants, net offering costs (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r60", "r61", "r88", "r517", "r596", "r617" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A common stock and pre-funded warrants, net offering costs", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r7", "r60", "r61", "r88", "r528", "r596", "r617", "r687" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity (deficit) attributable to vTv Therapeutics Inc.", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r61", "r64", "r65", "r79", "r554", "r570", "r597", "r598", "r668", "r688", "r793", "r812", "r838", "r882" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity (deficit):", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity (deficit)", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r41", "r42", "r44", "r119", "r120", "r133", "r149", "r150", "r151", "r153", "r158", "r160", "r230", "r231", "r240", "r279", "r352", "r353", "r359", "r360", "r361", "r363", "r364", "r365", "r374", "r375", "r376", "r377", "r378", "r379", "r382", "r408", "r409", "r413", "r415", "r425", "r507", "r508", "r526", "r554", "r570", "r597", "r598", "r621", "r687", "r793", "r812", "r838", "r882" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity (Deficit)", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r85", "r141", "r262", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r279", "r381", "r599", "r601", "r622" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Stock split conversion ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r89" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r435", "r436" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "vtvt_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "vtvt_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "documentation": "Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "vtvt_TDCowenSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "TDCowenSalesAgreementMember", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "TD Cowen Sales Agreement", "label": "TD Cowen Sales Agreement [Member]", "documentation": "TD Cowen Sales Agreement" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r744" ] }, "us-gaap_TemporaryEquityNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityNetIncome", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to redeemable noncontrolling interest", "label": "Temporary Equity, Net Income", "documentation": "The portion of net income or loss attributable to temporary equity interest." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r736" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r743" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r763" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r765" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r261", "r275", "r380", "r406", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r491", "r657", "r658", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r669", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r808", "r809", "r810", "r811", "r829", "r832", "r833", "r834", "r835", "r836" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r766" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r767" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r767" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r765" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r765" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r768" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r766" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r366" ] }, "vtvt_TypeOneDiabetesMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "TypeOneDiabetesMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Type 1 Diabetes", "label": "Type One Diabetes [Member]", "documentation": "Type 1 diabetes." } } }, "auth_ref": [] }, "vtvt_TypeTwoDiabetesMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "TypeTwoDiabetesMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Type 2 Diabetes", "label": "Type Two Diabetes [Member]", "documentation": "Type 2 diabetes." } } }, "auth_ref": [] }, "vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Unaudited Interim Financial Information", "label": "Unaudited Interim Financial Information Policy [Policy Text Block]", "documentation": "Unaudited interim financial information policy." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r762" ] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of investments", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": [ "r4" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r21", "r22", "r23", "r109", "r111", "r113", "r114" ] }, "vtvt_VTvLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "VTvLLCMember", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail", "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "vTv Therapeutics LLC", "label": "V Tv L L C [Member]", "documentation": "vTv LLC." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r732" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail", "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock warrants", "terseLabel": "Warrant liability, related party", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r677", "r678", "r681", "r682", "r683", "r684" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, fair value", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r832", "r833", "r834" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Inputs utilized in the valuation of warrants", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r832", "r833", "r834" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants, term", "terseLabel": "Expected life of options in years", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r832", "r833", "r834" ] }, "vtvt_WarrantyLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20240630", "localname": "WarrantyLiability", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability, related party", "label": "Warranty Liability", "documentation": "Warranty Liability" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r390", "r452", "r626", "r627", "r660", "r844", "r846", "r849" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r166", "r177" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r164", "r177" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r730" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(3)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4M", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4M" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(14)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(15)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r775": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 66 0001641489-24-000061-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001641489-24-000061-xbrl.zip M4$L#!!0 ( (*""%E#@WQGE1D! XV#@ 1 =G1V="TR,#(T,#8S,"YH M=&WLO7MWXLJQ-_S_^11Z27+V3!9@W;C.;)[E\7@2YYFQ'=NS<\[[3U8C-4;9 M0B*ZV":?_JEJ25R, D$M*#W2CPVZ-)=]:MK5U=__C]O(UMZH9YON).H9K6L[SK[]JU:+;KMSQQ+.>AX&DRJJ>7)9\ZW7[@]: M:D:C9NCZH*;W.Z365M1!C;2U@6JT!R:5Y>IS5^WHC2;IF#6J-IHUO=ENUOHM M1:FUM;[<:!#:;'=(U>PV^[*IF:1A&HVFWH*'D;:BDU;':)MJ6S^\P@#G# MO!V_&P;>KY5A$(R[%Q>OKZ_UM[YGUUWO^4*5Y5ULJ+M8OX MBN0&_-*TIM?/7]N\B+Y,+J6&N7B=3XWZL_MR 5]<(-6FS_2MA0&\:LDCE8O_ M^?']T1C2$:E9CA\0QZ#)7;;E_+YFW/AUG_C3R]^6KH]?HW0ZG0OV;7*I2:WT M@<,7"P.WWH+T$5@./(\BM"X"CS@^(H<$@$6\7:[):DU1DX?XWNPA ^+WV0/@ MPW=O6C5519M[6W+Y2_ R>RC^,:0>&=,PL R_;K@C]FRYJ?JUE]-JT7R0\F-OVU8EK^V":3KN,Z M% 9@O77Q0NI%OUJF21WV*WQ_"QK'LXSH_6_! QW\6C%J,&^'C/!)U.I>._"Z MR16,SB/VC6/2M_]+)Q7) KD:U-16I2>#B#1U16]W/E\L/#7'2ZY"SX,W?+-\ M@]C_2XEW[9A?00E6I(@MOU: E5T3/JF-X"G#FDEF8VA7>HH*W-K^]8GJG;W_ M&WSB3]_0J?20^D6]X!XN=\V%5X 4]/ZN;O^"2WBZR=Y@D^=%J@VL-VK6!L1& M/12_3:GTV 3K:1A-05M,E/YAV=0/0,;\E"%WVCCDQLX#UINI%(Z579>1=PB4!"_C M&A1+,+EU \H^?1S;5@!:)G9 'E"W*Q]K:]U8!ZX;./#( MZ&H'!23YZ,'%!ZW4WQY\?9%<6UE0IB/B/5M.+7#'W>8X^(3SK1';>G:Z_PK] MP!I,X')_3)SD>L.U7:_[!YG]]VD % +1&UGVI/O+DS6BOG1+7Z4'=T2<7ZH^ MF!VP3YXUB"[TK?_0KB+#:]B?KQ1]NZX.ST%351M&?RNJ_*=*[\.?/TJ7)HX! M/$6/!IZ+E !P3E#XX1.D)851 7DE'^G[^0+'"68#9M=C!$QFG$H]]>2I9]NN MP2R^Y ZDVZL;R:&!9+N^+[T27R) 0S^T VG@N2/FAGO4L(GO6P,KOBUPI3$% M1>N@UTX9I"7X^!OM>R'Q)I+:JD:>^8='2B5$N]3ZF),-VLFSH3 07RRZ-QX= M4' J#!CNLE>&KG;79TX]J"^)N=[= 'RQ7RN^-1K;Z,JQSX8>:K<%!ZS^YIO@ MGK'WS5X2O]-W0X_]Q7S&+NI,QDI_2.#+2O+YB!(_]&@O^BOZ\O/%XG?)W_B, MI>>%,(;W#XO#I.[/QZ]YGP7F[A$',7TFT-MM^=JE^_'#K]1Q M1Y:3]MBLI%EXQ,7BZ-?-.K9BZ:\=PZ^Y:.B1@"X]"X+<+ABS3$^*C2E[&#IW MR>>4^=_)7S K^'M@44]BZ*6IL+3Q\PQ3?Z"F,8+T MG MSF]-5N!_R7VS[Z;#-.G31GR:\ M[ UTC6$%/RA"1#)!YSDLBS/GS,"4\)XK- FQGWOY9H&$)Y=O$WV]!;.PUZ?RD+O74.Q'QQ9O.2N\O, M&GS-3*O%*8+=9];D548>J(UYXWO0S),G3&E%L9'_93+_S:+0S'^S;Z$I"EHM MP8 M&%"@!+1/B0&WKN.54 @Z@@='EP-%YI4)/+FG11)\[V'1*1"\0"VCG$@ MMM^ H$B$BPCLP CG(01[GVG1#Y]I47@(V!;HH&6G@U8@'?8>WFU!AZR9MR+I M<%)1UMX=3!XD6(1E6W/L2+I&!'&[R-@QUB.XC?CXY]AQ[)C*;YH:_Q'WL34H!WD1C?_(^SCJE@?>\!]W<^(#\L"L MLH?AAS*D'/!*%W$T[RF3HBI&];+'T4=G=6F*@_6RA^Q'2ID41O^R1^Z'3ID4 M1OBRQ_"'29D41F[^%_KY\/3V1'[^\PK+=I7U+'N@)J4CTK=I.@?VJW"TXE([ M>MF3!D=WJO:]B;,X5I<]!W%T5N][-V-QK"Y[!N,8_G.!]&^4/2MQ4/^Y2,+S MT+]K3U/C/R;FQUGBH!"R(6+H,G"I[ 'W<19FCL0L_L-U?E3@HA4JK+T<_R$[ MYT'$WN/%PE@M4@.\QXN%L;KLJ8$CQ8N%T;_L\?JAX\6B"-_<>Z!^O*GQOUS. MJ;-47,=:_D-VSBUH:3HD-LL>[1^=U:5I%=@4*8/CTI__+ !7SE)QA"][['^ MXI0BR5WV^/L(Q2E%DK_L,?'A-[T]R=%;O=R6E2%:7/7ESC)64 NG?YC]!<^P4 MYYX(S]DVA2*GQG]B@A]GZ7U-]1%ZSK;+GILX_#:%8W#I/#,%)646=R&[[P7@ M(#J^:ULFS,J\QF%9-.81?ALM0R'WB%.:LYC;W 7F)K6ZW^DSL1F%)W/6Y;>G ME^_?KTXR1=7F/S@O)&[BD/M[DBO^0_!"V]9[W MV.YM8K ![E_2U9K:RBCI\Y?N).G\!^QG"(Q%)3#/ZUV40(?;Y$#,XG\0SX/) MW7D/UO,PF%.V[RE^[]%OH6-2,[YC4X@@0'<\T'%;@L(/Z$Z8^_SFCG@@.@<. M0(??;!$/''K??E]N%"(6_"=_N#& 3!<_?;UR7ZF#7_J7SQX]E!)L%\)M_LZ1 M*&QJW.5K,/7U@_S+]:Y"/W!'U//G8'3GT.3CHI![Y3H&C,PCF M]L/S?OTR> M)F/Z3F3BERY=O,=1?*&.,1P1[YWT,A%ZH"_4">DM/>,20^G3H5EXYYY3X[Y,JU M;=)W4:.^4/CPNP4*=NZZDQ121>8N123@<\W0 M".Z\1^J]@-#.O3218<=\HL;0<6WW>?($?/8'-+EZWQKH\&#CP2=6RI:7/!-% MQ,%N'47A+CVZ6FO][>O#-[8?T2'1;JJ31H32JLGM;(B(+BTH):=PE\B=;J-[ M)9ZY7#%R/1K;[H125@AU-T9HG*@>YRY9R@-G]I2'5+C+0_) ;"Y,%G!R,6QOU"'>L0&AEV:(\NQ_"#*$YRT)5.YS1&4@&?'LF7< M9@]*P+-C63-NDQ EX-FQ[!FWZ8ETYV(NH7V%??^($3RY]]0;N-[HF^O=!4/J M^?,[]:)=II@R=^A7B_1I4-RZ'7L;[IJUH@*!N3?.#9E!ZH$^AS8)7&_RP[*I M'[@.O2>3#'GYS(-95\9PZ[ZXARQ*D%L%%B6HW"9UBH;HTZM[DA#%!=0'I,FL MB=T/\F:-PI$ _R;P,V M:5>LN.P*/07W-\IZ%NB]NW0WZ'&;GSLZ>^8$XAW%=Q,(;K-KF2F^)U6\+X+O M/35VQ+EQFU/A27PU=/_4@MP_;@/Y8CNO/QYN;SFVIQ[Z;[^Z&KR(] M5)W;@(Y['A16]ZQS6X[!3Q-J[AJ_'JO);W&HXRXVW=0]R'(>WF8[F?<Y"TF-S9;%SW#RA=X/_>42B9\M>;DM"CAZIO*O86?#G MUU?L+%RZFYH3H3O7[.$VSG^@-LS*O$=5Q3H9$ .76/POD_EOWE=XS[XYCD.Z M\TEO&Z8_I[!_$./2,3WZZL,_WURO3WTL'/3&N)F:;MK1SY%[RNVR>3DA6%A, M=#X0;'";G^(%@AQB@8/WU'L<$H]^F:0_ MX&@!Q;$8S%TVZU09?*0]'@WN$F,'9?#9=-QI<)N7.U$^'TN>N4W0'83/\0+9 MB26V]3@-V)YOQ$[!"[]H,0//98<^>;1?X?4,=Y%P].+YR[U M'Y"A'C!\S_'QP>/T;Y9#',,B]HWC!UXXVVVQ=\CN*S7#;79P#H737_\*3\1= M9I/ON&%K!1!O'- [/KM"*8SO0B3.1B2:W&8KBQ )58B$$(G<(L%='K9(D="$ M2 B1R"T2W";"3P2%MZ[C90/:4W&V7(;E;3CP<$VF23 M>6QRQR!B]NTE #7$KC^09$&U+Q\ M 4/Z3,L#,FYS5P)D1S&/169?.MQFP02XCF(>"P47MZD] :ZCFL="0<9M*K)T M('NP_-^_P6AN\, LZ@-HY M,)XC>IL\7X.=I%_$5%P-B!+6!ZP:.&]"*-/#UOLWE:C(MF6 M\_O#^D&R$>)U%2EPXV$Y-:4BN9Y)O5\K2N5B3W-7MU\?!IU?+#(9=19;_5%F\DGC/<''@CKM-N Q%HT9LZ]GI M_BOT06--X')_3)SD>L.U7:_[!]!P\F#P:0#"5!N0D65/NK\\@?;PI5OZ*CVX M(^+\4O6)X]=\$+_X0M_Z#X4AP&O8GZ_1 '59_@3THM,!J_*?HG&8U,##BP$" MW= !XN!5,!S"S5BDH4<'OU;^L)E+K4KOB?1M*KD#Z0HU$*CHSQ<$6(?$33BX MS,>5W#$H&M>8.;W/?>_BW;/R/25@@XNO[S.HUH"\-AG[M)O\\LFT_+%-)J!B M&9'839_BI_?=('!'W0:\ *KP#*(';^$O2_Z.H9ANU'O:"U$8@"(#\SDQ3%( MZP#2B^7/.^UZ1T[_2JXK[/,+]CPO^3+FHC8.*NP>F B2"(7PW5SCT<.5DNF& M2 N$U:_N5:NKK[\>/F\?'F M[C;+C/2#S.B].DF?T3\(6#3G.7"=JO2U?E67P!3I'7YGL:04V2S^N>8_?N:2 M#6/?[AY^2.AR.*YS&X[@(884^XD/J. -])\<@BX_GN_^U35"=%31%ZXP,PWN M6:6GR+6_,U,^>THFG5P6KF9E:]%#;V?BX85M48OL_ULU%M*)XO]7&4L$W.HCM_0(,ZCUJ:#91*XX^Q8^ <\&!_N M;ZU<54;;W%+\]Y!X('#VY(&.72^ B,'U1B0 W_LMZ ZL-VK6 B^<"KI:Z;VM ME/+ / ;IBK).C(!__WGY\'3]\/U_I8?K^[N')^G^Y\/CS\O;)^GI3@)C_ 06 M5X)(Z>Y!4AH?S(_2W3?IZ:_7TIR=GMKHRZLG_%KI:/H"B3)[43R9[6^N)P5# M*OT[P8L4918D"O& N87YN&>W7T>[QA9A9\(GM1$\8HBWU4PRJ4TH\6K426"H M57I_"QTJ:7)5PAS(*D@>PXA(_%J]=,S?><)F")N1Q_/#?A069@-6&XT!L?VI MU= K/?>4K<;3P^7MXPVS#<)L+% F,1O!%#*)W<#,Y'__06G*GXK]&;C[>&H6 M#:ER1/6/2FFIS0+BO<-,9F,8GU./1ZQ]H,^6CW(9W,(W"7N;E=[+TXOT-*0>&=,0 M]*LOW3A&O3RL3J?.A^LW8@2,")B%]J:3EX@O^6-JX/*D*5F.9 6^9 R9EYLI MF#YE0,]60^X+/F<6P[4JO:_4)J_$H\7ZAF4G[Q-YNXD+)@Q&XD4# MW*[T]%9-ZRC-1DM92[D2('1C=C-2W@QD$OB2+CB3GO2OT+-\TV(=\4";L_4_ M:QZ4[%+OF3C6?]C?'TN"J(SDN*D_U!_KTO5H;+L3ZK'Y+T)&NG7K']/ \&YQ ML+EF<7!I^2_C9?L(B>>L%2\>15ZQOC1-C_I^_,]W>)Z2B'2GTM,Z;5FZ]^@( M*ZR^>N_ENIK;D_LZ-4"*4NG] M%1XLW;N6$Q1&<::K[KQ[,'B@DV9+9&JE=WNUGMK%Y4(B;^JD!.?>!4?"_O^M M<>1EQ%35*CVUI38;&0A[.N8PI@@&,F,/0&:-B2W1-VI O/:"\0V8 >J?F-$# MSDO(^A2SEB4KQE4PFET$4&U=>I0L@%X'>Z$UWT/^8PZ-]=T%EMX/7>===D=I M5'IM7:G)FIS=,AR:RAD!,TMP_/<'+4NHWS]@Q ]"VR7!(HQ=>A!9_,-&>> M!-AB]7,ZT4X4?=D]Q=@^312US\1XZBDV*SVV)TNZA-M'(Q?GX!J_5Z4Q\:07 M;($L_5&NRPHN^$K^<+LTKV!1!A;%JB32)%/^M"J]WYY^>SH\T0^A@YC'PS=7 M$L&YCK75_"JKT@:5=OGX]7*I9%JZ(F,K "\="WIIL"J-L44=2.SH11]9#J:+ MNVKK&'XO*Y.[<4S,55.I/X% A!J_2R,L87X=4I;B1Q]W;I'V@_)1&A*?%3.8 M$K'M.%)!I_G?H84N,WC*?1I? ,^<>LT:+@9$53>Q[SSG6S0;!!8N36D263 M3/QZ[K3E5>AY\+BHE O52$""T)\BM5/I_2_UEV":L\(R=ZU:.FC>CEK8>>L> M:=KN%B6EI19W% .0@)$5!" SU 9)\%P'K8 ]D2A8A(G$MM?CH5@O5/I* B)A MJ=)[;3![QGQ _1#"E;K<0(%_H,]AM-%6>JP]21^PW*OU25(UM1Y?$0PM5A R MQH*0?>N&:,!3D:?^Q_P"/4<9)$PLW],*?ED(M!#H0PLTB!"1;)@;E8AA@$![ M>$P=@[B'UB_U4PGP64O]PA^!)H"W>(G1PA $B#"IHK&'QX&%1#H^2\^>^QH, MDZ_K8/LI&YM)!Y;#"E+9,@IFB%68YHH1LJ^53\EE&R]8/;[D0C3X\<4KQII< M:3F1PH( K*8F+LR\WU+?'DPER?IIK=IK@!G>XH* LS;&N"G[5)3.=;JG?)X828CQ%T:+JX@4&[=BJMIN>S'S%@/GJ1G. ME=3F( (>K(DTL;(H-4"V!FG)+I;B K/FN"Q#%?I1E H3C?;7I^R?A$ 7WV5/ M\.6O%KP:7BLY,#<7]>B+Y3,SZ1#'L(B-CC)NTL"+L4.@23S3EW!7AF6NJC?1 M/I"/J0%G*;(F' D?XK$'U+;3C D?0!DL$1%M#-M?1K@8UWZ7QC[<5B3V\#A M/#/KK'7[Q\\K]+:0:W/&A7K8DW+]X]0 M-QL5=8""><1RCJ/%(D?9P9"-0H]8S.)+=V' +"DK'F84NPR?0S^(.@:TD\XT M>?YW]A2'Y X=*S(X#*"0M2X:(2!0B8U+ @L_5\K6M4UM=INM!*[G8RS]ZZA1LSP MPKB'WS(N9N5>291W+KG[PI'0/FC2,%A]2]8.Z6E- MN-^W]<[6TKTU;>D^]&8ZZ)G6^AXEO]?( /R^+K%?R<1'0J7W?6^(KN\GWO5] M?S8AW>EG79'^>OUP>7_]\^GFZE&ZN;VJLZ;CF>2F[V(6'S/O=#Y.)27=# M[R__8>]"=T@TK2%243]*WF]O+VZN;R^]@Y- P7#ZQ@R:63'>.H/'8>#U4EZ+C M1/VIP-OC&Y> !W%H+LQIX'H$="0I]:U@M4,.>6$S?.?=8F&MLVZQ<&^2G$+0 MHVF5M6/)QV%P^H&JN P-OS$+P4JWOA";8,.)QR&E@1^ESAD*RCI/J=2CQT;Z MI9Z I)5Z^'*I1Q\%5]*'GPX)30O$^R/;VO"5&M&AFIK"KIC7\L[/=@70WIM$+ M9SNU W@?+;&[ $1 [>Y;;^6>1+Q;-SZ[J,PS*;?WUBRW]]8LM??6G'IO*-/" M21-.6D;4-(23)IPT'E4:[H3*[J2Q=6E6/N^SZGIJ4CIBZWRWKH,5/IYKLZ8[ MK*$&]0.F)UD9S]"U871^W%=6NOYW: 43Z<-7.K ,*_AX*OX>TK/T_AY.XC3\ M/9Q)J?T]G$")_3T$OY?/WT/4-(6_)_P]'E6:IN1.RET1?RA] ML]W765*NM!H=IP^N6:G'+YV&:X93*;5KQGA17M<,AU]>UPQ'+UPSX9KE<\T0 M-6WAFNWBFBEJ76V\=\_B#X6+5HAJT[%W5P!C"EQIP5>;>6C?IDU*9K[:HSLGIH-$R>\^D-)NQ"6_ZG%+?H7*W[?*1T[_( YY9II\>O;>5\LW M0M_'_=3HY%XZQ)[X%@O*9P8 8_BHS15>\T#]T'Y?3",L0VGD73VU<:U$1=+S1[ M>:15TTJMV47K 6Y:#VC3W@.SY@-WV&5GOO& 5)1NX*K1'!/_E)9MY9 AX1T= M:D\D)YT2A'>T_]W4P.KO])G8D5O$CI84?E&)Y+3D?I'0Z8?"2C/1Z9="J9^Z M4@=>8^92^D:,P/6$/B^1C&IB^4I@)0M6.J*TX5S4>0=W'$2G-E$\L_V1V)05 M*,1[0!^I$7I68-$HP?G39^V/8X=>:/\22;30_@(K6;"BJZ)XX4RT/[+Z*QT0 M5I3V<^PZH.X=R_7FM+[0\.616J'A!58R8:4A*A3.1<-C[3+< W[]@(([/U>- M)C1[>:15:':!E4Q8:<>:O2$T^ZEK=F#U'3MW^\:)CMR#1PF=7AXY%3I=8"4+ M5AI*K-.;0J>?N$Y'5E^_#:V^)3:,ETD\3TZ5B[85)Z=:]$KO$9A! A'[ETBY MX+ZSM>VI-QVIS X./M*)R@9&CN:$WB( MBJ5F%'7D#DE.5/[U2 M]HORJAF/1-U X/N/5>EU:!E#"4:!UWG3 M"ZIL]*N'\OW[U70D^"7\O>*98P\F9HV!-&[4.\1YEORP[UNF1;P)/AROF@VM M+OUT;.I'-R.Q@,MPP_,S];$%"=+SU?)I%08[H!YUC*AM/*/DWT/B@6:S)_ \ M1E/7D;ZYWHB=J(V=KU92JBHMDS7^)/03:B))X@_=T$L^9>/ AZ?S"V^"N BG M,FNU-26 1?WZ2A$X=UOXOOOA=K90$[90V,+T@^4/A.YTZYBJ+K8PAT>=1*:S M9Z'Y,2[]/7^,+H MZUB/==IUK:FA*HL3*_&+8RU7!TI<+'_>4NJ=EI+ZE5Q/_WS5HQ2U+C?S/6KU MY[K<*&Y0VMI'[3T9%8'_,#NDVYLD@ED[[*DM:7+U<]^[Z&&#Y(6]TN=#A_GS M=!-:: NT* 81.[FKP;9[N)[@>[/S?;!NP_3MFVY \SMEV% MGH>'GQ'&ONY6_'LW[=STW]?]!8F=Q/[5>&68O2V7 \!]WFB*W+6&B^-YZPV6/;QXQ6!_.B?]@NZ$&O43)=%S/A8$!T@"V5"A%F/04U3*SV]46VHS<\7BR--:V:3DS6) M[&5F43$V0PC(J0I(XP@"HE5ZG:JN\R(?!?DTY;")EX8!4PEP:<.@P,^^35H+XWY0_V,%'T.5*3V]655DNR$G( MO+#-NS=ZMFC;E(38!6T*IB2JS4:+>[2=PQ+UO8<5V\&$1?^XL#G&NO:JY-! MN*O;Q_T14>]MX@00QETG=+VE*4X)ML=J\9*C$U[K0>/]7#C10',J.ZM-OKS7 M_2NCN1OF(=(V]:9X[1(/.LZB 7/M6T,H6YP!Q/U Y9R>@QA:P/9 MV19\I?4I.=[CPU4:Y M)8;AA716/28VPIQ+G7_&2N;[""R7CGD9067..FRY[8824 M[%K&O045)E/QM[_E@8RJ$B#N8ZX@5K1W,.45BA;68-8-$:"8K M"[\:,DA%BY>U,['(>K1%@PQ0P0*59H<3J)Q5I)&B/5GB #BPL]H\CP6T3;O4 M8VK^PPJ&5Z$/!HE047ERXDZ(!==#;MK>#B\:1W@Y=_?3<0,Z3=T(AW-; MS7F+9(RCM=3 ;&"]4;/V'^JY*0*A5WHLN:U^XL2M$![H ;5H*G:6,();M7?/ M;?'E=G*M+!?WIA3D7Y[MEH$-^G/GO%:CB=G?3GOGW5MBD\J)(&Z#UMT=<:UH MIXJRT<, MX[YDK:@>.L+WX@D:G7S0R+HNV&P4MBXHG+#TY9V.L4Y1YG8D\NJ@-]_J.I;]:R7P\#"0]VGDZ9CQ()'Y$4_!U(X8>.Q] MHGE%:^=Y=Z;S/B$+/K>%V%G<0FS%6XA%(F6#X9Z1<'$3=K('.]IJG9S!6O*7_*E(Q1[/4NR-BHTEO*5BJHV@Y73YAMS<#(:U= HW;)9AQNX3M MMMJ7M%_"MLR;.[8[?D0-K^^J:KV1/,;"8\^#;JW#+/J!V1V=O&X3WY*C MD8MO!^Y7I3^N4P?WU'O$L\K?JP5%GM<+-[??TMP,UV$ NR?>G?<8X((%.Y9M M]LQ8U.6IJ*OKE=/*T2A[&8U6Z5GO+'V ZS#2"S[MD[1R_-$1\+L,G8W3 MOPR#H>L!V\ULBG0V'WT-=5>,+@>;=QT=MM>3Y:H<_3\#T:,A2V3ZQNK^B7\7 M!GX (0Y(>-[Y8>JBJFMJM9W2K)J%37MGS@ZCQ[BZ*K?U:J>U?)A0P@IW]GR) M^%B]@:? 1V9:DZL2'@//9IHZXK1Y2#LKJ/#0HA=?:IM/)/<4]S>,VEOX=7FQL<. MPP.WMM%J535]N3)NF?P[.E"97:9S77E?!.8VEK>-&\IZ2[!\K=.%<1W>:$ M+N>R0;N-!Q^WJBT]ITB*R/=X?0P+!P'&R8UF5=-R;O3F)%@NB=HSC' 41CL2 MXF6C,RL,_K"3)O1A_/#;\MIJ0.!-YC7Q'*"'/T?FN)=Y3FGHR%@"K_<(O;@H#JAGEZDIR'UR)B&,!]?NG&,NJA7WMHWG2^3B I:\LH(;C!K5O56WG8SHFRY MG%IV=\1HN&17;;:7D[8KE2KO)Z*_E;=P/Q2H-LFCY M+5M71A3I0D0@F6Z( V'\/,^37(LD#=]J;#\[R2\=<_>HNUW4B6 YQ#(L%H? !V\U>7ZQ^G*-5/)R&#C,8NSXK,>BR M%GK6"_WT:IG!,('UW%TQP^79+:0/(PB#U;?,,:5Y6)ZLY8#^KBYT[B<.'N7& M:O9E4S-)PS0:3;W5[Q#25G32ZAAM4VWK)OVG H%A?-/0FT5AS[36]RCYO48& M,,$NL5_)Q$?XSI,%:#+/@_SD^U?H!]9@LII^@\'>Z!>- _2-BQTQ 0:@(JB' M5\%P"#=CD88>JML_;.8DQ%Y/S.T':?$,W2O7^U< M,XOCB&CZ)*ZF>NYJ7L\]3K4;,BMNR@H72#7I9Z(CRS;5#Y8#2MX-X1DFA*'T MS:!@'<&N]ZF'LTRV($#L"?.-_I2 '.1CEIF^A^9,;BBHX.+,0OSB6/?5@1(7 MRY_K[;JJ=E*_DNM*ZN>K'J4H=4;O'(]:_;G6:8I!'7Y0VMI'95Q02,V0=K*L M.T1JXDAQQY+RB/)88.6H] .N&_K2->A,\W/?N^CA+AE)DZL9>E6<)%D>K;>, M1-D%-)D6JSBD#NZ:VA49)9Z[=L9S%WS/*/@GL>S> M.1P]/#OUDKZ-<=''WZ[';I;39,7]A[__K+9+/5"?$L\8LO4Z$_28[8YQP5+L ME]HA 1&1]-(QO\X(>AWIBMQ>%]L^I6N\G,LIMD\=-J N$DJ-2D^O-CMYSUX2 M4"H%E Z))&RB5Y7;195H"B1QA:2-T4Z14&I5>NUJ4UMN2L[E+L^L 4PYG+^_ M4(=B[2[Z?L0<68[E!QZKJMW*_4LAQ2F*QP;W+R8J2,?E DFW%1#L@U=M*3LW MIEP#U'WHVBS1F0#3)@>P:#!U$$R:O',T(<#$(Y@.BB5%KO1:$$[D/)A"8*D< M6-K@!!8-)G9(7(L;,!69 U0;G+N!T>9R=RFMO4L.\*0:-Q3I'DY7#V))\7.+ MBHIZ5VGD[457RG58 ;D"G,C=(:=AD'XF2_\"6WR:J_S2[/VEUOYU12"OMX1>IV5SBI'T#N'3:MWP9!ZDL4X694<*DHGUTA(:T,, MA[2\=1UW44"FBPI+8J#B(I1H+7^26&D7C16ETLM]D)P 2SG TBD:+*I0+">* M%; 9.V$EGZ.FXDE 544MR<'"IY$ZG'/)I _Q7(K55S547?>?R *AG@$RX;CU_.#I8$'0.]<%R[ PF.J!*QBQE1) M;MC@ 3B- E+! C%HT&+YNK1!Q[R+*_/#!AJPD")B<)D\)0HLE@,C61 M%#M)E&RHKLL#$P4]<%Z4R3GDNZ:N59SJ$CFM'7RKB)1QX#!=J<_1KTM3"^O7 M)4)1'I,7FQVO51A:Q@JN#I0G5[&K+2TO0 KUN'97,;I0,65#T(ZE9-NKF 87 M*N8<4EQ8R"?U*8@Q358? _(6'X:UXI!FL2!BG]O> MMD[PA.T6;OY1E>6U_?)B6R!XWULP> )PM)5#4Y=[&@H$GR&"LV[EX G"'0;A M3GN7'9ABZW(A^=C$]Y?&GOMB^< #D9/=(2<;RTX<[7ZA#AU808Y\B5[4NB^(V8T=\!B2R0@^4#&=^K[7>Q%$[FU) @\JQ\&I&]3*7 + M]6_+&_GMQXN%6&*V)G Y1_@GMY@TOXXK5555W<79%=D%+C&6U3W=/\9P*:G: MZ'!0-R8P=A2/=.\0:\C8%T5K+^\3$1 K.<2R>IK[QQCN1*JVFP7T2!1IU!QI MU/?^YLO3B_0TI!X9TQ!&ZTO ]OI^(H)4@>*.4G_H M*NU=^H64.WLBQ$Z(W7)5UKO.S M0NR$V/$=JN:6NP:3.T7A>HWN'-9%\D6H0(;1"!#D#XE'AZX-A"_J'"H-&&2Z M(;[]/%8?MUL^>2&6'26$KA@K'@/7^#WFQ!?B6T9N46SN'N_EX^8!$I(91E+ M82YG!]GM5F.*AVQK]UA)0/8\(,L)8ML%Q!D"LNT6BXK';*< 'WW_F#WT M,I)IO23/CA]1P^N[JEIO)(^Q'),Z0;?6 >P?V:T?4R_RUB5WL,*GO[()7'@Y M]>T1.%6ICYAA;5I,RPX#:B8\+W0Z34:T3?/Y-'9]"Y'790=56"_T$T*IIK&[ MWW.*^!0?4.E)'_X\0RKP3:RLB:0'4[GWU'M$F5AJJ;[@X*HK->\U\1R@@Y\\ MYVLD(5,E*D^5:%->OY^JZ)'$FGYY'$JE)]?;RS7X/.=?1-Y3J("#JX!FX2I MW5(%;#F2E2H &VO6F\M!LU !0@4(%3 G>*V"!4_?4@%L.8XUJ@B77>J=Y>(_ MH0*$"A J8$[TV@6K@.:6*F#+<:Q1 :U*3Z^G[$?C604<>B&V'#F>?[ _J"D1 MF =YII(3COK4$XF>%[$8O4;=L&R@OS[A(+]7, G6+B.HW3*DW0V8LO'OPL / M $! H1R9YCF=U#[0<&.UN#3JW /N1-TUM*JNZYLUZ79M:L0ZS\G+7/-X,M=: MEY@L(2=D3LA<-A"WCBASZS*!10ZW,)ECFQ+D3KO: M;F5(&@B9$S*7"N+V$65N7?*MR.$6)G.-(!#@$QBL3Z/@6_+'MK6ZR_G\'_ M@E71)[F(N6S2B'C/EA.ER-1%9!L4M_3O#[3LB5TK@+<9ZV&L(HR?AE0BAN&. M8#03;(GDN $>V^3!QP[KC_3L$5L:$R_ A%, EX<."4T+80_ZU,1NK^PWE@ XM&I?GTQ;S-'JW@X#1UFL)P6>K7,8)B8H[F[(MGORK-; M2!]& *IYY2US3&D>EB=K.=!XE]&:^XF#1W-A-?NRJ9FD81J-IM[J=PAI*SII M=8RVJ;9UD_Y319863^<==I]7[W/EL\ M9::VHLUP4\O"?&:@DDW&/NTFOWPR+7#CR*1K.6RN[*9/\>-CL%>&'T= MJ]9.IZZW.JA=8_.M NXOESU6U+NM*ZE=R??IYBD^3#!NB";J'JS(- MOEEOZ-JFL6?\7%7:N>XHUYC:C7Q/$F/B9TR*VN!L3)VZULK[[GV/J5576BIW M8U+;K;5/2DUW-/2I9EQ3@A!9J\,D+]J;+#-SZ[^Y'HOD O!*J32"ZX>^1,'' M,:6_A0Z5-+DJJ;*J+V0L-B5\MNM!F4NX1[0>+W,HLN:;M M&':BY/MR(/*)!X@';/V #2J8,T6;9XJET!31F@\?NJ$4!+L3GSY0B$8[F(?.+)#'"K(5,J3N\9Z/,%V(3Q\"% M\4#Z03QC*&E*2H[DN [WR9P"EHTG>:ZZ>Q>V]7$VBY=4ZOM1EH] MY1[VW;PG67K14LXJ,M[V?)[LSLYL@#^QC9T[2GE*2ZU%$5\^I7K>LD46#5PD M.T1*W+L>/C[;62Q+/;1:+1#XM!U"0M+%P:L'MG.:?#@[UZ[T&JU65=/3NHT( M[ LK)ZQ<\59N4< /:>5P.ZP0="'H0M /(^A+78WW(^CY^L6VY4I/DYO5=EN$ MMD(7"%VP_:1SM8O6U(SMHH^D%7#;?KM95=3EWJ,<=1@24BFDLD@+K7%IH560 M1;G:Z@AG7:@"H0H.I J6SGGB0A6PSAY*)ZTAN- $0A,(3; '3;!T?!87FD ' MIZ!1[8BH_0 =2",YUG@1Y"*.A"Q)G4L*/WA;Y5LE"6U543]MU^?GP VT=NV2 M);@CN".X([@CN".X([BS]:D&2X''0Q237 MH0"\+Y^QW5,U/)P.YSH:4\=G79]+LE"60OERA#W;!:5K@,;Q-D;!'<$=P1W! M'<&=XW,G5RJ]O;X$+#HXB!V,\N3.&GQA;Z\;)^[JQ?P+YEY5; M 7VDWHMET'N8BVL^4,-]=MA3?B-V2--2<^U*K]U8WJ+::E;UW M*P_YU]*6G8BB(,$=P1W!'<$=P1W!'<$=P1W!'<&=P^W26.IQG:60>ZFC@#<] MH[J8]@(=I=)3JJJZG$@2VSI*C;?M-@[L'V\J-W@[L^-/5I\0RV^R9;%O2'Q8 MNP:\-MT0LTFL=\@9]XS7#]0FSO@8Z(6+:] MS5,Z"T:H$*%"SE:%+!TLP4.[VDX+3YEI55NZT#)"RW @4D++[+:.H&MI:G)QY]<(>1?R?DKRGDO55KXGK?Y<59I'>A*/LQ-C$F,ZXS&UU;5/ M2JW3;2A3]W)-/:Y!T5#SY,)\I-(+KA[Y$'9.:"P6ZVH(UWE2I MO-'6II;^]+EU)45B0Q!S9#&;<@WSSYOAR( M?.(!6SY@@ZK+^,)2(?-ANL6&Q22+D2;[Z"9[BXS=]6UA/"T%\:/*S ]_7EHK M/(XS'/9[W#GNC&EC&.$H MM$D X=%7.K ,JT ;6"I*/+D !&D^:_U+*D4.M*EU9)FF30]."O7]IM8?Q#.& MDJ:D!,W94]CGO%IT/NM!2X>L+BX(/6S8Z!XM$ET1SYO IY'1RKW\@YO?.]6F MO'S.7EF7?_A<1,YS_[:A4/:=Y-ZYUJ+UQJLQVILMMO=II:4*P>*C.$!;U M'"SJA@;Y^]K#ILJX?WRYW%M(^I%WB)^EG6L?SLZ=X!YP/K$OK)RP4YGD&ULFA ] EO M++41RM(G?*,X%=PW7%5D[!O>V$FT..Q3G^'^?:Q/EA;:XD ,P1W!'<$=P1W! M'<$=P9UM'-ZL#>T6'-[<_JI2Z36JS9WR,P(^',)'6>I=M!?XJ-S IZ"*\E+D M"UB-1JU/?(IS'8VIXQ.D^E;Y@Q0ZE$,>MC-V:]A^GM6_@O$\UZP)[@CN".X( M[@CN')\[N<*W#8W]+DWLT#:B3N _N;.]M;BM]L:)-]0R-X]Y>5=S3MX#_7=H M^59 'ZGW8AGT'N;BF@_4<)\=]I3?B!W2-&==J_2TSK*K+M#&)=J$+N"9.[O% MXL?7!3I/NJ#0M?Y.2NS._K8<$TCGUE$Z6Q\32U9 XSU2R' F7HT=C!J@7 MY)SD#B1G86$:KMK09.#S!LTE6:Z MTRH6^$L-GXT+_$7!I\4)? [4,NZ8NTSF6\:M;K,NMAN=_':C7'9D0W;Q$!WC ME':EI[2K[99H^7$6-2-GW$FGT3Q8)QVE(SK&B0V\PJ(>W*)NZ,&ZMUXZJBPZ MQG&U+GW.=NYPG5%5172,$U9.6+D#6[EC]4555=$Q3@BZ$/2#"?J!6D/F2QFI M6M0Q3D^I0A.Z0.@"H0OVTYMJJ7TD5[VI5.R9WI:K;5ETC!-2>392V>2[CZ/: M0%M=5=O+66B.A+*@*O+C2%(K&ZC^_%&*=@M04_(H\!79\$+M"7(4/H&Q^A0& M!2B1_+&=Z1RZ316_R"H-^&&Z(6 JW]F/^RI&+JB8F<>IB:&)H8FAY1H:T_P7 MS.3!OZ;UTOL,/Y)7C(CW;#GL2:VT\S.+5N6*G.AR]L0N;M^RC/6Q)SLQ\FE( M)6)@0P_B8"V&Y+@!%@-Y\+'#-OX\>\26QL0+<&-0 )>'#@'C'[ ^(+B]*>H( MXC"KRHXC'5@.<0P+;O,#^(!M,JM/C<)[4L7#T7&#U-CUV1:RKD=M@D;FTZME M!L,D 3%W5V01N_+L%M*'$83!ZEOF>-(\+$_6L9E\V-9,T M3*/1U%O]#B%M12>MCM$VU;9NTG^J[4IRT]!+9C FS[36]RCYO48&,,$NL5_) MQ$?TSI,%:!(/J*'#B/.3#WT#:S!93;_!8&_TB\8!;J3KL=V)79!JZN%5,!S" MS5BDH8=>]Q\V<[(%,HE*!:7M"AUV$)[/%Z27AI)T[BCJ4="=?B+MR].+!#K& M(V,:@D?K2Q [K-8%1Q?1]$E<3?7>TRT&^,5JWKU<4?EK/I-6HR%I"08 M MUJ+IQ8S&KL6Y^2$ MBI9^/V:<%DR"V=B9WF_.%:+=9CBQ?+G:K.N-9JI7\EU)?7S58]JUM5. MOB>M_ER5&T=ZTJK9Z?5.JR/&),9TPF-JU!OM8TGPJC&UZPV5-UW0K+?DO._> M/^_TSOIWIZ;\FK/HB^E\ZTT:P=5#7Z+@ZY@+6T'TA83> MII3GQESKINBD%;%O^>Q.CL&5 C=7-O%]Z5**2O(B5S9+VE>0;XY\7PY$ M/O$ \8"M'[!!W6=\8:FD#9[2_+)"I='][20+)= M'^NX9NR6 C>U>+*^L@RP9">N9;45)W*M3NBW\$+SQU/-2L]1:[*^O*JI#C N=SXR=J)?S?\ MM 1^2H,?81UXYDZ^X]D/(MQM?H3[T#LBY[I4QH^(4QLJ:U3)4Z+-F_4@=19[ MD%KO-M\6.FJ]WFAD&'A*HV?,N-;4NJXO-^GL$Y]&'7T__/E=W]!<*<,4[I^@ M%FAE/=?CB8[&KD>\292IGVJ%W!JA QJA*K=W40CI@GG&NPO+!]+M' D.&2^X M([@CN".X([@CN".X([@CN".X([@CN,,3=PHM)NNDI,#8WQ8>>Q-T:WH]Y>B4 M8](^.FP'S]K!/-=HS)(B+\0.V;%)V7-?YU%QMEOV:#%I],-R7(_5=4:4C#AQ MXSQ,^? ;LB$E3:3+V-A#7TH2E7_E013"B24GP1W!'<$=P1W!'<$=P9WC%\*] M!"]!=X5S>C?(W*='5]*=5E''5&[X;*J#*PH^JH!/.> C; //W"FT#*XHV=8X MD>V"JN!*L;'T@1IX=)XU@/$P(&1*]V%!W)AZ\'(\K)O&ARP\4CR?.Z!2:_71 M'">9N=Y/.=E[UOAW@VF%V9-[GY _*C;+6V.FZY5>HZHV"]CAS=/"B*@Q*]&: MBU@1$]P1W!'<$=P1W!'<$=P1W!'<*3UWPF4P"<2^YY8YHUS1<960&SFYC$O[VK.R7O MA5C?"N@C]5XL@X(?;[DF^/KNLV/-[23(Z*UO(QB@*,7()1J J>N;-; M51WGJJ(M5$6IP"A4!<_<*3#AQYVFZ/"E*4QAZM#6"^U)1>B><1 $Y5PX#95QG[B,X.O&_(E9ZFMZKM M]LY;PCE$['G!*BUMD.5D]650,>L\AZDE2]Q0 #8",.4 S,D8(,$=P1V>E6V6 MT^TW*]M\,5%#K?0:=:':')X2FM#HHCR3!DON".X([@CN".X([@C MN".X([@CN%."_E!;G3IZ.1?"/KFWKC-KXK6J 5O.Y$4#*[;43OOX_=D$WHY^ MR.W^X=;D!FZ'/A1WKX!II0+F"[&Q(A S8=+?0H=*FER55%G5\V8DXT0*GCV[ M(H^R4HIXH\D?]S1W3C1'^J1S&:K&IB8#ZU5"U%W@BGC>!#Z]' %)WZF)@?5& MS=I_J.>F:8C6U.U9TA%[.8HYJR>V328_&W:.O6ITW++1'71+>>0LO:!4E]<6 ME%ZQZFVV9A45D=Z%@1\0!XF2NXRT7>FI55U3J^U&2PC67@5+6%-A3=-%?,6* M]-"U@2A^9#G!&[=#I,2]Z^'CEWSR;&VW&QT0^.62<2'IQRJ\.&<[IQS,SC7E M2J_1:E4U?7D/FL"^L'+"RNW%RF6IN]J'E6LJE5Y3"+H0="'HAQ'T#5UNBA+T M?%GEIEKI:7*KVM*%+A"Z0.B"[2>=:XE)7]J[NF*-Z4A: 0^>ZBA5359V/PU' M2"4? #U+J%O5*3VE6]=;R'@EAH(4J$*I@+ZI@PTKND51! YSU M:J>YO!U:: *A"80FV(LFX%(1-,$_EZNZ)M:CQ3$74?3YYX_2I6V[LS-K;Z]N M6'LZMI_SE?@2D0!JH1U( \\=2<&0PM_OCKI-.\06/OY&^UY(O(FDMJ(BN&PG MVV;?9HC,!P)+IAOBAM/-Q3$'V %9T Y*'JY_[WL74K]GP%+@G:EJ03",:+4S! M)F.?=I-?/IF6/[;)I&LYS)BRFS[%SXH,>3>E.0,;8_3UIU?+#(;=3JO>5EKH M5,:>1OSBZ%NE#L;Y8OESM5G7V\W4K^2ZDOKYJD4H\U.S$F,:8S'I.V?DRIT55#F1J0-9M](O7.4T;@F^NQB,BWWJ017#WT M)7&L':3 >;E 6D[%[9\=B?'X$J!FZ1;?%2'*;%L4)9X M6)!OCGQ?#D0^\8 M'[!!U65\8:F0.=NJQZ*/Q;0M^^AF4P^TW 3:=J=8'IZ6 M@OA1*?N'/V=*+>Y?#DI!LVBW:#::G1=E!)JX0%.YYF\F!T(Q78^G0M4LA_T> MGPUUQK0QC' 4VB2 \.@K'5B&%4AG2HHG%Y @S:\!_Y).D@-US!A9IFG3@]-" M?=\QXRLUZ*A//4E36.2LBJX9HL)B9=>,YKZ[9F0HJ&BQ(LM&RO%[HJ!"=,XH MIZRM.(JM=;@=Q:QSAMS6JYW6\HE:0K!$S:*PJ'NQJ*UC[2G&SAG+6X:$I(O. M&8>W<^V#V;F6Z)PAK)RPVZ@K)5>>,%G;.:#:JC90&DJ)SAI#*4Y7*K&&7&WI,L]">4[[59.31L_K!-%\,K74,"[+.20;Q:GH7O>!2 M'X,CSDC-&W>(\[8$=P1W!'<$=P1W!'<$=_([O%F;HBXXO+G]U2:+!16%@X/T M!'X*/;=QJ9!T+_AI\8.?@LK*2Y$Q8%4:M3[Q*%\M<_.8EW+(/>PUQ<\X$:[K/#GO(;L4.: MYJVW*[V6OMPPN_QH._;]9X_VY7#S^&CO$3V0M>S.RG1*?O;FUU/Z M-1X32U=#XCQ3R7(D7'(=C1F@7I!SV)[965A\A:LV=),YR?3.;LOAB^+VPW)< MC]631)2,R'_C/$R)'TM-OG1/&_=V5)64Y>WRIYS%&K=8:Q#<$=P1W!'<$=P1 MW!'<.?X:]TOP$G17^*YW@V)*-MO**I]6K("7&ET;5\ /@BZ5&W0=J.W:,;=I MS+==6]VL7.S7.?G].GGT1&/#\9:':+D&EK"GM*MMT7*-HQ4#T7)M'ZUH&LV# MM:)IZZ+EFM@!*RSJP2WJAL7 O36C:3=$RS6N2CS.V9_B1O&)$O&?+ M84]JI1U"6;0J5^1$E[,G=G%OF&6LCSW9J8M/0RH1 _MA$ =K,23'#; 8R(./ M';:KZ-DCMC0F7H"[C@*X/'0(&/^ M=' O5-10PV'655VJ.? \0TE9TTNH8;5-M MZR;]IZ94DIN&7C*#,7FFM;Y'R>\U,H )=HG]2B8^HG>>+$"3>1[D)Q_Z!M9@ MLII^@\'>Z!>- ]Q(UV-;'[L@U=3#JV XA)NQ2$,/O>X_;.9D"V02E0I*VQ4Z M[" \GR](+PTEZ=Q1U*.@._U4UY>G%PETC$?&- 2/UI<@=EBM"XXNHNF3N)KJ MN:MY/?6;:H?+ >4O!O",TS_8Y;1OX?;3!LP MXSA3V,RVPCQL,O9I-_GEDVE!T$ F7I-^P%5#7[H&V3:GI<]Y3MW.Z&Z6BS*J MC"=/; S@3W7N6AX + <21F=@$+>R3AI9K<&S&X-/'=O[%@BR#BW?/O!,BX1W'ONP JVZ8;:@ =A4)DP=-J-XPM#HDP)4\"E@P+(AFG6PV M$F_"2PUTKD+,'$!<79QGQM0F$'_G3J:UX/Y+\1R?*0G]>^EI MRG)-W%ZY?69NW:WKU)CC/O7F+7;:BR1\NVV57E(%&AV;^YD80=07I53 MVA\)SX\;SR\;X]_S5I/E+?KP"R\O%V-G[?4'Q/)FC?4MYX7&J5_A[VVKXGXZ M'H49_8>:&.1@C'/GW,P(F]WOTV1%^'UE U*A?E\N*&TTFYJL8H,S72M@KZ=P M#_/HU5?B>0085I58<3\XC[BI8"*\176II?.B 'P#,K(&N[-%R;O!/V)JIB%< MPYV3R^&/< N/I>+4I7/-5F0$<[-:K_2:V8L%A(=8J"8[,__FM8@D4Y[U'Q\0RDQ6TR"JZP9!ZDA%Z M'G@[L;D\E>-=#Y&1SBP?,?6_T@$%6IO7$1,N'?,..7#)")\F,>RPY.76Z>*8 MM1, T_;:-AN:\B6M%1G7>M6\=5^\GXM5%O7,.+>+!CX3%V5KF6$$GI;TK-2X M"IX[N+Q14"P#G@!V-E9_9<-,YDR0HIYR)J@$2G6:+!B3"6L4@SXO,0POI#-' M^,S\W;ULSEX=$-Y'E ??Y#*B^_=9(BZWBZ)5>EI5;RS[P^),6.YPME_-O!=X MZ>@!MUHYE[6/Y0$G3:U@H'0U)/=YU5FZZ',+"6?FIQ_(0SKJ*VW >F_]I-=M2Z!?;[,TL]C%6R_'L8?'U,; NS5=N^Y+Y9) MS2^3G\ *$*]I"#SE0V[GJ@7.E5Z5F[NL&N;B8PG<^C,&9-;D]QX1B:N12E73 M=CG]8^^(+'L0( 98?!AU AU X_[]Q74 /7:?S[QU627UT4 /&Y2:,1=]$C>1 MMXGO2Y>X57?DXICPG![,M8X]6AN$K/OQ;&\&-BV#F]S! ,8 "#!>F8Z?6K&8QCI])KR& < M<_8\$GL\CA<6%XF0M9&R*A^I)="9)1P7E>VFKEC3/6^!NUXQP_<&GHS0C\\0 M89OD'.J=63JS -W\$KP$"V+W"'2_&UPQ:C,!RR-58A?R:6-HA?K."Z+-QEN- M>OS*VLXK68=)9'(?@I74?CS0,9G@/B8T!=&A:W$AQ&EZVT7NC)C2SK\;W"+I MXI7F-''30-PZV8L2A(]\Q%8/>?BJ5WJJFCU?S95W6[IVZ-/5GW&/4Y6:]V*#, MX/^O9S1[H'[@649 3?SBTC$7/YB[\AZ&[YK+A36&'2))K]\,MJO^@03T>C"@ M1I!;]%J5GM:LRFW1-(@?0&U0Q(=&U#)HVI6>GG?#,%=N> E5\I,;$'NU'JY* M??IL.0XZY>Y &C,VB]3Q2B%K[%'&IZ4>Y/R3SN$T=:>Y\.0EZH M:3++02LJ+UC;QJ$N71)EH^ZFV/1AE=9.6+!]8,I="GSET9+9YG@ZRF&I/>0Q M=8."AVE5&[EUPX%3/VGV1LC(Z]'&-HYE/Y.C[HJJ-)W,\"/50.<8V2G67 P MZV8\5Y8V[6F\XASC#&F<)1=5;K'/-L43T@=K:G!O%Z"3:(3W M('MR+ZVF JUL32VXKP7G M9( 7 5:MPK^F]=+[##^2JT?$>[:<* A5%R7*H(BT_0D/>V(7$6H9Z\5)98L5 M0XK-^-P1C&:"QCHJ42<>]NECEOO98[;:8P7L 5P>.B0$D6"GPN(23'0^K,,B M;;;W*2X8A=O\ #Y@A;[U*<3?TRH>3D.'&8Q=G\E:EVVCLE[HIU?+#(:)Z,_= M%6&Y*\]N(7T801BLOF6.*]1\GN-#&""76*_DHF/\)TG"]!D MG@?YR8&T5U7;:5J MHL7Z +SHB,B1E*XDQ5[K;3B"!QG+\=!B0N1+Z,.C?/\K]0W/8AF02\?\0GS+ M9WO)?9A7Y)W"0[[8;'=BXFNV(B?8!9(X:^5P M!-\X]&C5- M\D96LA)_.OTI*7-=X#N\4$GP7OS:Z>CH'*9TEJX@7!;I M3I_9 E@/@M5T/R1554L?T.-#7:;*GZXB+['*_@35-O?5 WVV_ ![&$R_C;]Y MIX&NL>R['GF5+JJPT MZCA4*1Z0!&@ED@%3PF ';WVFTGA((#PSV%RP'">^=. :K+,=<"\ SX@UMAM1 M\.-!FQL2>/E8(,N4/?A%U@CHA\.Q/,EV0>F -AZQ1]EQ> A7#B% >QYB44_- M]9Z!;V,/I)Y%=YDLW?L @3? WWO 'VL,JCYV26+#!_,[5= S/ U=VXPZXT2H M9ZK1PC[F$4$ 5.RDB!A]<_E.+/8*)K.T)R!WZ3W?OU])'V)QP"_A[T0FJDP M8FPS-Z+U:?ZMLXZ,?MCW+=,B'HSN=6@9PSR20)UG^'8J< !]PWVAWH3-TZ0O MU';'R;YED$W;AF],% H?IV5*_@@^DT:N38T0W%73"X%6<"]SBI@$#2RX ->C M6#8%GA0Z(&H@;B8;B(-[[3.)"-\8FM=$0U!G)D4U 9>90%@22#%[(]Z\$,]" M][XV10>,'M&2@.&WF^NI.^M1;PC#>&+V=2@-B!-$PF,*F MC@7#90^@"6Y6BY?MN^MO@S=]A"$QBK+9N*]X-@N\.YI/P"!F6AZH6@F1&&@8C7WDPNSF0 HPMX"7QI1O4PF$N,YQ1V E0/Y8[L\Q M:'W%%.-10]#G@NE:R(Z\?RR0-[11K80>M@MBJR27,Z9#2.&8Q#-]P)@Y6V5Y M4XS)S87V(:4RA&X1)8U_=#.>?AX=!QYATP+P2 #*](1,U;$ M0O&+OTB %<]^M8(ANXV^&73J7^$'27=GM2D]MUI?;#8#7 #8@&OK*"N 3T'F_@1J#.) 92>H!,%X= M7/6KO;C!_(J?/Z+B3SWW5NH1[&RJ!"L*& \QL; MQ74LKTEJ?\I'"#ZFC.Q@VXCZA\7C!H2+MEQ*%T^>S2R M]Q^8RS1@_A)@AJ5,VA_7&=9I B*D)PNZ8XZ3QVPJ>@R>,)@\>U^&Z'P1&AE=W9A$'06+A]S"I/F711JWO>AYSB5B2F8WP-R GR)KT MW06#@/<^@FN.A37SU)X+VMEUTZ]F(3E2X:^N9_T'_0QJ#!TP*L^3V%M 0D3! M.N*8O04L."!7 N#9=")](<[O,^FISF<)OE,+DQ-PKV$.2E]S,9S3>:1+&T.0A?D*:V9/F M0?.5&I$?#O1H5:6_A6!MX-=V=>$;^',>-8_@/4V_BU$T?WE'^D )7$UF;&'T M>X^$R'>!F#8Q=.]XN7C3=-R9V$86%<9,_T^!RFCU%UV%FU_ >D5\O;P!8$9A M^?!Z*\E)T@3I81M+ MFT^Y:%I@NPQP^W&J<]DM@SG;4420FO%DHP%WQWUVK/]$$:#M^KL$P]RDR+]; M@'M039/R!_9/KH19FH4<-'.Z4<2?J4,CGP8_!0DW0_!>/4"C$T;G>B97@G]A MP^3C V9#C;.H0.CILYCOTH?7)CFJ<6Q MQHD!83%#;#?C#OQ1^^]X:8#90S=7Z-79ZL" MGJ7S=+724SM*?563FR2IER!\)@<8**(6HTQE,K=Z HQ-Z$K?,-)C>>),Y)P& MEW:B420?A,%@CV>I:W-U6G%W@A>3'-4UW%E>7SZT($F.SHQ]7,STKGA E ?. M*>3.ZO) 4>EW-I5^J\MK\A;2\.)H?"%Q&08:>XC1/&;[ITO;8$N=JO1*P;NU MT9.(%NOFKUVM!YFK0&S;?97"J)2#TNC>F5J-/8F9+86GVY3X09S_>X-?7JD- M+P8C'@Q/81K7DUC3FGG_#FMA\EJF;3S+'*<5XQ"P2M7P_]DY]"L"( MDX;KHGX8)UGVZM8/;!;E6Q^91_0, WB.\X3_C[TW;6X;R1)%_PI"?8U5RJS(SWE^>^M\/SS= +R_'^E:!'\@U;"D3/8I_7! T3AEZVG#&GQ M@1:([TZKTNRF"R>EXW_Y%?%6]+ ,TEY6I*""9&=&: 8P']DK]9C<@$E?!UMC M"=#N\#W+8B1M[%%;[64$21:V"'^PW7[NP'5G3-A: :([^,4G_H6,;BMXH?-$ M B1<4-'D=NC4KZT*).'5W([%3FZ];\@U%&(I(K]&![_U_D7N6#RX9E<5#;J= MLZMFI==N5OK]?!Q;@C8K@"OVE\3#7:):'*1;H5J742U=@4BHM@[J&.>QR#K" MYJWII[>4?G)81O)R*+N<,T)L;^1L?VGUI>?+I(*/XM5T8O6E0OUZUN'[>0'6 M[+/'T/6B:OP+':DCVT'W243VCQZ8F5%0DJ919568=Z ,]J%VD2&6=BNG5VUZ]4,/!=F(7HR*5T*4#OD; H5&+5_+-#3H6:G MX%R"4/B1UN*N5+X@$@60&XP?S$"T+ ,LIE$GJ_K.:#.@6[BB,-QS$-ZN6$C MH#:>AC;(0<-VEELGH1(F(ZQ1I'R9&I76RU;](E+:5$K&MK*OF2/[*'%F209% M&J?OQ0N*";MV'5EAI]+JI[U+>8Q06"0' ,NNK M("<)$2_*.*^LH9)5,,9$49TXU@K^K00W*[3%)%*.GY+P6%-*!O*UM^*M)+.S M)%$3QZ$LD40Q_5)=P^#ABR&7CD*U=]I=_$Y^X2DP-#_P0C[93?5]M8,G_X3I M1_>7S0J:EW/@<$_,2$&P/-MLFFJ6MY8DY'+ZDB=*;&A555C-22HB-RB&-?IV MF5^;(AL-$VQM2J*8H;BE$\+>!I,',^2ERS2FL93UZ1X'DJ%>N.2O"&B=:WA MNU06@[B3^HEGS\#>]]%_XSX7O/"FJ\8=*G\*L?97ME4]\<%ET::")1$]Q/@NH#"*HDGM<#!LL/V\S#[^_ MF*#1A;/('GMPW]OW<'"1_@E\.X)*5I9G&ZS:9@8P?E&Y\XIPTWJFG&8J6 'R M&,]V9D- ?UMY=Z;PZZDQMI%7R&B_Y?CT4%8;@&S/_WKEHAAF.,5RT4;AA_.9J)F1'N#7IL@W[%1:6@[LS2TS1[M MMO>3)CS,+04'"$*#0ZCLT8!R_ M"I7J69+5<(1S7H:VC069]L)DU8I^YUEDU[%,U,JKHD)'#O!2.8B#P5VD':2VFE.)\]Z<^S8!W(?[>MX M>R5#5B%PQC"*,Y&3+T+>QD=.5S@7(?R++;K/(1;&SFP8):&;"4)1W4-JA2? #?/LSG+/"I0"X]!YD1DQ&!R2)"Y3.P5@@ MDZ@%)M0K@D@0STU9OY"5S3&8@^R; G50VB/LCFR!>NWROYE#1-B2OHCE6"-L M Q_DH3&DM@VB7-+D5^:=NB*WZBZ?GF,E'Y@A M8O#0'*\:T[(P*$O67_3LA3$'>/D^JA!@FW!!_]AT/$JE2@,IVJK,V5C"!]D@ MXL))-%AVQ?&B@/)X8X[ =YJ-+.OQ?Y7K@Q6D<%'/5"+CD4=8*>1+$7L88M-S MVT]1*99Y3UT_]%A%WY@R3T.+T-):S<#4TGEU+B9 ILA;-+KQI<6=>0&R=D0\ MLRDVQF6+U.LDYN/7>,&2T#!+$0!+-<)/9*W))X4_$2-$'O.T$[E!Z;!6R$Y, M$C]!_'7G4LKSM>)GGCT! D3X8-^1&05;L&>\13*C>,%TA?FIJO:N1'OQD4MS M#$862YN:ZX:31-,;VJ!H.VU6Z^98(6OR#]^^'7^$B\;HD1]92?T,8ZV?MAJ/ MM,O)'UP+J,Y]&M3!>H)*5,[D5*PX(;M#_7NW1I$0+'XLMH0)6>9W&_!&P)I+ MZWP_Y&;?/N=ZF51A+20]*DX8#A6]R##$F=U%@)J7*!G')$8G(>++^8U2J"T1 M:LEEZU)AS-J1R(/GAU3 T@H]&93G'Q%4R7^*BG40DO[$7)IK*+#" GB5$/38 MJ$)!:@6=EXFT2^BA7BLS:R$:F-[)YEO\;%'_'*1QNT3@'Z_'1179$ MEF,B 0!#1<2;)=X5?T!E MSNGY;U'@D32BS,!C>JGHV61+!GPV].UQ. 4)\,0K+SPT'T6%-VZ3ZY"B-D?Z MTEF6*Y;<5% 2H%&,>J ?;T\WI)9R,3BBX3YQ,.F!6F&AM/ <6V:;T, >;K B MJ@N3PM$)9&*T+YH"8-,-=XY4D+*..41,[0_P&_83C*GKTG>\R#]#ZU&(MZ$; MLL@=B2*/Z.39PG-E0*>0[@G$BS*"6<$WQ_]^3>G!^#>EB.* N)-0.6.')=9% MAS7PM,>O?G[27(D8#6<$(^1=N,BAN5T48#ZWXHKIAR,=-%Q-Q[#Q #:&\$%% M"0K3%]5O">UUFW055F5G6*D*ZFO,M:E2T 6A#H7W1="W&)1&.C"H8< 2;.H+ MQG%SU)A1MT0R )4Y:ICECASBA+1'5CRU^QV+GBC9)0M D+"6\T@+# $&F+^- M-8-<*#LS_Z0).3(X3[^GS*S!8&!P*1JP'_L%GO2^8P1![%[$_1EZSZ!]3E[T M\Q=S KP]4MW.X78 S\%*]J)V4G#X@LV4^IV5K742C"AJL53/"JUW,,NKMB2T M+HMD;=-#1[%F%:SA$(J+$\NQXIX.N7:A19OH_M-^P1ZJM7V<.W0X9-<9YD5K M.XU38?^2&=!?M),?/^_7L968-37?HG)A> HX*==AB9H?K64/ZJ0R_Q;TI%#R MO!AR8N$S98:3WK-NE[VM4#1J+).+ELT304NMA\[^$/'-6YGH384<]HN3*PB# M+2I3.=[^0'4 P?YG6CZ,,Q^#A@SBHH)2'!ESD-U\M2+JQY%K4\P2W?6R62R9 MKYJI@:Y].8F(>F9&7843-+-B)98=^J]PZ1E8"Z3#@#JFO74HBS)-XZ_0):V" M]0G.WUQ0NS&'\P&IBX_XWI=ZEB/4%ZRA),E+.9_47&UB3]G%CB:&Y I*]PVB M@C7X$EN0G'_&IA!&_:)J_$Z9A&1Y<*T]'D&Y[6$S,FA#[O-SX7N[J%!YOBMC MLH4R)_88'GESY/^8C4EX+ZO04H82W>+!1,=VP8[' M<7-G;% ?J,4T)$'%3XQ$A@S;Y)2QA,Y==P@7^$2K,WV-HDP:FF(\?='I(HI& M.XA:Y#@@2 **F)YVDK=LI;1+J?N-]5JL-$*O'NK4_X(KNA8&0*XH;J4=>9W6 MR42J!%2,;]Q*Z712^B31AKX(&$F[QHM.:CR"WDBV.N Z4([C3UCB#.ZOC4ZM M4S$D>*@9D$0;W_@7-6P3F!,UD14_BQ+V_C6AEFY:J=/8G$Y]K>FWUGJZ U^>HB>&6*Z(<&J] M19VQ\'SG_025$^EW$0A756@I&Z QUII@Z+B/W X-V[Y+)';\2+TQ_423*$D6 MKC8I16DP[FMH,*_)%7375Y;S/6(2(M-%-@%3S;%$%].L+ENZVTYE#"::D;%< M%;>+F4+8F$ST/DNH&\+K)M)M6-W!20+/R%3$+ ,JS7T2+8NI:"1@-H/['KI8 M7&-Z:(L(-SZK5^+PXBN>Q45* %H'%=D53)2P)+\-1+,UVLN$\&DVPTI8C&US M\_Y1!"?0EMB[_R*[RNJ,I:M/QTC$ M>=%34LF(Q'7;CQ7A2-HJ<#JQP2K*4,5G8L&Y.,*B*2BU_Z%65X\VO\R/5AFC MTN<>S:B(\ (H_4/$%RHR&]L5\W*X=%*UZ=/P-R=$9U+[EU)CXZ43D M@3)0J#]HYE/Y,$CO,GT3DG4-;;2M(_(WU."7J#DA.A<"Y@XCI7[%8S$Y MM!#G5 I4Z4W1 !G0^67@F0@OAR-@J];'S"L8TO0=$9&5Z,/JW!2/@R69L=I5 M>DTNXT@QJ0?-#00@F<#C-'H,-RS?FOLZ1W:^$'=']B99E4SX+$=@0Y%J(90& MH5W@+*/B%_%+)F\AATSX9UXSHZLLC M%]2QC]\2^X)66"*EWM-/JQM-[+^7KF**R^$OX>:%66YAY![-+JF>H)U&EFW. MBMDI6A7Q)LKALK6IAZ%%]I/Z),">Y[**CJ6A^@Y $^(D.XJ$:RN2F6?I*I_Z M2G91YQ6QF_V4W@?+R)1B?+9"TFN"Q6GTTY32R(-$27**!ZA@SJ8V1XXE$F'0 MK%73S]CGI,)5I(3!,]2'6Q;AYT)1'XV7K94.[8DY':-*L?1JN9?2@L,I/, 5 MFW):)^)RD#H1NV!\ZE(9XG4KJT/+XQO'%1.I7=.$,%"2? 84.7+F6KKX,VID M6NN0A*H\1RZ+^7_*_HG=:@QI#1H[Z_PM>ZO?\-V*VKR12QT:8)]R:D'<'D^\ MF'N 2#\#IF*R?J<2$F-D]J+CE*PH%$FE"3>*2OI*^$ZBO"R]_T:LJ3G;R-&( ML;G]Z 9.5&)*=@\G6:$31;?X(VN)"(# QX95TN7+1:34\UZ5]@ARI#XO>J5A"E1YFU#\(S8G+-0@KCF33O%L%>*6K5#?WDP=-FG"6C9@CJZLB6),]]22:&XE;P6DT M'&&72!BI&0-@]V.E#OLS>9#?6M*%9K39 M),,D9E6QG5?LD^0=F[Y"$6>CD+VD0^V0-N5XZU8P6NUQO\[QW^P*:+/LH)"2>'XO8.?JMX9^6Z&FU3/D3=[C+.#" 2>MKX[ES M^*L8M+&\LTNG MIM($T3L!3OR6LC-+#Y@_(7#X-[M]SFW&XF_L_Z)O+6A='\25V M;YSSX.9&KW;Q3G:8.ZPP\]DX"0Q_D0-1%XR^L0H>+# I]QKF' MQ9NFXI">B+L!G@QLVI<-^J3Y^!\@!/E"]:X00SD<@91XO5W$.):U)7^KY+DF M9]#,]:CJ7;B.A>YX??OA"X\[2X3WR+6NBFIEGA:^4;R%YTA1[J_KDZ4L Q\L M@/R1YZBAX0[5TLY4'Y%Q-'I.+.> !B'L;=ER)7%44VR'$%_\[#_\Q#YDY;*- MU@Q&/!(0KHA<4(""3RJ*.*Z&(FQ,RVG2K&DY6&! 71K0) =&/2?Q3%V*U23/ M>EOVG^$V.U$7'_;T^USQ76"I1)T!6 QBU@:6?&/>I0JE8,J;J,TV4=((N.O' MBN;.N:J=P=(F!HED#3\9"SU&Z77#&:D/YH^WY90DN+09L,L%5_]()%,$W0.3 M2%I.DX)IO"<G^>A%,+@1<1!1O$K#)RDWA2 0 M 1BE,-Q85A:9;@'XJ6F97GX8SENA7@]C7Q$#B+V8.D+ZZUPTL/P9,JJ8/!8 MBD9&W7Q$ XZEBR9:3SHWXPW&(CBIT%Z<)X91*A9WMA+AS(BG_9GE6&]KNQ- 1(OM7?)]#1;]#]6 ML[]DZPHAG9YE##@*ZE.$/P([U@/FX,$6W2+6YZE7_QAZOUZE>?6:75P[65U< MCZ]K:[-PU]98.J:6C1FQL@R#-J-U:R>C=>MU++LDFM&]4:/63F:CULZJT6.' M=H<%;>[8K/!H8C2WE7RHYXSC$*>#5@S">'D^8K.7.CJ=<6U MUQS;U>F=737:_4JGO72D4I8#/7/$$D]+4F5?M$+!T3*YPIC4 6:>D<0[5"/747(1"?CQ'H9DF%&N$N/X:*+1;$ MBOKZ,ZRN.>4=UKP=$Y9$V)&%$TW"B=4D&L5.*"8NB]J%SRH.J"P@4X6[6;2O M1;T6F][5BO&HQ.E0S\3-?*.)%.F6%MT63HOHIM'_%[(Q\*?411C,T:G(8#=5 M>$C>?T6K>:1T?/*:%66]&1>:,QN<*H4_4Y'P[?SC#WQOZ/@3Q+?;\0=[F$GG M;9S7EC&=21_[C2PW'JPTHW2HJ!J,#3$N/,[)_"Y:B'Q4;K!L+3+)B:@.1HWZ MDHD2JCH#^\2#B.:@[GG4<"SV.2HJ$VRGS:GW6J:$7C)[(9*^XC\-'+4B<];QCEZ=\?DRG!LKQ+K54D\AG(S7+Q)J>+8!$&_O M"^A"GT-@M0A=R"#L"61\ M$2,#Y1/0S79#?_H252_G76P43G'G,:5CZ>#71)DB]?X49=697CAVC:;<;[P] M_O+!'DWF *?'%^,>E052OCY_ON:8_GA,<:-,T_EA*-D(E*& BP(?I^X0J^/U MJHTI[!(N0GQ6$F5XP!W;\@(U%L0PEHQMDVLEY)Q_+N"1,\&B/F%:VU>;6RTY)*7&X72,K\'U&(]&;D2OSN6@D M&Q1D^=V+D@7L@YS1-8B4& MJWE2 /IMUJ/MP7 @-R_KF\^BOD7"QSC/71I%N[A7MR^][9T)W/;MF) M%ZD_".A3\/K]D6#(*2DRD2U2\$?+63,^=L!X=)#LV: Y 5AKR"TU#>QIG?*% MXD]#7Q5/W=QI8P:GSCA("6J9-!6[4KTW"^OC42%54F]);Y3RJ'A%K-$C6S7> MARF)$9$](AB1GV!\2 MZ\ MT:F<8ZB:7>$,^%>2+".! \L"*3 MTJ**I@3J5@S;HE$ WW>3*D>Y07G)Z->N')X92P=\B%HE#N3N:/__Q!UFY=ATSJZ: MM25Y4ZCUG@\O8NED"0?A3A,VHP,7.RX.:\DZ7W?5^63>8_;ETPP8T7LD7BF4 MQ+ DPABB>Z4$6NHQ?>F*P1UH@4IY4ISC1XU%I I<[8Z/;RP:M1!+ND<"ZMU"GM@E/OR4K2>2;@W/?0%= M2G/<8*(V&-"6\^C(1MNLFPDW$B8]BFR\@_;ZOBE.QY)L=[9%>9T4+EXLE9,%(U3 MPKOC^4'*L5)>>F$7[0G8* .LC9TYX2RJ2I&UKUFZ+^ATR;2.XMG@K>7I_5G# M8CZ+D;4O7]WY*+_DHW]V5>]5,RJH5'H_C93"Q%XJ\/ 4F:FD^ W.T]Y ,\=L M_G0R_QW /^-K&J< M0/A,]_?IMT$M/U5.B)P?D0UL'@4AI+><6R.A"^1*\R:2=4/"0^3930>'!LL.M30B/=[ST \YKR+9)C+0 M^] .?1Y5''/L5L5]9M&T:3S9<\OU$MX+?2QL_$W& JV3"J76$;$O:R/+D6WJ MP+A6VT &%&:2\. ..>=W9"[,$7#NS%DK@F_05C5B2.21). E>9#(,_6CTA.: M1"B:E'*>1$7&Y["?9!P8(M]!YK/IF9(",)0GEVC)-Z/>$[;RHO[7A^LH QNO M4A%H@JM5> "2YN!3G?2I;B\:@R0G8PM57/%0.7 H 4JI]7-Q4\ZT(6HP1#U0 M,UL^)A@W#1\ *HICL>S4:6GZKS8_X 2TH?94=!$YLW$L62&4 M-=%".!+4A)#(?,42IHQ"/.VW7+O)@\V5XTB,6AAG#5RC=L(TC)!=[4N1I&(\ MVJ#?9B0BN>%4]&H1.R0((3XM.:3(-:3?SNV(:]'X$9>R%HBUZO%[RYZ"R/+4 MN*BL02X\F2-G7$B6%"69BW/@RIJJ C55S;*FJJRI6E)3=2354]H L@RA+.=&)B9@U:SS.K'@/L% TEU@U\! M%64A^LGQ>>P%+WT=.8YN.> TPJ-/'P;%[C^!7)HI'Z=8+;=7M7:2?H $(HIY M[2J52C[OY_Q [47L.>:T=$>CT-.B(>DI$P[:3CA[)2'4SYVQV "*,4L,6(GM M74V=R-[(12QY*EV O#]YFI:12I8.J#>P;3V8/XK(S691\5]$B]G]=EOKB?D@ MUB:&&(\^(U;*=N3WI6S70]@_5TNK@TQ=+=QG:T4WNS/EN] MSD[Z;+VEV,_I\760.+XMAN^P\5BON[SQV-M6^[]IT[.#1!WC(8>):%D "+(1 M)CZPP*'Y$#D1[F:]MJS/_FL\V+46#WB=X#:5*1\V^L_A##RDD7$HK%8CL!3 MY80H/I24GMZJE!YD:Y;-V=U*65\^@>Z].27OSOW$MFEL*TW2LZ-L%'2I4X0K MSQ>$[EWRN;! =YB[NF,URV5/1L"A3U"&A7W7],Q3[Z6.R598H\>NLW1/)2I@ M5L!X[[B+B0EH!+^O5K#+.OQ7,CGYE.)R>H5!/CS5XRR06)M6CW-O%Q)@V.MR M&OJRR;U/$XYPEC.*.[GSE<7[285@,7%]^#\.^PQ ZN,2+PO;: 'E39RA0\-5 MY0GO/GQLJ>TN//?1,V?)3F6DEH0'UR;D/^_NNLWNVZ8? 2^[GH!55#'^TP5H M_;>+9(V1$-GNI\+$21\:*R%A_N1PCWUP+-67L0&UE8:*/6Z^B MQ"K,RXG[G,PI2F(T8JG$3LG"/7-AAP& ,Q3#=2D&P< !**L1HEC-.!&W8\8/CM354UJ1BWU@(A=FL[_/E&FNGK]0'IJ8KW4 M49@:C8X>CLULAT=!&YQM9$4N'XD-2TZH[^>>?YZ_(<&(>6*?4*5$2PF)T!Q. MQR(UKM?2M,V\P?XJE/ME9W6%SM759F)Z !;Y 3 M!#)4M#[./5A6/%>-SHA.[G"!4%]1+]%?L0\@L=E:11']^MD58AP61:1J(J*@ ME3: .O>2R=UOQR^'*9_$RH#*@'O>#W MXJ^X,<<7[=KQE*@9^.02B_=_I^_4FB2FL.+VB5OFIO<@4I_Y+97$8L!C3*6- M8^13\G4J*5NZ%%4[:OWKV:V-B_)HT#5JNU:\01:J8A+#W(4+>LY/A*! NI;" MJJ58Y7(ZCB&+KR/^1Z,$-*8E)Y.Z:!]XMHRKIBM7ABN&%VTJYVADT8UX]WI# MG#3*;^9(0K;UE3B\B>?KQR;=ZX*ELF]97O!XK76.IVFY,3/;3! M5F1">C&>;2+P@,HR1 [HT!:SHD$O'04BH<;QL'E1//5#NT:]KH":KN4E9*NA MP]@E'"%VB= S9G8PP0J")]FV-G%.46(@FXRO]S($/+GE&/KQV$=F]B:)PXAO M_A6:7L",-3(FLLOFENV#G=3,0ZSBK*J^8BK64F_J=3@+.4G]V@Q&DS\6 PMI M!;GM@RMR+*[).KN9?Q0%';=C;2P8<< LZL>8[K(6&1BME696(LYIQNI.(HUS M'6>"*&X4(>%G15OQVY4HHB5AK.%U)=\O9Y1-96%+WH7R6Y7#MUHL6:>^8J;5 MTCL5U_9-G;A XDN_L\\TW9WGZ?2[.)%UC73DJ599$S YMEO'J>=2M MPO.HHU#T[1CU-?2J(]R_,7^\=OW IY93[U$ID8Z,](QJ;+N5G)74[Z=G5--: ME[28H;]OHQG5](+CU/R3BK^8X8.1#FSTQO8Z-\\0?>E,+A '00,O-Q]%Q(3C M-]]!1;=GBZG[0N8?&MGA-#"I\0*75\\OY?>@L8-$PU ;:3(V65;BCW[96F_/^)85> ]P(_>>?6#L\?^1F-O5U'+< M[;,K$K27F:Y;48(L3:;XTH63!EMFYQYN/K,P^29/RK'S_KM>UJU M^K+V/2E7-37"6E67%F&FQ5Y=T/TT-8CP4OB!1]H1U60F63:.$2] 0XK79B%S MLUX1?[(1X'R]VP<9N/B5Y=2BVW&./\!CZM_CRP0F.O_VD&D2-.HY%L> M!9FV>5HUT"1:2_O)Y-69:$ 6!,=0O59$7Q0O]P8.QM9/KO*'-X*9PF3V81/G9[0EY$YGK7%B!7U:R]FT1%#H'',J/%O--^< M +YLP/FFG%#@V>]X,/]&L(9_"< ,&"[TY0> BLHQ2QM)K5H+5>5JKY=&3#S^ MAJ=N'_JIV]2DLYV14(/Z*AXW M+]NN)_>PG\A:8[W(VIOF>Z=[ #^';9;4G/.LQS1#B#F";KY^BH43-N8' M7T0USS7UE2,!O%X@0N,$'>1_E68KPQNI:R?Q KUH^&:LI1TY@*(2HV3D":M1 MA:3&$6=RCF1W&8#H5>;FLSZ@7IU8%O8N]M.)!4W&;A<>S--@> M%JG4\[WVL4/R;>5: E3>2_ >B5BP_'2=#.>4)V!]Y\;]: +;G-JWXVRVHZOQ M ^YJ]4*.HY1_HX4QTK@GXRAE-2*?-C& G&1^.(/]PR(WRWN:(#L!([E8YK[$QU29TU%K[]3O[E-\OQ%U/SY9TSIY/3CWX3RPMO=QO> M .I&@.76XBWT0OY:.&[[O6JCWD+?;>#!_RWY8N'6K0(D?TU_WJU7^\WLKX"4 M,C_/6PJ+('O9/\E;*O]SD'N[VU1SZ5*_$KP89MA&#R[\_SL#9J610?5S@&S?ZW)5!!1_WKP&0UNR6@##*-0C4F M2 SC;N:B3&,U. 0SI*#%(C"H7,G D\4 53,RP$6)9 <%KX+J<,SU4-NUZ^$V MNK7-5.$Z9CBW^I5&*^T*9.&8O/C=7#9^19>^[F7G7Q7^V8^_^-N&?E2R^2>V$.NEXU]M@X(XLGF-AY)]< M;VP[F[+RC+,?"1F='Q0O%[<0PHMOLM)*UN'E&#>N]#*:55T4U9(.P$PY<>P[ M0":>@8)%.3G'\'N[LJ,/1"4_:/:=[;NBJGGIT]]&1_^9_5:M _=;=WF^U1*O?(Z8>'%&O[[1HUL!NKO50]S_]R9=KV%[DB7VK]W_],JJE,:IY;L6(S*N[]@=T?1&$]*7]>YS^&_1&H7G^UA8P8W=":G26+X5.[Y1?17.?<3R/S>$ MDUG^Q3'5/P'_J-:8AQ0I@&K5JKU.:S>U1O5JKU6L;"G_\V:_??R;>H7C-:O= M7K'ZM5?:U'*H_ M-Y!M[;.-5=&<1#G7FI%-V@9"K)=%M"5)_70DU=\726$OK%JZHN,$2:HDR9(D M=TB2C=J^2+(+4JYW^/7H)4F5)+5CDJKOBZ1Z:,$=/DG]#/5DO^<&3\I6#TM( MH[$OTNB?775:6Z/@G("Z4 [FUC7!\]&>CQS;CT9;IZN< MFMW4N&KX+#VN6EN> E>Q%VPRLUJ\)>/=C9V-BM_VGFC%=TX KQNM<7.?[4=S M:GPQ@\#6JN^.=ISE)YJ8C//[L'(,_HR/1*9ZL2=W^L3U8D^FY[BA;TP)" O/ M'=DV$AV@B^?0T$D> F?,46>9PL6'GD\31((L+@=GAO*,.S6S#EXVY(9C@)@C !3-#S9]=TX#NW$^'DY5MN+[ M-TT)JNEMC\.C9/.3P M'!_#B:N-VF\$D<_.B(H=U2/T9?VW"^2/(]NCNNO?I^'(_>[,<;XC#="O_H@\FG+1"Y3L7O0%FS/@.WBS^-[ 1C8TZG-1>. U L;<9YD/@VN M1,+!^=P5F1U? 4J8AV.L8O;@A1/SR=8_ 1H,?4&H(%&P)!HPY&^B89RC&$W2 M6WBPX)Q'$@= S0'/R*4B=G<*KW$"YY$%"OQB84Z!1_"_QL8DA%?BQ^8<]3+< M)0XD]?$C6,"BN=P^S7Y'(N:IED#A$B!4(EO)AJT$DX*J!HWD3=%@WM__>X"G M@S5G%5%ABU@1_0I..@(<1?6) 2/_@:$"5.5\N#>L05 RY;5Y0L[,W)&)@'TD MP,_?(<,EN_%2 2YVBW M4$UU?<+,=U2Q#;0;52'_$M>)A!I?BWYB#D%I#X/\G^0S9ZXU>B-67&\G@*7] M=^)%E5*/]N40X/W]TAS#9M^9TV?SQ4<#0S\BG$^'9W%0K!2[X_'>8,'[ %/2 M]0A-WA%;QJ=@.^;![,68>&B!_-MJVZQ[=D4S9)%$T%Q (OO'K^95UH4?AKZ_ M%%.7V#%@L?Q!,E0.8%9SDR43RM86XB)F MQDX2*84(_4JLV$7/#LQW"*NL-+ M%O<*,-*,@B5<(/LJ-D>YT5DR1_E.[NF+?*OH>I(Q+KG9.[OJ5S-&7LMQR2C> M@=%Z[A.P@L4J&2Q>$ ;]7<$ $ZN6@@ .&A&G#S_W14*'HD6X1!.'JD^G M^*?GOIA3T)4E@5:PQ^#,L2[1%@:F:#F/3J">PDGN\ BO"&\+'#)!Z#UR&KQ2 MEBVIJ%I*;:ZFM0PC;:>MZ5/KG:9/K5/8I_;9]GW;O@6C!S7C3-JC:YL@F7N. 0)O8 MIO47F.CH3#-D]R9AJZ)U)V^%%Q$F /V=J07L;U+^0?3RD&&R $A]I#V@=36U MI&S(Z'^@#[ BM/V-I C[[K,7OCEXFF23YOBM8#SN;9
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
~~~~!OHCKI=Z[5'L4PW@5DP$Z3@ ME"_> 7D_M/2"~~~~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
O]F/)YS?/Q?*Z M@R&F Q4XXO*/ N9N;K<,*G(<^$'QDG8?[*/'SBD V;IPX#I-XLN(Z:?4B8D MKS*^JC9OVW:^!2^>9:J9=%5!8#SK>JUH[MB58;G^2.TCFY,8$&]$_\&V"6ZJ M#XQ+KT_,DE%[V/RY[>L, =E4(U?LE=/1?$>'@-1D=EX8]$^8AYWKY("4#?(W MF:OG8X2$]YTZN!MAY3KJ#9_[$_F;+L/CU*CTM:*/QZB&D[%2_;5@]*O>8A[" MK$/TWN$MG$M\:(W+D'?FR--,5*][CHB]$%>G<[DL6ZY. YT8SHU\X>PTDV_; M24.GDL,*5)82&ESI"2S;?:Z+;8CX_6 ^.=_?,OS/6UZ.G/\\GJFEH](?ZW@I M.@.R1;4 Z[G9A6XCBYZ\U=$#Q>/\;?%2+\B\VRN\6L*(MS[/) O75TW$EAG* M#XV*1?VC/>.^Y]@)]7.AY_8)XE,D-NV[)U5&D619 E*1GA"#X8:KG6_[,ECZ MW/_#+3$-FYZ1: D 8X(&]88,\FH/&@?&&5,F6$(C&?PXU:3R5! -[44VJA[BBEB M LCPJ_@Q9RE M6$!Z^#X_!&6"5VBLV,J#.\A9>F:@)BY/B:M,:B1^3PT0BXJZX+C1+1 U'$I! M62$$N+FT8P\]*F@T;\IE8M)D$M"\NAA8Y$^F'Z$LQ0>=N/@$.9 DU&*6 MS /9Z'8!X>1"VQ[ER%=O92]-A#S>J_V>*Y!OR?DXD\$ZJ?U> ?-8;CT%!M^: MX#OXGM')"PC91[7SW:,-22&-M1/2KP/8N%(_7N=#^5RYOKO.5$1U>9SK-0OU ME67RM,["9!=B@\2YW0W#W38AB4FE_*KGWLJ$M+KDBY4NH5P4?#M'[=]4Y"EQ M)E>(^-[3O=HC< N&LS GR%1%PM"%Q;@D2M[M4T'HNQ,_* .50^FV(%J'EF+? M/U(4QW/1.,OPVJ Y,@QG21O_I+A8PFI!B"?>)CV@&+V8=)_@CX8)0MJ %[UG M?61+?UJY+#HNZGN 2M4ZF&;R[:@OVHLJW!Q>U(]\!ISW/U.KN%C?Y]JT$.\; MW)7B (SML,7+ZN%O^C@((\JVD2D!2_KL*%ZVMV"/U*,IS@V6%'HDO9C(&;\Y M\0Q;;14W^B>2[*NA=K-D;LC0W4_9M]MP<[^;NU#[JMKYL&LKG@\_(>PO05_S MW8+^H#JFYSMA9M<\?C)C>!O+IB<=%+74E)UQ6V4NO18@__X5-,O(7\PHB^9R MM%$JMMOCV/!"3#35_M>%#<5_7E\\>_L[#>MQU0'CFGJ ;"!:PH/M-8WXB,MV MA2!CDG[EL8U-9DV]3X2U>)I[CEV?M-6-<",'4CF!#]&*21(R M'PBS XWCR=609,NV HVE&F&G,=#2(\TDYI)[*1_J&8;G/Z+L15D_ZIX"M/80O&SGCP76A1R/]LD, M9U)F X0@(M-/!]KF*L(C;5AB-N012I^RGGVK5Z<\WMVVFMNG\0GHT0V;5EIB M9TMAHDX*)7$PDAG^N!$O1$S^%M<&?XP<\,^CPVHR10?,+D[T",EQNORDDI< M5NCE;KZG>]P<[?:3".N,#/H?,9P"TYDC&[41"N05,"XPMQF[[7^A?F?_':2] MN\O-\5WPZFXAJUEALQI,[CKM/OP)&,IR >T[=+7.B'SA%<44@Z[(M]CN0R@7 MGFY@*EZVM!DW3_55P)0_>N+(51;XL/"8EN$J%H#/'H#^..MF1IDK#\(A^8*P MSJW."_,=$A4FZ./'!EL^".5>0:?P\I(;=NZV(J@NEKM/KMT&7 .2&2@PEB8) M[[&[K)"-'>S$)9' T]#[W(7UFVVQO^=R3I8[F&G^!%[/Z!VNP!1[KQD/WS,: MZP&W%3?1[>2@61I8JQ<"%3"ZVWL3;B_[_.?F7Z> 3ZEU%P;? MM:?G@GS+,1S$ZC384-6OJX85'2G/UU[_MIW M8$0<26;-S,.,H+%F MT& :3F?[!4[8G]:5_U9MQC^BSOR548$;1F"U='(E<6:3+ZC41"R> H!0WS", M/P_T1B/!<4VRR0?&Z*,5H^<7S7O/QK8YR2,R'7Y#@O>!_GU\JWNX&,729UKR MUR$Q:U5)9"%H %ZBOF^5$RK[%0R?Q^I]S34=2\ZH?OY(V#0$X7FA!O_*RDE0 M1(KNAXA0/(E]BDPO"TS>4X4!H0\1.%@*2(@PU=.PA31\0PE8*1KSH3RB\\\? MO18/B/K(76@75J>LVZ)@25$LSU8VM^*3(O]E3973]4K?7W M9PH<3%PWMF\02U$PV0B4DH^6)\#ZVCQ>P$V%%$UFX2= HUE1T^>FC)JY*S.3 MXGK\XH%U;%P7?9VHFDVH8Y(.@*CTH]]GD@NS&(5\K"O_)DAR[M>$J6V\8=PU M%FG)' ](58$?ARD[VHB:&MX"!/C1B5"!_?Q18__IAI'^PB$T5<>WG/#*;N:W MF8,\MS3U>B;2W>96'/-4%!2(3=:6#S6==PEI_5J* M>.Y3_7J>BKI/[HF>4OKC%&K!]U1/YHB'.")F,A8WUCO?"<1-IK\EA!HC0I4< MO([8')#=XF\J[XDFG@L2:V+G"90*,07HTIIW^T>Z<)SD=W)ONM#@#%^V 6.? MQF4L+EY;'O@64B\W(=OJ562B[+SX&PR9U_@7U VP]RD "=,[28T 4&)SA[5; MG;,G2$!]<%T(1/-\Z) RP.R]>&8]J=GF%& '-:36YRR2%*V@2W@ MH54!%XCCP"J;7 0W(;$&N=J+G"R9=BR)X^7*V7WP!BVVR\9@R)NQ"/7C PA5 MD3C+R(R7L/XH[8$5==QJK(Y)S687+K'07_KS[3E>9?:2/6U1 M#WNG3@%46[(_5PD2KT@7;8 \WWZ2KQ&^^*#W^:!7\54Q]^?@A;*WYIJE%6O] M% QJCG8U7F9PH1AOIR8ZN:=W@+RQE%E*+L89FU^$WL6[]M6G"8LW$YZOI<<^ MBS_*^^:IE342%OB$R_]QWXC?_"Z5=9'REFG,"QHTJ>JH2Q>WGH\Q8QDR^?)K M%VPT\W31:F6T=U("T=24>M&(7]SGA8&!@"W UTJW6[/D HP5)+P)9H2RE4+\ M^XY\W,H)_N;Q)C.8$ VP>TL25RS;K4F37A$^.5:B_CO<*HJ2! :CP00I<3); M]N SV^1@XPXG1;/,Z9W=>A[UU8=RXS,3O!<,9C+4&T0$T:F58-0?\H4@RD9$ M9EBBB^,9TC)/4=/'*K8P2DY?0KS4E1_H>BWA59GL$W$* !BMN[_?B'0]GB(T M$_4AV]C"Y7J2Y(HR/C39\9:R?-ZV0^W G\6<47_C_DD4U6+^2W>AF&LJNL*E M_ZK<":Y9_9>TC70R P=EG_2= S]8Y2 TV1 :JTAR^+3W09*%P9CJ;1\88L4S M5)W\O&-Z+,COX_5C)>77QZ/4!Q=5_E)2G8,?Y2F%@Z+1%AO431Y2(@4>U4 ' M@.,=A6/QM!7#='%Z:YIT@:'(J8,4+CH:ZM7W]9.N!%DI$C?1_.3U+BD,5];] MD3"D1_A<-E21'![@U:+BE3G8B]S-A&X\8L*9-7<]U0,M<<533%%"+.#FEHQ>Y=YT@<3P9'+C7$6Y0E_TYJ/37 J M&(^T+O3;U>:X= R8T-CPV>NRQ8T[_)3N=3;OC'\4!. =T>/FL7 MG@RJ%2@S00!_A\RH0;0GQ.^"+N.6%]+KX'?GU>0='3P:6XH8'[9\O %TCR(' M+_LIB3(>:(QK(79721R'9(9DW,81WS2/<)TCRD#CVAHXX3PI_71-SI#A5% SCZ16P MC-Q:$9^1,T?6[Q9;%5G'5GF6O2O"WX/7VBV$DUT$QJ&Z_00$8+O MOC\K #PS(K%CR0P\:UVH%E^QH8\N$!T2Z Q6%:\Q*UIVMC5U?FZ)*BG:D\[B M37J?Q7!4)Y$21_,0XD8L(UZ)& &?2?^ZGG.!>&#JXRC15F!ZOQYUMPBICH-"5T.69?M&\E"0P1S+!@..T_L2QQ-?^S%M)K I# MS!C_N>ZE\V5C.!^==^F3A U=X'F(VEFW0ELPNA;AVL(SR.@X%1LA3JC& *F6 M(3Y$'AOE&"54@+1KZ0]M(4P>( M-(\"4NM<(:I"I6:@C.AJGFF21"F\WJ/JY(/)#+7
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~~NE0@_< 7A"ULG=T9,4O&+5\VRB%5V* 6B?P/AJN+BR,'9W7, MEF6V=L/;(27:XB_M#_D]# B[!0Z+6~~
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𘑑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Ð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�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end XML 67 vtvt-20240630_htm.xml IDEA: XBRL DOCUMENT 0001641489 2024-01-01 2024-06-30 0001641489 us-gaap:CommonClassAMember 2024-08-08 0001641489 us-gaap:CommonClassBMember 2024-08-08 0001641489 2024-06-30 0001641489 2023-12-31 0001641489 us-gaap:RelatedPartyMember 2024-06-30 0001641489 us-gaap:RelatedPartyMember 2023-12-31 0001641489 us-gaap:NonrelatedPartyMember 2024-06-30 0001641489 us-gaap:NonrelatedPartyMember 2023-12-31 0001641489 us-gaap:CommonClassAMember 2023-12-31 0001641489 us-gaap:CommonClassAMember 2024-06-30 0001641489 us-gaap:CommonClassBMember 2023-12-31 0001641489 us-gaap:CommonClassBMember 2024-06-30 0001641489 2024-04-01 2024-06-30 0001641489 2023-04-01 2023-06-30 0001641489 2023-01-01 2023-06-30 0001641489 us-gaap:NonrelatedPartyMember 2024-04-01 2024-06-30 0001641489 us-gaap:NonrelatedPartyMember 2023-04-01 2023-06-30 0001641489 us-gaap:NonrelatedPartyMember 2024-01-01 2024-06-30 0001641489 us-gaap:NonrelatedPartyMember 2023-01-01 2023-06-30 0001641489 us-gaap:RelatedPartyMember 2024-04-01 2024-06-30 0001641489 us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001641489 us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001641489 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001641489 us-gaap:CommonClassAMember 2024-04-01 2024-06-30 0001641489 us-gaap:CommonClassAMember 2023-04-01 2023-06-30 0001641489 us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001641489 us-gaap:CommonClassAMember 2023-01-01 2023-06-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-31 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-03-31 0001641489 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001641489 us-gaap:RetainedEarningsMember 2024-03-31 0001641489 us-gaap:ParentMember 2024-03-31 0001641489 us-gaap:NoncontrollingInterestMember 2024-03-31 0001641489 2024-03-31 0001641489 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001641489 us-gaap:ParentMember 2024-04-01 2024-06-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001641489 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-06-30 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-06-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001641489 us-gaap:RetainedEarningsMember 2024-06-30 0001641489 us-gaap:ParentMember 2024-06-30 0001641489 us-gaap:NoncontrollingInterestMember 2024-06-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember 2023-03-31 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-03-31 0001641489 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001641489 us-gaap:RetainedEarningsMember 2023-03-31 0001641489 2023-03-31 0001641489 vtvt:RedeemableNoncontrollingInterestsMember 2023-04-01 2023-06-30 0001641489 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember 2023-06-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-06-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001641489 us-gaap:RetainedEarningsMember 2023-06-30 0001641489 2023-06-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember 2023-12-31 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-12-31 0001641489 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001641489 us-gaap:RetainedEarningsMember 2023-12-31 0001641489 us-gaap:ParentMember 2023-12-31 0001641489 us-gaap:NoncontrollingInterestMember 2023-12-31 0001641489 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001641489 us-gaap:ParentMember 2024-01-01 2024-06-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember 2024-01-01 2024-06-30 0001641489 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-06-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001641489 us-gaap:CommonClassAMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember 2024-06-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember 2022-12-31 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001641489 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001641489 us-gaap:RetainedEarningsMember 2022-12-31 0001641489 2022-12-31 0001641489 vtvt:RedeemableNoncontrollingInterestsMember 2023-01-01 2023-06-30 0001641489 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001641489 srt:ParentCompanyMember 2024-06-30 0001641489 vtvt:VTvLLCMember 2024-01-01 2024-06-30 0001641489 us-gaap:CommonClassBMember vtvt:VTvLLCMember 2024-06-30 0001641489 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2024-02-27 2024-02-27 0001641489 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2024-02-27 0001641489 vtvt:PrivatePlacementPreFundedWarrantsMember us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2024-02-27 0001641489 vtvt:PrivatePlacementPreFundedWarrantsMember us-gaap:PrivatePlacementMember 2024-02-27 0001641489 us-gaap:PrivatePlacementMember 2024-02-27 2024-02-27 0001641489 us-gaap:PrivatePlacementMember 2024-03-05 0001641489 us-gaap:CommonClassAMember vtvt:TDCowenSalesAgreementMember 2024-02-28 0001641489 2024-02-28 0001641489 vtvt:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001641489 vtvt:G42InvestmentsMember 2022-05-31 2022-05-31 0001641489 vtvt:G42InvestmentsMember 2022-05-31 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-05-31 2022-05-31 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-05-31 0001641489 vtvt:G42InvestmentsMember 2023-02-28 2023-02-28 0001641489 vtvt:G42InvestmentsMember 2023-02-28 0001641489 vtvt:CognaMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-05-31 2022-05-31 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2024-06-30 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2024-01-01 2024-06-30 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2024-04-01 2024-06-30 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2023-02-28 2023-02-28 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2023-02-28 0001641489 us-gaap:CollaborativeArrangementMember vtvt:NewsoaraBiopharmaCoLtdMember 2024-06-26 0001641489 vtvt:LicenseAndTechnologyTransferServicesMember us-gaap:CollaborativeArrangementMember vtvt:NewsoaraBiopharmaCoLtdMember 2024-01-01 2024-06-30 0001641489 vtvt:NewsoaraBiopharmaCoLtdMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-06-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:JDRFInternationalMember 2017-08-01 2017-08-31 0001641489 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001641489 us-gaap:EmployeeStockOptionMember 2024-06-30 0001641489 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001641489 us-gaap:EmployeeStockOptionMember 2024-02-23 0001641489 us-gaap:EmployeeStockOptionMember 2024-02-23 2024-02-23 0001641489 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001641489 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001641489 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001641489 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001641489 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001641489 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001641489 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001641489 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001641489 vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember vtvt:TypeOneDiabetesMember vtvt:NovoLicenseAgreementMember 2007-02-28 0001641489 srt:MaximumMember vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember vtvt:TypeTwoDiabetesMember vtvt:NovoLicenseAgreementMember 2007-02-28 0001641489 srt:MaximumMember vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember vtvt:OtherIndicationMember vtvt:NovoLicenseAgreementMember 2007-02-28 0001641489 vtvt:SalesBasedMilestonesPaymentMember vtvt:NovoLicenseAgreementMember 2007-02-28 0001641489 2022-11-30 0001641489 vtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0001641489 2024-02-27 0001641489 us-gaap:CommonClassAMember 2021-05-04 2021-05-04 0001641489 us-gaap:CommonClassAMember 2021-05-04 0001641489 us-gaap:CommonStockMember 2021-05-04 0001641489 2021-05-04 0001641489 us-gaap:CommonClassAMember 2023-11-20 0001641489 us-gaap:CommonClassBMember 2023-11-20 0001641489 2023-11-20 0001641489 vtvt:PrivatePlacementPreFundedWarrantsMember 2024-02-27 0001641489 vtvt:PrivatePlacementPreFundedWarrantsMember 2024-06-30 0001641489 vtvt:PrivatePlacementPreFundedWarrantsMember us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2024-06-30 0001641489 vtvt:CinRxInvestmentMember 2022-07-22 2022-07-22 0001641489 vtvt:CinRxInvestmentMember 2022-07-22 0001641489 vtvt:CinRxInvestmentMember us-gaap:CommonStockMember 2022-07-22 0001641489 us-gaap:CommonClassBMember 2023-11-20 2023-11-20 0001641489 us-gaap:CommonClassAMember 2023-11-20 2023-11-20 0001641489 vtvt:MacAndrewsAndForbesIncorporatedMember us-gaap:RelatedPartyMember us-gaap:CommonClassBMember 2024-06-30 0001641489 vtvt:MacAndrewsAndForbesIncorporatedMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2024-06-30 0001641489 vtvt:MacAndrewsAndForbesIncorporatedMember us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001641489 vtvt:MFTTPHoldingsLLCMember 2024-01-01 2024-06-30 0001641489 us-gaap:CommonClassBMember 2024-01-01 2024-06-30 0001641489 us-gaap:CommonClassBMember 2023-01-01 2023-06-30 0001641489 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001641489 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001641489 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001641489 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001641489 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:RelatedPartyMember 2024-06-30 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:RelatedPartyMember 2024-06-30 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:RelatedPartyMember 2024-06-30 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:RelatedPartyMember 2024-06-30 0001641489 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NonrelatedPartyMember 2024-06-30 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NonrelatedPartyMember 2024-06-30 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NonrelatedPartyMember 2024-06-30 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NonrelatedPartyMember 2024-06-30 0001641489 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001641489 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:RelatedPartyMember 2023-12-31 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:RelatedPartyMember 2024-06-30 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:NonrelatedPartyMember 2023-12-31 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:NonrelatedPartyMember 2024-01-01 2024-06-30 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:NonrelatedPartyMember 2024-06-30 0001641489 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001641489 us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-06-30 0001641489 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001641489 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001641489 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001641489 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001641489 srt:MinimumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001641489 srt:MaximumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001641489 srt:WeightedAverageMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001641489 srt:MinimumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001641489 srt:MaximumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001641489 srt:WeightedAverageMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001641489 srt:MinimumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001641489 srt:MaximumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001641489 srt:WeightedAverageMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001641489 srt:MinimumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001641489 srt:MaximumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001641489 srt:WeightedAverageMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001641489 vtvt:CinRxWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001641489 vtvt:CinRxWarrantsMember 2024-06-30 0001641489 vtvt:CinRxWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001641489 vtvt:CinRxWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 shares iso4217:USD iso4217:USD shares pure utr:Rate 0001641489 --12-31 2024 Q2 false 0.333 0.5 0.025 0.025 10-Q true 2024-06-30 false 001-37524 vTv Therapeutics Inc. DE 47-3916571 3980 Premier Dr Suite 310 High Point NC 27265 336 841-0300 Class A common stock, par value $0.01 per share VTVT NASDAQ Yes Yes Non-accelerated Filer true false false 2432857 577349 45526000 9446000 306000 102000 303000 1044000 65000 65000 46200000 10657000 72000 117000 186000 244000 46458000 11018000 6791000 10242000 177000 169000 17000 17000 0 191000 6985000 10619000 18669000 18669000 79000 169000 158000 110000 130000 0 26021000 29567000 0 6131000 0.01 0.01 200000000 200000000 2432857 2084973 24000 21000 0.01 0.01 100000000 100000000 577349 577349 6000 6000 307746000 256335000 -291301000 -281042000 16475000 -24680000 3962000 0 20437000 -24680000 46458000 11018000 0 0 1000000 0 3439000 4691000 6088000 8633000 3716000 3309000 7694000 6794000 7155000 8000000 13782000 15427000 -7155000 -8000000 -12782000 -15427000 72000 335000 72000 2126000 121000 303000 -250000 65000 553000 153000 632000 253000 0 2000 0 2000 -6409000 -7211000 -12328000 -12985000 0 0 100000 0 -6409000 -7211000 -12428000 -12985000 -1229000 -1592000 -2383000 -2867000 -5180000 -5619000 -10045000 -10118000 -5180000 -5619000 -10045000 -10118000 -0.81 -0.81 -2.69 -2.69 -1.97 -1.97 -4.85 -4.85 6403444 6403444 2084973 2084973 5098877 5098877 2084973 2084973 2432857 24000 577349 6000 306887000 -286121000 20796000 5191000 25987000 -5180000 -5180000 -5180000 859000 859000 859000 -1229000 -1229000 2432857 24000 577349 6000 307746000 -291301000 16475000 3962000 20437000 19600000 2084973 21000 577349 6000 255100000 -274319000 -19192000 -1592000 -5619000 -5619000 399000 399000 871000 -871000 -871000 18879000 2084973 21000 577349 6000 255499000 -280809000 -25283000 6131000 2084973 21000 577349 6000 256335000 -281042000 -24680000 0 -24680000 -10045000 -10045000 -10045000 -1085000 214000 -214000 -214000 -214000 -5260000 5260000 5260000 1079000 1079000 1079000 347884 3000 50332000 50335000 50335000 -1298000 -1298000 0 2432857 24000 577349 6000 307746000 -291301000 16475000 3962000 20437000 16579000 2084973 21000 577349 6000 254757000 -265524000 -10740000 -2867000 -10118000 -10118000 742000 742000 5167000 -5167000 -5167000 18879000 2084973 21000 577349 6000 255499000 -280809000 -25283000 -12428000 -12985000 45000 45000 0 -313000 0 100000 1079000 742000 0 2439000 250000 -65000 -72000 0 204000 -173000 -741000 -1213000 -58000 0 -3451000 1770000 -82000 0 -14064000 -11333000 50335000 0 0 12030000 191000 224000 50144000 11806000 36080000 473000 9446000 12126000 45526000 12599000 -214000 5167000 5260000 0 Description of Business and Basis of Presentation <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Condensed Consolidated Financial Statements. The assets and liabilities of vTv LLC represent substantially all of the Company's consolidated assets and liabilities with the exception of the Warrants and $26.1 million of cash and cash equivalents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various holders own non-voting interests in vTv LLC, representing a 19.2% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 80.8% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company’s Class B common stock, par value $0.01 (“Class B common stock”)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 8). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (“M&F Group”), a related party and an affiliate of MacAndrews & Forbes Incorporated (together with its affiliates “MacAndrews”) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a “Letter Agreement” and collectively, the “Letter Agreements”). vTv Therapeutics Inc. entered into a common stock purchase agreement with G42 Investments AI Holding RSC Ltd (“G42 Investments”) (the “G42 Purchase </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement”),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the “CinRx Purchase Agreement”). In addition vTv Therapeutics Inc. also entered into a Securities Purchase Agreement with Private Placement Investors and the sales agreement with Cowen and Company, LLC (“TD Cowen”) (“TD Cowen Sales Agreement”). v</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through June 30, 2024, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of June 30, 2024, the Company had an accumulated deficit of $291.3 million and has generated net losses in each year of its existence. As of June 30, 2024, the Company’s liquidity sources included cash and cash equivalents of $45.5 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements for at least the next twelve months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2024, we entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Private Placement Investors”), pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (the “Private Placement”) (i) an aggregate of 464,377 shares (the “Private Placement Shares”) of our Class A common stock, at a purchase price of $11.81 per share, and (ii) pre-funded warrants (the “Private Placement Pre-Funded Warrants”) to purchase up to an aggregate of 3,853,997 shares of our Class A common stock (the “Private Placement Warrant Shares”) at a purchase price of $11.80 per Private Placement Pre-Funded Warrant (representing the $11.81 per Private Placement Share purchase price less the exercise price of $0.01 per Private Placement Warrant Share). We received aggregate gross proceeds from the Private Placement of approximately $51.0 million, before deducting offering expenses payable by us. The Private Placement Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, we entered into the TD Cowen Sales Agreement, pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the “TD Cowen ATM Offering”). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements.</span></div> 26100000 0.192 0.808 0.01 -291300000 45500000 464377 11.81 3853997 11.80 11.81 0.01 51000000.0 116493 116590 50000000.0 75000000.0 0.030 Summary of Significant Accounting Policies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of June 30, 2024, Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit) for the three and six months ended June 30, 2024 and 2023 and Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of June 30, 2024, the results of operations for the three and six months ended June 30, 2024 and 2023 and cash flows for the six months ended June 30, 2024 and 2023. The December 31, 2023 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One customer represented 100% of the revenue earned during the six months ended June 30, 2024. The Company did not have any revenue during the six months ended June 30, 2023 or during the three months ended June 30, 2024 and 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (ASU 2023-07)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. For public entities, the provisions within ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and for interim periods of fiscal years beginning after December 15, 2024. The Company is currently assessing the impact the adoption of ASU 2023-07 will have on its Consolidated Financial Statement and disclosures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In December 2023, the FASB issued ASU 2023-09: “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” (“ASU 2023-09”). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, and we expect considerable changes to our income tax disclosures.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of June 30, 2024, Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit) for the three and six months ended June 30, 2024 and 2023 and Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of June 30, 2024, the results of operations for the three and six months ended June 30, 2024 and 2023 and cash flows for the six months ended June 30, 2024 and 2023. The December 31, 2023 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One customer represented 100% of the revenue earned during the six months ended June 30, 2024. The Company did not have any revenue during the six months ended June 30, 2023 or during the three months ended June 30, 2024 and 2023.</span></div> 1 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. </span></div>The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided. <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (ASU 2023-07)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. For public entities, the provisions within ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and for interim periods of fiscal years beginning after December 15, 2024. The Company is currently assessing the impact the adoption of ASU 2023-07 will have on its Consolidated Financial Statement and disclosures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In December 2023, the FASB issued ASU 2023-09: “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” (“ASU 2023-09”). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, and we expect considerable changes to our income tax disclosures.</span></div> Collaboration Agreements<div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Purchase Agreement and Cogna Collaborative and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and G42 Investments AI Holding RSC Ltd, a private limited company (“G42 Investments”), entered into a Common Stock Purchase Agreement (the “G42 Purchase Agreement”), pursuant to which the Company sold to G42 Investments 259,657 shares of the Company’s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the “G42 Promissory Note”). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company’s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Administration (“FDA”) approval in the U.S. for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the “Cogna Agreement”) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (“Cogna”), which requires Cogna to work with the Company in performing clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as jointly creating a global development plan to develop, market, and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in certain countries in the Middle East, Africa, and Central Asia (the “Partner Territory”). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory, but will not have access to the various intellectual property (“IP”) related to the license and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed to conduct the trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cogna Agreement, Cogna has the right to develop and commercialize the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for commercial sale under terms to be agreed upon by the parties at a later date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company will conduct its clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of the Partner Territory at its own cost. The Company may combine the results of each party’s clinical trials to seek FDA approval in the United States for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (“G42 Healthcare”), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G42 Purchase Agreement also provides for, following the receipt of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA Approval, at the option of G42 Investments, either (a) the issuance of the Company’s Class A common stock (the “Milestone Shares”) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the “Milestone Cash Payment”). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> FDA Approval will be granted or as to the timing thereof.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a period of at least ten years after the first commercial sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company’s behalf to complete research and development activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (“JDC”) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within the 808 unit of account are concentrated in the clinical trials. As of June 30, 2024, the clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and six months ended June 30, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified certain commitments that are in the scope of ASC 606 as Cogna’s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved by the FDA. The Company will recognize revenue from the material right related to Cogna’s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and six months ended June 30, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company receive</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting in a loss of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and was recognized as a component of other income, net in the Company’s Condensed Consolidated Statements of Operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The G42 Promissory Note receivable was classified and accounted for under ASC 310 “</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables“ </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 310”) and was initially measured at its fair value of $11.9 million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recorded the $18.7 million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and six months ended June 30, 2024. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newsoara License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (“Newsoara”) (the “Newsoara License Agreement”) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company’s phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the “Newsoara License Territory”). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company’s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the “First Newsoara Amendment”). On June 26, 2024, the Company entered into the second amendment to the Newsoara License Agreement (the “Second Newsoara Amendment”) which expanded the global license contingent upon Newsoara paying an upfront global rights fee (the “Upfront Fees”) of $20.0 million. Newsoara has up to one year from the date of the Second Newsoara Amendment to pay the Upfront Fees; if it fails to do so, then the Second Newsoara Amendment will be null and void. As amended, the Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$76.5 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, Newsoara is obligated to pay the Company royalty payments at mid to upper single digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. There are no new performance obligations to be considered within the Second Newsoara Amendment. The Second Amendment has a potential impact to increase the transaction price by $20.0 million. If the Company receives the Upfront Fees, $20.0 million of revenue will be recognized at a point in time. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The revenue for this performance obligation has been fully recognized as of June 30, 2024. In the first quarter of 2024, the transaction price for this performance obligation was increased by $1.0 million due to the satisfaction of a development milestone under the Newsoara License Agreement. This amount was fully recognized as revenue during the six months ended June 30, 2024, as the related performance obligation was fully satisfied. No revenue related to this performance obligation was recognized and there were no changes to the transaction price during the three and six months ended June 30, 2023.</span></div> 259657 96.40 25000000.0 12500000 12500000 12000000.0 0.0375 -300000 30000000.0 30000000.0 P10Y 18700000 600000 0 0 0 0 12000000.0 0.0375 -300000 11900000 18700000 20000000.0 P1Y 76500000 20000000 20000000 1000000.0 0 0 Share-Based Compensation<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of June 30, 2024, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $4.7 million, which is expected to be recognized over a weighted average period of 2.5 years. The weighted average grant date fair value of options granted during the six months ended June 30, 2024 and 2023 was $14.88 and $30.59 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at June 30, 2024 was de minimis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2024, in connection with the Private Placement, several directors resigned as members of the Company’s Board of Directors, effective on the closing of the Private Placement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a result of their resignations, 14,340 stock options to purchase shares of common stock were modified to increase the time period to exercise the options and 7,590 stock options to purchase shares of common stock were modified to accelerate vesting at the termination date. All the unvested options were modified to be fully vested as of the posting of the Private Placement which resulted in a reduction in their fair value. The Company incurred $0.1 million reduction in stock compensation expense for the modifications for the six months ended June 30, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the six months ended June 30, 2024:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,247 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.53 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,875)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.87 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,171 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.34 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2024</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,812 </span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.34 </span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at June 30, 2024</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,109 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.32 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P3Y P10Y 4700000 P2Y6M 14.88 30.59 14340 7590 100000 <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the six months ended June 30, 2024:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,247 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.53 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,875)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.87 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,171 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.34 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2024</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,812 </span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.34 </span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at June 30, 2024</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,109 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.32 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 249247 77.53 406799 12.68 1875 30.87 654171 37.34 199812 86.34 P6Y9M18D 499109 44.32 P8Y4M24D <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 217000 105000 283000 203000 642000 294000 796000 539000 859000 399000 1079000 742000 Commitments and Contingencies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novo Nordisk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an Agreement (the “Novo License Agreement”) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo Nordisk”) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use. </span></div>Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. 9000000.0 50500000 115000000.0 75000000.0 Leases<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election is not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. As a result of the remeasurement of the associated lease liabilities, the Company recognized additional right of use assets and corresponding lease liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Further, th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e second amendment to the lease does not include any material residual value guarantee or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of June 30, 2024 and December 31, 2023, the weighted average incremental borrowing rate for the operating leases held by the Company was 9.5%. At June 30, 2024 and December 31, 2023, the weighted average remaining lease terms for the operating leases held by the Company were 1.4 years and 1.9 years, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company’s operating leases as of June 30, 2024 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remaining six months)</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost and the related operating cash flows for the six months ended June 30, 2024 was $0.1 million and was immaterial for the six months ended June 30, 2023.</span></div> P5Y P3Y 100000 100000 0.095 0.095 P1Y4M24D P1Y10M24D <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company’s operating leases as of June 30, 2024 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remaining six months)</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 97000 177000 0 0 0 0 274000 18000 256000 100000 0 Noncontrolling Interest<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 19.2% noncontrolling interest in vTv LLC outstanding as of June 30, 2024 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2024, in connection with the Private Placement financing, the Investor Rights Agreement altered M&F TTP Holdings Two LLC (“M&F”) governance rights such that directors designated by M&F no longer comprised a majority of the Company’s Board of Directors (see Note 9). The redeemable noncontrolling interest redemption feature to exchange vTv Units for cash rather than shares of Class A common stock is a contingent event that is now within control of the Company through the Company’s independent Board of Directors. As a result, $5.3 million representing the fair value of redeemable noncontrolling interest on February 27, 2024, was reclassified from temporary equity in the mezzanine section of the Condensed Consolidated Balance Sheets to noncontrolling interest as a component of permanent equity. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to February 27, 2024, the Company recorded redeemable noncontrolling interest at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balance sheet date. At December 31, 2023, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $6.1 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,180)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,619)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,045)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,118)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,180)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,344)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,498)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.192 1 P20D 5300000 6100000 The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,180)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,619)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,045)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,118)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,180)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,344)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,498)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -5180000 -5619000 -10045000 -10118000 0 1275000 9564000 2620000 -5180000 -4344000 -481000 -7498000 Stockholders’ Equity (Deficit)<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Certificate of Incorporation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation as amended, to effect a reverse stock split at a ratio of 1-for-40 (the "Reverse Stock Split"). Pursuant to the Reverse Stock Split, every 40 shares of the Company’s Class A common stock was combined into one issued and outstanding share of Class A Common Stock and every 40 shares of the Company’s Class B common stock was combined into one issued and outstanding share of Class B Common Stock. The Reverse Stock Split did not reduce the number of authorized shares of Class A and Class B common stock, which remained at 200,000,000 and 100,000,000 respectively and did not change the par value of the common stock, which remained at $0.01 per share. The Reverse Stock Split did not have any effect on the number of authorized shares of the Company’s preferred stock, par value of $0.01 per share, which would remain at 50,000,000 shares. Currently no shares of preferred stock are outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock and Pre-funded Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entered into a Securities Purchase Agreement with certain Private Placement Investors, pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (i) an aggregate of 464,377 shares of our Class A common stock, at a purchase price of $11.81 per share and (ii) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued pre-funded warrants to purchase an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,853,997</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of the Company’s Class A common stock at a price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.80</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per pre-funded warrant. The pre-funded warrants were immediately exercisable, have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.01</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and may be exercised at any time after the date of issuance. A holder of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.99%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. A holder of the pre-funded warrants may increase or decrease this percentage not in excess of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.99%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by providing at least 61 days’ prior notice to the Company. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were pre-funded warrants to purchase an aggregate o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f 3,970,587 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of the Company’s common stock that remained available for exercise.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants were classified as a component of permanent equity in the Company's Condensed Consolidated Balance Sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the pre-funded warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 259,657 shares of the Company's Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the “G42 Promissory Note”). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company’s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CinPax and CinRx Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022 (the “Transaction Date”), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (“CinPax”) and CinRx-Pharma, LLC (“CinRx”), pursuant to which the Company agreed to sell to CinPax 103,864 shares of the Company’s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 30,000 shares of common stock at an initial exercise of price of approximately $28.80 per share (the “CinRx Warrants”). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 12)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (“FDA Approval”) to market and distribute the pharmaceutical product containing the Company’s proprietary candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the “Product”), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (“CinRx MSA”) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 9)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par. The Company, CinPax and CinRx subsequently amended the CinRx Purchase Agreement on February 27, 2024, in connection with the Private Placement. The CinRx Purchase Agreement provides CinPax the right for two years following the Closing to designate a board observer, which has been subsequently approved by the Company’s board.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, we entered into a sales agreement (the “TD Cowen Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the “TD Cowen ATM Offering”). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered </span></div>on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. 100000000 200000000 100000000 200000000 300000000 250000000 350000000 200000000 100000000 0.01 0.01 50000000 464377 11.81 3853997 11.80 0.01 0.0999 0.1999 3970587 116493 116590 259657 96.40 25000000.0 12500000 12500000 P1Y 12000000.0 0.0375 -300000 103864 96.40 10000000.0 6000000.0 4000000.0 30000 28.80 400000 P5Y 50000000.0 75000000.0 0.030 Related-Party Transactions<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacAndrews & Forbes Incorporated</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacAndrews directly or indirectly controls 577,108 shares of Class B common stock. Further, as of June 30, 2024, MacAndrews directly or indirectly holds 912,982 shares of the Company’s Class A common stock. As a result, MacAndrews’ holdings represent approximately 49.5% of the combined voting power of the Company’s outstanding common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letter Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company’s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company’s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of June 30, 2024, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to a tax receivable agreement (the “Tax Receivable Agreement”), which provides for the payment by the Company to M&F TTP Holdings Two LLC (“M&F”), as successor in interest to vTv Therapeutics Holdings, LLC (“vTv Therapeutics Holdings”), and M&F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of June 30, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. The Investor Rights Agreement was amended on February 27, 2024 to alter M&F governance rights that now entitles M&F the right to designate two members of our Board of Directors, and as part of the Private Placement, the Private Placement Investors have rights to designate three members of our Board of Directors, making it more difficult for a third party to acquire control of our Board. The agreement with the Private Placement Investors also provides that five of our directors must approve certain actions including any acquisition by a third party, which makes it more difficult for our Board of Directors to approve such a transaction.</span></div> 577108 912982 0.495 0.85 Income Taxes<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes as well as state taxes. The Company’s income tax provision for the six months ended June 30, 2024 was $0.1 million representing foreign withholding taxes accrued in connection with revenue recorded under license agreements with foreign entities. The Company did not record an income tax provision for the three months ended June 30, 2024 and 2023. The Company did not record an income tax provision for the six months ended June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on June 30, 2024, is due to the valuation allowance against the Company’s expected net operating losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 9, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of June 30, 2024.</span></div> 100000 0 0 0 0.85 Net Loss per Share<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,409)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,229)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,592)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,383)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,867)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,180)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,619)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,045)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,118)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(*)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,403,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,098,877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.81)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.69)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.97)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.85)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">The shares underlying the pre-funded warrants to purchase shares of the Company’s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and six months ended June 30, 2024.</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(*)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,349 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,349 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,595 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,359 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307,115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,344 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div> <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,409)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,229)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,592)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,383)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,867)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,180)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,619)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,045)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,118)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(*)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,403,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,098,877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.81)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.69)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.97)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.85)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">The shares underlying the pre-funded warrants to purchase shares of the Company’s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and six months ended June 30, 2024.</span></div></td></tr></table></div> -6409000 -7211000 -12428000 -12985000 -1229000 -1592000 -2383000 -2867000 -5180000 -5180000 -5619000 -5619000 -10045000 -10045000 -10118000 -10118000 6403444 6403444 2084973 2084973 5098877 5098877 2084973 2084973 -0.81 -0.81 -2.69 -2.69 -1.97 -1.97 -4.85 -4.85 <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(*)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,349 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,349 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,595 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,359 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307,115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,344 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div> 577349 577349 654171 238636 75595 80359 1307115 896344 Fair Value of Financial Instruments<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The following table summarizes the conclusions reached regarding fair value measurements as of June 30, 2024 and December 31, 2023 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability </span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and six months ended June 30, 2024. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income (expense), related party in the Company’s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of June 30, 2024 and December 31, 2023, were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.96% - 145.41%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.42%</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.96% - 89.61%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.55%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62% - 5.36%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.79%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01% - 4.87%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of June 30, 2024, were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.</span></div>Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability. The following table summarizes the conclusions reached regarding fair value measurements as of June 30, 2024 and December 31, 2023 (in thousands):<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability </span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.</span></div></td></tr></table></div> 158000 0 0 158000 130000 0 0 130000 288000 0 0 288000 110000 0 0 110000 110000 0 0 110000 110000 250000 0 0 360000 0 -72000 0 0 -72000 110000 178000 0 0 288000 684000 -65000 0 0 619000 684000 -65000 0 0 619000 Significant inputs utilized in the valuation of the Letter Agreement Warrants as of June 30, 2024 and December 31, 2023, were:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.96% - 145.41%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.42%</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.96% - 89.61%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.55%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62% - 5.36%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.79%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01% - 4.87%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of June 30, 2024, were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.9896 1.4541 1.0642 0.7996 0.8961 0.8155 0.0462 0.0536 0.0479 0.0401 0.0487 0.0415 0.917 P3Y 0.045 0 Subsequent Events<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2024 the Company announced that the Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (“CATT1”) Phase 3 trial in type 1 diabetes.</span></div> false false false false (*) Adjusted retroactively for reverse stock split (*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 7) (*) Adjusted retroactively for reverse stock split

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2024	Aug. 08, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-37524
Entity Registrant Name	vTv Therapeutics Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-3916571
Entity Address, Address Line One	3980 Premier Dr
Entity Address, Address Line Two	Suite 310
Entity Address, City or Town	High Point
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27265
City Area Code	336
Local Phone Number	841-0300
Title of 12(b) Security	Class A common stock, par value $0.01 per share
Trading Symbol	VTVT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001641489
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		2,432,857
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		577,349

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 45,526	$ 9,446
Accounts receivable	306	102
Prepaid expenses and other current assets	303	1,044
Current deposits	65	65
Total current assets	46,200	10,657
Property and equipment, net	72	117
Operating lease right-of-use assets	186	244
Total assets	46,458	11,018
Current liabilities:
Accounts payable and accrued expenses	6,791	10,242
Current portion of operating lease liabilities	177	169
Current portion of contract liabilities	17	17
Current portion of notes payable	0	191
Total current liabilities	6,985	10,619
Contract liabilities, net of current portion	18,669	18,669
Operating lease liabilities, net of current portion	79	169
Total liabilities	26,021	29,567
Commitments and contingencies
Redeemable noncontrolling interest	0	6,131
Stockholders’ equity (deficit):
Additional paid-in capital	307,746	256,335
Accumulated deficit	(291,301)	(281,042)
Total stockholders’ equity (deficit) attributable to vTv Therapeutics Inc.	16,475	(24,680)
Noncontrolling interest	3,962	0
Total stockholders’ equity (deficit)	20,437	(24,680)
Total liabilities, redeemable noncontrolling interest and stockholders’ equity (deficit)	46,458	11,018
Related Party
Current liabilities:
Warrant liability, related party	158	110
Nonrelated Party
Current liabilities:
Warrant liability, related party	130	0
Class A Common Stock
Stockholders’ equity (deficit):
Common stock value	24	21
Class B Common Stock
Stockholders’ equity (deficit):
Common stock value	$ 6	$ 6

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023	Nov. 20, 2023	May 04, 2021
Common stock par value (in usd per share)			$ 0.01
Class A Common Stock
Common stock par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	200,000,000	200,000,000	200,000,000
Common stock, shares outstanding (in shares)	2,432,857	2,084,973
Class B Common Stock
Common stock par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000	100,000,000
Common stock, shares outstanding (in shares)	577,349	577,349

Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss before noncontrolling interest	$ (12,428)	$ (12,985)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
Depreciation expense	45	45
Loss from promissory note early redemption	0	313
Non-cash interest income	0	(100)
Share-based compensation expense	1,079	742
Change in fair value of investments	0	(2,439)
Changes in assets and liabilities:
Accounts receivable	(204)	173
Prepaid expenses and other current assets	741	1,213
Other assets	58	0
Accounts payable and accrued expenses	(3,451)	1,770
Other liabilities	(82)	0
Net cash used in operating activities	(14,064)	(11,333)
Cash flows from financing activities:
Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs	50,335	0
Proceeds from promissory note early redemption related to sale of Class A common stock to collaboration partner	0	12,030
Repayment of notes payable	(191)	(224)
Net cash provided by financing activities	50,144	11,806
Net increase in cash and cash equivalents	36,080	473
Total cash and cash equivalents, beginning of period	9,446	12,126
Total cash and cash equivalents, end of period	45,526	12,599
Non-cash activities:
Change in redemption value of noncontrolling interest	(214)	5,167
Reclassification of noncontrolling interest to additional paid-in capital	5,260	0
Related Party
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
Change in fair value of warrants	250	(65)
Nonrelated Party
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
Change in fair value of warrants	$ (72)	$ 0

Description of Business and Basis of Presentation	6 Months Ended
Description of Business and Basis of Presentation	Jun. 30, 2024
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Description of Business vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection. Principles of Consolidation vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Condensed Consolidated Financial Statements. The assets and liabilities of vTv LLC represent substantially all of the Company's consolidated assets and liabilities with the exception of the Warrants and $26.1 million of cash and cash equivalents. Various holders own non-voting interests in vTv LLC, representing a 19.2% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 80.8% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company’s Class B common stock, par value $0.01 (“Class B common stock”)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 8). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (“M&F Group”), a related party and an affiliate of MacAndrews & Forbes Incorporated (together with its affiliates “MacAndrews”) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a “Letter Agreement” and collectively, the “Letter Agreements”). vTv Therapeutics Inc. entered into a common stock purchase agreement with G42 Investments AI Holding RSC Ltd (“G42 Investments”) (the “G42 Purchase Agreement”), the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the “CinRx Purchase Agreement”). In addition vTv Therapeutics Inc. also entered into a Securities Purchase Agreement with Private Placement Investors and the sales agreement with Cowen and Company, LLC (“TD Cowen”) (“TD Cowen Sales Agreement”). vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss. Liquidity To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through June 30, 2024, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of June 30, 2024, the Company had an accumulated deficit of $291.3 million and has generated net losses in each year of its existence. As of June 30, 2024, the Company’s liquidity sources included cash and cash equivalents of $45.5 million. Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements for at least the next twelve months. On February 27, 2024, we entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Private Placement Investors”), pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (the “Private Placement”) (i) an aggregate of 464,377 shares (the “Private Placement Shares”) of our Class A common stock, at a purchase price of $11.81 per share, and (ii) pre-funded warrants (the “Private Placement Pre-Funded Warrants”) to purchase up to an aggregate of 3,853,997 shares of our Class A common stock (the “Private Placement Warrant Shares”) at a purchase price of $11.80 per Private Placement Pre-Funded Warrant (representing the $11.81 per Private Placement Share purchase price less the exercise price of $0.01 per Private Placement Warrant Share). We received aggregate gross proceeds from the Private Placement of approximately $51.0 million, before deducting offering expenses payable by us. The Private Placement Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire. On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants. On February 28, 2024, we entered into the TD Cowen Sales Agreement, pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the “TD Cowen ATM Offering”). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements.

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Unaudited Interim Financial Information The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of June 30, 2024, Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit) for the three and six months ended June 30, 2024 and 2023 and Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of June 30, 2024, the results of operations for the three and six months ended June 30, 2024 and 2023 and cash flows for the six months ended June 30, 2024 and 2023. The December 31, 2023 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year. The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution. One customer represented 100% of the revenue earned during the six months ended June 30, 2024. The Company did not have any revenue during the six months ended June 30, 2023 or during the three months ended June 30, 2024 and 2023. Cash and Cash Equivalents The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. Investments Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations. Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. Revenue Recognition The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations. The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided. Research and Development Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred. The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study. The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services. Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense. Recently Issued Accounting Pronouncements Not Yet Adopted Segment Reporting: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): “Improvements to Reportable Segment Disclosures” (ASU 2023-07). The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. For public entities, the provisions within ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and for interim periods of fiscal years beginning after December 15, 2024. The Company is currently assessing the impact the adoption of ASU 2023-07 will have on its Consolidated Financial Statement and disclosures. Income Taxes: In December 2023, the FASB issued ASU 2023-09: “Improvements to Income Tax Disclosures” (“ASU 2023-09”). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, and we expect considerable changes to our income tax disclosures.

Collaboration Agreements	6 Months Ended
Collaboration Agreements	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration Agreements	Collaboration Agreements G42 Purchase Agreement and Cogna Collaborative and License Agreement The Company and G42 Investments AI Holding RSC Ltd, a private limited company (“G42 Investments”), entered into a Common Stock Purchase Agreement (the “G42 Purchase Agreement”), pursuant to which the Company sold to G42 Investments 259,657 shares of the Company’s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the “G42 Promissory Note”). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company’s Condensed Consolidated Statements of Operations. G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and Drug Administration (“FDA”) approval in the U.S. for cadisegliatin, the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions. Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the “Cogna Agreement”) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (“Cogna”), which requires Cogna to work with the Company in performing clinical trials for cadisegliatin as well as jointly creating a global development plan to develop, market, and commercialize cadisegliatin in certain countries in the Middle East, Africa, and Central Asia (the “Partner Territory”). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercialize cadisegliatin in the Partner Territory, but will not have access to the various intellectual property (“IP”) related to the license and cadisegliatin. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of cadisegliatin needed to conduct the trials. Under the Cogna Agreement, Cogna has the right to develop and commercialize the cadisegliatin in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, cadisegliatin for commercial sale under terms to be agreed upon by the parties at a later date. Separately, the Company will conduct its clinical trials for cadisegliatin outside of the Partner Territory at its own cost. The Company may combine the results of each party’s clinical trials to seek FDA approval in the United States for cadisegliatin. On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (“G42 Healthcare”), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare. The G42 Purchase Agreement also provides for, following the receipt of the cadisegliatin FDA Approval, at the option of G42 Investments, either (a) the issuance of the Company’s Class A common stock (the “Milestone Shares”) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the “Milestone Cash Payment”). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the cadisegliatin FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the cadisegliatin FDA Approval will be granted or as to the timing thereof. Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of cadisegliatin for a period of at least ten years after the first commercial sale of cadisegliatin in the Partner Territory. A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account. The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of cadisegliatin, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company’s behalf to complete research and development activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (“JDC”) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance. By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall within the 808 unit of account are concentrated in the clinical trials. As of June 30, 2024, the clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and six months ended June 30, 2024. The Company identified certain commitments that are in the scope of ASC 606 as Cogna’s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after cadisegliatin is approved by the FDA. The Company will recognize revenue from the material right related to Cogna’s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and six months ended June 30, 2024. On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company’s Condensed Consolidated Statements of Operations. The G42 Promissory Note receivable was classified and accounted for under ASC 310 “Receivables“ (“ASC 310”) and was initially measured at its fair value of $11.9 million. The Company also recorded the $18.7 million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and six months ended June 30, 2024. Newsoara License Agreement The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (“Newsoara”) (the “Newsoara License Agreement”) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company’s phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound HPP737, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the “Newsoara License Territory”). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company’s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory. The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the “First Newsoara Amendment”). On June 26, 2024, the Company entered into the second amendment to the Newsoara License Agreement (the “Second Newsoara Amendment”) which expanded the global license contingent upon Newsoara paying an upfront global rights fee (the “Upfront Fees”) of $20.0 million. Newsoara has up to one year from the date of the Second Newsoara Amendment to pay the Upfront Fees; if it fails to do so, then the Second Newsoara Amendment will be null and void. As amended, the Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to $76.5 million. In addition, Newsoara is obligated to pay the Company royalty payments at mid to upper single digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. There are no new performance obligations to be considered within the Second Newsoara Amendment. The Second Amendment has a potential impact to increase the transaction price by $20.0 million. If the Company receives the Upfront Fees, $20.0 million of revenue will be recognized at a point in time. The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The revenue for this performance obligation has been fully recognized as of June 30, 2024. In the first quarter of 2024, the transaction price for this performance obligation was increased by $1.0 million due to the satisfaction of a development milestone under the Newsoara License Agreement. This amount was fully recognized as revenue during the six months ended June 30, 2024, as the related performance obligation was fully satisfied. No revenue related to this performance obligation was recognized and there were no changes to the transaction price during the three and six months ended June 30, 2023.

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Matters From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings. Novo Nordisk In February 2007, the Company entered into an Agreement (the “Novo License Agreement”) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo Nordisk”) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as cadisegliatin. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products.

Stockholders' Equity (Deficit)	6 Months Ended
Stockholders' Equity (Deficit)	Jun. 30, 2024
Equity [Abstract]
Stockholders' Equity (Deficit)	Stockholders’ Equity (Deficit) Amendment to Certificate of Incorporation On May 4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares. On November 20, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation as amended, to effect a reverse stock split at a ratio of 1-for-40 (the "Reverse Stock Split"). Pursuant to the Reverse Stock Split, every 40 shares of the Company’s Class A common stock was combined into one issued and outstanding share of Class A Common Stock and every 40 shares of the Company’s Class B common stock was combined into one issued and outstanding share of Class B Common Stock. The Reverse Stock Split did not reduce the number of authorized shares of Class A and Class B common stock, which remained at 200,000,000 and 100,000,000 respectively and did not change the par value of the common stock, which remained at $0.01 per share. The Reverse Stock Split did not have any effect on the number of authorized shares of the Company’s preferred stock, par value of $0.01 per share, which would remain at 50,000,000 shares. Currently no shares of preferred stock are outstanding. Common Stock and Pre-funded Warrants In February 2024, the Company entered into a Securities Purchase Agreement with certain Private Placement Investors, pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (i) an aggregate of 464,377 shares of our Class A common stock, at a purchase price of $11.81 per share and (ii) issued pre-funded warrants to purchase an aggregate of 3,853,997 shares of the Company’s Class A common stock at a price of $11.80 per pre-funded warrant. The pre-funded warrants were immediately exercisable, have an exercise price of $0.01 and may be exercised at any time after the date of issuance. A holder of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. A holder of the pre-funded warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. As of June 30, 2024, there were pre-funded warrants to purchase an aggregate of 3,970,587 shares of the Company’s common stock that remained available for exercise. The pre-funded warrants were classified as a component of permanent equity in the Company's Condensed Consolidated Balance Sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the pre-funded warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants. On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants. G42 Investments Transaction On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 259,657 shares of the Company's Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the “G42 Promissory Note”). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company’s Condensed Consolidated Statements of Operations. CinPax and CinRx Transaction On July 22, 2022 (the “Transaction Date”), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (“CinPax”) and CinRx-Pharma, LLC (“CinRx”), pursuant to which the Company agreed to sell to CinPax 103,864 shares of the Company’s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022. The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 30,000 shares of common stock at an initial exercise of price of approximately $28.80 per share (the “CinRx Warrants”). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 12) The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (“FDA Approval”) to market and distribute the pharmaceutical product containing the Company’s proprietary candidate, cadisegliatin (the “Product”), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants. Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (“CinRx MSA”) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 9) The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par. The Company, CinPax and CinRx subsequently amended the CinRx Purchase Agreement on February 27, 2024, in connection with the Private Placement. The CinRx Purchase Agreement provides CinPax the right for two years following the Closing to designate a board observer, which has been subsequently approved by the Company’s board. ATM Offering On February 28, 2024, we entered into a sales agreement (the “TD Cowen Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the “TD Cowen ATM Offering”). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements.

Related-Party Transactions	6 Months Ended
Related-Party Transactions	Jun. 30, 2024
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions MacAndrews & Forbes Incorporated MacAndrews directly or indirectly controls 577,108 shares of Class B common stock. Further, as of June 30, 2024, MacAndrews directly or indirectly holds 912,982 shares of the Company’s Class A common stock. As a result, MacAndrews’ holdings represent approximately 49.5% of the combined voting power of the Company’s outstanding common stock. The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below: Letter Agreements The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A common stock. The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company’s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. Exchange Agreement Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company’s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of June 30, 2024, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement. Tax Receivable Agreement The Company and MacAndrews are party to a tax receivable agreement (the “Tax Receivable Agreement”), which provides for the payment by the Company to M&F TTP Holdings Two LLC (“M&F”), as successor in interest to vTv Therapeutics Holdings, LLC (“vTv Therapeutics Holdings”), and M&F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of June 30, 2024. Investor Rights Agreement The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. The Investor Rights Agreement was amended on February 27, 2024 to alter M&F governance rights that now entitles M&F the right to designate two members of our Board of Directors, and as part of the Private Placement, the Private Placement Investors have rights to designate three members of our Board of Directors, making it more difficult for a third party to acquire control of our Board. The agreement with the Private Placement Investors also provides that five of our directors must approve certain actions including any acquisition by a third party, which makes it more difficult for our Board of Directors to approve such a transaction.

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company is subject to U.S. federal income taxes as well as state taxes. The Company’s income tax provision for the six months ended June 30, 2024 was $0.1 million representing foreign withholding taxes accrued in connection with revenue recorded under license agreements with foreign entities. The Company did not record an income tax provision for the three months ended June 30, 2024 and 2023. The Company did not record an income tax provision for the six months ended June 30, 2023. Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on June 30, 2024, is due to the valuation allowance against the Company’s expected net operating losses. As discussed in Note 9, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of June 30, 2024.

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On July 26, 2024 the Company announced that the Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (“CATT1”) Phase 3 trial in type 1 diabetes.

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net loss attributable to vTv Therapeutics Inc.	$ (5,180)	$ (5,619)	$ (10,045)	$ (10,118)

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Description of Business and Basis of Presentation (Detail) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended
	Feb. 27, 2024	Jun. 30, 2024	Mar. 05, 2024	Feb. 28, 2024	Feb. 28, 2024	Feb. 28, 2024	Dec. 31, 2023	Nov. 20, 2023
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Cash and cash equivalents		$ 45,526					$ 9,446
Common stock par value (in usd per share)								$ 0.01
Retained earnings (accumulated deficit)		(291,301)					$ (281,042)
Entity public float, threshold					$ 75,000
Percent of public float				33.30%		3.00%
Parent Company
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Cash and cash equivalents		$ 26,100
Private Placement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Proceeds from issuance of private placement	$ 51,000
Private placement, shares (in shares)			116,493
Private placement pre-funded warrants, shares (in shares)			116,590
Private Placement \| Private Placement Pre-Funded Warrants
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Exercise price of warrants or rights (in usd per share)	$ 0.01
Class A Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock par value (in usd per share)		$ 0.01					$ 0.01
Class A Common Stock \| Private Placement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Shares sold (in shares)	464,377
Sale of stock, price per share (in usd per share)	$ 11.81
Class A Common Stock \| Private Placement \| Private Placement Pre-Funded Warrants
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Sale of stock, price per share (in usd per share)	$ 11.80
Number of securities called by warrants or rights (in shares)	3,853,997	3,970,587
Class A Common Stock \| TD Cowen Sales Agreement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Aggregate offering price					$ 50,000
Class B Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock par value (in usd per share)		$ 0.01					$ 0.01
vTv Therapeutics LLC
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC		19.20%
Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC		80.80%
vTv Therapeutics LLC \| Class B Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock par value (in usd per share)		$ 0.01

Summary of Significant Accounting Policies - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2024
Revenue \| Customer \| One Customer
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	100.00%

Collaboration Agreements - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 28, 2023	May 31, 2022	Aug. 31, 2017	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 26, 2024	Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Gain (loss) on extinguishment of debt						$ 0	$ (313)
Contract liabilities, net of current portion				$ 18,669		18,669			$ 18,669
Revenue				0	$ 0	1,000	0
G42 Investments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Shares sold (in shares)		259,657
Sale of stock, price per share (in usd per share)		$ 96.40
Sale of stock, consideration received on transaction, gross		$ 25,000
Sale of stock, consideration received on transaction		12,500
Accounts and financing receivable, after allowance for credit loss		12,500
Proceeds from collection of notes receivable	$ 12,000
Discount rate	3.75%
Gain (loss) on extinguishment of debt	$ (300)
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement \| G42 Investments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sale of stock, consideration received on transaction, gross		25,000
Accounts and financing receivable, after allowance for credit loss		12,500
Proceeds from collection of notes receivable	$ 12,000
Discount rate	3.75%
Gain (loss) on extinguishment of debt	$ (300)
Collaborative arrangement, contingent consideration		30,000
Collaborate arrangement, contingent consideration transferred, cash		$ 30,000
Contract liabilities, net of current portion				18,700		18,700
Discount on note receivable						600
Collaboration revenue recognized				0		0
Revenue				0		0
Receivables, fair value disclosure				$ 11,900		11,900
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement \| Cogna
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties receivable, period		10 years
Collaborative Arrangements \| Newsoara Biopharma Co Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contract with customer, liability, revenue recognized							$ 0
Collaborative Arrangements \| JDRF
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum funding percentage of research and development milestones			50.00%
Collaborative Arrangements \| Newsoara Biopharma Co Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fee received								$ 20,000
License fee received, term								1 year
License fee price increase								$ 20,000
Potential development and regulatory milestone payments								$ 76,500
Collaborative Arrangements \| Newsoara Biopharma Co Ltd \| License And Technology Transfer Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized from change in estimated transaction prices						$ 1,000

Share-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
	Feb. 23, 2024	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		406,799
Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-qualified stock option awards vesting period		3 years
Non-qualified stock option awards expiration term		10 years
Unrecognized compensation cost related to non-vested share-based compensation arrangements		$ 4.7
Weighted average period to recognize unrecognized share-based compensation cost		2 years 6 months
Weighted average grant date fair value of options granted (in usd per share)		$ 14.88	$ 30.59
Modified common stock (in shares)	14,340
Accelerated vesting (in shares)	7,590
Expense reduction		$ 0.1

Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Number of Shares
Awards outstanding, Beginning balance (in shares) \| shares	249,247
Granted (in shares) \| shares	406,799
Forfeited (in shares) \| shares	(1,875)
Awards outstanding, Ending balance (in shares) \| shares	654,171
Options exercisable (in shares) \| shares	199,812
Options exercisable, weighted average remaining contractual term	6 years 9 months 18 days
Options vested and expected to vest (in shares) \| shares	499,109
Options vested and expected to vest, weighted average remaining contractual term	8 years 4 months 24 days
Weighted Average Exercise Price
Awards outstanding, Beginning balance (in usd per share) \| $ / shares	$ 77.53
Granted (in usd per share) \| $ / shares	12.68
Forfeited (in usd per share) \| $ / shares	30.87
Awards outstanding, Ending balance (in usd per share) \| $ / shares	37.34
Options exercisable (in usd per share) \| $ / shares	86.34
Options vested and expected to vest (in usd per share) \| $ / shares	$ 44.32

Commitments and Contingencies - Additional Information (Detail) - Novo License Agreement $ in Millions	Feb. 28, 2007 USD ($)
Developmental and Regulatory Milestone Payment \| Type 1 Diabetes
Commitments And Contingencies [Line Items]
Potential milestone payment	$ 9.0
Developmental and Regulatory Milestone Payment \| Type 2 Diabetes \| Maximum
Commitments And Contingencies [Line Items]
Potential milestone payment	50.5
Developmental and Regulatory Milestone Payment \| Other Indication \| Maximum
Commitments And Contingencies [Line Items]
Potential milestone payment	115.0
Sales-based Milestones Payment
Commitments And Contingencies [Line Items]
Potential milestone payment	$ 75.0

Leases - Additional Information (Details) - USD ($)	6 Months Ended
Leases - Additional Information (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Nov. 30, 2022
Leases [Abstract]
Lessee, operating lease, renewal term	5 years
Lessee, operating lease, termination period	3 years
Present value of lease liabilities	$ 256,000			$ 100,000
Operating lease right-of-use assets	$ 186,000		$ 244,000	$ 100,000
Weighted average incremental borrowing rate	9.50%		9.50%
Remaining operating lease term	1 year 4 months 24 days		1 year 10 months 24 days
Operating lease cost	$ 100,000	$ 0

Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Nov. 30, 2022
Leases [Abstract]
2024 (remaining six months)	$ 97
2025	177
2026	0
2027	0
2028	0
Thereafter	0
Total lease payments	274
Less: imputed interest	(18)
Present value of lease liabilities	$ 256	$ 100

Stockholders' Equity (Deficit) - Additional Information (Detail) $ / shares in Units, $ in Thousands							6 Months Ended
	Feb. 27, 2024 $ / shares shares	Nov. 20, 2023 $ / shares shares	Feb. 28, 2023 USD ($)	Jul. 22, 2022 USD ($) $ / shares shares	May 31, 2022 USD ($) $ / shares shares	May 04, 2021 shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Mar. 05, 2024 shares	Feb. 28, 2024	Feb. 28, 2024 USD ($)	Feb. 28, 2024 Rate	Dec. 31, 2023 $ / shares shares
Class Of Stock [Line Items]
Capital stock, shares authorized (in shares)						350,000,000	250,000,000
Common stock par value (in usd per share) \| $ / shares		$ 0.01
Preferred stock, par or stated value per share (in usd per share) \| $ / shares		$ 0.01
Shares authorized (in shares)		50,000,000
Gain (loss) on extinguishment of debt \| $							$ 0	$ (313)
Entity public float, threshold \| $											$ 75,000
Percent of public float										33.30%		3.00%
Private Placement Pre-Funded Warrants
Class Of Stock [Line Items]
Percent of securities called by warrants	9.99%						19.99%
Private Placement
Class Of Stock [Line Items]
Private placement, shares (in shares)									116,493
Private placement pre-funded warrants, shares (in shares)									116,590
Private Placement \| Private Placement Pre-Funded Warrants
Class Of Stock [Line Items]
Exercise price of warrants or rights (in usd per share) \| $ / shares	$ 0.01
G42 Investments
Class Of Stock [Line Items]
Shares sold (in shares)					259,657
Sale of stock, price per share (in usd per share) \| $ / shares					$ 96.40
Sale of stock, consideration received on transaction, gross \| $					$ 25,000
Sale of stock, consideration received on transaction \| $					12,500
Accounts and financing receivable, after allowance for credit loss \| $					$ 12,500
Sale of stock, consideration, receivables, payment term					1 year
Proceeds from collection of notes receivable \| $			$ 12,000
Discount rate			3.75%
Gain (loss) on extinguishment of debt \| $			$ (300)
CinRx Investment
Class Of Stock [Line Items]
Shares sold (in shares)				103,864
Sale of stock, price per share (in usd per share) \| $ / shares				$ 96.40
Sale of stock, consideration received on transaction, gross \| $				$ 10,000
Sale of stock, consideration received on transaction \| $				6,000
Accounts and financing receivable, after allowance for credit loss \| $				$ 4,000
Warrants, term				5 years
Class A Common Stock
Class Of Stock [Line Items]
Increase in shares authorized (in shares)						100,000,000
Common stock, shares authorized (in shares)		200,000,000				200,000,000	200,000,000						200,000,000
Common stock par value (in usd per share) \| $ / shares							$ 0.01						$ 0.01
Stock split conversion ratio		0.025
Class A Common Stock \| Private Placement
Class Of Stock [Line Items]
Shares sold (in shares)	464,377
Sale of stock, price per share (in usd per share) \| $ / shares	$ 11.81
Class A Common Stock \| Private Placement \| Private Placement Pre-Funded Warrants
Class Of Stock [Line Items]
Sale of stock, price per share (in usd per share) \| $ / shares	$ 11.80
Number of securities called by warrants or rights (in shares)	3,853,997						3,970,587
Class A Common Stock \| TD Cowen Sales Agreement
Class Of Stock [Line Items]
Aggregate offering price \| $											$ 50,000
Common Stock
Class Of Stock [Line Items]
Common stock, shares authorized (in shares)						300,000,000
Common Stock \| CinRx Investment
Class Of Stock [Line Items]
Number of securities called by warrants or rights (in shares)				30,000
Exercise price of warrants or rights (in usd per share) \| $ / shares				$ 28.80
Warrants, fair value \| $				$ 400
Class B Common Stock
Class Of Stock [Line Items]
Common stock, shares authorized (in shares)		100,000,000					100,000,000						100,000,000
Common stock par value (in usd per share) \| $ / shares							$ 0.01						$ 0.01
Stock split conversion ratio		0.025

Related-Party Transactions - Additional Information (Detail) - Related Party - MacAndrews & Forbes Incorporated	6 Months Ended
	Jun. 30, 2024 shares
Related Party Transaction [Line Items]
Ownership percentage of majority owner	49.50%
Amount of cash savings percentage	85.00%
Class B Common Stock
Related Party Transaction [Line Items]
Share held by related party (in shares)	577,108
Class A Common Stock
Related Party Transaction [Line Items]
Share held by related party (in shares)	912,982

Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)	1,307,115	896,344
Class B Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)	577,349	577,349
Common stock options granted under the Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)	654,171	238,636
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)	75,595	80,359

Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)	Jun. 30, 2024	Dec. 31, 2023
CinRx Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected life of options in years	3 years
Expected volatility \| CinRx Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.917
Risk-free interest rate \| CinRx Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.045
Expected dividend yield \| CinRx Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0
Minimum \| Expected volatility \| Letter Agreement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.9896	0.7996
Minimum \| Risk-free interest rate \| Letter Agreement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.0462	0.0401
Maximum \| Expected volatility \| Letter Agreement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	1.4541	0.8961
Maximum \| Risk-free interest rate \| Letter Agreement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.0536	0.0487
Weighted Average \| Expected volatility \| Letter Agreement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	1.0642	0.8155
Weighted Average \| Risk-free interest rate \| Letter Agreement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.0479	0.0415